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ABSTRACT 
     Polycyclic polyprenylated acylphloroglucinols (PPAPs) are structurally complex 
natural products with promising biological activities.  These compounds have interesting 
anticancer and anti-HIV properties as well as other biological activities making them 
highly attractive synthetic targets.  We report a stereodivergent, asymmetric total 
synthesis of (−)-clusianone in six steps from commercial materials. We have 
implemented a challenging cationic cyclization forging a bond between two sterically 
encumbered quaternary carbon atoms. Mechanistic studies point to the unique ability of 
formic acid to mediate the cyclization forming the clusianone framework.   
     We also present a biosynthesis-inspired, diversity-oriented synthesis approach for 
rapid construction of PPAP analogs via palladium-catalyzed dearomative conjunctive 
allylic alkylation (DCAA).  These efficient palladium-catalyzed protocols construct the 
[3.3.1]-bicyclic PPAP core in a single step from their stable aromatic precursors.  
     The first syntheses of 13,14-didehydroxyisogarcinol and garcimultiflorone A 
stereoisomers are reported in six steps from a commercially available phloroglucinol. 
Lewis acid-controlled, diastereoselective cationic oxycyclizations enabled asymmetric 
syntheses of (−)-6-epi-13,14-didehydroxyisogarcinol and (+)-30-epi-13,14-
	  	  
	  
didehydroxyisogarcinol. A similar strategy enabled production of the meso-derived 
isomers (±)-6,30-epi-13,14-didehydroxyisogarcinol and (±)-6,30-epi-garcmultiflorone A. 
A convenient strategy for gram scale synthesis of these stereoisomers was developed 
utilizing diastereomer separation at a later stage in the synthesis that minimized the 
number of necessary synthetic operations to access all possible stereoisomers. 
     Finally, we report cationic rearrangements of dearomatized acylphloroglucinols 
leading to the formation of unprecedented PPAP scaffolds.  A novel type A [3.3.1]-
bicyclic PPAP was produced as a major product and the structure confirmed by X-ray 
crystallographic analysis. A novel [3.3.1]-bicyclolactone was also produced utilizing an 
alternative substrate.  Efforts will be described to determine the scope of these 
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Yb(OTf)3  ..................................................................................................  ytterbium triflate 




 Chapter 1 
 
         Polycyclic Polyprenylated Acylphloroglucinol 
Natural Products: Biogenesis, and Synthetic Accounts 
1.1 Introduction to Polycyclic Polyprenylated Acylphloroglucinol Natural Products   
1.1.1 Isolation and Structure 
     Polycyclic polyprenylated acylphloroglucinols (PPAPs) are a structurally intriguing 
class of natural products containing a bicyclo[3.3.1]nonane-2,4,9-trione core and are 
comprised of more than 260 members (Figure 1.1).1  For the past 15 years, the synthetic 
and biological communities have been interested in PPAPs as natural product targets and 
starting points for SAR studies due to their diverse bioactivity profiles.  Not surprisingly, 
with minor structural differences leading to significant variation in bioactivity, PPAP 
natural products and their analogs are considered high priority targets for isolation, 
chemical synthesis, and biological studies.2,3   
     (+)-Clusianone (1, Figure 1.1), a type B PPAP as indicated by the α-acyl β-hydroxy 
enone,1f was first isolated and characterized in 1976 from the bark of Clusia 
congestiflora.4a  Since the early 1990’s, there have been a handful of isolation studies that 
address the molecule’s structure.4  Nemorosone (2), isolated from Clusia species in 
Brazil, Cuba, and Venezuela and from the propola of Cuban honeybees,5 is a type A 
PPAP as indicated by the bridgehead-substituted acyl function α to the dimethyl 
 2 
function.[1f] Structurally, clusianone (1) and nemorosone (2) possess synthetically 
challenging, highly oxygenated bicyclo[3.3.1]nonane-2,4,9-trione cores adorned with 
isoprenyl side chains and three stereocenters (Figure 1.1A).  Hyperforin (9, Figure 
1.1B), a type A PPAP found in St. John’s wort, possesses an even more complex 
oxygenated bicyclo[3.3.1]nonane core that consists of four stereocenters and an 
isobutyryl group at a bridgehead carbon alpha to a quaternary center.1,6   
     The 3-dimentional structure of the bicyclo[3.3.1]nonane core of the PPAPs is 
illustrated in Figure 1.1B.  The absolute configuration (+)-clusianone (1) was determined 
 




























B. Unique 3-Dimentional Structure of Select PPAP Natural Products.





























































by Simpkins (vide infra),7a but that of nemorosone (2) still remains undetermined. 
Although an X-ray crystal structure of nemorosone was reported, the anomalous 
dispersion effect was small and no reliable evidence of the absolute configuration could 
be obtained.8 
     The absolute configuration of (+)-clusianone was established by Simpkins and 
coworkers using the Effenburger cyclization7b to produce racemic [3.3.1]-bicycle 13 
followed by a chiral base kinetic resolution to produce unreacted starting material (+)-14 
in high enantiopurity (Scheme 1.1).7a  In order to acquire suitable crystals for X-ray 
crystal structure determination, compound (+)-14 underwent bridgehead benzylation 
 
 Scheme 1.1 Chiral Base Promoted Kinetic Resolution Enabled Assignment of the 
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followed by reduction of the bridgehead ketone to provide the crystalline derivative (+)-
19.  The crystal structure of this compound validated the stereochemistries of all previous 
intermediates and confirmed the absolute configuration of (+)-clusianone (1). 
     Surprisingly, the sign of rotation changed after vinyl benzoylation and bridgehead 
prenylation of (+)-14 to provide (-)-methyl clusianone 17 (Scheme 1.1).  Furthermore, 
the rotation sign of (-)-methyl clusianone 17 reversed again upon demethylation to (+)-
clusianone (1).  This result was confirmed when the synthesis of natural product (+)-
methyl clusianone [(+)-17] from (-)-15 showed the same change in rotation sign upon 
demethylation to (-)-clusianone (-)-1.  Hence, due to the isolation of methyl ether isomer 
[(+)-17], the investigators speculate that (-)-1 may also one day be found in Nature that 
would render clusianone among the examples of natural products that are produced in 
either enantiomeric form.7 
    The natural product garcinol (8) and its cyclized isomer isogarcinol (5) have gained 
significant attention in recent years due to their diverse bioactivities (Figure 1.1).9,10  
These compounds, along with isogarcinol’s stereoisomers 30-epi-cambogin (6) and 7-epi-
isogarcinol (7), have been isolated from numerous sources,11 , 12  and a large scale 
extraction procedure was developed for the procurement of isogarcinol (5).11g  
Isogarcinol’s dehydroxy isomer 13,14-didehydroxyisogarcinol (3) and the type A variant 
garcimultiflorone A (4) were isolated in 2009 from the fruits of Garcinia multiflora in 
Southern China. 13   Natural products 3 – 7 possess complex highly oxygenated 
bicyclo[3.3.1]nonane cores with a fused pyran and four stereocenters (Figure 1.1).  
Although 5 and 8 were originally isolated from the latex of Garcinia cambogia in 1980 
 5 
and again from Garcinia indica in 1981,11a,11b their structures were not unambiguously 
determined until an X-ray crystallographic analysis of isogarcinol (5) was reported two 
years later.11c  The structure of garcinol (8) was inferred from its conversion into 
isogarcinol (5) by treatment with HCl (Scheme 1.2) along with additional spectral 
evidence, comparisons, and correlations.11a-11c  However, the stereochemistry of 8 was 
later confirmed in an elegant total synthesis of 5 and 8 by Plietker and coworkers where  
 
Scheme 1.2 Conversion of Garcinol into Isogarcinol.14 
 
CD spectroscopy in combination with computational methods were employed for the 
unambiguous determination of the absolute configuration of both garcinol (5) and 
isogarcinol (8).14 
 
1.1.2  Biosynthesis and Synthetic Challenges      
     Alkylative dearomatization reactions play a fundamental role in the biogenesis of 
PPAPs (Scheme 1.3).15   The efficiency of their biosyntheses has inspired several 
synthetic groups to utilize alkylative dearomatizations in the chemical synthesis of these 
highly bioactive natural products.16  The representative set of PPAPs shown in Scheme 
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a series of prenylation reactions, proton transfers, double bond isomerizations, and 
oxidations initiated by prenyl pyrophosphate.11a,17  
 
Scheme 1.3 Biosynthesis of a Representative Set of PPAPs via Alkene-Intercepted 
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 7 
     Grandone (20a) and colupulone (20b) are natural products that derive biosynthetically 
from a series of dearomative alkylation reactions as illustrated in Scheme 1.4 for the case 
of grandone (20a).  Prenyl pyrophosphate leads to alkylative dearomatization of 
acylphloroglucinol 26 that rearomatizes following proton transfer to provide alkylated 
acylphloroglucinol 28.  The prenylation of 28 is again induced by another equivalent of 
prenyl pyrophosphate leading to a dearomatized product 29 that undergoes a subsequent 
alkylative dearomatization/deprotonation sequence to provide grandone (20a).  
 
Scheme 1.4  Biosynthesis of Grandone (20a), a Common Intermediate in the Biogenesis 
of Several PPAP Natural Products. 
     Grandone (20a) has been synthesized in the laboratory, but a biomimetic synthesis has 
not been reported.  However, such a synthesis of 20 may be possible since allyl iodide in 
combination with acylphloroglucinol 26 provided the allyl-variant of grandone (20a) 
(unpublished results, Boyce and Porco), which may be replicated under similar 
























































synthesis of phenyl lupone (32) from clusiaphenone B (31) via the intermediacy of 
grandone (20a) in a one-pot synthesis using excess prenyl bromide as the alkylating agent 
(Scheme 1.5).16c  The only reported isolation of 20 was accomplished by Marazano and 
coworkers for use as an intermediate in the synthesis of PPAPs (vide infra).18 
 
Scheme 1.5 Synthesis of Clusiaphenone B by Qi and Porco. 
     Clusianone (1) and nemorosone (2) derive biosynthetically from the common cationic 
intermediate 33 (Scheme 1.6).15c  For more than a decade, synthetic groups have been 
largely unsuccessful at achieving similar cationic cyclizations to access the fully  
 
Scheme 1.6  Biosyntheses of (+)-clusianone (1) and nemorosone (2). 














































functionalized cores of type A and B PPAPs.  Such cyclizations have been reported only 
in the case of systems lacking the full functionality of the natural 
products.16a,c,d,e,f,g,18,19,20,21  For example, Marazano and coworkers could not isolate C-
cyclized products via cationic intermediates analogous to 33 (Scheme 1.7B).18,16n The 
cyclization of grandone (20a) with tin tetrachloride only provided O-cyclization product 
37.  Additionally, it was stated that all conditions failed to give C-cyclization products 
from intermediates 20 and 36, which were synthesized from phloroglucinol 34 utilizing 
an alkylative dearomatization strategy (Scheme 1.7A).    
 
Scheme 1.7  Marazano and coworkers did not report the isolation of C-cyclized products 










































35b weddellianone A isomer (36)
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weddellianone A isomer (36)
A  Synthesis of Cyclization Precursors.








     In a study by Couladouros and coworkers involving cationic cyclizations to PPAP 
scaffolds,16d it was also shown that carbocations similar to 33 could not be C-cyclized to 
their respective [3.3.1]-bicyclic cores. The difficulty of mediating a cyclization via 
carbocation 33 likely stems from a high degree of strain in the transition state and from  
 
 Scheme 1.8  Tertiary Alcohol 39 did not Provide C-cyclization Products. 
the steric demands of forming a hindered carbon bond between two sterically congested 
quaternary carbons.16n  For example, tertiary alcohol 39 did not provide C-cyclization 
products under numerous cation-forming conditions (Scheme 1.8).  C-cyclization was 
only observed in the case of conjugated tertiary carbocations.  For example, compound 
40 was acylated in high yield to deactivate the enol at C3 in compound 41, which 
rendered C1 more electron rich.17 The combination of triethylamine and methanesulfonyl 
chloride generated a strong electrophile capable of mesylating the tertiary alcohol in 
compound 41.16d,22  This presumably lead to the formation of a resonance stabilized 
carbocation 42 with likely ion pair stabilization.17  Intramolecular cyclization provided a 
1:1 mixture of the C-cyclization product 43 via path a and O-cyclization product 44 via 




















elimination or degradation products
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Scheme 1.9  Biomimetic Approach to Access Type A PPAPs by Couladouros and 
Coworkers. 
1.1.3   Bioactivity Comparisons of Select PPAP Natural Products 
     It was not until 20 years after its initial isolation4a that reports began to emerge on 
clusianone’s bioactivity.2a,4c,5a,11e,23  In 2005, the compound was shown to possess notable 
anti-HIV activity (EC50 = 20 nM) by inhibiting the gp120-sCD4 viral-receptor interaction 
suggesting its potential for preventing HIV infection.4c  Clusianone’s chemopreventative 
properties11e,2a are thought in part to arise from its ability to inhibit histone 
acetyltransferase (HAT) enzymes.  Nemorosone (2) has notable anticancer properties in 
part due to its ability to activate HAT enzymes2a,23a,c and serve as a protonophoric 













































are active against parental and chemoresistant leukemia.24  Hyperforin (9), a type A 
PPAP found in St. John’s Wort, is used to treat depression and possesses anti-
inflammatory and antibiotic properties.1,6  Furthermore, hyperforin (9) inhibits 
angiogenesis25 and the human deacetylation enzymes sirtuins SIRT1 and SIRT2.25c  
Hyperforin’s antidepressant properties are mediated by TRPC6 channel activation.25d,e 
Isogarcinol’s dehydroxy isomer 13,14-didehydroxyisogarcinol (3) and the type A variant 
garcimultiflorone A (4) were reported to possess anti-inflammatory activity by inhibiting 
superoxide anion (O2• ¯) and elastase enzymes released from human neutrophils (Figure 
1.2).13 
 



























































     The natural product isogarcinol (5) has activity in numerous therapeutic indications26 
including leukemia,26a,i colon cancer,26b,i HIV,26c,d brain tumors (medulloblastoma),26e 
antioxidant,26f antimicrobial,26f transplantation rejection and autoimmune diseases,26g,h,l 
collagen-induced and rheumatoid arthritis,26j breast cancer,26k and Parkinson’s disease.26m  
Interestingly, isogarcinol (5) is also available for human consumption in mangosteen 
drinks and capsules as a remedy for arthritis.9  In parts of India, people consume the 
Garcinia indica choisy (kokum) fruit that is considered to possess antibacterial, 
antifungal, antioxidant, neuroprotective, antidiabetic, cardioprotective, antitumor, and 
chemotherapeutic effects, which are thought to result from the properties of 5 and 8.10 
     Garcinol (8) and isogarcinol (5) are the first natural products discovered to expand 
human cord blood hematopoietic stem cells and progenitor cells (HSCs/PCs) ex vivo, 
which may prove useful for gene transplantation in the future.  This effect was found to 
be directly correlated with their inhibition of p300 histone acetyltransferase (HAT), 
which is important for HIV-replication and cytotoxicity.26  Interestingly, isogarcinol (5), 
was almost two times more active than garcinol (8) to bring about expansion of hCB 
HSCs/PCs ex vivo.26   
     Isogarcinol (5) was found to have immunosuppressive activity in vitro by directly 
inhibiting calcineurin (CN).26h In contrast to isogarcinol, the immunosuppressive drugs 
cyclosporin A (CsA) and tacrolimus (FK506) do not bind directly to CN, but their 
immunosuppressive effects are attributed to the indirect inhibition of CN.26l Isogarcinol’s 
immunosuppressive activity in vivo is thought to arise from its inhibition of T-cells. 
Interestingly, isogarcinol displayed notably improved allogeneic skin graft rejection time 
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in mice suggesting it has the potential to prevent organ failure during organ 
transplantation.26  
     Isogarcinol (5) also has potential as a treatment for rheumatoid arthritis.  In vivo 
studies demonstrated that the anti-inflammatory effects of 5 and aspirin are similar.26  It 
inhibited joint swelling and prevented joint damage caused by collagen in mice through 
the inhibition of pro-inflammatory cytokines, such as IL-17. 
     Isogarcinol (5) and garcinol (8) possess antibacterial activity against methicillin-
resistant Staphylococcus aureus, comparable to vancomycin. However, garcinol’s 
antibacterial properties are superior to that of isogarcinol. The β-hydroxyenone of 
garcinol plays a crucial role in its inhibition of methicillin-resistant Staphylococcus 
aureus (MSRA). As a result of its antimicrobial activity, garcinol has been implicated as a 
therapy for acne.  Additionally, isogarcinol (5) and 7-epi-isogarcinol (7) displayed 
antiplasmodial activity against the chloroquine-resistant strain of Plasmodium falciparum 
(FcB1, ~3 µM).26 
     Isogarcinol triggers cell death in multiple cancer cell lines with selectivity for 
medulloblastoma (MB) Daoy cells by inhibiting the overexpression of PDGFR receptors.  
Interestingly, isogarcinol displayed selective activity against brain tumors that are most 
prevalent in children and does not trigger cell death in normal cells suggesting a 
favorable therapeutic index for this compound.26  
     Isogarcinol (5) was selectively cytotoxic against the HepG2 human hepatocellular 
carcinoma cell line (IC50=7.3 µM) and two human breast adenocarcinoma cell lines 
(MCF-7 [IC50=4.8 µM] and MDA-MB-231 [IC50=5.7 µM]) with lower potency against 
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normal hepatic HL-7702 cells (IC50= 9.3 µM).  It was also cytotoxic against HL60 cells 
(4.70 µM), HCT116 colon cells (p53+/+) [0.86 µM], and leukemia CCRF_CEM cell lines 
(1.38 µM) by inducing apoptosis through the activation of caspases 3/7, 8, and 9 and the 
breakdown of MMP.26   
     30-epi-Isogarcinol (6) shows antiproliferative effects against stomach (4.45 µM), 
cervix (10.64 µM) and lung (13.60 µM) cancer cell lines and effectively induced 
apoptosis in HeLa-C3 cells via caspase-3 activation. In a dose-response relationship 
study, 6 was cytotoxic against HT29 cancer cells with a greater potency (IC50=5.1 µM) 
than the chemotherapy drug cisplatin (26.6 µM).26   Additionally, 30-epi-isogarcinol (6) 
and isogarcinol (5) were selectively cytotoxic against HT-29 and HCT116 colon cancer 
cell lines over normal colon cells (CCD-18Co).26   
1.1.4 Conclusion 
     The complex, synthetically challenging structures of PPAPs along with the efficient 
way Nature constructs these molecules has inspired synthetic chemists to pursue these 
molecules for the past two decades. The challenges in replicating their biosyntheses in the 
laboratory have been detailed in Section 1.1.2 and in Chapters 2 and 4, we show how our 
work has enabled chemists to overcome these challenges. Furthermore, the diverse 
bioactivities of these compounds points to the importance of synthesizing diverse analogs 
of these compounds to further probe their biological activities which was recently 
emphasized.26n,o  In the following section, we outline previously reported synthetic 
strategies to PPAP natural products.   
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1.2 Previous Total Syntheses of PPAP Natural Products 
     For the past 10 years, synthetic groups have reported total syntheses of clusianone, 
nemorosone, and other PPAPs.  The early elegant work toward these natural products laid 
the groundwork for subsequent syntheses of PPAPs in recent years.  Herein, we outline 
total syntheses of clusianone, nemorosone, and isogarcinol as well as other biomimetic 
syntheses. The order of discussion will proceed as follows: racemic syntheses of 
clusianone, asymmetric syntheses of (+)- and (-)-clusianone, syntheses of nemorosone, 7-
epi-nemorosone and plukenetionone A, one total synthesis of garcinol and isogarcinol, 
and biomimetic syntheses of ialibinones A and B, hyperguinone B, garcibracteatone, 5-
epi-garcibracteatone, doitunggarcinone A. 
 
1.2.1  Total Synthesis of (±)-Clusianone 
     Several elegant total syntheses of (±)-clusianone have appeared in the literature.  The 
first total synthesis was reported in 2006 by Simpkins and co-works27 utilizing an 
Effenburger cyclization as a key step to furnish the bicyclo[3.3.1]nonane intermediate 14 
in 24 % yield over 2 steps from a diastereomeric mixture of 11 and 12 (75:25 d.r.).  After 
four additional steps, Simpkins was able to afford (±)-clusianone (Scheme 1.10). 
     Porco and Qi developed an efficient biomimetic synthesis of (±)-1 utilizing an 
alkylative dearomatization/annulation process involving intermolecular Michael addition 
into an α-acetoxy acrylate followed by E1CB elimination and subsequent intramolecular 
Michael addition to access [3.3.1]-bicyclic aldehyde 46 (Scheme 1.10).16c Grignard 
addition to the aldehyde followed by acetylation of the resulting secondary alcohol  
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provided allylic acetate 47.  Formate reduction followed by olefin cross-metathesis 
proceeded in excellent yield to afford methyl clusianone (±)-17.  Demethylation with 
LiOH and dioxane then provided (±)-1. 
     In the same year as Porco’s synthesis of (±)-clusianone was published, Danishefsky 
and coworkers demonstrated a total synthesis of both clusianone and nemorosone from 
commercially available phloroglucinol 48.16a  After palladium-catalyzed dearomative 
alkylation, olefin cross-metathesis, and demethylation provided cyclization precursor 49, 
iodonium-ion formation led to the formation of three cyclization products resulting from 
C-cyclization to desired core 50 (32%), 6-endo O-cyclization to pyranodienone 52, and 5-
exo O-cyclization to furanodienone 51.  Compound 50 gave a bridgehead anion upon 
subjection to the Grignard reagent leading to intramolecular displacement of the iodide 
providing a strained, fused cyclopropane at the bridgehead. Cyclopropane ring opening 
was induced with TMSI providing iodide 53 in excellent yield.  Keck allylation with allyl 
tributyltin led to the production of 54, which served as a common intermediate to both 
clusianone and nemorosone (vide infra).  After five additional steps, a synthesis of (±)-
clusianone was achieved.  
Scheme 1.11 Synthesis of (±)-Clusianone by Nakada and Coworkers 
     The most recent total synthesis of (±)-clusianone was reported in 2013 by Nakada and 
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nemorosone (vide infra).  Diazo intermediate 56 was accessed in 9 steps from the methyl 
ester 55 (Scheme 1.11).  Intramolecular cyclopropanation of 56 using copper(I) triflate 
and an achiral bisoxazolidine ligand provided strained cyclopropane 57.  Cyclopropane 
opening and dimethylation in the presence of base and excess methyl iodide followed by 
HCl-mediated rearrangement to bicyclo[3.3.1]nonane 58 allowed for subsequent 
elaboration to (±)-clusianone in 19 steps. 
 
1.2.2  Asymmetric Syntheses of (+)- and (-)-Clusianone 
     There have been five reported asymmetric syntheses of clusianone, one of which was 
discussed in Section 1.1.1 (Scheme 1.1) detailing work by Simpkins and coworkers for 
the determination of the absolute configuration of (+)-clusianone.  Another asymmetric 
synthesis of (-)-clusianone will be described in Chapter 2.  The first asymmetric synthesis 
of clusianone was achieved by Coltart and coworkers (Scheme 1.12) utilizing a similar 
strategy to that reported by Simpkins.29a Compound 59, available in three steps from 
commercial starting materials, was reacted to a chiral oxazolidinone-hydrazide reagent 
under acidic conditions to provide chiral hydrazone 60. Asymmetric prenylation followed 
acid-mediated removal of the hydrazone furnished ketone 61a in excellent yield and 99:1 
er.  Compounds 11a and 12a (same intermediates obtained by Simpkins, but with high 
enantiopurity) were obtained as a mixture after four steps and next subjected to the key 
Effenburger cyclization.  The resulting [3.3.1]-bicyclic enol was then methylated with 
trimethyl orthoformate and p-TsOH at 50 oC providing methyl enol ether (+)-14.  After 
three additional steps, (+)-clusianone (1) was provided in high enantiopurity. A total 
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synthesis of (-)-clusianone [(-)-1] was also achieved by Coltart by the same route 
utilizing the opposite enantiomer of the chiral auxiliary (Scheme 1.12).29b 
     Most recently, Plietker and coworkers published an elegant asymmetric synthesis of 
(+)-clusianone (1) in 12-steps from acetylacetone (Scheme 1.13).30  Their synthesis was 
rendered enantioselective through the use of a palladium-catalyzed decarboxylative 
asymmetric allylation reaction to access compound 64 in 97 % ee.  Olefin ring-closing 
metathesis (RCM) was used to provide bicyclic diene 65.  Cuprate addition to the α,β-
unsaturated olefin of 65 followed by reaction with allyl chloroformate provided acyl enol  
 
Scheme 1.13 Synthesis of (+)-Clusianone by Plietker and Coworkers. 
ether 66 in excellent yield.  Product 67 was formed as mixture of diastereomers in a ratio 
of 15:85 d.r. following a diastereoselective Pd-catalyzed decarboxylative allylation.  A 
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KOtBu and benzoyl cyanide to provide tetracyclic bicyclo[3.3.1]nonane core structure 68.  
Ring opening metathesis with the Grubbs 2nd generation catalyst provided the natural 
product (+)-clusianone (1) in an overall 8 % yield from acetylacetone.   
1.2.3  Syntheses of Nemorosone and 7-epi-Nemorosone 
     The number of syntheses of nemorosone are limited due to the instability of the 
natural product (tendency to oxidize) and the challenges its structure poses to total 
synthesis. Herein, we will describe total syntheses of this compound along with a recent 
asymmetric synthesis of (-)-nemorosone.  Finally, we will discuss synthesis of 7-epi-
nemorosone.    
     Danishefsky and coworkers completed the first total synthesis of nemorosone (2) via 
common intermediate 54 (Scheme 1.14), which was produced in the same manner 
described above in Section 1.2.1 for clusianone (1).16a  A successful strategy to achieve 
nemorosone required access to the bridgehead iodide 69.  The TMS protecting group 
enables bridgehead substitution prior to vinyl functionalization that normally proceeds at 
a faster rate.  Hence, intermediate 69 was subjected to another six steps involving 
bridgehead benzoyl substitution, deprotection of the TMS group, vinyl allylation, olefin 
cross-metathesis, and demethylation to afford nemorosone (2).   
     Simpkins and coworkers reported a similar strategy to access nemorosone where they 
required access to the bridgehead iodide 74 (Scheme 1.14),31a the methyl ether congener 
of intermediate 69 that was utilized by Danishefsky.16a  As described above, the TMS 
protecting group served the same purpose in Simpkins approach by blocking vinyl 




Scheme 1.14 Syntheses of (±)-Nemorosone by Danishefsky and Simpkins. 
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began with prenylation of compound 70, followed by Michael addition of a methyl 
cuprate, and subsequent TBS enol ether formation to afford product 71 in 60% yield over 
3 steps.  The Effenburger cyclization7b was utilized to access the bicyclic core followed 
by methylation with dimethyl sulfate and base to access a 1:1 mixture of methyl enol 
ether isomers 72 and 73.  Compound 73 displayed markedly improved yields over 72 for 
vinyl TMS protection and subsequent iodination.31b  Thus, the ratio of methyl enol ether 
73 to 72 was maximized by utilizing acid-mediated methylation conditions (trimethyl 
orthoformate and p-TsOH), which completely avoided the formation of undesired 
product 72 because of the greater thermodynamic stability of regioisomer 73.  Lithium 
tetramethylpiperidide (LTMP) and TMSCl invoked vinylic TMS substitution of 73, and 
the subsequent formation of a bridgehead anion that was quenched with iodine to provide 
nemorosone precursor 74.  After four additional steps, Simpkins and coworkers 
completed their total synthesis of nemorosone (2).   
     In 2012, Nakada and coworkers completed a total synthesis of (±)-nemorosone (2) 
utilizing common intermediate 58 (Scheme 1.15) that was used to access clusianone as 
described in Section 1.2.1 (Scheme 1.11).  As described above, diazo intermediate 56 
was achieved in 9 steps from methyl ester 55.  Intramolecular cyclopropanation of 56 
using copper(I) triflate and an achiral bisoxazolidine ligand provided strained 
cyclopropane 57.  Cyclopropane opening and dimethylation in the presence of base and 
excess methyl iodide followed by HCl-mediated rearrangement to bicyclo[3.3.1]nonane 
58 allowed for subsequent elaboration to nemorosone (2) in 19 steps.32 
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Scheme 1.15 Synthesis of (±)-Nemorosone by Nakada and Coworkers. 
     The first enantioselective total synthesis of (-)-nemorosone was achieved by Shair and 
coworkers in 2015 utilizing a Sharpless Asymmetric Epoxidation (SAE) to set the 
stereocenter that would then control the stereochemistry through the entire synthesis to 
enable production of enantiopure nemorosone (Scheme 1.16).33a  Enantiopure epoxide 76 
was provided in four steps from allylic alcohol 75.  After extensive experimentation, it 
was revealed that cyclization to 77 was only possible through the use of TIPSOTf in 
combination with 2,6-lutidine and slow warming to room temperature, which provided 
95% yield of the desired product.  Cyclic ketal formation was problematic for the 
majority of conditions tried to affect the cyclization of 76, and this was circumvented 
through the installation of a bulky TIPS protecting group that is thought to sterically 
disfavor the formation of the undesired ketal.  Allylic oxidation of 77 with Pearlman’s 
catalyst and TBHP provided a mixture of vinylogous methyl ether 79 with undesired 
peroxide 78 that was converted to 79 with DBU.  Silyl deprotection followed by 
installation of the thiocarbonate enabled radical formation and allylation with allyl 
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Scheme 1.16 Asymmetric Synthesis of (-)-Nemorosone by Shair and Coworkers. 
vinylogous ester of 72 with a TMS group to enable benzoyl substitution at the 
bridgehead, a common strategy employed in all total syntheses of nemorosone (2) to date. 
Compound 72 was smoothly converted to (-)-nemorosone following standard functional 
group manipulations utilized in other syntheses of 2 (TMS protection, bridgehead 
benzoylation, TMS deprotection, vinylic prenylation, and demethylation). 
     Porco and Zhang demonstrated a concise 10-step synthesis of (±)-7-epi-nemorosone 
from commercial starting materials (Scheme 1.17).16f Acylphloroglucinol 83 was 
subjected to a highly reactive α-acetoxy acrylate leading to intermolecular Michael 
addition followed by E1CB elimination of the acetate group in 92 % yield.   Hydrochloric 
acid in tetrahydrofuran then induced an intramolecular Michael addition that was 
followed by a subsequent demethylation-aldol cyclization sequence to provide the type A 
PPAP adamantane core 84 in 75% yield.  Product 84 is a common intermediate enroute to 
the type A natural products 7-epi-nemorosone (10) and plukenetione A (90); adamantane 
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precursor to clusianone (Scheme 1.17).16c,16f  Porco and Zhang showed that the 
nucleophilic organocerium reagent, generated from allylmagnesium bromide and  
 
Scheme 1.17 Syntheses of 7-epi-Nemorosone, Clusianone, and Plukenetione A by Porco 
and Coworkers. 
cerium(III) chloride, avoided deprotonation of the α-proton in intermediate 86 and 
preferentially reacted with the aldehyde at C7 leading to type A PPAP 85.17  In contrast, 
use of the more basic Grignard reagent favored deprotonation of 86 causing 
fragmentation to 87 followed by intramolecular Michael addition to provide a type B 
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methylation with trimethylsilyldiazomethane, provided 88.16e  The type A intermediate 
85 was smoothly converted to 7-epi-nemorosone (10) after five additional steps.  
Additionally, Porco and coworkers also demonstrated that adduct 89, deriving from 
prenyl 1,2-addition to the C7 aldehyde of 86, furnished plukenetione A (90) following 
methylation, cyclization, and olefin cross-metathesis. (Scheme 1.17) 
 
1.2.4  Total Synthesis of Garcinol (8) and Isogarcinol (5) 
     Plietker and coworkers demonstrated an elegant total synthesis of isogarcinol in 15 
steps from commercial starting materials (Scheme 1.18).14  β-Ketoester 91a, which is 
synthesized in four steps from acetylacetone, was alkylated with a 4-acetoxylated 
prenylchloride leading to the production of 91b.  Methyl cuprate addition into the α,β-
unsaturated olefin of 91b provided compound 92.  Allyl vinyl carbonates 93 and 94 were 
formed as a 2.8:1 mixture following the subjection of 92 to allyl chloroformate.  A highly 
diastereoselective, decarboxylative Tsuji-Trost allylation funished the allyl-allyl cross 
coupling precursor 95 necessary for installation of the isogarcinol side chain.  After 
extensive experimentation, palladium-catalyzed cross coupling with allyl boronate 
enabled exclusive formation of 96 as a single diastereomer with exclusive formation of 
the desired side chain stereocenter; the formation of β-hydride elimination products were 
also observed.  Isogarcinol’s bicyclo[3.3.1]nonane core was constructed via base-
mediated intramolecular Claisen condensation providing trione 97 following olefin cross-
metathesis.  A total synthesis of garcinol (8) was completed following benzoylation at the 
α-position of the β-diketone of 97 and subsequent saponification.  Garcinol (8) was then 
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converted to isogarcinol (5) following treatment with HCl which promoted the final acid-
induced enolization-cyclization. 
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1.2.5  Biomimetic Syntheses of PPAPs 
    Biomimetic strategies to access PPAPs are highly attractive due to the efficiency of 
their biosyntheses.  Additionally, the biosyntheses of PPAPs are unique in that the 
biosynthetic transformations that construct these molecules, namely dearomatization 
followed by cationic or radical cyclization reactions, are feasibly carried out in a 
laboratory setting.  In recent years, work by Porco,16c,e,f,g,h,m,n George16j,k, Simpkins16l and 
Adlington16i have demonstrated the successful application and efficiency of these 
transformations for PPAP synthesis.  Here, we outline biomimetic PPAP syntheses by the 
groups of George, Simpkins, and Adlington.  
     Following the seminal publication by Porco and Mitasev to access unique PPAP 
scaffolds via radical cyclizations (Scheme 1.19A),16h Simpkins16l and Adlington16i 
independently achieved biomimetic total syntheses of ialibinones A and B (Schemes 
1.19B and C).  Simpkins and Adlington both demonstrated an efficient four-step 
synthesis of these natural products involving a dearomative methylation of 
acylphloroglucinol 100 to provide 101 in good yield.  A total synthesis of ialibinones A 
(102) and B (103) were accomplished via one-electron oxidation through the use of 
Mn(OAc)3/Cu(OAc)2 (Simpkins) or PhI(OAc)2 (Adlington).  Furthermore, Adlington also 
demonstrating that a total synthesis of (±)-hyperguinone B (104) could be achieved under 
the same conditions in the presence of TEMPO resulting from a 6π-electrocyclization of 
an in situ-generated o-quinone methide intermediate that derives from hydride abstraction 
of 101 by a TEMPO cation.16i  The synthetic work outlined in Scheme 1.19 represents 
the first application of radical-based cyclizations for PPAP synthesis.   
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     Sequential radical cascade cyclizations of dearomatized acylphloroglucinols were 
demonstrated by George and coworkers leading to rapid biomimetic syntheses of 
garcibracteatone, 5-epi-garcibracteatone, doitunggarcinone A, and 5-epi- 
Scheme 1.19   Biomimetic Syntheses of Ialibinones A and B as well as Hyperguinone B. 
 
doitunggarcinone A (Scheme 1.20).  The syntheses began from a known 
acylphloroglucinol 31, previously employed by Porco and coworkers for the synthesis of 
clusianone and hyperibone K.16c,16g  Dearomative alkylation of 31 with iodides 113 and 
112 enabled the respective formation of 106 and 109. Oxidative radical cyclization of 
compound 109 induced by Mn(OAc)3 and Cu(OAc)2 led to the production of 
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oxidation of compound 106 led to radical cyclization provided garcibracteatone (108) and 
5-epi-garcibracteatone (107), which are alkene isomers of 110 and 111. 
 
Scheme 1.20  Syntheses of garcibracteatone, 5-epi-garcibracteatone, doitunggarcinone A, 
and 5-epi-doitunggarcinone A. 
 
1.3 Current and Future Outlook 
     In the previous sections, we have outlined previous syntheses of PPAP-derived natural 
products, and in doing so illustrated how the early syntheses of PPAPs have inspired 
other research groups to design novel, innovative, and highly efficient syntheses of these 
complex natural products. For example, Ting and Maimone recently developed the most 
efficient route to hyperforin (9) utilizing a 10-step strategy that highlights a completely 
novel approach for the construction of these natural products (Scheme 1.21).33b  Indeed, 
the efficiency of this synthesis is not only reflected in the low-step count and high yields, 
but also in that C-C bond forming and rearrangement processes are involved in more than 

































































     Their synthesis began with conjugate addition of (3-methylbut-3-en-1-yl) cuprate to 2-
methylcyclopentenone 100a and alkylation with homoprenyl iodide to afford 101b in 3:1 
d.r. following acid-catalyzed isomerization of the 1,1-dibstituted olefin.  Subsequent 
alkylation with prenyl bromide then provided 102c which enabled construction of the cis-
5/6-fused bicycle 103d as a single diastereomer following a formal C-acylation/ring 
annulation.  This novel diketene annulation is a higher-oxidation state variant of the 
Robinson annulation and will likely play an important role in the construction of 5/6-
fused bicyclic ring systems analogous to diketone 103d.  Methylation with TMSCH2N2 
(96 %) provided a 1:1 mixture of 104e and 105f that were easily separable, and undesired 
104e could be hydrolyzed to regenerate diketone 103d.  After significant 
experimentation, an oxidative rearrangement mediated by PhI(OAc)2 was implemented 
via intermediate 106g to provide bicyclo[3.3.1]nonane 107h.  For the first time, a novel 
strategy to install the bridgehead acyl group along with the vinyl prenyl function was 
implemented.  They utilized chloride 108i to enable bridgehead anion generation and 
substitution to provide 109j.  It is believed that the inductive electron withdrawing effects 
of the chloride contributed to stabilization of the bridgehead anion leading to the highest 
yield yet reported for this type of substitution. The chloride was then converted to a 
cuprate with lithium 2-thienylcyanocuprate followed by alkylation with prenyl bromide, 
and the resulting methyl hyperforin was demethylated with LiCl and DMSO at 120 oC to 
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     Many more possibilities remain that can make the syntheses of these compounds even 
more efficient, and Chapters 2, 4, and 5 will outline our biomimetic strategies that have 
simplified the syntheses of both type A and B PPAPs.  Furthermore, additional  
biomimetic work by Porco, Simpkins, Adlington, and George have shown that radical 
and cationic cyclizations can be implemented to rapidly access these natural products.  
The following chapters will focus on our efforts to circumvent the previously reported 
challenges by Marazano18 and Couladouros16d (described in Section 1.1.2) associated 
with utilizing biosynthetic intermediate 33 to access PPAPs (Scheme 1.22). 
 
Scheme 1.22  The Challenge of Accessing C-Cyclized Type A and B PPAP Natural 
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 Asymmetric, Stereodivergent Synthesis of (-)-
Clusianone Utilizing a Biomimetic Cationic Cyclization 
2.1 Introduction   
 
Figure 2.1  Representative PPAP Natural Products (For a more complete list of PPAPs, 
see Figure 1.1). 
 
     As previously described in section 1.1.1, (+)-clusianone, nemorosone, and hyperforin 
(Figures 1.1 and 2.1) are members of the class of natural products known as 
polyprenylated polycyclic acylphloroglucinols (PPAPs)1 that contain a 
bicyclo[3.3.1]nonane-2,4,9-triketone core.  (+)-Clusianone (1), a type B PPAP as 





         











1976 from the bark of Clusia congestiflora.3a  Since the early 1990’s, there have been a 
handful of additional isolation and identification studies that address this molecule’s 
structure.4  
     A more detailed account of the bioactivies of these compounds is provided in section 
1.1.3, but we will briefly review highlights of bioactivities here.  It was not until 20 years 
after its initial isolation that reports began to emerge on clusianone’s 
bioactivity.2a,4c,5a,11e,23 In 2005, the compound was shown to possess notable anti-HIV 
activity (EC50 = 20 nM) by inhibiting the gp120-sCD4 viral-receptor interaction 
suggesting its potential for preventing HIV infection.4c  Clusianone’s chemopreventative 
properties2a,11e are thought, in part, to arise from its ability to inhibit histone 
acetyltransferase (HAT) enzymes. Nemorosone (2), an isomeric type A PPAP as 
indicated by the bridgehead substituted acyl group α to a quaternary center,1f has notable 
anticancer properties, in part, due to its ability to activate HAT enzymes2a,23a,c and also 
serve as a protonophoric mitochondrial uncoupler.23d Hyperforin (3), a type A PPAP 
found in St. John’s Wort, is used to treat depression and possesses anti-inflammatory and 
antibiotic properties.1,6  Given the great diversity of bioactivities attributed to small 
structural changes among these PPAPs, it is not surprising that these compounds have 
become popular targets for synthetic chemists.7,16a,c,19,27-29,31b For example, elegant 
asymmetric syntheses of clusianone have been reported by the Simpkins,7 Coltart,29 and 
Plietker30 groups. 
     Structurally, clusianone (1) and nemorosone (2) possess synthetically challenging 




three stereocenters that derive biosynthetically from the common cationic intermediate 33 
(Scheme 2.1, also Scheme 1.6).15c   
 
Scheme 2.2  Biosyntheses of (+)-clusianone (1) and nemorosone (2).  
     Research groups addressing the synthesis have been largely unsuccessful at achieving 
similar cationic cyclizations to access the fully functionalized cores of type A and B 
PPAPs.  Such cyclizations have been reported only in the case of systems lacking the full 
functionality of the natural products.16a,c,d,e,f,g,18-21  For example, Marazano and coworkers 
could not isolate C-cyclized products via cationic intermediates analogous to 33 (see 
section 1.1.2 for a more in-depth discussion).18,16n In a study by Couladouros and 
coworkers,16d it was shown that unconjugated tertiary carbocations could not be cyclized 
to the [3.3.1]-bicyclic core of 9 (see section 1.1.2 for a more in-depth discussion).  The 
















































transition state and from the steric demands of forming a hindered carbon bond between 
two sterically congested quaternary carbons. 
     In line with our group’s interest in achieving rapid syntheses to PPAP natural products 
and derivatives,16c,e,f,g,h we hoped to develop a route to 1 and/or 2 possessing the brevity 
and flexibility necessary for SAR studies.  In this chapter, a stereodivergent, asymmetric 
synthesis of (-)-1 in only six steps from 5-methoxyresorcinol is outlined employing the 
first cationic cyclization to access the fully functionalized core of (-)-clusianone.16n  
Additionally, we reveal the selective synthesis of five novel architectures from the key 
cyclization substrate.  Furthermore, the tendency of PPAP natural products to bind to 
silica and form salts has prevented the production of ample quantities of enolic PPAPs 
and dearomatized acylphloroglucinols in previous syntheses (evidence for this is also 
provided in section 2.4).16a-l Therefore, to overcome this problem, we also developed a 
general method for the purification of dearomatized acylphloroglucinols and enolic 
PPAPs by extraction with aqueous base, which leads to precipitation of pure potassium 
salts.  All salt products can be converted to their protonated, tautomeric forms by 
treatment with 1M HCl.  This simple and convenient extractive isolation method 






Figure 2.2  Retrosynthetic Analysis for the PPAP Core (-)-112. 
 
     Inspired by the efficiency of their biosyntheses (Scheme 2.1), we considered the 
synthesis of 1 and/or 2 from 83 (Figure 2.1), a common intermediate employed in our 
group’s total syntheses of both 7-epi-nemorosone (10)16f and plukenetione A (90) [cf 
Scheme 1.17].16e As one possibility, we envisioned that compound (-)-112 could be 
obtained via cationic cyclization of dearomatized substrate 113 involving protonation of 
the 1,1-disubstituted olefin to generate a tertiary carbocation at C8 followed by 
intramolecular enol attack at C3 (Figure 2.1). 
     At the outset of our investigation, we had three principal concerns regarding the 
success of a protonative, cationic cyclization to access bicyclo[3.3.1]nonane core (-)-112: 
1) control of O- vs. C- selectivity in the cyclization, 2)  whether the O-methyl protecting 






































rearomatize under acidic conditions given reports that similar dearomatized intermediates 
have undergone rearomatization under acidic conditions.18,20a   
2.2 Results  
     We began our study by developing an improved synthesis to acylphloroglucinol 83 
which was previously prepared in 20 % yield from 115 by direct aromatic substitution.16h  
After optimization experiments, we discovered that selective O-allylation of 115 
proceeded in 71 % yield which was followed by a thermolytic Claisen rearrangement to 
produce 83 (92 %) on a multigram-scale.  We developed an improved, modified 
procedure to prepare chiral, racemic alcohol 116 in a single pot in 93 % yield (Scheme 
2.2).  Triflation of 116 with triflic anhydride afforded 114 that was used in situ by 
transferring the solution directly into a solution of 83. 
 
Scheme 2.2  Synthesis of chiral, racemic triflate 114. 
     Alkylative dearomatization of 83 proved challenging in initial studies as little was 
known regarding factors that may control C- vs. O-selectivity for dearomatization of 
phloroglucinol substrates.34   Due to the lack of literature precedent for alkylative 




















carry out a systematic evaluation of reaction conditions.  Table 1 shows how the base 
counterion plays a critical role in preventing undesired O-alkylation.  The lithium 
counterion of the phenolate derived from 83 is likely tightly bound to the phenolate  
Table 2.1 Optimizing C- vs. O-selectivity of the alkylative dearomatization to 113. 
 
a Isolated yield of product after silica gel chromatography. b Reaction was carried out in THF:benzene 
(3:1). KHMDS = potassium bis(trimethylsilyl)amide; NaHMDS = sodium bis(trimethylsilyl)amide; 
LiHMDS = lithium bis(trimethylsilyl)amide. 
oxygen thereby preventing significant O-alkylation.35,36   Not surprisingly, KHMDS 
produced only O-alkylation products as the relatively non-coordinating potassium 
counterion exposes a naked oxygen enolate.  Furthermore, a solvent screen revealed that 
the reaction does not proceed to full conversion in THF and is very slow in toluene; 
optimal results were achieved with a combination of THF/toluene (3:1, 0.057 M). 
     We hypothesize that lithium coordination to both the sulfonate and enolate oxygen 
helps to facilitate C-alkylation.37  In that regard, it is proposed that lithium coordinates 
tightly to the phenolate oxygen and the S=O oxygen of the sulfonate ester to form either a 













0 oC, 15 min
1.3:1 d.r.
Entry Base Yielda 
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Figure 2.3   Lithium Coordination May Facilitate C-Alkylative Dearomatization. 
 
     With ample quantities of the dearomatized product 113 in hand, we evaluated 
conditions for cationic cyclization to 112 (Table 2.2).  Utility of biomimetic cationic 
cyclization to achieve bond formation at C3 was revealed after investigating >70 different 
reaction conditions consisting of various Brønsted acids, Lewis acids, solvents, 
concentrations, temperatures, and work-up variations.  Over 13 different products were 
isolated, five could be obtained selectively depending on the conditions,18,20a,38 and only 
formic acid successfully formed a C-cyclized adduct.  Highly polar solvents, such as 
TFA, HFIP, CH3NO2, and CH3CN, favored the O-cyclized Cope rearrangement products 
117 and 119.  However, the unique combination of LiBr and p-TsOH39 in CH2Cl2 
provided clean formation of 118 without Cope rearrangement. Using the latter 
combination in EtOAc, acetone, and 1,4-dioxane also afforded 118 but in significantly 
lower yields.  Rearomatized product 120 was obtained in 97% yield under similar 
conditions in CH2Cl2 at slightly higher temperatures (Table 2.2, entry 7).  We presume 

























Table 2.2 Conditions Favoring Unique Cationic Cyclization Products. 
 
















2 p-TsOH (10 equiv) 
LiOTf (10 equiv) 
HFIP 
(0.015 M) 
50 oC, 12 h 
 
89 
3 TFA (0.14 M) Neat 





4 p-TsOH (10 equiv) 
LiBr (10 equiv) 
CH3NO2 
(0.015 M) 
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a Isolated yield of product after silica gel chromatography. b Product 117 also produced in 34 % yield. c 








































sulfonic acid such that cyclization is observed at temperatures below -40 oC. 
     In rationalizing the various O-cyclization outcomes, we observed that pyranodienone 
117 could be demethylated to afford product 119 (79 %, Scheme 2.3).  Rearomatization 
to product 120 proceeds strictly from intermediate 118, while 119 is obtained directly 
from demethylation of O-cyclized Cope product 117. In all cases, demethylation and 
Cope rearrangement occurred after cyclization to 118.  Based on these observations, we 
propose a mechanism that accounts for the formation of O-cyclized products 117-120 
(Scheme 2.3).  In contrast to the results described above, neat formic acid uniquely led to 
diastereoselective cyclization of 113 which proceeded to afford both allyl clusianone 112 
(30 %) and the Cope product 117 (34 %, Table 2.2, entry 1).  
     Alkylative dearomatization of 83 utilizing the enantioenriched triflate (-)-(R)-114 
(Figure 2.1)40 led to the production of (-)-(S,S)-113 and (+)-(R,S)-113 as a 1.3:1 mixture 
of diastereomers which were separated by preparative thin layer chromatography.  When 
each was individually subjected to neat formic acid, diastereomer (-)-(S,S)-113 converted 
in a stereodivergent manner to (-)-allyl clusianone (-)-112 (72 %) and Cope product (-)-
(S)-117 (13 %), while diastereomer (+)-(R,S)-113 exclusively afforded (-)-(S)-117 (84 %, 
Scheme 2.4).  Interestingly, if formic acid-d2 was used, Cope rearrangement was not 
observed for (-)-(S,S)-113 and exclusive formation of deuterated (-)-allyl clusianone 112 
was observed (please refer to mechanistic studies section C in the experimental section 
2.4 for corresponding spectra and additional details).  (-)-Clusianone (-)-1 was obtained 
following cross metathesis of (-)-112;  the yield of 46 % was improved to 81 % when 





Scheme 2.3 Mechanistic rationale for O-cyclized products. a) LiBr, p-TsOH, CH2Cl2, -40 
oC, 30 h, 55 %; b) formic acid, 10 oC to r.t., 12 h, quant.;  c) LiBr, p-TsOH, CH2Cl2, -25 
oC, 30 h, 97 % d) LiBr, p-TsOH, CH2Cl2, r.t. 5 min, 79 %. 
 
selectively converted into their corresponding O-cyclized adducts, (R,S)-118 and (S,S)-
118, in reasonable yields utilizing LiBr/p-TsOH at -40 oC (Scheme 2.4). Additionally, we 
observed that C-cyclization proceeded less efficiently in the absence of an enol methyl 
ether at C4 providing decomposition and small quantities of O-cyclization products 



























































c) formic acid,   
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     As formic acid was the only condition out of >70 others that led to C-cyclization 
products, it seemed likely that it may mediate cyclization via a unique mechanism (vide 
infra).41  To simplify our analysis of this mechanism and the observed stereodivergency, 
we considered the possibility that one tautomer of methyl enol ether 113 might be 
responsible for the majority of C-cyclization to allyl clusianone 112.  We sought to test 
this hypothesis by first methylating 113 with TMSCHN2 which was followed by 
treatment of the resulting mixture of permethylated isomers 122 and 123 with formic acid 
(Scheme 2.6). Indeed, methyl ether (±)-124 was the only clusianone-type product isolated 
from the reaction in significant yield thereby indicating that cross-conjugated isomer 123 
was largely responsible for C-cyclization. Only O-cyclization products derived from 
product 122 were isolated from the reaction.  It should be noted that compound 124 was 
structurally confirmed after prenylation employing olefin metathesis as detailed in the 
experimental section of this chapter.  
 
Scheme 2.6 Cross-Conjugated Isomer 123 is Largely Responsible for C-cyclization. 
 
     Analyzing the cross-conjugated tautomer of 113, we determined that the observed 
stereodivergent outcome for the cyclization to the clusianone core may be governed by 





















cations 125b/126b, deriving from (-)-(S,S)-113, between the allyl group and the 
cyclohexadiene ring system likely cause the equilibrium to favor cations 125a/126a 
(Scheme 2.7).  In our rendering in Scheme 2.7, the cations are proximal to the 
nucleophilic carbon at C3 in 125a/126a, we observe dominant formation of the C-
cyclized product. The preference for O-cyclization in the case of (+)-(R,S)-113 may be  
 
Scheme 2.7 Mechanistic Rationale for Observed Stereochemical Divergency via 
Analysis of the Cross-Conjugated Tautomer of 113. 
 
rationalized by close proximity of the cation to the enol depicted in the sterically favored 
conformation 126b (Scheme 2.7), while 126a experiences steric interactions that would 
lead to a more hindered transition state for C-cyclization. The destabilizing interactions 

































































the equilibrium to favor 126b.  Hence, 126b should react to give O-cyclization as the 
preferred stereodivergent outcome for diastereomer (+)-(R,S)-113.   
     Based on evidence provided by UPLC-MS (vide infra), findings in the literature (vide 
infra), and supportive mechanistic experimentation (vide infra), we proposed that formic 
acid may facilitate the rare C-cyclization to clusianone core (-)-112 in two ways: 1) by 
stabilization of the carbocation in the form of a tight ion pair illustrated in Scheme 2.8  
 
Scheme 2.8   Reaction of Formic Acid with Trisubstituted Alkene 127. 
 
thereby providing time for the carbocation of (-)-(S,S)-113 to react through the sterically 
favored conformation 125a, and 2) by formate addition to the C2 ketone of (-)-(S,S)-113 
rendering the enol at C3 more electron rich (Scheme 2.9).  
     Contrary to other carboxylic acids (e.g. acetic acid), formic acid can add efficiently to 
1,1-disubstituted olefins under ambient conditions42 which we have demonstrated for the 














































acid, the formic acid was removed in vacuo providing tertiary formate ester 129 that 
likely resulted from the formation of a stabilized ion pair 128 in solution. Similarly, in the 
cyclization of (-)-(S,S)-113, formic acid may stabilize the carbocation via ion pair 
formation decreasing carbocation reactivity and thereby increasing selectivity for C-
cyclization through the sterically favored conformation 125a. 
     It is also known that formic acid can add to electron-deficient and strained bridgehead 
ketones (Scheme 2.9).43   For example, Schaefer isolated the strained bridged hemiketal 
132 following multiple distillations over a silica-steric acid column, and further 
characterization of 132 was accomplished by IR and elemental analysis.43a  Moreover, 
Noe and coworkers revealed that formic acid can add to hexfluoroacetone 133 to form 
hemiketal 134 at -90 oC utilizing low-temperature NMR.43b  In comparison, if we  
 
Scheme 2.9  Formate Addition to the C2 Ketone of 113 May Enable Selective 
Cyclization to the Clusianone Core by Rendering the C3 Enol Ether more Electron Rich. 
Alternative 2: Formate Addition Renders C3 More Nucleophilic.

























































consider the possibility of formate addition to the C2 ketone of (-)-(S,S)-113 to form 
carbocation 130 (Scheme 2.9), this may render C3 of 130 more electron-rich than C3 of 
125.   
 
Scheme 2.10 UPLC Experiments Suggest Formate Adducts are likely Formed in the 
Reaction Mixture Prior to Product Formation. 
 
     Evidence for the proposed formate adduct intermediates in our cyclizations were 
obtained from Ultra High Performance Liquid Chromatography (UPLC) measurements in 
the reaction medium (98 % formic acid) at various time intervals for both (-)-(S,S)-113 
and (±)-(S,S)-123.  The [M+H+] of the observed reaction components in the Evaporative 
Light Scattering Detector (ELSD) trace for (-)-(S,S)-113 corresponded to monoformate 
and tetraformate adducts in the first 30 minutes of reaction; this indicated possible 
addition to the C2 and/or C13 ketones in addition to the 1,1-disubstituted double bond 



























































details).  Additionally, for the case of substrate (±)-(S,S)-123, the formation of a 
monoformate adducts (135, 136, and/or 137) was observed in the ELSD trace (Scheme 
2.10). The formate adduct peaks corresponding to 135, 136, and/or 137 gradually 
disappeared as the reaction proceeded to completion.  For both substrates (-)-(S,S)-113 
and (±)-(S,S)-123, the disappearance of all formate intermediates was observed after 24 h 
with only product remaining (product (-)-112 in the case of substrate (-)-113; product (±)-
124 in the case of substrate (±)-123]. 
     We also synthesized the triallylated substrate 138, which lacks a 1,1-disubstituted 
olefin and is therefore unable to cyclize in the presence of formic acid. Examination of 
the UPLC data for compound 138 in neat formic acid provided additional evidence that 
formate addition to the C2 or C13 ketones may be occurring in compounds analogous to 
123 (Scheme 2.10).  The [M+H+] of the observed reaction components in the ELSD trace 
revealed a mass corresponding to monoformate adduct 139 after 24 h of reaction time. 
This suggested that formate may be adding to the C2 or C13 ketones of 138 in neat 
formic acid.  The data provided by the UPLC experiments support our hypothesis that 
formate addition to the C2 ketone of (-)-(S,S)-113 and (±)-(S,S)-123 may contribute to the 
unique ability of formic acid to enable C-cyclization to the clusianone core.  
     Other biomimetic cyclizations uniquely mediated by formic acid have been reported.41 
In Scheme 2.11 we show four examples by Trost, Andersen, Johnson, and Heathcock.  
For example, Trost and coworkers found after extensive experimentation that only formic 
acid could mediate the cyclization of alcohol 135a to furan 137c that served as a key 




biomimetic cyclization en route to liphagal that was uniquely mediated by formic acid.41b  
Interestingly, after initial cyclization to cyclohexene isomers 139e, further cyclization to 
the desired 8/6-fused tetracycle 140f occurred after stirring for four weeks in formic acid.  
Formic acid may be stabilizing the cation generated from 139e leading to slow equilibria 
in favor of the thermodynamic cyclization product.  Johnson and coworkers studied 
biomimetic polyene cyclizations41c-g in formic acid and discovered that the cyclization of 
polyene 141g in formic acid led to the production of 142h and 143i in 94 % yield en 
route to (±)-fichtelite (144j) (Scheme 2.11).41d,e  Heathcock and coworkers also reported 
a unique cyclization of allylic alcohol 145k in 98 % formic acid providing exclusive 





Scheme 2.11 Biomimetic Cyclizations in Formic Acid. 
 
      To conclude our study, we successfully demonstrated that our synthesis of (±)-1 
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scale.  As previously noted, the difficulty associated with synthesizing large quantities of 
PPAP natural products derives from their tendency to bind to silica and form salts18 (see 
section 2.4 for silica-gel-induced formation of a clusianone calcium salt). Our synthesis 
of racemic clusianone (±)-1-K utilized a general purification strategy for dearomatized 
phloroglucinols and enolic PPAPs (see section 2.4).  The synthesis of acylphloroglucinol 
83 and the subsequent alkylative dearomatization were achieved on a 5.0-gram scale to 
provide (±)-(S,S)-113 and (±)-(R,S)-113 (30 - 37 % over four steps, 1.3:1 d.r., Scheme 
2.12).  Without the need to separate diastereomers, the key cyclization in formic acid was 
conducted on scales up to two-grams where products were separated by basic extraction 
to provide the potassium salt of allyl clusianone (±)-112 (26 – 32 %, 61 % from (±)-(S,S)-
113) as a single isomer. Olefin metathesis proceeded in 81 % yield using the Grubbs 2nd 
generation catalyst, which was followed by basic workup to isolate more than 210 mg of 
racemic clusianone potassium salt (±)-1-K.  All salt products could be converted to their 
conventional protonated, tautomeric forms via simple treatment with 1 M HCl followed 





Scheme 2.12 Large Scale Synthesis of (±)-Clusianone Potassium Salt [(±)-1-K].  
 
2.3 Conclusion and Outlook 
     In conclusion, we have developed a scalable, asymmetric, and stereodivergent 
synthesis of (-)-clusianone (-)-1 in only six steps from commercial starting materials.  
Protonative cationic cyclization of 113 allowed selective access to five novel 
architectures.  Mechanistic studies are described that underscore the ability of formic acid 
to mediate a unique biomimetic, cationic cyclization to access allyl clusianone 112.  
Finally, we developed a general purification strategy for dearomatized phloroglucinols 
and type B PPAP derivatives, rendering our entire synthesis column-free from 
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2.4 Experimental Section 
General Information 
1H NMR spectra were recorded at 400 MHz or 500MHz at ambient temperature with 
CDCl3, MeOD, or CD3CN (Cambridge Isotope Laboratories, Inc.) as solvents unless 
otherwise stated.  Data for 1H NMR are reported as follows: chemical shift, integration, 
multiplicity (app = apparent, br = broad, par obsc = partially obscure, ovrlp = overlapping, 
s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet) and coupling constants.  
13C NMR were recorded at 100 MHz or 125.0 MHz at ambient temperature with the same 
solvents unless otherwise stated.  Chemical shifts are reported in parts per million relative 
to CDCl3 (1H, δ 7.26; 13C, δ 77.0), C6D6 (1H, δ 7.16), DMSO-D6 (1H, δ 2.50; 13C δ 39.4), 
CD3OD (1H, δ 3.31, 4.78; 13C, δ 49.3) or CD2O2 (1H, δ 10.35; 13C δ 165.5).  All 13C NMR 
spectra were recorded with complete proton decoupling.  Infrared spectra were recorded 
on a Nicolet Nexus 670 FT-IR spectrophotometer.  Analytical testing for magnesium, 
calcium, and aluminum was carried out by Galbraith Laboratories, Inc.  High-resolution 
mass spectra were obtained in the Boston University Chemical Instrumentation Center 
using a Waters Q-TOF mass spectrometer.  Melting points were recorded on a Mel-temp 
(Laboratory Devices).  Analytical thin layer chromatography was performed using 200-
400 mesh silica gel (Scientific Absorbents, Inc.).  Yields refer to chromatographically 
and spectroscopically pure materials, unless otherwise stated.  All reactions were carried 
out in oven dried glassware under an argon atmosphere unless otherwise noted.  




Performance Liquid Chromatography) with a Binary solvent manager, SQ mass 
spectrometer, Water 2996 PDA (PhotoDiode Array) detector, and Evaporative Light 
Scattering Detector (ELSD).  An Acquity UPLC BEH C18 1.7 µm column was used for 
analytical UPLC-MS.  HPLC grade tetrahydrofuran, methylene chloride, diethyl ether, 
toluene, acetonitrile, and benzene were purchased from Fisher and VWR and were 
purified and dried by passing through a PURE SOLV® solvent purification system 
(Innovative Technology, Inc.).  Other ACS grade solvents for chromatography were 
purchased from Clean Harbors. All other reagents and relevant catalysts were purchased 
from Sigma-Aldrich, Acros, Alfa Aesar, and Strem Chemicals.  Zinc bromide was fused 
using a torch under high vacuum prior to dissolution in diethyl ether.  Magnesium Iodide 
(98% from Sigma Aldrich) was dried in a vacuum oven overnight at 110 oC.  
Diisopropylamine was distilled over KOH before use. Phloroglucinol was purchased 
from Sigma-Aldrich.  Optical rotations were recorded on an AUTOPUL III digital 
polarimeter at 589 nm and are recorded as [α]22D  (concentration in grams/100 mL 
solvent).  A Lux® 5u Cellulose-2 (Phenomenex, 150 x 4 60 mm I.D.) column was used 
for enantiomeric excess determination.    Electronic 1H and 13C NMR spectra of methyl 









Experimental Procedures and Compound Characterization 
 
 
5-Methoxyresorcinol 140: To an oven-dried 2-L round-bottom flask fitted 
with a magnetic stir bar was added 105 (30.0 g, 238 mmol) and 347 mL of 
methanol under an argon atmosphere.  Concentrated H2SO4 (50 mL, 933 
mmol) was added dropwise with an addition funnel over the course of 30 minutes.  The 
flask was then fitted with a reflux condenser and heated to 70 oC for 48 h with occasional 
cooling to room temperature to check reaction progress by TLC analysis.  Methanol was 
removed by concentration in vacuo and the resulting liquid residue was poured into 500 
mL of water.  The aqueous layer was extracted with CH2Cl2 (3 x 250 mL) and was 
further extracted with EtOAc (3 x 500 mL).  The EtOAc extracts were then dried over 
Na2SO4, filtered, and concentrated in vacuo.  The CH2Cl2 extracts were separately dried 
over Na2SO4, filtered, and concentrated in vacuo.  Purification on silica gel (10 – 50 % 
EtOAc/hexanes) provided 17.5 g (53 %) of compound 140 as a white solid.  
Spectroscopic data for 5-methoxyresorcinol (140) were found to be identical with those 
reported in the literature.44  
(2,6-Dihydroxy-4-methoxyphenyl)(phenyl)methanone 115: (Scheme 








H2SO4, MeOH AlCl3, BzCl





48 h, 70 oC
53 % 71 %
TBAI, K2CO3
Br














was added compound 140 (19.4 g, 138.4 mmol).  The flask was charged with CH2Cl2 
(276 mL) under an argon atmosphere.  The solution was cooled to 0 oC in an ice water 
bath.  Aluminum chloride (37.3 g, 280 mmol) was added in three portions which was 
followed by dropwise addition of benzoyl chloride (16.26 mL, 140 mmol) over 5 
minutes.  The reaction mixture was slowly warmed to room temperature over the course 
of 3 h without removing the ice water bath.  Once at room tempertature, the reaction 
mixture was concentrated over the course of an hour while stirring over a slow stream of 
nitrogen until it became viscous.  Ice (~50 g) was then added to the viscous residue until 
the quench was complete.  The crude product mixure was then poured into 1N HCl (150 
mL) and extracted with EtOAc (3 x 100 mL).  The combined organic layers were washed 
with water (150 mL), brine (150 mL), dried over Na2SO4, and concentrated in vacuo.  
Purification by silica gel chromatography (10 – 25 % EtOAc in hexanes) provided a solid 
that was subsequently dissolved in CHCl3 (50 mL). Hexanes (300 mL) was then added 
and the flask was vigorously shaken to provide 23 g (69 %) of 115 as a yellow solid after 
filtration.  The filtrate contained additional impure product.  Spectroscopic data for 
acylphloroglucinol 115 were found to be identical with those reported in the literature.16h 
 
 (2,6-Bis(allyloxy)-4-methoxyphenyl)(phenyl)methanone 141: 
(Scheme 2.11) An oven-dried 250-mL glass pressure tube fitted 
with a stir bar (7 cm x 1 cm) was charged with 115 (8.0 g, 32.7 
mmol) and K2CO3 (13.6 g, 98.3 mmol).  The tube was then fitted with a septum and 








stirred for 10 minutes. Tetrabutylammonium iodide (9.07 g, 24.6 mmol) was added in a 
single portion followed by 4 mL of additional acetone to rinse the sides of the tube.  After 
flushing the tube with argon for 30 seconds, allyl bromide (6.29 mL, 74.4 mmol) was 
added in one portion via syringe.  The septum was removed, and the tube was quickly 
sealed and heated to 75 oC for 16 h.  The reaction was allowed to cool to room 
temperature before adding water (200 mL) with stirring until all K2CO3 dissolved.  The 
aqueous solution was then poured into a separatory funnel and extracted with CH2Cl2 (3 x 
200 mL).  The combined organic layers were washed with water (100 mL), brine (100 
mL), dried over Na2SO4, filtered, and concentrated.  Purification by silica gel 
chromatography  (2 % – 15 % EtOAc/hexanes) afforded 7.54 g (71 %) of 141 as a viscous 
yellow-green oil. 141: Rf = 0.43 (15 % EtOAc/Hex); IR νmax 3082, 3023, 2920, 2848, 
1668, 1604, 1582, 1462, 1448, 1433, 1421, 1364, 1313, 1268, 1222, 1196, 1164, 1139, 
1106, 1031, 1000, 953, 919, 814, 750, 723 cm-1;  1H NMR (500 MHz, CDCl3) δ 7.83 – 
7.86 (m, 2H), 7.49 – 7.53 (m, 1H), 7.38 – 7.42 (m, 2H), 6.16 (s, 2H), 5.78 (ddt, J = 17.3, 
10.6, 5.0 Hz, 2H), 5.12 (ddd, J = 17.3, 3.2, 1.7 Hz, 2H), 5.09 (ddd, J = 10.6, 3.2, 1.7 Hz, 
2H), 4.44 (ddd, J = 5.0, 1.7, 1.7 Hz, 4H), 3.82 (s, 3H);  13C NMR (125 MHz, CDCl3) δ 
194.6, 162.1, 157.8, 138.6, 132.7, 132.6, 129.3, 128.2, 117.0, 111.9, 92.3, 69.2, 55.4;  
HR-MS: m/z Calcd. for C20H20O4 [M+H+]:  325.1440 , Found 325.1432.  
 
 (3,5-Diallyl-2,6-dihydroxy-4-methoxyphenyl)(phenyl)methanone 
83: (Scheme 2.11) To a 125-mL glass pressure tube was added a 








Argon was bubbled through the solution for 2 – 3 h.  The pressure tube was then sealed 
and heated to 210 oC for 48 h.  The solution was then cooled to room temperature and 
was added directly to a short silica plug, which was initially flushed with hexanes to 
remove 1,2-dichlorobenzene.  The product was eluted with 5 % EtOAc/hexanes to obtain 
6.22 g (92 %) of 83 as a yellow crystalline solid.  83: Rf = 0.40 (20 % EtOAc/hexanes); 
m.p. 50.0 – 55.0 oC (CH2Cl2); IR νmax 3512, 3081, 2978, 2945, 2840, 1617, 1597, 1449, 
1423, 1318, 1293, 1218, 1201, 1125, 1014, 914 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.53 
(s, 2H), 7.69 – 7.65 (m, 2H), 7.59 – 7.54 (m, 1H), 7.50 – 7.45 (m, 2H), 6.02 (ddt, J = 
17.1, 10.1, 5.9 Hz, 2H), 5.05 – 5.12 (m, 4H), 3.78 (s, 3H), 3.40 (ddd, J = 5.9, 1.8, 1.7 Hz, 
4H); 13C NMR (125 MHz, CDCl3) δ 198.9, 163.6, 157.7, 140.0, 136.4, 132.2, 128.7, 
128.2, 115.2, 112.1, 107.5, 62.1, 27.9. HR-MS: m/z Calcd. for C20H20O4 [M+H+]: 
325.1440, Found 325.1434.  
 
 
2-(Prop-1-en-2-yl)pent-4-en-1-ol 116: (Scheme 2.2)  To an oven-dried 1-L round-
bottom flask was added freshly distilled i-Pr2NH (5.16 mL, 36.8 mmol) and THF (88.4 
mL).  The solution was cooled to 0 oC using a dry ice/acetone bath and n-BuLi (14.8 mL, 
2.5 M in THF) was added dropwise over 15 minutes.  The reaction was stirred at 0 oC for 
18 minutes and was then cooled to -78 oC.  A solution of methyl 3,3-dimethylacrylate 
(4.3 mL, 35.05 mmol) in THF (41.6 mL) was added dropwise over 30 minutes, and the 












dropwise and the reaction mixture was allowed to warm to 0 oC over the course of 15 h in 
a dry ice/acetone bath.  Lithium aluminum hydride (2.0 g, 52.57 mmol) was added in 
three portions and stirred for 3 h.  Water (8 mL) was added in a dropwise fashion at a rate 
of 1 drop/30 sec followed by addition of a saturated solution of Rochelle’s salt (111 mL).  
The mixture was vigorously stirred for 12 h and then extracted with Et2O (3 x 150 mL).  
The combined organic extracts were washed with water (20 mL) and brine (50 mL), dried 
(MgSO4), and concentrated in vacuo.  Purification by distillation (b.p. 140 oC, oil bath at 
230 oC) afforded 4.13 g (93 %) of 116 as a clear oil.  After product 116 was converted to 
benzoylated derivate 116a, the enantiomers were separated using 100 % hexanes and a 
Lux® 5u Cellulose-2 (Phenomenex, 150 x 4 60 mm I.D.) column.  116:  Rf = 0.58 (33 % 
EtOAc/hexanes, cerium ammonium molybdate stain); IR νmax 3364, 3076, 2975, 2927, 
2876, 1642, 1443, 1376, 1041, 994, 912, 892 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.74 
(dddd, J = 17.1, 10.2, 7.0, 7.0 Hz, 1H), 5.04 (ddd, J = 17.1, 2.8, 1.5 Hz, 1H), 4.99 (dddd, 
J = 10.2, 2.8, 1.1, 1.1 Hz, 1H), 4.93 (dt, J = 3.4, 1.5 Hz, 1H), 4.82 – 4.80 (m, 1H), 3.56 
(dd, J = 10.7, 5.6 Hz, 1H), 3.51 (dd, J = 10.7, 7.8 Hz, 1H), 2.34 (ddd, J = 13.5, 7.8, 5.6 
Hz, 1H), 2.19 – 2.10 (m, 2H), 1.69 (s, 3H), 1.57 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 
144.8, 136.3, 116.0, 113.4, 63.5, 49.3, 34.1, 19.4. 
 
 (-)-(R)-2-(Prop-1-en-2-yl)pent-4-en-1-ol (-)-(R)-116: Chiral alcohol (-)-(R)-
116 was prepared according to a known protocol;40 the [α]22D   of -1.9 (c. 0.835, 







CHCl3).40 After (-)-(R)-116 was converted to its benzoylated derivative (-)-(R)-116a, 

































1.3 : 1 d.r.












113 and (±)-(R,S)-113: [note: only one enantiomer of each diastereomer is shown for 
clarity] 
Procedure A [small scale preparation]:   
In-situ Preparation of Triflate 114: To a flame-dried pear-shaped 10-mL flask under 
argon containing 116 (187 mg, 1.48 mmol) was added toluene (1.3 mL), hexane (3.0 
mL), and diisopropylethylamine (0.34 mL, 1.97 mmol).  The solution was cooled to -10 
oC and trifluoromethansulfonic anhydride (0.26 mL, 1.5 mmol) was added dropwise over 
the course of 1 minute.  The reaction was allowed to stir for 5 minutes and was then taken 
forward without further purification as a solution (see below). 
Preparation of (±)-(S,S)-113 and (±)-(R,S)-113:  To a flame dried 25-mL round-bottom 
flask fitted with a stir bar was added 83 (160 mg, 0.49 mmol). The flask was charged 
with argon, toluene (2.16 mL) and THF (6.49 mL) were added, and the reaction was then 
cooled to -20 oC.  LiHMDS (1.47 mL, 1.0 M in THF) was added over the course of 1 
minute giving a dark red solution.  The reaction was stirred for 3 minutes, and the 
solution of triflate 114 (379 mg, 1.48 mmol) was then pulled into a luer lock syringe; the 
needle was quickly replaced with a wide needle fitted with a cotton plug, and the solution 
was filtered directly into the reaction mixture over 30 minutes.  The reaction was allowed 
to warm to 5 oC and stirred for 2 h.  If not complete by TLC analysis, the reaction was 
then warmed to room temperature until acylphloroglucinol 83 was consumed.  The 
reaction was quenched with saturated aqueous NH4Cl, poured into water, and extracted 
with CH2Cl2 (3 x 10 mL). The combined organic layers were washed with saturated 




filtered, and concentrated in vacuo.  Purification on silica gel (0 – 15 % EtOAc/hexanes) 
provided 176 mg (83 %) of (±)-(R,S)-113 (green-yellow oil) and (±)-(S,S)-113 (dark red 
oil) as a 1.3:1 mixture by 1H NMR analysis.   
 
Procedure B [large scale preparation]:   
In-situ Preparation of Triflate 114:  Prepared as described for 114 above.   
Large Scale Preparation of (±)-(S,S)-113 and (±)-(R,S)-113: (Scheme 2.11)  To an oven-
dried 1-L round-bottom flask fitted with a stir bar was added 83 (5.0 g, 15.4 mmol).  The 
flask was charged with argon, THF (203 mL), and toluene (68 mL).  The solution was 
cooled to -20 oC and LiHMDS (56.2 mL, 1.0 M in THF) was added over the course of 3 
minutes.  The solution of triflate 114 (10.0 g, 38.5 mmol) was filtered dropwise into the 
reaction mixture (note: removal of the protonated amine salts was crucial for success of 
the reaction).  After the addition was complete, the reaction mixture was warmed 
between 5 oC and 10 oC for 2 h.  The reaction was then stirred for an additional 5.5 h at 
room temperature and was quenched with a saturated aqueous solution of NH4Cl, poured 
into water, and extracted with CH2Cl2 (3 x 300 mL).  The combined organic layers were 
washed with saturated aqueous NaHCO3 (1 x 300 mL), water (1 x 300 mL), and brine (1 
x 300 mL).  The aqueous bicarbonate layer was re-extracted with CH2Cl2 (1 x 300 mL).  
The combined organic extracts were dried over Na2SO4, filtered, and concentrated in 
vacuo to yield a dark brown oil which was purified by silica gel chromatography (0 - 15 
% EtOAc/hexanes) to provide 4.5 g (67 %) of (±)-(R,S)-113 (green-yellow oil) and (±)-




%, 59 % purity by NMR analysis) of (±)-(S,S)-113 (dark red oil) was also isolated as a 
single diastereomer from the silica gel column (15 % - 50 % EtOAc/hexanes).  
[Alternatively, compound 113 could be purified without column chromatography by the 
General Purification Procedure for Dearomatized Phloroglucinols and Type B PPAP 
Derivatives as described below.] 
 
General Purification Procedure for Dearomatized Phloroglucinols and Enolic PPAP 
Derivatives: 
The crude product residue (protonated enol form) was dissolved in pentane [a few drops 
of glacial AcOH was sometimes found to be necessary to ensure that the product was in 
protonated form] and mixed vigorously with saturated aqueous K2CO3 (1x) in a 
separatory funnel.  Water was added and the mixture was again shaken vigorously.  A 
precipitate formed and the layers were separated, leaving the precipitate in the separatory 
funnel.  The precipitate was then dissolved in acetone and concentrated to provide 
product as the potassium salt.  Re-extraction of the pentane layer in this manner was 
repeated (2x).  The combined aqueous extracts were washed with pentane (3x) [pentane 
layers were concentrated to confirm the presence of impurities or product], hexanes (1x), 
Et2O (3x), and EtOAc (3x). The combined Et2O layers and EtOAc layers were separately 
washed with 1M HCl (1x) and brine (1x), dried over Na2SO4, and concentrated in vacuo 










113 and (+)-(R,S)-113: (Scheme 2.4)  Compounds (-)-(S,S)-113 and (+)-(R,S)-113 were 
prepared from 83 (108 mg, 0.331 mmol) and (-)-(R)-114 (135 mg, 1.07 mmol) as 
described above for the small-scale preparation of (±)-(S,S)-113 and (±)-(R,S)-113.  
Purification by the General Purification Procedure for Dearomatized Phloroglucinols 
and PPAP Derivatives as described above provided 33.9 mg (22 %, 1.3:1 d.r.) of (S,S)-
113-K and (R,S)-113-K as a yellow precipitate (amorphous solid), and 26.3 mg (18 %, 
1.3:1 d.r.) of (-)-(S,S)-113 and (+)-(R,S)-113 were obtained from the extracts.  
[Compounds (-)-(S,S)-113 and (+)-(R,S)-113 were separated via preparative thin layer 
chromatography (silica gel, 5 % EtOAc/hexanes) over the course of 24 h].  (-)-(S,S)-113: 
Rf = 0.42 (20 % EtOAc/hexanes); IR νmax 3633, 3076, 2978, 2927, 2850, 1640, 1588, 
1517, 1428, 1352, 1230, 1180, 1136, 993, 916 cm -1; 1H NMR (500 MHz, CDCl3, 2:1 
mixture of enol tautomers as determined by 1H NMR analysis) δ 18.53 (s, 1H)*, 16.48 (s, 
0.5H)**, 7.53 – 7.46 (m, 4.5H), 7.41 – 7.36 (m, 3H), 6.04 (dddd, J = 17.2, 10.4, 5.4, 5.3 
Hz, 1H)*, 5.96 – 5.88 (m, 0.5H)**, 5.66 – 5.48 (m, 3H), 5.17 – 4.98 (m, 6H), 4.95 – 4.86 
(m, 3H), 4.64 (br s, 1.5H), 4.53 – 4.50 (m, 1.5H), 4.08 (s, 3H)*, 3.98 (s, 1.5H)**, 3.32 































1.8, 1.8 Hz, 0.5H)**, 2.70 (ddd, J = 7.3, 1.0, 1.0 Hz, 1H)**, 2.59 (dddd, J = 13.5, 6.9, 
1.0, 0.9 Hz, 1H)*, 2.51 (dddd, J = 13.5, 7.6, 1.0, 0.9 Hz, 1H)*, 2.24 – 2.16 (m, 1H), 2.10 
– 1.98 (m, 7H), 1.96 – 1.91 (m, 2H), 1.69 (br s, 0.5H), 1.60 (dd, J = 1.5, 0.8 Hz, 1.5H)**, 
1.56 (dd, J = 1.3, 0.7 Hz, 3H)*; 
*denotes conjugated enol tautomer (major) 
** denotes cross-conjugated enol tautomer (minor) 
13C NMR (125 MHz, CDCl3, 2:1 mixture of enol tautomers as determined by 1H NMR 
analysis) δ 199.2**, 197.0*, 194.1*, 191.0**, 189.7*, 184.0**, 175.8*, 167.9**, 146.6, 
146.4, 140.3, 136.9, 136.6, 136.4, 136.4, 133.8, 132.7, 131.8, 131.8, 131.2, 128.2, 127.8, 
127.7, 127.6, 120.0, 119.0, 118.4, 115.9, 115.8, 115.4, 114.8, 113.3, 113.0, 112.0, 112.0, 
108.5, 62.1, 61.9, 58.8, 53.5, 45.9, 44.7, 44.3, 43.4, 41.3, 39.9, 39.0, 38.8, 28.2, 28.1, 
18.3, 17.9.  HR-MS: m/z Calcd. for C28H32O4 [M+H+]: 433.2379, Found 433.2390; [α]29𝐷  
= -21.7 (c. 0.250, CHCl3).   
(+)-(R,S)-113:  Rf = 0.42 (20 % EtOAc/hexanes); IR νmax 3632, 3077, 3001, 2978, 2927, 
2849, 1664, 1640, 1588, 1515, 1430, 1376, 1351, 1293, 1228, 1180, 1136, 1074, 992, 914 
cm-1; 1H NMR (500 MHz, CDCl3, 1:1 mixture of enol tautomers as determined by 1H 
NMR analysis) δ 18.64 (s, 1H), 16.79 (s, 1H), 7.51 – 7.41 (m, 6H), 7.40 – 7.35 (m, 4H), 
6.06 (dddd, J = 16.8, 10.3, 5.4, 5.4 Hz, 1H), 5.93 (dddd, J = 17.2, 10.2, 5.8, 5.8 Hz, 1H), 
5.67 – 5.44 (m, 4H), 5.18 (ddd, J = 8.7, 3.3, 1.7 Hz, 1H), 5.15 (ddd, J = 3.5, 1.9, 1.9 Hz, 
1H), 5.09 – 4.91 (m, 10H), 4.57 (ddd, J = 3.9, 2.7, 1.5 Hz, 2H), 4.53 (br d, J = 1.8 Hz, 
1H), 4.50 (br d, J = 1.8 Hz, 1H), 4.11 (s, 3H), 4.02 (s, 3H), 3.38 (ddd, J = 5.4, 1.8, 1.8 




7.2, 1.2, 1.2 Hz, 1H), 2.45 (dddd, J = 13.4, 7.6, 1.2, 1.2 Hz, 1H), 2.30-1.91 (m, 9H), 1.74 
(dd, J = 13.5, 2.8 Hz, 1H), 1.57 (dd, J = 1.3, 0.6 Hz, 3H), 1.42 (ddd, J = 2.8, 2.0, 1.9 Hz, 
3H); 13C NMR (125 MHz, CDCl3, 1:1 mixture of enol tautomers as determined by 1H 
NMR analysis) δ 198.1, 196.3, 192.9, 192.3, 190.1, 183.9, 175.2, 167.5, 146.7, 145.9, 
138.9, 138.7, 136.7, 136.5, 136.1, 132.4, 131.5, 131.5, 130.7, 128.1, 127.6, 127.5, 127.4, 
121.7, 119.0, 118.5, 115.9, 115.8, 115.6, 115.4, 114.9, 113.4, 113.4, 113.3, 109.1, 62.7, 
62.2, 58.6, 53.7, 46.1, 45.2, 44.7, 43.8, 40.5, 39.2, 38.9, 38.8, 28.2, 28.1, 17.4, 17.2. HR-




yl)cyclohexa-1,4-dien-1-olate and Potassium (S)-
4,6-diallyl-2-benzoyl-5-methoxy-3-oxo-6-((S)-2-(prop-1-en-2-yl)pent-4-en-1-
yl)cyclohexa-1,4-dien-1-olate (R,S)-113-K and (S,S)-113-K: Rf = 0.35 (15 % 
EtOAc/hexanes); IR νmax 3073, 2976, 2922, 2842, 1703, 1630, 1558, 1509, 1444, 1393, 
1247, 1216, 1173, 1126, 1065, 995, 908, 781, 733 cm-1;  1H NMR (500 MHz, Acetone-d6, 
1.3:1 mixture of diastereomers as determined by 1H NMR analysis) δ 7.62 – 7.54 (m, 
2H), 7.30 – 7.20 (m, 3H), 6.01 – 5.90 (m, 1H), 5.78 – 5.68 (m, 1H), 5.67 – 5.54 (m, 1H), 
5.08 – 4.76 (m, 6H), 4.60 (dddd, J = 2.8, 1.4, 1.3, 1.3 Hz, 0.5H), 4.58 – 4.54 (m, 1.5H), 
3.91 (s, 1.3H), 3.85 (s, 1.7H), 3.24 (dddd, J = 15.1, 6.2, 1.7, 1.7 Hz, 0.6H), 3.22 – 3.16 
(m, 1H), 3.14 (dddd, J = 15.3, 6.2, 1.7, 1.6 Hz, 0.8H), 2.76 – 2.45 (m, 1H), 2.42 – 2.36 













1.63 (m, 1H), 1.60 (dd, J = 1.4, 0.7 Hz, 1.7H), 1.56 (dd, J = 1.0, 0.9 Hz, 1.3H); 13C NMR 
(125 MHz, Acetone-d6, 1.3:1 mixture of diastereomers as determined by 1H NMR 
analysis) δ 198.0, 197.8, 191.1, 190.7, 185.8, 185.7, 167.4, 167.3, 149.2, 149.0, 145.5, 
140.1, 139.8, 139.1, 138.9, 136.8, 129.9, 129.9, 129.4, 129.4, 129.3, 127.8, 127.8, 127.8, 
122.8, 122.5, 116.3, 116.3, 115.0, 115.0, 114.9, 114.0, 113.8, 111.5, 111.1, 62.4, 62.3, 
56.5, 56.4, 45.1, 45.0, 44.9, 44.9, 42.7, 42.2, 39.3, 38.9, 29.7, 19.3, 19.2; HR-MS: m/z 
Calcd. for 433.2379 [M+H+]: Found 433.2358. 
 
(±)-Allyl clusianone potassium salt (±)-112-K: (Scheme 2.11)  To a round-bottom flask 
fitted with a stir bar was added 113 (127 mg, 0.294 mmol) as a 1.3:1 mixture of 
diastereomers by 1H NMR analysis.  The flask was charged with argon, placed in an ice 
water bath between 10 - 15 oC, and 98 % formic acid (12 mL) was then poured directly 
into the reaction flask using a graduated cylinder.  The reaction was warmed to room 
temperature and stirred for five days. The reaction was concentrated in vacuo using 
benzene as an azeotrope with formic acid to provide an amorphous red solid.  Pentane (10 
mL) was added to dissolve product 112 and the solution was decanted leaving the 
majority of O-cyclized product 117 undissolved in the reaction flask.  The decanted 
pentane solution was concentrated and 112 was redissolved in 0.5 mL CH2Cl2 with 0.3 
mL formic acid.  The acidic solution was passed through a short silica plug (5 % 






























fractions were then purified by the General Procedure for Dearomatized Phloroglucinols 
and Type B PPAP Derivatives to provide 23.5 mg (18 %) of the potassium salt (±)-112-K 
as a yellow solid and 15.6 mg (13 %) of (±)-112 as a yellow oil. [31 % total yield of allyl 
clusianone]  
 
Alternative Purification of (±)-112-K via Recrystallization:  The reaction of 113 (411 
mg, 0.951 mmol) with formic acid to provide potassium salt (±)-112-K was 
accomplished in the same manner described above.  Purification by the General 
Purification Procedure for Dearomatized Phloroglucinols and PPAP Derivatives [did 
not extract with 1 M HCl or brine] provided 100 mg (23 %) of (±)-112-K as a white 
crystalline powder after recrystallization of the precipitate from Et2O (50 oC to r.t.). 
 
 (±)-112-K: Rf = 0.20 (33 % EtOAc/hexanes); m.p.  170 – 175 oC 
(Et2O); IR (thin film): νmax 3400, 3075, 2976, 2929, 1710, 1642, 1574, 
1528, 1445, 1394, 1360, 1303, 1226, 999, 911 cm-1; 1H NMR (500 
MHz, Acetone-d6) δ 7.64 – 7.52 (m, 2H), 7.34 – 7.29 (m, 1H), 7.26 – 
7.21 (m, 2H), 6.02 – 5.91 (m, 1H), 5.81 – 5.66 (m, 2H), 5.04 – 4.93 (m, 4H), 4.90 (dddd, 
J = 10.2, 2.5, 1.2, 1.2 Hz, 1H), 4.84 (dddd, J = 10.2, 2.7, 1.4, 1.4 Hz, 1H), 2.61 (dddd, J = 
12.9, 7.1, 1.2, 1.2 Hz, 1H), 2.50 (dddd, J = 12.9, 6.1, 1.4, 1.4 Hz, 1H), 2.45 (dddd, J = 
13.7, 6.5, 1.4, 1.4 Hz, 1H), 2.40 (dddd, J = 13.7, 7.5, 1.2, 1.2 Hz, 1H), 2.37 – 2.30 (m, 
1H), 2.27 – 2.18 (m, 1H), 1.92 (dd, J = 13.3, 4.6 Hz, 1H), 1.73 – 1.66 (m, 1H), 1.34 (dd, J 









212.3, 198.2, 189.8, 188.7, 144.2, 139.2, 138.9, 138.1, 130.6, 129.7, 128.0, 119.5, 116.6, 
116.2, 116.1, 70.0, 62.5, 45.6, 42.2, 41.3, 37.2, 35.5, 31.7, 23.5, 16.8; HR-MS: m/z 
Calcd. for C27H30O4 [M+H+]: 419.2222, Found 419.2208.    
 
 
(±)-Allyl clusianone salt (±)-112-M:[the metal ion is derived from the silica gel] To a 1-
L flame-dried round-bottom flask fitted with a stir bar was added 113 (2.0 g, 4.66 mmol).  
The flask was charged with argon, placed in an ice water bath between 10 – 15 oC, and 98 
% formic acid (191 mL) was then poured directly into the reaction flask using a 
graduated cylinder.  The reaction was warmed to room temperature over the course of 48 
h. (note: minor improvements in yield were observed if the reaction was allowed to stir 
longer than 3 days)  Upon completion, the reaction was concentrated in vacuo using 
benzene as an azeotrope with formic acid to provide 1.89 g of crude (±)-112 as an 
amorphous dark red solid.  Purification by silica gel chromatography (2 – 8 % 
EtOAc/hexanes; 5 % AcOH/ 3 – 9 % EtOAc/hexanes; 100 % EtOAc) provided 248 mg 
(13 %) of (±)-112-M as a dark red crystalline solid, 676 mg (34 %) of pyranodienone 
117, and 896 mg of crude (±)-112. Crude (±)-112 was further purified by the General 
Purification Procedure for Dearomatized Phloroglucinols and PPAP Derivatives 
described above to provide 253 mg (13 %) of (±)-112 as a yellow oil. [26 % total yield of 

























1.5:1 mixture of tautomers
M






 (±)-112-M:[note: the metal ion comes from the silica gel] Rf = 0.53 
(33 % EtOAc/hexanes); m.p. 78 – 81 oC (CH2Cl2); IR νmax 3078, 2979, 
2944, 1729, 1670, 1640, 1600, 1556, 1397, 1295, 1239, 1138, 1000, 
919 cm-1; 1H NMR (500 MHz, Acetone-d6) δ 7.60 – 7.50 (m, 3H), 7.43 
– 7.36 (m, 2H), 5.89 (dddd, J = 17.2, 10.3, 7.8, 6.2 Hz, 1H), 5.75 – 5.64 (m, 2H), 5.15 – 
4.95 (m, 6H), 2.78 (dddd, J = 13.3, 5.5, 1.5, 1.5 Hz, 1H), 2.69 (dddd, J = 13.3, 8.1, 1.0, 
1.0 Hz, 1H), 2.60 (dddd, J = 13.8, 6.2, 1.4, 1.4 Hz, 1H), 2.56 – 2.49 (m, 1H), 2.36 (dddd, 
J = 13.6, 5.7, 2.4, 1.7 Hz, 1H), 2.09 – 2.02 (m, 1H), 1.83 (dddd, J = 12.8, 10.3, 4.3, 2.6 
Hz, 1H), 1.78 – 1.69 (m, 1H), 1.56 (dd, J = 13.3, 13.3 Hz, 1H), 1.18 (s, 3H), 0.80 (s, 3H); 
13C NMR (125 MHz, Acetone-d6) δ 207.8, 198.6, 193.1, 192.1, 138.3, 135.7, 135.4, 
135.4, 133.2, 129.9, 128.6, 119.1, 118.9, 118.5, 117.1, 69.5, 63.2, 48.4, 42.8, 42.5, 36.6, 
35.2, 31.2, 23.6, 16.6; HR-MS: m/z Calcd. for C27H30O4 [M+H+]: 419.2222, Found 
419.2212. Elemental Analysis:  Ca: 0.118 mg/L, 734 ppm; Mg: 0.006 mg/L, 124 ppm; 
Al: 0.026 mg/L; 298 ppm.  
 
(-)-Allyl clusianone (-)-112: (Scheme 2.4) To a round-bottom flask fitted with a stir bar 
was added (-)-(S,S)-113 (5.3 mg, 0.012 mmol).  The flask was charged with argon and 





























added via syringe.  The reaction was stirred at this temperature for 4 days. The reaction 
mixture was purified by adding the formic acid solution directly to a prep plate (silica gel, 
15 % EtOAc/hexanes) to afford 3.7 mg (72 %) of (-)-112 as a red amorphous solid. [A 60 
% yield of (-)-112 was achieved when the formic acid solution was allowed to stir for 3 
days using 16.4 mg of (-)-(S,S)-113]  (-)-112: Rf = 0.33 (33 % EtOAc/hexanes); IR νmax 
3441, 3076, 2980, 2929, 1728, 1669, 1640, 1599, 1552, 1446, 1397, 1384, 1296, 1238, 
1181, 1140, 1001, 918, 751 cm-1;  1H NMR (400 MHz, CDCl3, 1.5:1 mixture of enol 
tautomers as determined by 1H NMR analysis) δ 17.57 (s, 0.9H), 17.38 (s, 0.6H), 7.59 – 
7.50 (m, 5H), 7.40 – 7.34 (m, 3.3H), 5.93 – 5.52 (m, 5H), 5.25 – 4.93 (m, 10H), 2.93 
(dddd, J = 13.2, 5.4, 1.5 Hz, 1H), 2.81 – 2.52 (m, 6H), 2.39 – 2.28 (m, 2H), 2.27 – 2.17 
(m, 1H), 2.07 (dd, J = 13.0, 3.5 Hz, 1.2H), 1.77 – 1.57 (m, 5H), 1.50 – 1.39 (m, 1.3H), 
1.27 (s, 3H), 1.07 (s, 2H), 0.87 (s, 3H), 0.78 (s, 2H); 13C NMR (125 MHz, CDCl3, 1.5:1 
mixture of enol tautomers as determined by 1H NMR analysis) δ 206.8, 206.6, 198.2, 
197.8, 194.8, 194.0, 193.0, 191.8, 137.0, 137.0, 136.4, 136.3, 134.5, 133.9, 133.3, 133.1, 
132.7, 129.0, 127.7, 127.6, 119.4, 119.1, 118.8, 117.0, 116.9, 71.2, 67.2, 64.3, 59.2, 48.4, 
47.7, 42.7, 41.7, 41.3, 41.3, 35.8, 35.1, 34.5, 34.0, 30.9, 30.0, 29.7, 23.6, 22.5, 16.3, 16.1; 






(-)-Clusianone (-)-1: (Scheme 2.4) A 15-mL glass pressure tube containing (-)-112 (5.6 
mg, 0.0134 mmol) was charged with argon and Grubbs 2nd generation catalyst (1.0 mg, 
0.0012 mmol).  The tube was then cooled to -78 oC and excess isobutylene (1.5 mL) was 
condensed along the side of the tube.  The tube was sealed and slowly warmed to 60 oC.  
After stirring for 24 h at this temperature, the tube was re-cooled to -78 oC for 5 minutes 
and was opened to the air.  Removal of the dry ice bath allowed for evaporation of 
isobutylene.  The crude product was dissolved in CH2Cl2 (0.5 mL) and purified by 
preparative plate chromatography (silica gel, 10 % EtOAc/hexanes) to obtain 3.1 mg (46 
%) of (-)-1 as a clear oil.  Spectroscopic data for (-)-1 were found to be identical with 
those reported in the literature.29b  (-)-1:  Rf = 0.37 (15 % EtOAc/hexanes); IR νmax 3633, 
2975, 2925, 2855, 1729, 1668, 1600, 1551, 1448, 1396, 1376, 1303 1246, 1182, 1136, 
1061, 1009, 955, 840, 788, 748 cm-1; 1H NMR (500 MHz, CDCl3, 1.5:1 mixture of enol 
tautomers as determined by 1H NMR analysis) δ 17.56 (s, 0.9H), 17.50 (s, 0.6H), 7.57 – 
7.47 (m, 5H), 7.42 – 7.32 (m, 3.3H), 5.20 – 5.11 (m, 1.7H), 5.06 – 5.00 (m, 0.6H), 4.96 
(dd, J = 6.4, 6.4 Hz, 0.6H), 4.90 (dd, J = 6.9, 6.9 Hz, 1H), 4.82 (dd, J = 6.3, 6.3 Hz, 1H), 
2.72 (dd, J = 13.2, 8.5 Hz, 2.8H), 2.63 (ddd, J = 22.4, 14.5, 7.4 Hz, 1.1H), 2.54 (dd, J = 























(m, 1.7H), 2.00 (dd, J = 13.2, 4.1 Hz, 1H), 1.78 (s, 2H), 1.76 (s, 2H), 1.72 – 1.68 (m, 7H), 
1.66 (s, 2H), 1.64 (s, 3H), 1.62 (s, 3H), 1.61 (s, 2H), 1.59 – 1.56 (m, 1H), 1.55 (s, 3H), 
1.54 (s, 3H), 1.52 (s, 3H), 1.38 (dd, J = 13.2, 13.2 Hz, 1H), 1.23 (s, 3H), 1.05 (s, 2H), 
0.84 (s, 3H), 0.73 (s, 2H); 13C NMR (125 MHz, CDCl3, 1.5:1 mixture of enol tautomers 
as determined by 1H NMR analysis) δ 207.5, 207.3, 197.8, 197.5, 195.4, 194.7, 193.9, 
192.6, 137.2, 134.6, 134.5, 133.3, 132.5, 132.5, 128.9, 128.9, 127.8, 127.7, 122.3, 122.2, 
120.4, 119.9, 119.1, 119.1, 116.9, 116.1, 71.0, 67.3, 64.6, 59.6, 48.6, 47.6, 42.9, 42.3, 
41.5, 30.6, 29.9, 29.7, 28.5, 28.1, 26.1, 26.1, 26.0, 25.8, 25.7, 25.6, 24.9, 23.7, 22.6, 18.2, 
18.1, 18.1, 18.1, 17.9, 16.4, 16.2; HR-MS: m/z Calcd. for C33H42O4 [M+H+]: 503.3161, 
Found 503.3171; [α]28𝐷  = - 30.6  (c. 0.125, CHCl3). 
 
 
(±)-Clusianone Potassium Salt (±)-1-K: (Scheme 2.11)[note: isobutylene is the solvent] 
A 250-mL glass pressure tube containing (±)-112 (201 mg, 0.480 mmol) was charged 
with argon and Grubbs 2nd generation catalyst (81.4 mg, 0.096 mmol).  The tube was then 
cooled to -78 oC and excess isobutylene (18 mL, 188 mmol) was condensed along the 
side of the tube.  The tube was sealed and slowly warmed to 60 oC.  After stirring for 18 














of the dry ice bath allowed for evaporation of isobutylene.  The crude product was 
dissolved in pentane (45 mL) and transferred to a separatory funnel leaving behind 
insoluble solid impurities in the pressure tube.  Saturated aqueous K2CO3 (5 mL) was 
added to the black-colored pentane solution and mixed vigorously.  Water (30 mL) was 
then added, which was followed by vigorous mixing causing the immediate formation of 
a precipitate in the aqueous layer.  The layers were separated, and the pentane layer was 
extracted two more times in this manner or until solid had been completely removed.  
The combined aqueous layers were washed with pentane (3 x 40 mL) and Et2O (3 x 40 
mL); the Et2O fully dissolved any solid precipitate in the aqueous layer.  The combined 
organic layers were washed with brine (30 mL), dried over Na2SO4, and concentrated in 
vacuo to afford 211 mg (81 %) of potassium salt (±)-1-K as a brown solid (single isomer 
as determined by 1H NMR analysis). (±)-1-K:  Rf = 0.68 (33 % EtOAc/hexanes); m.p. 
170-175 oC (Et2O/pentane); IR νmax 2972, 2924, 2856, 1714, 1641, 1590, 1571, 1531, 
1446, 1373, 1293, 1257 cm-1; 1H NMR (400 MHz, Acetone-d6) δ 7.57 – 7.39 (m, 2H), 
7.32 – 7.23 (m, 1H), 7.24 – 7.15 (m, 2H), 5.26 (dd, J = 6.5, 6.5 Hz, 1H), 5.10 – 4.88 (m, 
2H), 2.57 (dd, J = 13.7, 6.5 Hz, 1H), 2.47 – 2.19 (m, 3H), 2.18 – 2.10 (m, 1H), 2.03 – 
1.82 (m, 3H), 1.66 (s, 3H), 1.65 (s, 3H), 1.61 (s, 3H), 1.59 (s, 6H), 1.56 (s, 3H), 1.42 – 
1.33 (m, 1H), 1.09 (s, 3H), 0.71 (s, 3H); 13C NMR (100 MHz, Acetone-d6) δ 212.1, 
198.0, 191.6, 190.7, 144.6, 132.5, 131.7, 130.5, 130.3, 129.3, 127.9, 124.7, 124.6, 123.8, 
119.5, 69.9, 63.2, 58.6, 46.0, 43.1, 41.7, 31.4, 27.5, 27.4, 26.9, 26.3, 26.3, 26.1, 23.6, 








chromen-7-one (-)-(S)-117: (Scheme 2.4) Formic acid (0.64 mL) was added to (+)-
(R,S)-8 (6.8 mg, 0.0157 mmol) in a 20-mL scintillation vial via syringe.  The reaction 
was stirred for two days at room temperature and then concentrated using benzene as an 
azeotrope with formic acid to provide 5.7 mg (84 %) of (-)-(S)-117 as a dark brown solid.  
(-)-(S)-117:  Rf = 0.07 (20 % EtOAc/hexanes); m.p. 75 – 80 oC (CH2Cl2); IR νmax 3077, 
2979, 2940, 1674, 1639, 1598, 1536, 1448, 1390, 1379, 1225, 1171, 1133, 996, 918, 821 
cm-1; 1H NMR (500 MHz, CDCl3) δ 7.73 – 7.70 (m, 2H), 7.42 – 7.37 (m, 1H), 7.31 – 7.27 
(m, 2H), 5.70 – 5.51 (m, 3H), 5.04 – 4.92 (m, 6H), 3.88 (s, 3H), 2.68 – 2.58 (m, 3H), 2.51 
– 2.42 (m, 2H), 2.26 – 2.20 (m, 1H), 2.21 (dd, J = 16.3, 9.9 Hz, 1H), 1.75 – 1.62 (m, 2H), 
1.07 (s, 3H), 1.01 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 194.9, 194.5, 170.5, 168.8, 
138.6, 135.4, 133.4, 133.0, 132.3, 128.8, 128.0, 117.9, 117.8, 117.4, 114.4, 108.6, 81.6, 
61.7, 59.5, 43.5, 43.3, 40.1, 34.9, 27.4, 23.1, 21.6; HR-MS: m/z Calcd. for C28H32O4 

















2,4-dien-1-one 19 and 2,4-Diallyl-6-benzoyl-3,5-dimethoxy-4-(2-(prop-1-en-2-
yl)pent-4-en-1-yl)cyclohexa-2,5-dien-1-one 123: To a 10-mL flame-dried round-bottom 
flask under an argon atmosphere was added compound 113 (11.7 mg, 0.027 mmol), Et2O 
(1.4 mL), and MeOH (0.14 mL).  TMSCHN2 (0.36 mL, 0.54 mmol) was then added 
dropwise and allowed to stir for 72 h at room temperature.  The reaction was cooled to 0 
oC and glacial acetic acid was added dropwise until bubbling ceased.  Saturated aqueous 
NaHCO3 (2 mL) was added, and the mixture was poured into water (3 mL) and extracted 
with EtOAc (3 x 5 mL).  The combined organic layers were washed with water (3 mL) 
and saturated brine (3 mL).  The organic solution was dried over Na2SO4, filtered, and 
concentrated in vacuo.  Purification by silica gel chromatography (3-12 % 
EtOAc/hexanes) afforded 10.6 mg (88 %, 1.9:1 mixture of 123:122 as determined by 1H 
NMR analysis) of 122 (1.5:1 d.r.) and 123 (1.2:1 d.r.). Compounds 122 and 123 were 
separated by column chromatography (silica gel, 1 – 12 % EtOAc/hexanes).  
122: Rf = 0.25 (10 % EtOAc/hexanes); IR νmax 3076, 3001, 2977, 2951, 2924, 2849, 
1665, 1646, 1598, 1582, 1548, 1448, 1354, 1333, 1278, 1220, 1174, 1129, 993, 913, 849, 
777 cm-1; 1H NMR (400 MHz, CDCl3, 1.5:1 mixture of diastereomers as determined by 
1H NMR analysis) δ 7.96 – 7.84 (m, 2H), 7.55 – 7.48 (m, 1H), 7.45 – 7.37 (m, 2H), 6.04 














1.5:1 mixture of diastereomers 1.2:1 mixture of diastereomers1.3:1 mixture of diastereomers




(m, 1.5H), 4.00 (s, 1.2H), 3.96 (s, 1.8H), 3.70 (m, 1.8H), 3.65 (s, 1.2H), 3.29 (dddd, J = 
16.0, 5.8, 1.8, 1.8 Hz, 0.4H), 3.21 (dddd, J = 16.0, 5.4, 1.7, 1.7 Hz, 0.4H), 3.20 (dddd, J = 
17.1, 5.4, 1.6, 1.6 Hz, 0.6H), 3.15 (dddd, J = 17.1, 5.3, 1.7, 1.7 Hz, 0.6H), 2.55 (ddd, J = 
14.6, 14.4, 7.6 Hz, 1.2H), 2.50 (ddd, J = 13.9, 13.7, 8.4 Hz, 0.8H), 2.26 – 2.10 (m, 1.4H), 
2.09 – 1.91 (m, 2.9H), 1.84 – 1.75 (m, 0.5H), 1.70 (br d, J = 6.3 Hz, 0.2H), 1.62 (dd, J = 
1.2, 0.7 Hz, 1.8H), 1.50 (dd, J = 1.4, 0.7 Hz, 1.2H); 13C NMR (100 MHz, CDCl3, 1.5:1 
mixture of diastereomers as determined by 1H NMR analysis) δ 199.0, 197.7, 196.5, 
196.2, 172.1, 171.4, 168.8, 168.0, 147.0, 146.3, 138.7, 138.6, 137.0, 136.9, 136.8, 136.7, 
133.1, 132.9, 132.9, 132.5, 129.5, 129.4, 128.4, 128.2, 118.5, 118.4, 117.2, 115.8, 115.4, 
115.3, 115.3, 115.2, 114.8, 114.4, 113.6, 111.6, 63.2, 63.0, 60.7, 60.7, 58.5, 58.5, 46.5, 
45.6, 45.1, 44.4, 42.1, 40.7, 38.9, 38.5, 29.2, 29.1, 18.1, 17.3; HR-MS:  m/z Calcd. for 
C29H34NaO4 [M+Na+]: 469.2355, Found 469.2357.  
123: Rf = 0.18 (10 % EtOAc/hexanes); IR νmax 3074, 2977, 2947, 2850, 1674, 1651, 
1610, 1449, 1364, 1276, 1223, 1134, 1073, 992, 915, 851 cm-1; 1H NMR (400 MHz, 
CDCl3, 1.2:1 mixture of diastereomers as determined by 1H NMR analysis) δ 7.94 – 7.86 
(m, 2H), 7.55 – 7.47 (m, 1H), 7.47 – 7.37 (m, 2H), 5.98 – 5.82 (m, 1H), 5.75 – 5.58 (m, 
2H), 5.19 – 4.94 (m, 6H), 4.81 (ddd, J = 3.1, 1.5, 1.5 Hz, 0.5H), 4.69 (m, 0.5H), 4.67 
(ddd, J = 3.1, 1.5, 1.5 Hz, 0.5H), 4.64 (m, 0.5H), 4.05 (s, 1.4H), 3.99 (s, 1.6H), 3.67 (s, 
1.6H), 3.58 (s, 1.4H), 3.32 – 3.18 (m, 1.5H), 3.13 (dddd, J = 16.0, 5.8, 1.8, 1.8 Hz, 0.5H), 
2.73 – 2.58 (m, 2H), 2.22 – 2.04 (m, 4H), 2.02 – 1.91 (m, 1H), 1.67 (s, 1.4H), 1.65 (s, 
1.6H); 13C NMR (125 MHz, CDCl3, 1.2:1 mixture of diastereomers as determined by 1H 




138.5, 138.4, 136.8, 136.7, 136.7, 136.4, 133.0, 133.0, 132.9, 132.8, 129.2, 129.2, 128.5, 
128.4, 120.5, 119.3, 118.5, 118.4, 118.3, 117.6, 115.8, 115.6, 115.1, 114.8, 112.7, 112.0, 
62.1, 61.8, 59.6, 59.2, 53.3, 53.3, 44.1, 43.9, 43.4, 43.0, 39.7, 39.4, 39.0, 28.1, 28.1, 18.4, 




only one enantiomer is shown for clarity]  Compound (±)-(S,S)-123 
could be isolated as a single diastereomer from 123 (1.2:1 d.r.) by preparative plate 
chromatography (5 % EtOAc/hexanes) via 7 elutions.  
(±)-(S,S)-123: Rf = 0.21 (10 % EtOAc/hexanes); IR νmax 3074, 2932, 2851, 1674, 1652, 
1614, 1450, 1365, 1277, 1226, 1206, 1130, 993, 915 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.94 – 7.90 (m, 2H), 7.56 – 7.49 (m, 1H), 7.45 – 7.40 (m, 2H), 5.88 (dddd, J = 17.2, 10.2, 
5.7, 5.7 Hz, 1H), 5.73 – 5.57 (m, 2H), 5.16 – 4.90 (m, 6H), 4.65 (ddd, J = 3.2, 1.4, 1.4 
Hz, 1H), 4.63 – 4.59 (m, 1H), 3.97 (s, 3H), 3.64 (s, 3H), 3.19 (dddd, J = 16.1, 5.6, 1.9, 
1.9 Hz, 1H), 3.10 (dddd, J = 16.1, 5.8, 1.7, 1.7 Hz, 1H), 2.66 (dddd, J = 13.5, 6.7, 1.0, 1.0 
Hz, 1H), 2.60 (dd, J = 13.5, 8.0 Hz, 1H), 2.18 – 2.02 (m, 4H), 1.95 – 1.88 (m, 1H), 1.62 – 
1.60 (dd, J = 1.4, 0.8 Hz, 3H);  13C NMR (100 MHz, CDCl3) δ 196.2, 187.4, 170.0, 
169.3, 146.7, 138.4, 136.7, 136.7, 133.0, 132.9, 129.2, 128.5, 119.3, 118.5, 118.3, 115.8, 
114.8, 112.0, 61.8, 59.6, 53.3, 43.9, 43.0, 39.7, 39.0, 28.1, 18.4; HR-MS: m/z Calcd. for 











(±)-O-Methyl allyl clusianone (±)-124: (Scheme 2.6) To a round-bottom flask fitted 
with a stir bar was added compounds 122 and 123 (20.3 mg, 0.045 mmol, 1.9:1 (123:122) 
as determined by 1H NMR analysis).  The flask was charged with argon and placed in an 
ice water bath between 10 – 15 oC, and 98 % formic acid (1.9 mL) was then added via 
syringe.  The reaction was warmed to room temperature and stirred for 48 h.  The 
reaction mixture was transferred directly to a preparative thin-layer chromatography plate 
(silica gel, 10 % EtOAc/hexanes) and purified to afford 4.9 mg (25 %) of (±)-124 as a 
clear oil. [Product (±)-124 derives exclusively from the reaction of cross-conjugated 
diastereomer (±)-(S,S)-123 with formic acid.] (±)-124: Rf = 0.35 (10 % EtOAc/hexanes); 
IR νmax 3076, 2978, 2943, 2917, 2853, 1727, 1676, 1641, 1598, 1449, 1398, 1376, 1339, 
1282, 1223, 1177, 1068, 1002, 917, 839, 787 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.85 – 
7.78 (m, 2H), 7.58 – 7.51 (m, 1H), 7.47 – 7.39 (m, 2H), 5.91 – 5.70 (m, 2H), 5.58 (dddd, 
J = 16.4, 10.2, 7.3, 6.3 Hz, 1H), 5.16 – 4.94 (m, 6H), 3.66 (s, 3H), 2.73 (dd, J = 13.9, 5.4 
Hz, 1H), 2.63 (ddd, J = 18.5, 13.1, 7.3 Hz, 2H), 2.52 (dd, J = 13.9, 8.1 Hz, 1H), 2.42 – 
2.35 (m, 1H), 2.17 (dd, J = 13.9, 4.4 Hz, 1H), 2.08 – 1.99 (m, 1H), 1.74 (ddd, J = 13.9, 
9.7, 9.7 Hz, 1H), 1.50 (dd, J = 13.9, 13.3 Hz, 1H), 1.07 (s, 3H), 0.78 (s, 3H); 13C NMR 
















1.9:1 mixture of 123 to 122




128.6, 122.8, 119.2, 117.9, 116.8, 71.4, 61.0, 57.2, 47.1, 40.7, 40.3, 36.0, 33.9, 29.6, 22.3, 
15.8; HR-MS: m/z Calcd. for C28H32O4 [M+H+]: 433.2379, Found 433.2365. 
 
 
(±)-O-Methyl clusianone (±)-17:  A 15-mL glass pressure tube containing (±)-124 (5.5 
mg, 0.0127 mmol) was charged with argon and Grubbs 2nd generation catalyst (2.2 mg, 
0.0026 mmol).  The tube was then cooled to -78 oC and isobutylene (3 mL, 31.7 mmol) 
was condensed along the side of the tube.  The tube was sealed and slowly warmed to 60 
oC.  After stirring for 4 h, the tube was re-cooled to -78 oC for 5 minutes and was opened 
to the air.  Removal of the dry ice bath allowed for evaporation of isobutylene.  The crude 
product was dissolved in CH2Cl2 (0.5 mL) and was purified by preparative plate 
chromatography (silica gel, 10 % EtOAc/hexanes) to obtain 4.4 mg (67 %) of (±)-17 as 
an amorphous white solid.  Spectroscopic data for (±)-O-methyl clusianone (±)-17 were 
found to be identical with those reported in the literature.27  (±)-17:  Rf = 0.35 (10 % 
EtOAc/hexanes); IR νmax 2977, 2978, 2860, 1728, 1680, 1643, 1600, 1449, 1399, 1376, 
1338, 1281, 1224 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.84 – 7.79 (m, 2H), 7.56 – 7.51 
(m, 1H), 7.44 – 7.39 (m, 2H), 5.13 – 5.05 (m, 2H), 4.81 (dd, J = 6.9, 6.9 Hz, 1H), 3.62 (s, 
3H), 2.62 – 2.52 (m, 2H), 2.51 – 2.40 (m, 2H), 2.19 – 2.11 (m, 1H), 2.07 (dd, J = 13.4, 














3H), 1.59 (s, 6H), 1.55 (s, 3H), 1.44 (dd, J = 13.4, 13.4 Hz, 1H), 1.05 (s, 3H), 0.74 (s, 
3H); 13C NMR (125 MHz, CDCl3) δ 207.7, 195.6, 195.5, 172.9, 138.0, 134.2, 133.6, 
133.3, 133.1, 129.2, 128.7, 122.7, 122.6, 120.1, 120.1, 71.1, 60.7, 57.7, 47.1, 41.8, 40.2, 
30.7, 28.0, 26.1, 26.0, 26.0, 25.0, 22.5, 18.1, 18.0, 17.9, 15.9; HR-MS: m/z Calcd. for 
C34H44O4 [M+H+]: 517.3318, Found 517.3320. 
 
Phenyl(2,4,6-trihydroxyphenyl)methanone S6:16j  Phloroglucinol 105 (2.0 
g, 15.9 mmol) was dissolved in nitrobenzene.  AlCl3 (8.46 g, 63.4 mmol) 
was added in three portions.  Benzoyl chloride (2.13 mL, 18.33 mmol) was 
then added dropwise.  The reaction flask was fitted with a reflux condenser and heated to 
65 oC for 3 h.  The reaction was then cooled to room temperature, added to ice water (20 
mL), and extracted with EtOAc (3 x 20 mL).  The combined organic layers were 
extracted with 2 M NaOH (3 x 20 mL), and the combined aqueous NaOH extracts were 
neutralized with concentrated HCl and extracted with EtOAc (3 x 20 mL).  The combined 
EtOAc layers were washed with brine (1 x 20 mL), dried over Na2SO4, and concentrated 
in vacuo.  Purification by silica gel chromatography (5 – 33 % EtOAc/hexanes) afforded 
2.63 g (72 %) of 26 as a yellow solid.  Spectroscopic data for 26 were found to be 





















 (3,5-Diallyl-2,4,6-trihydroxyphenyl)(phenyl)methanone 142:  To a 
round-bottom flask containing 26 (333 mg, 1.45 mmol) and KOH (189 
mg, 2.9 mmol) under an argon atmosphere was added degassed water 
(1.14 mL).  The water had been previously degassed by bubbling argon for 1 h.  The red 
aqueous solution was stirred at room temperature for 5 to 10 minutes until all solid was 
dissolved.  Allyl iodide (0.81 mL, 8.7 mmol) was added dropwise at room temperature.  
The reaction flask was placed in an oil bath preheated to 60 oC.  The reaction was 
quenched after 40 minutes by adding 1,3-propanedithiol (0.87 mL, 8.7 mmol) at 60 oC. 
[note: The allylation is time sensitive and cannot be monitored by TLC analysis; 
accordingly, ULPC was used for reaction monitoring.]  The mixture was stirred at this 
temperature for 5 minutes, cooled to room temperature, and was then stirred for 1.5 h. 
The mixture was added to 1 M HCl and extracted into CH2Cl2 (3 x 10 mL).  The 
combined organic layers were washed with water (1 x 20 mL) and brine (1 x 20 mL), 
dried over Na2SO4, and concentrated in vacuo.  Purification by silica gel chromatography 
(0 – 3 % EtOAc/hexanes to remove 1,3-propanedithiol; 4 – 6 % EtOAc/hexanes) 
provided 163 mg (36 %) of 142 as a yellow crystalline solid.  142: Rf = 0.35 (20 % 
EtOAc/hexanes); m.p. 75.0 – 79.0 oC (CH2Cl2); IR νmax 3498, 3079, 3060, 3004, 2973, 
2920, 2854, 1624, 1605, 1570, 1448, 1427, 1322, 1293, 1214, 1127, 1113, 1002, 958, 
812, 773, 737 cm-1; 1H NMR (400 MHz, CDCl3) δ 18.65 (s, 0.05H), 8.94 (s, 2H), 7.66 – 
7.61 (m, 2H), 7.61 – 7.55 (m, 1H), 7.55 – 7.48 (m, 2H), 6.06 (br s, 1H), 5.97 (ddt, J = 
16.1, 9.9, 5.9 Hz, 2H), 5.16 (ddd, J = 28.5, 3.4, 1.7 Hz, 2H), 5.17 – 5.14 (m, 2H), 3.44 








139.8, 136.0, 132.2, 129.1, 127.8, 115.9, 104.6, 104.7, 26.9; HR-MS: m/z Calcd. for 





yl)cyclohexa-1,3-dien-1-olate 121:   
In-situ Preparation of Triflate 114:  Prepared in the same manner as described for the 
preparation of compound 113. 
Preparation of 121: To a flame-dried 50-mL round-bottom flask containing 142 (147 mg, 
0.474 mmol) under an argon atmosphere was added THF (6.2 mL) and toluene (2.1 mL).  
The solution was cooled to 0 oC, and LiHMDS (1.9 mL, 1 M in THF) was added.  
Immediately following, the solution of freshly prepared triflate 114 (306 mg, 1.18 mmol) 
was pulled into a syringe and filtered through a plug of cotton directly into the reaction 
mixture in a dropwise fashion.  The reaction mixture was stirred for 25 minutes at 0 oC 
and was then quenched with saturated aqueous NH4Cl (10 mL).  The mixture was poured 
into water (5 mL) and extracted with CH2Cl2 (3 x 15 mL).  The combined organic layers 
were then washed with saturated aqueous NaHCO3 (10 mL), water (10 mL), and brine 
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residue was re-dissolved in Et2O (50 mL) and mixed vigorously with a solution of 
saturated aqueous K2CO3 (1 x 10 mL).  Water (5 mL) was added and the mixture was 
shaken vigorously; a precipitate formed at this point.  The layers were separated leaving 
the precipitate behind in the separatory funnel; acetone (15 mL) was added to remove the 
precipitate.  The Et2O layer was re-extracted in this manner two more times.  The 
precipitate was isolated and purified by removing acetone in vacuo and washing with a 
mixture of pentane/Et2O (15 mL) to remove minor impurities.  The product was dried in 
vacuo to provide 93.6 mg (43 %) of potassium salt 121 as a gold, amorphous solid in a 
1.3:1 mixture of diastereomers as determined by 1H NMR analysis.  The combined 
aqueous layers were then washed with pentane (3 x 30 mL), hexane (1 x 30 mL), and 
EtOAc (3 x 30 mL).  The combined EtOAc layers were concentrated in vacuo to provide 
7.5 mg (4 %) of free enol 143 as a 1.3:1 mixture of diastereomers as determined by 1H 
NMR analysis.  Compound 121 converted to enol 143 after extraction with 1 M HCl. [47 
% overall yield of compound 143] 
121: Rf = 0.30 (25 % EtOAc/hexanes); m.p. 125 – 130 oC (acetone); 
IR νmax 3373, 3073, 2976, 2922, 1615, 1528, 1470, 1408, 1372, 1300, 
1218, 1177, 1120, 992, 913 cm-1; 1H NMR (400 MHz, CD3OD, 1.3:1 
mixture of diastereomers as determined by 1H NMR analysis) δ 7.64 – 7.20 (m, 5H), 5.94 
– 5.79 (m, 1H), 5.66 – 5.46 (m, 2H), 5.11 – 4.74 (m, 6H), 4.58 – 4.49 (m, 2H), 3.17 – 
3.04 (m, 2H), 2.46 (ddd, J = 12.5, 12.5, 6.6 Hz, 1H), 2.26 (ddd, J = 12.7, 12.7, 7.8 Hz, 
0.8H), 2.21 – 2.13 (m, 0.9H), 2.08 – 1.88 (m, 2.3H), 1.87 – 1.80 (m, 0.8H), 1.80 – 1.71 









CD3OD, 1.3:1 mixture of diastereomers as determined by 1H NMR analysis) δ 199.9, 
198.7, 195.9, 195.2, 194.9, 181.2, 179.8, 148.2, 148.1, 145.4, 145.3, 139.1, 139.0, 138.8, 
138.7, 135.2, 135.0, 130.4, 129.3, 129.1, 128.9, 128.5, 128.4, 128.3, 128.1, 127.9, 127.8, 
117.2, 115.1, 113.4, 113.2, 113.1, 112.3, 107.4, 107.2, 106.8, 61.3, 61.2, 45.8, 45.7, 43.6, 
43.5, 39.6, 39.5, 27.6, 24.3, 18.8, 18.3, 14.3; HR-MS: m/z Calcd. for C27H30O4 [M+H+]: 





2,4-dien-1-one 143:  In-situ Preparation of Triflate 114:  Prepared in the same manner as 
described for the preparation of compound 113. 
Preparation of 143:  LiHMDS (1.0 mL, 0.967 mmol, 1.0 M in THF) was added to 142 
(75.0 mg, 0.242 mmol) followed by the addition of triflate 114 (0.605 mmol) as described 
above for the preparation of 121; the initial acidic work-up was also done in the same 
manner as described above for the preparation of 121.  Purification by column 
chromatography (silica gel, 2 – 100 % EtOAc/hexanes, 20 % MeOH/EtOAc with 5 % 
AcOH) afforded 36.4 mg (36 %) of 143 (green/yellow oil) as a 1.3:1 mixture of 




















EtOAc/hexanes); IR νmax 3265, 3077, 2978, 2927, 1641, 1600, 1559, 1512, 1448, 1376, 
1215, 1137, 993, 917 cm-1; 1H NMR (500 MHz, CDCl3, 1.3:1 mixture of diastereomers 
and 1.3:1 mixture of tautomers as determined by 1H NMR analysis) δ 18.77 (s, 0.3H), 
18.66 (s, 0.23H), 17.19 (s, 0.26H), 16.92 (s, 0.2H), 7.98 – 7.32 (m, 5H), 6.68 (s, 0.26H), 
6.64 (s, 0.34H), 6.14 (s, 0.28H), 6.12 (s, 0.12H), 6.02 – 5.79 (m, 1H), 5.67 – 4.88 (m, 
8H), 4.73 – 4.49 (m, 2H), 3.65 – 2.97 (m, 2.6H), 2.72 – 2.42 (m, 1.8H), 2.40 – 1.90 (m, 
3.8H), 1.74 (dd, J = 13.7, 3.0 Hz, 0.3H), 1.72 – 1.62 (m, 0.5H), 1.61 (dd, J = 1.5, 0.8 Hz, 
0.44H), 1.59 (dd, J = 1.4, 0.8 Hz, 0.81H), 1.58 (dd, J = 1.4, 0.8 Hz, 0.65H), 1.45 (dd, J = 
1.3, 0.6 Hz, 1.1H); 13C NMR (100 MHz, CDCl3, 1.3:1 mixture of diastereomers and 1.3:1 
mixture of tautomers as determined by 1H NMR analysis) δ 196.3, 195.5, 193.8, 192.4, 
188.8, 188.3, 173.2, 172.1, 164.6, 156.0, 152.3, 146.6, 146.3, 146.2, 146.0, 138.7, 138.6, 
138.5, 136.6, 136.5, 136.3, 135.3, 132.1, 131.9, 131.6, 131.3, 131.1, 130.2, 128.5, 128.0, 
127.8, 127.7, 127.7, 127.6, 127.4, 119.2, 119.1, 118.8, 118.8, 118.0, 117.9, 117.3, 116.0, 
115.9, 115.8, 115.6, 113.7, 113.5, 113.4, 112.3, 109.1, 108.4, 108.2, 108.0, 56.6, 56.3, 
46.0, 45.5, 45.0, 44.6, 44.6, 44.4, 44.0, 43.6, 40.6, 40.0, 39.2, 39.2, 38.8, 38.5, 29.7, 26.9, 







one 119: (Scheme 2.5)  To a 20-mL scintillation vial containing 121 (55.7 mg, 0.1337 
mmol) was added formic acid (5.45 mL).  The vial was capped and the reaction mixture 
was stirred for 3 days.  The reaction mixture was concentrated in vacuo to a volume of 
~0.5 mL formic acid.  Purification by preparative thin layer chromatography (silica gel, 
20 % EtOAc/hexanes) provided 13 mg (23 %) of 119 as a yellow residue. [Note: When 
substrate 143 was reacted under these conditions, racemic allyl clusianone (±)-112 could 
































1.3:1 mixture of diastereomers
1.3:1 mixture of diastereomers















113 (23.8 mg, 0.055 mmol) under an argon atmosphere was added CH2Cl2 (4.0 mL).  
LiBr (47.8 mg, 0.55 mmol) was added at room temperature, and the suspension was 
cooled to -78 oC and stirred for 5 minutes.  p-TsOH (106 mg, 0.55 mmol) was added after 
the reaction mixture was at -78 oC.  The reaction was warmed between -40 and -45 oC 
and stirred at this temperature for 27 h. [note: The decomposition threshold was between 
-39 oC and -35 oC.]  The reaction mixture was diluted with water and extracted with 
CH2Cl2 (3 x 10 mL).  The combined organic layers were washed with saturated aqueous 
NaHCO3 (1 x 20 mL), water (1 x 20 mL), and brine (1 x 20 mL).  The organic solution 
was dried over Na2SO4, filtered, and concentrated in vacuo.  Purification by column 
chromatography (silica gel, 3 % – 9 % EtOAc/hexanes) provided 14 mg (59 %) of (S,S)-
118 as a clear oil. (S,S)-118:  Rf = 0.2 (20 % EtOAc/hexanes); IR νmax 3077, 2978, 2926, 
2851, 1677, 1657, 1621, 1449, 1389, 1371, 1277, 1228, 1177, 1131, 1073, 995, 914, 857, 
744 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.88 – 7.85 (m, 2H), 7.53 – 7.48 (m, 1H), 7.42 – 
7.37 (m, 2H), 5.90 (dddd, J = 17.3, 10.1, 6.0, 6.0 Hz, 1H), 5.75 (dddd, J = 16.9, 10.2, 8.0, 
5.8 Hz, 1H), 5.65 (dddd, J = 17.3, 10.1, 7.4, 7.3 Hz, 1H), 5.17 – 4.99 (m, 6H), 3.96 (s, 
3H), 3.22 (ddddd, J = 21.5, 15.8, 6.0, 1.7 Hz, 2H), 2.87 (dd, J = 13.4, 7.4 Hz, 1H), 2.55 
(dd, J = 13.4, 7.3 Hz, 1H), 2.28 (dd, J = 13.8, 4.1 Hz, 1H), 2.23 – 2.11 (m, 2H), 1.71 
(ddd, J = 13.5, 9.4 Hz, 1H), 1.51 (dd, J = 12.9, 12.9 Hz, 1H), 1.32 (s, 3H), 1.06 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ 194.2, 186.4, 171.5, 168.1, 137.5, 136.3, 135.8, 133.0, 
132.2, 129.3, 128.2, 125.5, 121.0, 119.2, 117.3, 115.1, 86.8, 62.1, 47.3, 41.5, 40.0, 36.0, 








chromen-7-one (R,S)-118: (Scheme 2.4) Compound (R,S)-118 was prepared from (+)-
(R,S)-113 in the same manner as described for (S,S)-118.  The reaction was diluted with 
water and extracted with CH2Cl2 (3 x 5 mL).  The combined organic extracts were 
washed with water (1 x 10 mL) and brine (1 x 10 mL), dried over Na2SO4, filtered, and 
concentrated in vacuo.  Purification by column chromatography (silica gel, 3 – 12 % 
EtOAc/hexanes) provided 3.7 mg (30 %) of (R,S)-118 as a clear oil.  The reaction also 
afforded 2.4 mg (20 %) of 120.  (R,S)-118:  Rf = 0.23 (20 % EtOAc/hexanes); IR νmax 
3630, 3076, 2978, 2923, 2850, 1676, 1656, 1618, 1596, 1449, 1389, 1372, 1276, 1227, 
1173, 1131, 995, 919, 836, 742 cm-1; 1H NMR (400 MHz, CDCl3) 7.90 – 7.85 (m, 2H), 
7.54 – 7.49 (m, 1H), 7.44 – 7.37 (m, 2H), 5.90 (dddd, J = 17.0, 10.0, 6.0, 6.0 Hz, 1H), 
5.76 – 5.64 (m, 1H), 5.63 (dddd, J = 17.7, 10.3, 7.5, 7.5 Hz, 1H), 5.18 – 4.98 (m, 6H), 
3.98 (s, 3H), 3.22 (app d, J = 6.0 Hz, 2H), 2.71 (ddd, J = 19.7, 13.4, 6.7 Hz, 2H), 2.47 
(dd, J = 14.0, 4.0 Hz, 1H), 2.25 – 2.14 (m, 1H), 1.77 (ddd, J = 14.0, 9.2 Hz, 1H), 1.63 
(ddddd, J = 12.9, 10.2, 3.7, 3.5, 3.4 Hz, 1H), 1.52 (dd, J = 13.4, 12.9 Hz, 1H), 1.27 (s, 
3H), 1.19 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 194.5, 186.2, 171.2, 169.7, 137.6, 






















49.6, 46.5, 42.5, 35.5, 33.7, 28.5, 28.2, 21.7; HR-MS: m/z Calcd. for C28H32O4 [M+H+]: 




one 117: (Scheme 2.3, conditions b) To a round-bottom flask containing compound 118 
(2.0 mg, 0.00462 mmol, 1.5:1 trans:cis diastereomers as determined by 1H NMR 
analysis) was added formic acid (0.3 mL).  The reaction mixture was stirred for 12 h open 
to the air.  The reaction mixture was then concentrated to yield 2.0 mg (>99 %) of 13 
without the need for further purification.   
 
4,6,6-Triallyl-2-benzoyl-3-hydroxy-5-methoxycyclohexa-2,4-dien-1-
one 144:   Method 1:  To a flame-dried 50-mL round-bottom flask was 
added 83 (36.9 mg, 0.114 mmol).  The flask was charged with argon, 
THF (1.5 mL), toluene (0.5 mL), and was cooled to -10 oC.  LiHMDS (0.34 mL, 0.342 
mmol, 1.0 M in THF) was added over 30 sec and stirred for 2 – 5 minutes.  Added allyl 
iodide (0.01 mL, 0.114 mmol) over 5 seconds, stirred at room temperature for 10 
minutes, and then heated to 50 oC for 35 minutes.  The reaction was quenched by addition 
of aqueous 1 M HCl (3 mL) and was stirred for 15 minutes.  The mixture was extracted 



















and concentrated in vacuo to give 44.6 mg of a crude residue, which was purified by 
preparative thin layer chromatography (silica gel, 20 % Et2O/hexanes) via three 
consecutive elutions to provide 27.8 mg (67 %) of 144.   
Method 2:  To a flame-dried flask was added 83 (111 mg, 0.343 mmol), THF (4.5 mL), 
and toluene (1.5 mL) under an argon atmosphere.  The solution was cooled to -10 oC, and 
LiHMDS (0.10 mL, 1.03 mmol, 1.0 M in THF) was added over 30 sec and stirred 2 – 5 
minutes.   Allyl bromide (0.03 mL, 0.360 mmol) was added in one portion and the 
reaction was heated to 50 oC for 30 minutes.  Aqueous 1 M HCl was added; the mixture 
was poured into water and extracted with CH2Cl2 (3 x 10 mL).  The combined organic 
layers were washed with water (1 x 20 mL) and brine (1 x 20 mL), dried over Na2SO4, 
filtered, and concentrated in vacuo. Purification by the General Purification Procedure 
for Dearomatized Phloroglucinols and PPAP Derivatives provided 107.6 mg (85 %) of 
144 as an orange oil.  144: Rf = 0.2 (20 % Et2O/hexanes); IR νmax 3078, 2979, 2927, 
1665, 1642, 1589, 1520, 1435, 1339, 1232, 1144, 993, 922 cm-1; 1H NMR (500 MHz, 
CDCl3, 2:1 mixture of tautomers as determined by 1H NMR analysis) δ 18.50 (s, 1H)*, 
16.43 (s, 0.5H)**, 7.51 – 7.45 (m, 4.5H), 7.41 – 7.35 (m, 3H), 6.07 – 5.97 (m, 1H)*, 5.94 
– 5.85 (m, 0.5H)**, 5.63 – 5.48 (m, 3H), 5.16 – 4.99 (m, 9H), 4.09 (s, 3H)*, 4.00 (s, 
1.5H)**, 3.35 (dt, J = 5.2, 1.8 Hz, 2H)*, 3.22 (dt, J = 5.5, 1.8 Hz, 1H)**, 2.75 (app d, J = 
7.6 Hz, 2H)**, 2.69 (dd, J = 13.4, 6.9, 1.3 Hz, 2H)*, 2.53 (dd, J = 13.4, 7.6 Hz, 2H)*; 
*denotes conjugated enol tautomer (major) 




13C NMR (125 MHz, CDCl3, 2:1 mixture of tautomers as determined by 1H NMR 
analysis) δ 198.3**, 196.0*, 192.9*, 189.6**, 188.6*, 182.9**, 174.3*, 166.5**, 137.8, 
137.5, 135.6, 135.0, 131.9, 130.9, 130.8, 130.2, 127.1, 126.9, 126.7, 126.6, 120.5, 118.0, 
117.4, 114.8, 113.9, 113.8, 112.1, 109.0, 107.6, 61.6, 61.2, 58.4, 53.1, 42.1, 40.5, 27.0, 
26.8; HR-MS: m/z Calcd. for C23H24O4 [M+H+]: 365.1753 , Found 365.1766. 
 
3,6,6-Triallyl-8-benzoyl-5-methoxy-2,2-dimethyl-2,3,4,6-tetrahydro-7H-chromen-7-
one 117:   
Method 1: (Table 2.2, entry 2) To a flask [no argon atmosphere] containing a solution of 
113 (1.9 mg, 0.00439 mmol) in HFIP (0.283 mL) was added LiOTf (6.9 mg, 0.0439 
mmol), and p-TsOH (8.5 mg, 0.0439 mmol).  The reaction mixture was heated to 50 oC 
and stirred for 12 h.  The reaction was then cooled to room temperature, added to water, 
and extracted into EtOAc (3 x 5 mL).  The combined EtOAc extracts were then washed 
with water (1 x 10 mL) and brine (1 x 10 mL), dried over Na2SO4, filtered, and 
concentrated in vacuo to provide 2.4 mg of crude residue.  Purification by column 
chromatography (silica gel, 20 % EtOAc/hexanes) provided 1.7 mg (89 %) of 117. 
Method 2: (Table 2.2, entry 3) To a flame-dried round-bottom flask under an argon 
atmosphere containing 113 (58.3 mg, 0.135 mmol) was added TFA (1.0 mL).  The 
reaction mixture was stirred for 24 h and then quenched with saturated aqueous NaHCO3. 














brine (1 x 10 mL), dried over Na2SO4, and concentrated in vacuo.  Purification by 
preparative thin layer chromatography (silica gel, 20 % EtOAc/hexanes) afforded 56.7 
mg (97 %) of 117 as a dark oil.   
Method 3 (Table 2.2, entry 4):  To a flame-dried round-bottom flask under an argon 
atmosphere containing 8 (31.2 mg, 0.0721 mmol) was added CH3NO2 (4.8 mL).  LiBr 
(62.6 mg, 0.7213) and TsOH (145 mg, 0.721 mmol) were added, and the reaction was 
stirred for 10 minutes.  Water was added and the mixture was extracted with EtOAc (3 x 
10 mL). The combined organic layers were washed with saturated aqueous NaHCO3 (1 x 
20 mL), water (1 x 20 mL), and brine (1 x 20 mL).  The organic solution was dried over 
Na2SO4, filtered, and concentrated in vacuo.  Purification by column chromatography 
(silica gel, 5 – 20 % EtOAc/hexanes) provided 17.1 mg (55 %) of 117. 
 
3,6,6-Triallyl-8-benzoyl-7-hydroxy-2,2-dimethyl-2,3,4,6-tetrahydro-5H-chromen-5-
one 119:  (Scheme 2.3, conditions d) Lithium bromide (250 mg, 1.31 mmol) and p-TsOH 
(114 mg, 1.31 mmol) were added to a solution of 117 (56.7 mg, 0.131 mmol) in CH2Cl2 
(9.0 mL).  The reaction mixture was stirred open to the air for 5 minutes, was quenched 
with water (10 mL), and finally extracted with CH2Cl2 (3 x 10 mL).  The combined 
organic layers were washed with water (1 x 20 mL) and brine (1 x 20 mL), dried over 
Na2SO4, filtered, and concentrated in vacuo.  The product was purified by silica gel 













yellow oil. 119: Rf = 0.43 (15 % EtOAc/hexanes); IR νmax 3633, 3078, 2980, 2923, 2845, 
1641, 1590, 1441, 1387, 1372, 1295, 1241, 1155, 1131, 993, 918, 824 cm-1;  1H NMR 
(500 MHz, CDCl3) δ 16.88 (s, 1H), 7.50 – 7.41 (m, 1H), 7.43 – 7.34 (m, 4H), 5.79 – 5.66 
(m, 1H), 5.56 – 5.50 (m, 2H), 5.07 – 4.98 (m, 4H), 4.95 (dd, J = 9.6, 1.4 Hz, 2H), 2.81 
(dd, J = 13.0, 6.6 Hz, 1H), 2.74 (dd, J = 13.0, 7.0 Hz, 1H), 2.70 – 2.60 (m, 2H), 2.56 (dd, 
J = 17.3, 5.3 Hz, 1H), 2.22 – 2.11 (m, 1H), 1.88 (dd, J = 17.3, 10.0 Hz, 1H), 1.73 – 1.62 
(m, 1H), 1.50 (dddd, J = 10.3, 10.3, 5.4, 3.6 Hz, 1H), 0.85 (s, 3H), 0.77 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ 197.1, 194.6, 189.8, 162.1, 138.9, 135.9, 132.4, 132.2, 130.5, 127.6, 
127.4, 118.3, 118.3, 116.8, 106.9, 105.8, 81.1, 59.6, 43.9, 42.9, 40.0, 35.1, 26.1, 21.5, 




one 119:  [Table 2.2, entry 6]:  To a flask containing a solution of 113 (18 mg, 0.0416 
mmol) in CH3CN (2.77 mL) was added LiBr (36.1 mg, 0.416 mmol), and p-TsOH (80.4 
mg, 0.416 mmol).  The reaction mixture was heated to 60 oC and stirred for 10 minutes.  
The reaction was then cooled to room temperature, water was added, and CH3CN was 
removed in vacuo.  The aqueous layer was extracted into CH2Cl2 (3 x 10 mL), and the 
combined CH2Cl2 layers were washed with water (1 x 20 mL) and brine (1 x 20 mL), 















Purification by silica gel chromatography (3 % - 12 % EtOAc/hexanes) provided 6.1 mg 




(Table 2.2, entry 7) Lithium bromide (68.9 mg, 0.793 mmol) was added to a stirred 
solution of 113 (34.3 mg, 0.0793 mmol, 1.3:1 d.r. as determined by 1H NMR analysis) in 
CH2Cl2 (6.0 mL).  The reaction mixture was cooled to -25 oC before adding p-TsOH (153 
mg, 0.793 mmol). The reaction was stirred for 30 h, quenched with water (5 mL), and 
extracted into CH2Cl2 (3 x 5 mL).  The combined organic layers were washed with water 
(1 x 5 mL) and brine (1 x 5 mL), dried over Na2SO4, filtered, and concentrated in vacuo 
to provide 30.3 mg (97 %) of 120 without the need for further purification. 120:  Rf = 
0.55 (20 % EtOAc/hexanes); IR νmax 3077, 2978, 2924, 2850, 1599, 1448, 1419, 1387, 
1371, 1323, 1290, 1215, 1160, 1131, 1019, 995, 913, 837, 741 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 11.86 (s, 1H), 7.53 – 7.49 (m, 2H), 7.48 – 7.44 (m, 1H), 7.39 – 7.35 (m, 2H), 
6.06 (dddd, J = 17.1, 10.0, 6.0, 6.0 Hz, 1H), 5.79 – 5.70 (m, 1H), 5.08 (ddd, J = 17.1, 3.7, 
1.8 Hz, 1H), 5.06 – 5.04 (m, 1H), 5.04 – 5.01 (m, 2H), 3.78 (s, 3H), 3.43 (dddd, J = 15.0, 
6.0, 1.5, 1.5 Hz, 1H), 3.38 (dddd, J = 15.0, 6.0, 1.5, 1.5 Hz, 1H),  2.77 (dd, J = 16.7, 5.3 
Hz, 1H), 2.25 (dddd, J = 13.8, 7.2, 3.4, 1.5 Hz, 1H), 2.20 (dd, J = 16.7, 10.1 Hz, 1H), 
















CDCl3) δ 199.8, 162.0, 160.0, 153.1, 141.6, 136.1, 136.1, 135.3, 129.4, 126.6, 126.5, 
115.6, 115.6, 113.4, 111.3, 106.8, 104.7, 77.2, 59.8, 38.8, 34.0, 26.7, 25.6, 21.4, 19.2; 
HR-MS: m/z Calcd. for C25H28O4 [M+H+]: 393.2066, Found 393.2077.  
 
Effect of Base Counterion in Alkylative Dearomatization: 

















a Isolated yield of product after silica gel chromatography. 
b Reaction was carried out in THF:benzene (3:1). 
KHMDS = potassium bis(trimethylsilyl)amide 
NaHMDS = sodium bis(trimethylsilyl)amide 
   LiHMDS = lithium bis(trimethylsilyl)amide 
General Procedure for Table 2.1:   
Preparation of Triflate 114:16h  A solution of 116 (18.7 mg, 0.148 mmol) in hexanes (0.3 
mL) and toluene (0.13 mL) was cooled to 0 oC.  N,N-Diisopropylethylamine (35 µL, 0.20 
mmol) was added followed by trifluoromethanesulfonic anhydride (25.7 µL, 0.15 mmol) 
over 1 minute.  The reaction was allowed to stir for 5 minutes.  The resulting suspension 
was then filtered through a cotton plug to remove amine salts.  The solution was 
   Entry Base    Yielda   
%C   %O 
      1 KHMDS     0     53 
      2b 
      3 
  NaHMDS 
LiHMDS 
 47     31 






















concentrated to a volume of roughly 0.5 mL and was used immediately without 
purification (see below).   
General Procedure for Table 2.1 [shown for entry 1]:  To a round bottom flask 
containing 83 (18.7 mg, 0.148 mmol) under an argon atmosphere was added THF (0.66 
mL) and toluene (0.22 mL).  The solution was cooled to 0 oC, and KHMDS (0.1 mL, 0.5 
M in toluene) was added dropwise over 1 minute.  Stirred for 2 minutes and then added a 
solution of triflate 114 (39 mg, 0.15 mmol) in toluene (0.5 mL).  The reaction was 
allowed to stir for 15 minutes and was quenched with saturated aqueous NH4Cl (3 mL).  
The mixture was poured into water (1 mL), extracted with EtOAc (3 x 3 mL).  The 
combined organic layers were washed with water (1 x 1 mL) and brine (1 x 1 mL), dried 
over Na2SO4, and concentrated in vacuo to give 27.4 mg of crude residue.  Purification 
by silica gel chromatography provided 11.4 mg (53 %) of 145 as a yellow residue; C-
alkylation product 113 was not observed when using KHMDS as base. 
 
 (3,5-Diallyl-2-hydroxy-4-methoxy-6-((2-(prop-1-en-2-yl)pent-4-
en-1-yl)oxy)phenyl)(phenyl)methanone 145: Rf = 0.62 (20 % 
EtOAc/hexanes); IR νmax 3079, 2977, 2920, 1638, 1612, 1597, 
1579, 1448, 1417, 1378, 1338, 1283, 1224, 1178, 1120, 1032, 1015, 995, 912 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 11.10 (s, 1H), 7.77 – 7.71 (m, 2H), 7.61 – 7.48 (m, 1H), 7.48 
– 7.38 (m, 2H), 6.07 (dddd, J = 17.1, 10.1, 6.0, 6.0 Hz, 1H), 5.98 (dddd, J = 17.0, 10.0, 
5.7, 5.7 Hz, 1H), 5.45 (dddd, J = 17.1, 10.2, 6.9 Hz, 1H), 5.16 – 4.79 (m, 8H), 4.67 (ddd, 








30.0, 30.1, 6.0, 1.7, 1.7 Hz, 2H), 3.42 – 3.28 (m, 4H), 1.81 (ddddd, J = 14.2, 7.0, 5.7, 1.4, 
1.4 Hz, 1H), 1.69 (ddddd, J = 14.2, 9.4, 7.0, 1.2, 1.2 Hz, 1H), 1.57 – 1.44 (m, 1H), 1.42 
(dd, J = 1.6, 0.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 199.4, 163.3, 159.8, 157.4, 
144.1, 139.2, 137.7, 136.5, 136.2, 132.4, 129.8, 127.7, 118.3, 117.4, 115.6, 114.9, 114.6, 
112.5, 111.5, 78.1, 62.1, 46.4, 33.8, 28.3, 28.1, 20.0;  HR-MS: m/z Calcd. for C28H32O4 
[M+H+]: 433.2379, Found 433.2367. 
 
2,4,4-Triallyl-6-benzoyl-3,5-dimethoxycyclohexa-2,5-dien-1-one 138:   Compound 
144 (12.1 mg, 0.0332 mmol) was treated with TMSCHN2 (0.33 mL, 0.664 mmol) in the 
same manner as described above for the preparation of 122 and 123 to provide 14.4 mg 
of crude residue.  The mixture was then purified by preparative silica gel chromatography 
(9 % EtOAc/hexanes) via four elutions to provide 3.7 mg (29 %) of 138.  138: Rf = 0.16 
(10 % EtOAc/hexanes); IR νmax 3078, 3004, 2980, 2948, 2928, 2850, 1675, 1653, 1613, 
1450, 1362, 1277, 1224, 1139, 1060, 995, 920, 852 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.96 – 7.88 (m, 2H), 7.58 – 7.48 (m, 1H), 7.45 – 7.39 (m, 2H), 5.86 (ddt, J = 16.3, 11.0, 
6.9, 5.8 Hz, 1H), 5.75 – 5.56 (m, 2H), 5.16 – 4.93 (m, 6H), 4.00 (s, 1H), 3.64 (s, 3H), 
3.19 (ddd, J = 5.8, 1.9 Hz, 2H), 2.67 (ddd, J = 25.4, 13.5, 7.0 Hz, 4H); 13C NMR (100 
MHz, CDCl3) δ 196.2, 187.2, 169.8, 169.0, 138.2, 136.3, 133.1, 132.8, 129.3, 128.5, 
120.8, 118.6, 118.4, 115.0, 62.1, 59.8, 53.7, 41.3, 27.9; HR-MS: m/z Calcd. for C24H26O4 
















2-Methylhex-5-en-2-yl formate 129:  To a flame-dried 10-mL round bottom flask under 
an argon atmosphere fitted with a stir bar was added 2-methyl-1,5-hexadiene 127.  The 
flask was then cooled to 15 oC and 98 % formic acid was added to provide a biphasic 
mixture; this was warmed to room temperature and stirred for 1.5 h to provide a uniform 
solution.  A short path distillation head was fitted to the reaction flask and heated to 80 oC 
under reduced pressure to remove formic acid.  The temperature was then increased to 
120 oC to provide 804 mg (76 %) of 129 as a clear oil.  129: Rf = 0.28 (1 % 
Et2O/hexanes, cerium ammonium molybdate stain); IR νmax 3080, 2981, 2938, 2892, 
1724, 1643, 1453, 1371, 1195, 1147, 996, 912, 859, 814 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 8.00 (s, 1H), 5.83 (ddt, J = 16.9, 10.1, 6.5 Hz, 1H), 5.05 (ddd, J = 16.9, 3.0, 1.6 
Hz, 1H), 4.98 (ddd, J = 10.1, 3.0, 1.4 Hz, 1H), 2.19 – 2.11 (m, 2H), 1.92 – 1.85 (m, 2H), 
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    Chapter 3 
 
         Rapid Synthesis of Polycyclic Polyprenylated 
Acylphloroglucinol Analogs via Dearomative 
Conjugative Allylic Annulation 
3.1 Introduction to PPAP Analog Synthesis 
     Polycyclic polyprenylated acylphloroglucinol (PPAP) natural products including 
nemorosone (2), clusianone (1), and hyperforin (9) are structurally complex, highly 
substituted bicyclic molecules having promising chemotherapeutic properties (Figure 
3.1).1,2a,11e,24,25a,c, 45  As such, their laboratory syntheses have received considerable 
attention.46,6,16a,c-h,n,29a,32  PPAPs are highly regarded for their biological activities1 which 
include anticancer,2a,24,25a,c,45a,c antiviral,45b and antibacterial45d properties. However, 
several inherent barriers have limited the clinical development of these natural products: 
1) short half-life,45c 2) instability (ease of oxidation),16a,47a,b  3) synthetic challenges,6,16a,c-  
 













nemorosone (2) clusianone (1) hyperforin (9)
"type A" "type B" "type A"
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h,n,29a,32,46 and 4) promiscuous biological activity.1h Thus, medicinal chemistry and 
biological evaluation of novel analogs within the PPAP family is of high interest but 
remains underdeveloped.6,48  With these challenges in mind, we sought to design a route 
that would be both chemically efficient and applicable to diversity-oriented synthesis 
(DOS).49 
     As described by Mulzer in a recent review,50 there are numerous tactics to render a 
given synthesis efficient including biosynthetic considerations. By considering a 
biosynthetic hypothesis for a natural product, innate reactivity can be exploited that 
ideally results in an efficient synthetic strategy.  Although not conclusively determined, 
PPAP natural products are presumed to be derived from three building blocks: an 
acylphloroglucinol substrate such as 31 and two additional prenyl cations that react 
distinctly to assemble the bicyclo[3.3.1]nonane core.  Dearomative prenylation provides 
intermediate 151 followed by alkene-intercepted prenylation and cyclization at C1 or C3 
to provide clusianone (1) or nemorosone (2) respectively (Scheme 3.1).1 Although the 
biosynthesis of PPAP’s is efficient and complexity-generating, it has yet to be realized in 
a laboratory setting.6,16a,c-h,n,29a,32,46 
 
















1st prenylation: dearomative prenylation
2nd prenylation: alkene-intercepted prenylation
2 equiv.






     We hypothesized that Pd-catalyzed dearomative conjunctive allylic annulation 
(DCAA) of acylphloroglucinol variants 152 utilizing 2-methylene-1,3-propanediol 
derivative 153 as a conjunctive reagent47c would allow for an efficient biosynthesis-
inspired, diversity-oriented synthesis of a plethora of type A PPAP analogs 155 and type 
B PPAP analogs 157 that would possess many of the essential structural features for 
bioactivity (Scheme 3.2).2a,11e,24,25a,c,45  Such an approach to bicyclo[3.3.1]nonane 
structures would take advantage of the innate reactivity51 ,52  of acylphloroglucinols 
(dearomatization) and would utilize the simple conjunctive reagent 153 to which new 
bonds are readily made to the terminal carbon atoms,47c that has been extensively 
employed in palladium-catalyzed annulation processes.53  In this chapter, we outline our 
studies enabling the rapid construction of diverse PPAP analogs for biological evaluation 
through this modular and step-economic sequence.54 
 












































3.2 Investigations by Dr. Alexander Grenning (former postdoc in the Porco lab) to 
Access Type A PPAP Analogs 
3.2.1  Pd-Catalyzed C-Allylation of Acylphloroglucinols 
     In order to realize a diversity-oriented approach to PPAP-type structures, it was 
necessary to establish a modular, scalable, and robust route to C-allylated 
acylphloroglucinol scaffolds 152. Studies in this regard were initiated in our laboratories 
by Dr. Alex Grenning.  The synthesis of allyl desoxyhumulone 152a, a common 
intermediate en route to the natural products plukenetione A (90),16e 7-epi-nemorosone 
(10),16f and clusianone (1) (Scheme 3.3A),16n has been achieved by two related 
approaches: 1) by direct C-allylation of 2-acylphloroglucinol 158a with allyl bromide in 
20 % yield16h and 2) by selective O-allylation followed by Claisen rearrangement in 65 % 
yield, which requires temperatures of 210 ºC in deoxygenated 1,2-dichlorobenzene 
(Scheme 3.3B).16n   Moreover, C-allylated phenols 159 can be accessed through high  
 
Scheme 3.3 A) C-Allylated Acylphloroglucinols in PPAP Biomimetic Synthesis and B) 














A C-Allylated Acylphloroglucinols are Intermediates Utilized in the Synthesis of PPAPs.

















temperature (>200 ºC) or Lewis acid-promoted [3,3]-allyl phenyl ether Claisen 
rearrangements (Scheme 3.4).55  However, due to the instability of acylphloroglucinols 
(unstable to oxygen), neutral conditions involving moderate-temperatures (75-110 oC) 
and Pd(0)-catalysis were investigated for the synthesis of C-allylated acylphloroglucinols 
(Scheme 3.4).  This would proceed by Pd-catalyzed decarboxylative allylation (DcA)56 
that would generate diallyl phenyl ether57 160a in accord with the site-specificity of the 
DcA process  
 
Scheme 3.4 Alternative Approach to C-Allylated Phenol Synthesis. 
 
(Scheme 3.5).58 The Pd-catalyst could then trigger a “formal” Claisen rearrangement 
under mild conditions via allyl phenyl ether ionization59 and concomitant ortho-C-
allylation to provide product 152a. 
 
Scheme 3.5 Double DcA/Formal Claisen Rearrangment. 
 
     The requisite starting material 160a for a mild Pd-catalyzed double decarboxylative 
allylation/Claisen rearrangement sequence was prepared previously by Dr. Alex 






















Grenning in >95 % yield from benzoylphloroglucinol 158a and allyl chloroformate (not 
shown).  The synthesis of C-allylated acylphloroglucinol 152a was achieved in 87 % 
yield and only required 1 mol% Pd(PPh3)4 in cyclohexane at 75 ºC for 2h (Table 3.1, 
entry 1).  Evidence for the intermediacy of 161a in this reaction was confirmed by its 
formation and isolation after 5 min of reaction time (Table 3.1, entry 2). 
 
Table 3.1 Double DcA/Formal Claisen Rearrangement. 
 
Dichloromethane and THF yielded only O-allylated products (Table 3.1, entries 3 and 4), 
whereas toluene provided the C-allylated acylphloroglucinol 152a in 64 % yield (Table 
1, entry 5). 
     The isolated aryl ether 161a was resubjected to the reaction conditions without 
palladium catalyst to confirm that Pd(0) was necessary to induce the formal Claisen 
rearrangement to the bis-allylated product 152a.  Not surprisingly, no conversion was 
observed without the presence of the palladium catalyst, and upon addition of the 
palladium-catalyst under the optimized conditions (cyclohexane, 75 ºC), conversion to 















































a Isolated yields after silica gel chromatography. b Percent conversion as 





Scheme 3.6   Requirement of Pd(0) in DcA. 
 
3.2.2 Investigations on the Scope of the Pd-Catalyzed Allylation of 
Acylphloroglucinols, Resorcinols, and Orcinols 
     Regarding the scope of C-allylated acylphloroglucinol synthesis via double 
DcA/formal Claisen rearrangement, phloroglucinols with a variety of acyl groups were 
found to be compatible coupling partners (Scheme 3.7). For example, C-allylated 
acylphloroglucinols 152a – 152d having benzoyl-, acetyl-, isobutyryl-, and isovaleroyl 
groups were prepared. Internal allylic substitution proceeded as desired to afford 152e 
and 152f; however, terminally substituted allylic coupling partners (e.g. cinnamyl and 
prenyl) afforded complex mixtures.60  The reaction was extended to related aromatic 
starting materials such as resorcinol 152g and orcinols 152h – 152j. Importantly, a 
variety of large-scale (2-4 gram-scale) reactions were performed for each of the 







152a161a, prepared from 160a in 99% 
yield
Pd-free: 0% conversion
1 mol% Pd(PPh3)4: 76% yield
CyH, 75 ºC, 2h
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Scheme 3.7 Scope of Allyl-Desoxyhumulone Synthesis. 
 
152h). All multigram scale reactions were successful with reduced catalyst loading (0.25 
mol% Pd(PPh3)4) at an increased concentration (0.5 M in cyclohexane). 
     In addition to synthesizing C-allylated acylphloroglucinols 152a – 152j, the synthesis 
of related scaffolds was also accomplished (Scheme 3.8).  Interestingly, mono-allyl 
phenyl carbonate 162a only underwent DcA to provide allyl phenyl ether 162b under the 
optimized conditions and did not undergo formal allyl phenyl ether [3,3]-Claisen 
rearrangement regardless of the reaction duration (Scheme 3.8A). In addition, the double 
DcA/Claisen rearrangement was extended to the chrysin-derived flavone scaffold 163a 
under slightly modified conditions (Scheme 3.8B). From the commercially available 
a 2.5 equiv. allyl chloroformate, 3 equiv. Et3N, CH2Cl2 (0.1M), 5 min, > 95% yields 
in all cases. b Standard conditions, < 1 gram scale: 1 mol% Pd(PPh3)4, 
cyclohexane (CyH, 0.2M), 75 ºC, 2 - 3h. c Multigram scale: 0.25 mol% Pd(PPh3)4, 









































4-grams 160a: 91%c 152b 74%
b 152c 93%b
152d 
2-grams 160d: 54%c 152e 69%b 152f 55%b
152g 74%b
2-grams of 160g: 42%c
152h 93%b
2-grams of 160h: 91%c 152i 95%b 152j 83%b
158 R3 = H
160 R3 = CO2Allyl
a.
b. < 1 gram of 160
1 mol% Pd(PPh3)4, CyH (0.2M), 75 ºC
OR
c. 2 - 4 grams of 160
0.25 mol% Pd(PPh3)4, CyH (0.5M), 75 ºC
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flavone chrysin, 6,8-diallylchrysin 163a was synthesized without the need for silica gel 
chromatography in 99% yield over the two-step sequence.61 
 
Scheme 3.8  Related Scaffolds for Pd-Catalyzed DcA. 
 
3.2.3 Biosynthesis-Inspired, Diversity-Oriented Synthesis of Type A PPAP Analogs   
     With a variety of p-methyl C-allylated acylphloroglucinol scaffolds in hand, some of 
which were prepared in multigram quantities, the key dearomative conjunctive allylic 
annulation (DCAA) was developed to provide a diversified set of “type A” PPAP 
analogs.  After evaluation of conditions for the coupling of 152a and 153, two sets of 
optimized conditions (A and B, Table 3.2, entries 1 and 2) were identified for the “type 
A” PPAP analogs. Optimized conditions A (cyclohexane, Pd(PPh3)4) for the type A 
analogs were found to be highly solvent dependent as related conditions in DCE, toluene, 
and THF did not produce the desired product (Table 3.2, entries 3 – 5). Optimized 
conditions B (Pd2(dba)3/BINAP) for the “type A” PPAP analogs appeared to be less 
dependent on solvent, though reaction times were significantly longer in lower boiling 

















5 min or 6 h
162b,  100% conversion
by 1H NMR analysis
162a
163b,  99% yield 
from chrysin
R = H, chrysin








     o-Methyl C-allylated acylphloroglucinols 152a – 152f were found to react under 
optimized conditions A (Table 2, entry 1) to provide the “type A” PPAP analogs 155a – 
155f in excellent yields (Scheme 3.9A). The reaction tolerated both allyl (155a – 155d) 
and β-methylallyl (155e and 155f) substitution at C4 and C6.  Moreover, using the 
Grubbs second-generation catalyst, the type A prenylated analogs of 155 could be 
accessed in good yields as shown for the case of 155c (Scheme 3.9B).  All products 155 
led to selective prenylation of the mono-substituted allyl groups leaving the exo-
methylene intact.62  Removal of the methyl enol ether of 155c was accomplished in good 
yield, and the resulting vinylogous acid was stored as its dicyclohexyl ammonium salt 
155cb (Scheme 3.9B) due to its enhanced stability and shelf life.63  
 
































aOptimized conditions A  b Optimized conditions B  c 2.5 mol% Pd(PPh3)4  d2 mol% Pd2dba3,
4 mol% rac-BINAP, premixed in reaction solvent for 10 min, Δ  eDetermined by 1H  NMR of 




















Scheme 3.9 Type A PPAP Analogs via DCAA. 
     Interestingly, alkyl substitution at C3 and C5 was also essential for success of the 
DCAA reaction for type A analogs (Scheme 3.9). While the standard C-allylated 
acylphloroglucinol 153a underwent clean reaction under optimized conditions A and B to 
afford 155a, neither the proteo-(158a) or the chlorinated (164a) variants reacted with 
conjunctive reagent 153, likely due to a combination of steric and electronic influences. 
 



















a Isolated yields, purification by silica chromatography






















155a  87%a 155b 82%a 155c 93%a,b[gram-scale]






















a Isolated yields, purification by silica chromatography
























153152a, 158a, 164a a Determined by 1H NMR
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3.3 Results by Boyce to Access Type B PPAP Analogs 
3.3.1  Development of Optimized Conditions for Demethylation of Methylated C-
Allylated Acylphloroglucinols 
     In order to develop a diversity-oriented approach to type B PPAP analogs, it was 
necessary to establish a route to demethylated C-allylated acylphloroglucinol scaffolds 
152.  In contrast to the methylated precursors 152a, 152b, and 152d, the demethylated 
acylphloroglucinol scaffolds 152k – 152m are particularly suited for type B PPAP 
formation because the enols at the C3 and C5 positions are more electron rich than the 
enol at C1 (Scheme 3.11).  Thus, there would be a preference for reaction with the Pd-π-
allyl electrophile at positions C3 and C5 that would result in type B analogs.  Although 
we recently developed an improved strategy for the direct bis-allylation of unprotected 
acylphloroglucinol scaffolds in 36% yield with allyl iodide,16n a slight improvement from 
the traditional 20% achieved with allyl bromide,16h we anticipated that a more efficient 
route might involve direct demethylation of 152 with BBr3. Pleasingly, BBr3 successfully 
demethylated scaffolds 152a, 152b, and 152d to provide unprotected variants 152k – 
152m in excellent yields after 5 min of reaction time (Scheme 3.11).  After quenching  
 



















the reaction mixture with 1 M HCl, the biphasic mixture was allowed to stir vigorously 
for 2h to ensure the decomposition of any boron-phenolate complexes in solution. The 
yield was compromised significantly without stirring for 2h in 1M HCl.   
3.3.2  Biosynthesis-Inspired, Diversity-Oriented Synthesis of Type B PPAP Analogs. 
     With a variety of demethylated C-allylated acylphloroglucinol scaffolds in hand, the 
key dearomative conjunctive allylic annulation (DCAA) was developed to provide a 
diversified set of type B PPAP analogs.  At the outset of our investigation, optimized 
conditions A and B for type A PPAP analogs provided low yields of type B analogs 
(Scheme 3.12).  Preliminary investigations by Dr. Alex Grenning of the Porco group 
revealed that the C-prenylated acylphloroglucinol clusiaphenone B (31) provided the type 
B scaffold 157a in only 27% yield suggesting greater optimization could be achieved 
(unpublished results, Grenning and Porco, Jr.).  To parallel Dr. Grenning’s studies on the 
type A analogs, we sought to evaluate optimized conditions for DCAA of demethylated 
C-allylated acylphloroglucinols 152k-152m.  Promisingly, optimized conditions B for the 
type A analogs provided a 9-fold improvement in yield of bicyclo[3.3.1]nonane 157b 
relative to optimized conditions A (Scheme 3.12).  However, when similar conditions 
were applied to 152n, only 5 % yield of the type B scaffold 157e was isolated (Scheme 
3.12).  Hence, we began a systematic evaluation of reaction conditions that would allow 
access to ample quantities of type B analogs.   
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Scheme 3.12  Preliminary Investigations to Synthesize Type B PPAP Analogs by DCAA.   
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(0.9 equiv.)








110 oC, 3 h










Optimized Conditions A 
for Type A Analogs
Optimized Conditions B 
for Type A Analogs153152k
157a
157b
Optimized Conditions A 























75 oC, 3 h
75 oC, 3 h
Optimized Conditions B 
for Type A Analogs
Grenning:
Boyce:





a Pd2dba3 and BINAP were premixed in reaction solvent for 10 min, Δ.
b Isolated yields, purification by extractive isolation.
Pd2dba3






























     The DCAA of 152m provided 4% of the type B analog 157d under optimized 
conditions B, albeit at slightly lower temperatures.  Increasing the catalyst loading to 5 
mol% and the temperature to 115 oC provided a 5-fold increase in yield for 157d 
(Scheme 3.13, entry 2).  Similarly, type B analog 157c deriving from demethylated C-
allylated acylphloroglucinol 152l was produced in similar yields of 23-33% the same 
enhanced catalyst loading of 5 mol% (Scheme 3.14, entries 2 and 3).  Although we were 
 
Scheme 3.14 Initial DCAA Investigations for the Formation of Type B Analog 157c. 
 
Scheme 3.15 DCAA Optimization Screen to Access Type B PPAP analog 157b.   
a Pd2dba3 and BINAP were premixed in reaction solvent for 10 min, Δ.
b Isolated yields, purification by extractive isolation.
Pd2dba3




































solventPd2dba3(mol%) yield (%)temp (o C) time (h)entry







a Pd2dba3 and BINAP were premixed in reaction solvent for 10 min, Δ.
b 1.0 equiv Ti(OiPr)4 was added.
c % conversion determined by 1H-NMR analysis of the crude reaction mixture.






nr1.0 2 4 CyH
1.0 2 4
2 0.95 2.5 5 toluene 85 10 nr
4 0.95 20 40 toluene 65 2 no product
6 0.95 10 20 toluene 50 12 50 (conversion)c
5b toluene 65 24 decomp.0.95 2.5 5
















3 toluene 75 0.25 nr0.95 2.5 5.5
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able to achieve 44 % yield of 157b as shown in Scheme 3.12, extensive experimentation 
revealed this result was only reproducible upon increasing the catalyst loading to 5 mol% 
(Scheme 3.15), which we previously indicated was also beneficial for the formation of 
type B scaffolds 157c and 157d (Schemes 3.13 and 3.14).  All other reaction variables 
evaluated in Scheme 3.15 utilizing 2.5 mol% Pd(BINAP) led to decomposition or no 
reaction.  Hence, catalyst loadings of 5 or 10 mol% in toluene at temperatures between 50 
to 100 oC provided us with a strong starting point for reaction optimization. 
     With an optimal catalyst loading in-hand, different temperatures and reaction times 
were investigated, along with variations in the equivalencies of conjunctive reagent 153 
(Scheme 3.16). The use of excess 153 did not significantly impact the reaction yield for 
the case of substrate 152k.  However, it was ideal to use substoichiometric amounts to 
avoid potential side reactions that may result when using the alternative C-allylated  
 
Scheme 3.16  Optimized Conditions Revealed for Type B PPAP Analogs. 
a Pd2dba3 and BINAP were premixed in reaction solvent for 10 min, Δ.
b Isolated yields, purification by extractive isolation.
c No reaction due to temperature fluxuations.
Pd2dba3
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acylphloroglucinol substrates 152l and 152m that possess α-acyl protons with the 
potential for alkylation at those positions following product formation.  Suprisingly, 
fluctionations in temperatures were not tolerated leading to no reaction (Scheme 3.16, 
entry 5), and 90 oC was preferred over 100 oC for preventing the precipitation of 
palladium black and maintaining catalyst activity for 24 hours (Scheme 3.16, entries 3 
and 4).  Finally, the optimized conditions for accessing the type B PPAP analogs were 
revealed upon reducing the catalyst loading to 5 mol% without compromising reaction 
yields (Scheme 3.16, entry 7). 
     The optimized conditions to access product 157b were then applied to the DCAA of 
demethylated C-allylated acylphloroglucinol 152m that afforded type B analog 157d in  
 
Scheme 3.17  Optimized Conditions Applied to C-Allylated Acylphloroglucinol 152m. 
 
an optimized 80% yield (Scheme 3.17, entry 3).  Temperatures of 90 oC at 24 hours 
provided improved results over longer reaction times at lower temperatures and it was not 
a Pd2dba3 and BINAP were premixed in reaction solvent for 10 min, Δ.
b Isolated yields, purification by extractive isolation.
Pd2dba3





































necessary to use more than one equivalent of conjunctive reagent 153 (Scheme 3.17, 
entries 1-3).  Additionally, the coupling of 152l with 153 cleanly furnished the type B 
analog 157c in an optimized 80% yield under the same conditions (Scheme 3.18, entry 
4).  The experiments investigated in entries 1-3 of Scheme 3.18 emphasize the 
importance of running the reactions at 90 oC utilizing slightly less than one equivalent of 
conjunctive reagent 153. 
 
Scheme 3.18 Optimized Conditions Applied to C-Allylated Acylphloroglucinol 152l. 
3.4 Conclusion and Future Outlook 
     In summary, relative to the optimized conditions for type A analogs, the type B 
analogs required longer reaction times, lower temperatures, and increased catalyst 
loadings (Scheme 3.19A). Several type B PPAP scaffolds were synthesized for biological 
evaluation, and all products could be conveniently purified during work-up by potassium 
salt formation without the need for column chromatography (Scheme 3.20).  In addition 
to increasing the stability of the PPAP, the potassium salt is particularly ideal because it 
a Pd2dba3 and BINAP were premixed in reaction solvent for 10 min, Δ.
b Isolated yields, purification by extractive isolation.
Pd2dba3



































is prevalently used in marketed medications and provides a benign counterion for in vivo 
studies.64,65   Finally, olefin cross-metathesis proceeded in good yields for the type B 
analogs 157 as shown for the case of 157da (Schemes 3.19B and 3.20). 
 
Scheme 3.19 Summary of Optimized Results for Type B PPAP Analog Synthesis. 
 
Scheme 3.20 Type B PPAP Analogs Synthesized for Biological Evaluation. 
 
a  5 mol% Pd2dba3 and 10 mol% rac-BINAP, premixed in reaction solvent, 5 min,
110 oC.
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     Studies were also carried out to enhance the structural diversity of analogs to include 
those of nemorosone (2) and nemorosone II (172h) as illustrated in Scheme 3.21.  Since 
iridium π−allyl complexes are better at stabilizing branched cations than palladium,60d,e 
we envisioned that acylphloroglucinol 83 may react with Ir−π−allyl complex generated 
from conjunctive reagent 153c to afford 165a in-situ.  This intermediate would then 
undergo oxidative addition to generate π−allyl complex 166b that could cyclize in an 
intramolecular fashion to provide nemorosone analog 167c (Scheme 3.21). Additionally, 
conjunctive reagent 168d may react with 83 to provide 170f followed by a Lewis or 
Brønsted acid-induced cyclization to provide nemorosone II analog 171g.  
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Scheme 3.22 Cyclizations to Clusianone and Nemorosone Analogs Utilizing Branched 
Conjunctive Reagent 153c. 
 
     Although, after extensive experimentation, we were unable to synthesize 167c or 171g 
utilizing rhodium− and iridium−π−allyl complexes, we did generate clusianone analog 
173i and nemorosone analog 174j that possess a tetrasubstituted olefin in place of the 
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base was added to the reaction mixture, byproduct 177m was produced in 32 % whereas 
byproduct 175k was not formed.   
     One of the greatest challenges PPAP synthetic chemists have yet to accomplish is a 
biomimetic synthesis of nemorosone (2) and other PPAPs (Scheme 3.23).  If a metal-
catalyzed process were able to selectively enable alkene prenylation as shown for step 1 
in Scheme 3.23, the efficiency of such a transformation to construct 2 could only be 
paralleled by Nature.  The barrier to conducting such to a transformation in the laboratory 
may be due its many inherent obstacles:  1) the enhanced nucleophilicity of the C1 and 
C3 enols of 178n would enable alkylation at these positions prior to alkene interception, 
2) controlling the selectivity of cyclization at C1 or C3 in step 3, 3) controlling O- vs. C- 
cyclization selectivity in step 3, and 4) avoiding undesired alkylation of the unstable 
PPAP 180p.  This process would be the most efficient way to construct any PPAP natural 
product if a set of conditions were discovered to successfully mediate the formation of 
180p from 178n.  In the interest of enabling step 1 (Scheme 3.23), one might consider a 
way in which the enol carbons at C1 and C3 could be rendered less electron rich than the 
prenyl alkene required to intercept the metal−π−allyl electrophile. 
 











Step 1: Allylation of Alkene




















3.5 Experimental Section 
1. General methods 
Chemical Materials: Reagents not described in the experimentals below were purchased 
from commercial sources. Pd(PPh3)4 and Pd2dba3 were purchased from Strem Chemicals, 
Inc. and the bulk catalysts were stored in a glove box. Aliquots of Pd were removed and 
stored in continuously argon-purged vials for > 1 month periods without depreciation in 
catalytic activity. Racemic-BINAP was purchased from Aldrich and was used as 
received. Cyclohexane (anhydrous, reagent grade) was purchased from Aldrich and was 
used as received. Anhydrous THF, toluene, and CH2Cl2 were passed through an alumina 
column solvent drying system. 
 
Structure Analysis: 1H and 13C NMR, were obtained at one of two field strengths as 
indicated:  (1) 93.94 kG (400 MHz for 1H; 100 MHz for 13C) (2) 117.42 kG (500 MHz 
for 1H; 125 MHz for 13C) at ambient temperature. Hydrogen chemical shifts are 
expressed in parts per million (ppm) relative to the residual protio solvent resonance: 
CDCl3 δ 7.26. For 13C spectra, the center line of the solvent resonance was used as 
internal reference: CDCl3 δ 77.16, Mass correction was done by an external reference 
using a lockspray accessory. Mobile phases (direct flow analysis) were water and 
acetonitrile gradient with 0.1% formic acid. The MS settings were: capillary voltage = 




2. Synthesis of bis-Boc-protected methylenepropane-1,3-diol (153)66 
Diallyl alcohol (2-methylene-1,3-propandiol, 35 mmol, 3.083 g) and Boc2O (75 mmol, 
16.150 g) were charged into a 50-mL flame-dried round-bottom flask.  The inner-sides of 
the flask were rinsed with THF (~5 mL) forming a homogeneous solution in the bottom 
of the flask, which was stirred with a stir bar. The DMAP catalyst (50 mg) was then 
added as a solid. The reaction vessel was gently heated with a heat gun to initiate the 
coupling process as witnessed by CO2 effervescence. The flask was capped with a rubber 
septum and vented with a needle.  Once CO2 effervescence ceased, the reaction was 
directly subjected to silica gel column chromatography (gradient 1 – 5 % EtOAc in 
hexanes) yielding the bis-Boc-protected allylic alcohol 153 in near-quantitative yield. 
Bulk material was stored in a screw-cap vial on the bench-top for the entirety of the study 
(> 9 months) without any issues. Spectroscopic data was in agreement with the 
literature.67 
 
3. Synthesis of 5-Methoxyresorcinol (140) 
Prepared as described in Chapter 2, Section 2.4 of the Experimental Section 













A 500-mL flame-dried round-bottom flask equipped with a stir bar was charged with 
phloroglucinol-derivative (25 mmol) and AlCl3 (50 mmol). Methylene chloride (45 mL) 
was added and the reaction vessel was capped with a rubber septum attached to a balloon 
of argon and submerged in an ice bath. Once chilled, the acyl chloride (25 mmol) was 
added dropwise over 1 – 2 minutes. The syringe was rinsed with CH2Cl2 (5 mL) and the 
reaction was left to slowly warm to room-temperature overnight. After the allotted 
reaction time, CH2Cl2 was removed with a steady stream of nitrogen. Crushed ice was 
then added until the reaction was stopped (caution: addition of ice was exothermic). The 
quenched reaction mixture was then transferred to a separatory funnel with EtOAc (200 
mL) and was extracted with 1 M HCl (2 x 50 mL) followed by brine (1 x 50 mL).  The 
organic layer was then dried over MgSO4 and evaporated. The product (158) was either 
subjected to silica gel chromatography (10 – 20 % EtOAc in hexanes) or was used 















1 equiv. 1 equiv. 2 equiv.
158
(R2 = Ph, Alkyl)
(R1= H, Me, OMe, OH)
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 A 100-mL flame-dried round-bottom flask equipped with a stir bar was charged 
with 2-acylphloroglucinol-derivative (2 mmol), triethylamine (6 mmol), and CH2Cl2 (20 
mL). The solution assumed a bright yellow color similar to that of the starting material 2-
acylphloroglucinol. Allyl chloroformate (15 mmol) was then added dropwise over 1 
minute.  Following complete addition, the reaction immediately turned clear and 
colorless. Over a 5 minute time period, formation of a thick salt precipitate was observed. 
After 5 min, the reaction was diluted with 25 % EtOAc/hexanes (20 mL) and filtered 
through a plug of silica gel (using an additional 50 mL of 25% EtOAc in hexanes) to 
separate the salt from the desired product. The volatile organics were removed in vacuo 




















1 equiv. 2.5 equiv. 3.0 equiv. > 95% yields
158 160
(R2 = Ph, Alkyl)
(R1= H, Me, OMe, OH)
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6.1  General procedure for double decarboxylative allylation yielding C-allylated 




 A 25-mL flame-dried Schlenk flask equipped with a stir bar was charged with the 
diallyl phenyl bis-carbonate derivative 160 (2.5 mmol). Cyclohexane (10 mL) was added 
and the flask was capped with a septum equipped with an argon balloon and outlet 
needle. Argon was bubbled through the solvent for approximately 5 minutes. The vessel 
was then submerged in an oil bath at 75 ºC and Pd(PPh3)4 (1 mol%, 0.025 mmol, 25 mg) 
was added as a slurry in cyclohexane (2 mL) via pipette. Rapid CO2 effervescence was 
observed for the first minute. Once this process ceased, the reaction was determined to be 
at the intermediate stage (O-allylation) which was confirmed by TLC and/or 1H NMR 
analysis. The reaction was heated for 1 – 3 additional hours until full conversion to the 
final product was observed as determined by TLC and/or 1H NMR analysis. After the 
allotted reaction time, the reaction vessel was cooled to room temperature and the 
contents of the flask were directly subjected to silica gel column chromatography (10 -  











2 = Ph, Alkyl)
(R1= H, Me, OMe, OH)
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Methyl 3,5-diallyl-2,4,6-trihydroxybenzoate 152n:  To a flame-dried round-bottom 
flask fitted with a stir bar was added trialkoxybenzoate 165 (559 mg, 2.12 mmol), argon, 
and THF (37 mL).  The solution was then cooled to 0 oC, and allyl iodide (0.39 mL, 4.13 
mmol) was added dropwise over 10 – 15 min via syringe.  The reaction was allowed to 
warm slowly to room temperature over the course of 12 h and was quenched with 1 M 
HCl.  After stirring for 10 min, 1,3-propanedithiol (0.1 mL, 1.07 mmol) was added to 
remove allyl iodide.  The mixture was then concentrated in vacuo to remove organic 
solvent.  The residue was then rinsed with pentane (3 x 30 mL) and then decanted to 
remove 1,3-propanedithiol.  The product was then dissolved in Et2O (20 mL), transferred 
to a separatory funnel and mixed vigorously with saturated aqueous K2CO3 (1 x 10 mL) 
in a separatory funnel. After separating the layers, the Et2O layer was re-extracted in this 
manner (2x) and washed with brine (1 x 20 mL), dried over Na2SO4, filtered, and 















7. General procedure for the synthesis of 152k – 152m 
 
 
 To a 20-mL scintillation vial under argon containing a stirred solution of 152a 
(267.4 mg, 0.824 mmol, 1.0 equiv.) in CH2Cl2 (8.2 mL) was added BBr3 (0.24 mL, 2.47 
mmol, 3.0 equiv.) in a single portion.  The reaction was allowed to stir for 5 – 10 min and 
was then poured into 1 M HCl (100 mL).  The biphasic mixture was stirred vigorously 
for 2 h during which time the color changed from bright yellow to faint yellow.  The 
mixture was then added to water (50 mL) and extracted into CH2Cl2 (3 x 100 mL).  The 
combined organic layers were washed with a saturated solution of NaHCO3 (50 mL), 
water (50 mL), and brine (50 mL), dried over Na2SO4, and concentrated in vacuo.  The 
crude product was purified by silica gel column chromatography (gradient 2 – 10 % 
EtOAc in hexanes) to afford 152k (206 mg, 80 % yield) as a yellow crystalline solid. 
Spectroscopic data for acylphloroglucinol 152k were found to be identical with those 















8.1 General procedure for dearomative conjunctive allylic annulation for type B 




 To a flame-dried round-bottom flask fitted with a stir bar was added Pd2dba3 (5 
mol%, 0.00245 mmol, 2.2 mg) and (±)-BINAP (10 mol%, 0.00490 mmol, 3.0 mg). The 
flask was purged with argon and degassed toluene (0.1 mL) was added to provide a 
purple suspension which was then heated to 110 oC for 5 min or until the formation of a 
clear red solution. After removing the flask from the oil bath, the clear red solution was 
pulled into a 1-mL syringe and transferred to a solution of 152k (15.2 mg, 0.0490 mmol, 
1.0 equiv.) and 153 (11.7 µL, 0.0421 mmol, 0.86 equiv.) in degassed toluene (0.26 mL) at 
room temperature. The argon balloon and septum were removed and the system was 
quickly sealed with a polyethylene yellow cap, Teflon® tape, and Keck clamp; the 
reaction mixture was then placed in an oil bath at 90 oC and stirred for 24 h.  The crude 
reaction mixture was then cooled to room temperature, diluted with hexanes (3 mL), and 
filtered through a cotton plug into a round-bottom flask to remove BINAP and palladium 


























in a -20 oC fridge for 1 h; the solution was then decanted to a separatory funnel.  
Purification by the General Purification Procedure for Dearomatized Phloroglucinols and 
Enolic PPAP Derivatives provided potassium salt 157b-K (8.3 mg, 49 %) as a precipitate 
and vinylogous acid 157b (3.1 mg, 20 %) from the organic extracts.[69 % yield]  
 
8.2 General Purification Procedure for Dearomatized Phloroglucinols and Enolic 
PPAP Analogs16n 
 
 The pentane/hexane solution was mixed vigorously with saturated aqueous 
K2CO3 (1x) in a separatory funnel.  Water was added and the mixture was again shaken 
vigorously.  A precipitate formed and the layers were separated, leaving the precipitate in 
the separatory funnel.  The precipitate was then dissolved in acetone and concentrated to 
provide product as the potassium salt (>97 % purity as indicated by 1H NMR analysis). 
The pentane/hexane layer was re-extracted in this manner (2x) and then concentrated in 
vacuo to produce a crude residue.  The residue was washed with pentane to remove 
impurities providing additional product as the potassium salt (>97 % purity as indicated 
by 1H NMR analysis). The combined aqueous extracts were washed with pentane (3x) 
[enol 3m was isolated from the pentane extracts] and EtOAc (3x). The organic layers 
containing product as indicated by TLC were separately washed with 1M HCl (1x) and 
brine (1x), dried over Na2SO4, and concentrated in vacuo to provide product as the 
vinylogous acid (>97 % purity as indicated by 1H NMR analysis). 
 
 211 
8.3 Procedure for the formation of 157e. 
 
Methyl 1,5-diallyl-2-hydroxy-7-methylene-4,9-dioxobicyclo[3.3.1]non-2-ene-3-
carboxylate 157e: Compound 157e was prepared from 152n (43.7 mg, 0.165 mmol) and 
153 (0.05 mL, 0.165 mmol) in the same manner as described above for the preparation of 
157b and 157b-K.  The crude product was dissolved in CH2Cl2 (0.5 mL) and was 
purified by preparative plate chromatography (silica gel, 10 % EtOAc/hexanes) to obtain 
2.5 mg (5 %) of 157e. 
9. General Procedure for cross-metathesis of PPAP vinylogous acid analogs 
 
 A 15-mL glass pressure tube containing 3d (6.7 mg, 0.0196 mmol, 1.0 equiv.) 

























10 mol% Grubbs II
76 %




10 mol%).  The tube was then cooled to -78 oC and isobutylene (5 mL) was condensed 
along the side of the tube.  The tube was sealed and slowly warmed to 60 oC.  After 
stirring for 20 min at this temperature, the tube was recooled to -78 oC for 5 min and was 
opened to the air.  Removal of the dry ice bath allowed for evaporation of isobutylene.  
The crude product was dissolved in CH2Cl2 (0.5 mL) and was purified by preparative 
plate chromatography (silica gel, 12 % EtOAc in hexanes) to obtain pure 3da (5.9 mg, 76 
%). 
 




Spectroscopic data for acylphloroglucinol 152a were found to be identical with those 














Isolated as a light yellow solid in 74% yield. 1H NMR (400 MHz, CDCl3) δ 6.03 (m, 2H), 
5.17 (dq, J = 6.6, 1.7 Hz, 2H), 5.14 (t, J = 1.5 Hz, 2H), 3.72 (s, 3H), 3.42 (dt, J = 5.9, 1.7 
Hz, 4H), 2.70 (s, 3H). 
 
13C NMR (100 MHz, CDCl3) δ 204.6, 162.8, 159.8, 136.4, 136.4, 116.0, 110.7, 108.0, 
62.0, 33.4, 28.0. 
 




Isolated as a light yellow solid in 54% yield. 1H NMR (400 MHz, CDCl3) δ 9.80 (s, 2H), 
6.03 (ddt, J = 15.1, 11.3, 5.8 Hz, 2H), 5.17 (dq, J = 6.7, 1.8 Hz, 2H), 5.13 (m, 2H), 3.71 
(s, 3H), 3.41 (dt, J = 6.0, 1.8 Hz, 5H), 2.97 (d, J = 6.7 Hz, 2H), 2.25 (hept, J = 6.6 Hz, 











13C NMR (100 MHz, CDCl3) δ 206.9, 162.4, 159.6, 136.4, 116.0, 110.7, 108.0, 62.0, 
53.5, 28.0, 25.0, 22.8. 
 




Spectroscopic data for acylphloroglucinol 152k were found to be identical with those 




Purification by silica gel chromatography (2 – 12 % EtOAc in hexanes) provided 29.8 mg 











3079, 3005, 2978, 2928, 2854, 1608, 1468, 1433, 1392, 1367, 1291, 1214, 1169, 1124, 
1027, 997, 958, 920, 880, 828 cm-1. 
 
1H NMR (400 MHz, CDCl3) δ 18.77 (s, 0.01H), 13.52 (s, 0.025H), 9.99 (br s, 1.965H), 
6.04 – 5.92 (m, 3H), 5.25 (ddt, J = 17.0, 3.0, 1.7 Hz, 2H), 5.22 (ddt, J = 8.9, 3.0, 1.7 Hz, 
2H), 3.47 (dt, J = 6.2, 3.0, 1.7 Hz, 4H), 2.71 (m, 3H). 
 
13C NMR (100 MHz, CDCl3) δ 203.9, 159.7, 159.4, 136.0, 116.9, 105.4, 103.0, 33.1, 
27.1. 
 




Purification by silica gel chromatography (2 – 10 % EtOAc in hexanes) provided 37.8 mg 
(79 %) of 152m. 
Rf = 0.24 (10 % EtOAc in hexanes); IR νmax 3476, 3080, 3007, 2959, 2932, 2871, 1608, 







1H NMR (400 MHz, CDCl3) δ 10.04 (s, 2H), 5.98 (ddt, J = 17.2, 9.9, 6.1 Hz, 2H), 5.93 
(s, 1H), 5.26 (ddd, J = 17.2, 3.3, 1.7 Hz, 2H), 5.23 (ddd, J = 9.9, 3.3, 1.7 Hz, 2H), 3.48 
(dt, J = 6.1, 1.7 Hz, 4H), 2.98 (d, J = 6.6 Hz, 2H), 2.28 (hept, J = 6.6 Hz, 1H), 1.01 (d, J 
= 6.6 Hz, 6H);  
 
13C NMR (100 MHz, CDCl3) δ 206.2, 159.6, 159.0, 136.0, 116.8, 105.4, 103.0, 53.1, 
27.1, 25.2, 22.8; 
 





Purification of 152n was achieved in the following manner: Following work-up described 
above for the preparation of 152n, the crude residue then rinsed with pentane (3 x 30 mL) 
and then decanted to remove 1,3-propanedithiol.  The crude residue was then dissolved in 
Et2O (20 mL), transferred to a separatory funnel and mixed vigorously with saturated 







layer was re-extracted in this manner (2x) and washed with brine (20 mL), dried over 
Na2SO4, and concentrated in vacuo to provide 111.3 mg (20 %, 99% purity) of S18 as an 
orange oil.  Rf = 0.34 (20 % EtOAc/hexanes); IR νmax 3434, 3077, 3008, 2976, 2958, 
2929, 2854, 1664, 1638, 1610, 1436, 1308, 1196, 1181, 1122, 986, 915, 803 cm-1; 
 
1H NMR (400 MHz, CDCl3) δ 10.10 (br s, 2H), 5.97 (ddt, J = 16.6, 9.2, 6.0 Hz, 2H), 5.83 
(s, 1H), 5.12 (ddd, J = 16.6, 3.5, 1.8 Hz, 2H), 5.08 (ddd, J = 9.2, 3.5, 1.8 Hz, 2H), 4.03 (s, 
3H), 3.40 (dt, J = 6.0, 1.8 Hz, 4H); 
 
 13C NMR (125 MHz, CDCl3) δ 170.2, 160.4, 136.3, 115.4, 104.4, 93.6, 52.5, 27.0;   
 
HR-MS: m/z Calcd. for C14H16O5 [M+H+]: 265.1076, Found 265.1070. 
 
10.2 Spectroscopic characterization of type B PPAP analogs and related compounds 
 









Purification by the General Purification Procedure for Dearomatized Phloroglucinols 
and Enolic PPAP Analogs provided vinylogous acid 157b (3.1 mg, 20 %) from the 
EtOAc extracts. Rf = 0.24 (51 % EtOAc in hexanes); IR νmax 3076, 2925, 2856, 1715, 
1645, 1586, 1576, 1532, 1367, 1316, 1299, 1232, 1004, 914 cm-1. 
 
1H NMR (500 MHz, CDCl3) δ 17.50 (s, 1H), 7.57 – 7.49 (m, 3H), 7.42 – 7.34 (m, 2H), 
5.95 – 5.81 (m, 2H), 5.25 – 5.17 (m, 1H), 5.17 – 5.07 (m, 3H), 4.91 (app s, 2H), 2.80 (dd, 
J = 14.0, 6.7 Hz, 1H), 2.77 – 2.68 (m, 2H), 2.68 – 2.53 (m, 4H), 2.48 – 2.40 (m, 1H). 
 
13C NMR (125 MHz, CDCl3) δ 206.1, 198.1, 194.5, 192.2, 137.8, 136.9, 133.8, 132.9, 
132.6, 128.8, 127.7, 119.4, 118.9, 117.0, 65.3, 60.3, 48.9, 48.1, 35.1, 34.5. 
 
HRMS: Calc’d for C23H22O4 (M+H) = 363.1596, found 363.1591. 
 
157k-K   
 
Purification by the General Purification Procedure for Dearomatized Phloroglucinols 








precipitate. Rf = 0.62 (5 % MeOH/CH2Cl2);  IR νmax 3075, 2976, 2931, 2851, 1702, 1644, 
1575, 1523, 1446, 1431, 1363, 1317, 1296, 1250, 1175, 1031, 1003, 962, 911 cm-1. 
 
1H NMR (400 MHz, Acetone-d6) δ 7.66 – 7.59 (m, 2H), 7.33 – 7.26 (m, 1H), 7.26 – 7.18 
(m, 2H), 5.95 (dddd, J = 16.6, 10.1, 7.6, 6.5 Hz, 2H), 5.00 (dddd, J = 17.2, 2.7, 1.4, 1.4 
Hz, 2H), 4.91 (dddd, J = 10.0, 2.4, 1.1, 1.1 Hz, 2H), 4.86 (dd, J = 2.0 Hz, 2H), 2.55 – 
2.33 (m, 8H). 
 
13C NMR (100 MHz, CDCl3) δ 211.4, 198.5, 189.4, 143.6, 143.5, 137.8, 130.7, 129.7, 
129.6, 127.9, 116.9, 116.6, 113.7, 63.1, 46.5, 36.5.   
 




Purification by the General Purification Procedure for Dearomatized Phloroglucinols 
and Enolic PPAP Derivatives provided vinylogous acid 157c (3.5 mg, 25 %) from the 
EtOAc extracts. Rf = 0.17 (10 % EtOAc in hexanes); IR νmax 3080, 2983, 2927, 2854, 









 1H NMR (500 MHz, CDCl3) δ 18.58 (s, 1H), 5.82 (dtt, J = 17.2, 10.3, 7.0 Hz, 2H), 5.16 
(ddd, J = 17.2, 2.9, 1.6 Hz, 1H), 5.11 (ddt, J = 17.2, 2.9, 1.4 Hz, 1H), 5.08 (ddt, J = 10.2, 
2.1, 1.1 Hz, 1H), 5.04 (ddt, J = 10.2, 2.1, 1.1 Hz, 1H), 4.86 (ddd, J = 13.2, 3.3, 1.7 Hz, 
2H), 2.64 (s, 3H), 2.78 – 2.44 (m, 8H). 
 
13C NMR (125 MHz, CDCl3) δ 206.0, 202.3, 197.5, 193.2, 138.1, 133.9, 133.2, 119.2, 
118.5, 116.5, 65.3, 61.1, 48.4, 48.1, 34.8, 34.4, 28.2. 
 




Purification by the General Purification Procedure for Dearomatized Phloroglucinols 
and Enolic PPAP Analogs provided potassium salt 157c-K (8.7 mg, 55 %) as a 
precipitate.  Rf = 0.16 (10 % EtOAc in hexanes); IR νmax 3077, 2978, 2931, 1704, 1642, 









 1H NMR (400 MHz, Acetone-d6) δ 5.89 (dddd, J = 17.1, 10.1, 7.0, 7.0 Hz, 2H), 4.98 
(app dd, J = 17.1, 1.2 Hz, 2H), 4.87 (app dd, J = 10.1, 1.7 Hz, 2H), 4.64 (dd, J = 2.1, 2.1 
Hz, 2H), 2.53 – 2.40 (m, 4H), 2.37 (app d, J = 13.3 Hz, 2H), 2.30 (ddd, J = 13.3, 2.1, 2.1 
Hz, 2H), 2.18 (s, 3H). 
 
13C NMR (100 MHz, Acetone-d6) δ 211.4, 198.2, 190.8, 143.2, 137.9, 118.4, 116.9, 
113.2, 63.5, 47.0, 36.9. 
 





Purification by the General Purification Procedure for Dearomatized Phloroglucinols 
and Enolic PPAP Analogs provided 157d (1.9 mg, 8.5 %) from the pentane and EtOAc 
extracts. Rf = 0.46 (10 % EtOAc in hexanes); IR νmax 3079, 2959, 2929, 2871, 1731, 









1H NMR (500 MHz, CDCl3) δ 18.81 (s, 1H), 5.82 (tdt, J = 17.2, 10.2, 7.0 Hz, 2H), 5.16 
(ddt, J = 17.2, 2.1, 1.4 Hz, 1H), 5.13 – 5.06 (m, 2H), 5.04 (ddt, J = 10.2, 2.1, 1.1 Hz, 1H), 
4.86 – 4.83 (m, 2H), 3.04 (dd, J = 14.5, 6.7 Hz, 1H), 2.85 (dd, J = 14.5, 7.2 Hz, 1H), 2.74 
– 2.56 (m, 8H), 2.54 (dd, J = 13.5, 2.4 Hz, 1H), 2.47 (dt, J = 13.5, 3.2, 1.9 Hz, 1H), 2.11 
(hept, J = 6.7 Hz, 1H), 0.97 (d, J = 6.7 Hz, 3H), 0.94 (d, J = 6.7 Hz, 3H). 
 
13C NMR (125 MHz, CDCl3) δ 206.0, 204.9, 197.8, 193.0, 138.3, 133.9, 133.3, 129.0, 
128.4, 119.1, 118.5, 116.3, 110.0, 76.7, 70.5, 67.1, 65.4, 61.2, 48.5, 48.1, 48.0, 34.9, 34.4, 
27.8, 26.0, 22.7, 22.5   
 














Purification by the General Purification Procedure for Dearomatized Phloroglucinols 
and Enolic PPAP Analogs provided potassium salt 157d-K (17.6 mg, 71 %) as a 
precipitate. Rf = 0.34 (10 % EtOAc in hexanes); IR νmax 3077, 2957, 2929, 2901, 2870, 
1708, 1648, 1585, 1530, 1432, 1371, 914 cm-1. 
 
1H NMR (400 MHz, Acetone-d6) δ 5.90 (dddd, J = 17.1, 10.1, 7.7, 6.5 Hz, 2H), 4.98 
(dddd, J = 17.1, 2.6, 1.4, 1.4 Hz, 2H), 4.87 (dddd, J = 10.1, 2.4, 1.1, 1.1 Hz, 2H), 4.65 
(dd, J = 2.0, 2.1 Hz, 2H), 2.56 (d, J = 6.8 Hz, 2H), 2.54 – 2.39 (m, 4H), 2.37 (ddd, J = 
13.6, 2.1, 2.1 Hz, 2H), 2.29 (ddd, J = 13.6, 2.0, 2.0 Hz, 2H), 2.10 – 1.99 (m, 1H), 0.80 (d, 
J = 6.8 Hz, 6H). 
 
13C NMR (100 MHz, Acetone-d6) δ 211.4, 203.0, 190.0, 143.2, 138.0, 118.6, 116.8, 
113.3, 63.3, 53.6, 46.8, 36.9, 26.6, 23.6. 
 











157e (Full characterization data is provided for 157ea, which accounts for the full 
characterization of its precursor 157e): Rf = 0.10 (40 % EtOAc/hexanes);  1H NMR 
(400 MHz, CDCl3) δ 1H NMR (400 MHz, CDCl3) δ 15.12 (s, 1H), 5.89 – 5.75 (m, 2H), 
5.24 – 5.02 (m, 4H), 4.91 (dd, J = 13.4, 1.3 Hz, 2H), 3.95 (s, 3H), 2.79 (dd, J = 14.0, 6.5 




Purification of 157ca was achieved by preparative plate chromatography (silica gel, 10 % 
EtOAc/hexanes with 0.5 % AcOH). Rf = 0.38 (10 % EtOAc/hexanes); IR νmax 2966, 
2913, 2864, 1732, 1667, 1556, 1429, 910 cm-1;  
 
1H NMR (400 MHz, CDCl3) δ 18.51 (s, 1H), 5.08 (ddt, J = 14.1, 7.2, 1.7 Hz, 2H), 4.85 
(dt, J = 10.7, 1.7 Hz, 2H), 2.74 – 2.47 (m, 8H), 2.68 (s, 3H), 1.72 (br d, J = 9.0 Hz, 12H); 
 
 13C NMR (100 MHz, CDCl3) δ 206.3, 202.3, 197.9, 193.9, 138.6, 134.8, 134.3, 119.7, 













Purification by preparative plate chromatography (silica gel, 10 % EtOAc/hexanes) 
provided 157da (5.9 mg, 76 % yield).  Rf = 0.41 (10 % EtOAc in hexanes); IR νmax 2962, 
2930, 2873, 1732, 1666, 1549, 1448, 1377, 912 cm-1. 
 
1H NMR (400 MHz, CDCl3) δ 18.70 (s, 1H), 5.16 – 5.02 (m, 2H), 4.86 – 4.82 (m, 2H), 
3.03 (dd, J = 14.3, 6.8 Hz, 1H), 2.93 (dd, J = 14.3, 7.0 Hz, 1H), 2.74 – 2.48 (m, 8H), 2.13 
(hept, J = 6.6 Hz, 1H), 1.73 (dd, J = 2.8, 1.4 Hz, 6H), 1.72 (br d, J = 1.4 Hz, 3H), 1.70 (br 
d, J = 1.5 Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H), 0.99 (d, J = 6.6 Hz, 3H).   
 
13C NMR (100 MHz, CDCl3) δ 206.4, 204.9, 198.1, 193.7, 138.8, 134.8, 134.3, 119.7, 














Purification by preparative plate chromatography (silica gel, 10 % EtOAc/hexanes) 
provided 157ea (3.2 mg, 98 % yield). Rf = 0.28 (40 % EtOAc/hexanes); IR νmax 2963, 
2916, 2856, 1734, 1679, 1574, 1446, 1381, 1299, 1250, 989, 914 cm-1; 
 
1H NMR (400 MHz, CDCl3) δ 15.06 (s, 1H), 5.07 (dd, J = 15.9, 7.4 Hz, 2H), 4.89 (br d, J 
= 11.8 Hz, 2H), 3.96 (s, 2H), 2.74 – 2.44 (m, 8H), 1.73 (s, 3H), 1.72 – 1.68 (m, 9H); 
 
 13C NMR (100 MHz, CDCl3) δ 205.9, 172.3, 138.4, 119.7, 116.7, 107.4, 105.0, 66.0, 
47.6, 47.3, 29.3, 29.2, 26.0, 18.0;   
 










11. Select 1H and 13C NMR spectra 
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    Chapter 4 
 
Syntheses of (+)-30-epi-, (-)-6-epi-, (±)-6,30-epi-13,14-
Didehydroxyisogarcinol, and (±)-6,30-epi-
Garcimultiflorone A Utilizing Highly Diastereoselective, 
Lewis Acid-Promoted Cyclizations  
 
4.1 Introduction 
     For the past 15 years, the synthetic and biological communities have been interested in 
polyprenylated polycyclic acylphloroglucinols (PPAPs) as natural product targets and 
starting points for SAR studies due to their diverse bioactivity profiles (Figure 4.1A).  
Not surprisingly, with minor structural differences leading to significant variation in 
bioactivity, PPAP natural products and their analogs are considered high priority targets 
for isolation, chemical synthesis, and biological studies.2,3  The natural products 
isogarcinol (5) and garcinol (8) have gained significant attention in recent years and are 
lead compounds for several clinical indications.9,10  The importance of synthesizing 





Figure 4.1  Representative PPAP Natural Products and Diastereomers of 13,14-



























































A. Representative PPAP Natural Products
B.  Diastereomers of 13,14-Didehydroxyisogarcinol and Garcimultiflorone A 










































     Isogarcinol’s dehydroxy isomer 13,14-didehydroxyisogarcinol (3) and the type A 
variant garcimultiflorone A (4) were isolated in 2009 from the fruits of Garcinia 
multiflora in South China and were reported to possess anti-inflammatory activity by 
inhibiting superoxide and elastase enzymes released from human neutrophils (Figure 
4.1A).13  Apart from this single report, however, no additional information on the 
biological activities of natural products 3 and 4 exist further emphasizing the need for an 
efficient and scalable synthetic route to this class.  Although studies have reported the 
importance of 13,14-hydroxyls with regard to isogarcinol’s histone acetyltransferase 
(HAT) inhibition and radical-scavenging abilities,3a,26o,26c,26d,11e biological data on analogs 
that lack the hydroxyl functionalities (e.g. 3 and 4) are limited.13  Given that we were able 
to procure natural products 3 and 4 from the isolation team led by Chen and co-workers,13 
our goal was to develop a strategy for accessing non-natural diastereomers of 3 and/or 4 
for further biological studies (Figure 4.1B).     
     We were intrigued by the marked structural similarity of 13,14-
didehydroxyisogarcinol (3) to isogarcinol (5), a compound which has activity in 
numerous therapeutic indications including leukemia,26a,i colon cancer,26b,i HIV,26c,d brain 
tumors (medulloblastoma),26e antioxidant,26f antimicrobial,26f transplantation rejection 
and autoimmune diseases,26g,h,l collagen-induced and rheumatoid arthritis,26j breast 
cancer,26k and Parkinson’s disease.26m  Interestingly, isogarcinol (5) is also available for 
human consumption in mangosteen fruit drinks and capsules as a remedy for arthritis.68  
Only one total synthesis of 5 has been reported since its isolation in 1980, an elegant 
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strategy accomplished in 15-steps by Pleitker (refer to chapter 1, Scheme 1.18 for a 
detailed summary).14,11a The compound has been isolated from numerous sources,11 and a 
12 g extraction procedure was developed for its procurement.11g 
     Stereoisomers of 3 and 4 have not yet been isolated in nature which further 
emphasizes the need for a synthetic strategy to access such candidates (Figure 4.1B),26i,69 
especially given the diverse bioactivities of isogarcinol’s closely related congeners, 
including garcinol (8),11a cycloxanthochymol,12b,d 30-epi-cambogin A (6),12a,c,f,h and 7-
epi-isogarcinol (7).12b,d,e,g  In this chapter, we describe asymmetric syntheses of (+)-30-
epi-13,14-didehydroxyisogarcinol and (-)-6-epi-13,14-didehydroxyisogarcinol in six 
steps from the commercially available phloroglucinol 140 utilizing a Lewis acid-
dependent diastereoselective oxycyclization (Figure 4.2).  Using a similar strategy, we 
also demonstrate the syntheses of the meso-derived isomers (±)-6,30-epi-3 and (±)-6,30-
epi-4 (c.f. Scheme 4.3B).  Finally, a convenient strategy for large scale synthesis of both 
enantiopure and chiral, racemic stereoisomers is outlined (c.f. Scheme 4.4). 
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Figure 4.2 Retrosynthetic Analysis for (-)-6-epi-3 and (+)-30-epi-3. 
 
     Retrosynthetic analysis of enantioenritched isomers (-)-6-epi-13,14-
didehydroxyisogarcinol and (+)-30-epi-13,14-didehydroxyisogarcinol from the 
commercially available phloroglucinol 140 is shown in Figure 4.2.  Isomers (-)-6-epi-3 
and (+)-30-epi-3 may be derived from cross metathesis and cationic cyclization of 




































































precursors (-)-167 and (+)-169 should enable access to respective pyranodienones (-)-166 
and (+)-170.  We envisioned that diastereoselective, cationic oxycyclization mediated 
through Lewis-acid chelation of (+)-(S,S)-168A may furnish (-)-167 and/or (+)-169 in 
useful levels of diastereoselectivity.  Regioselective bis-alkylation of acylphloroglucinol 
115 using the primary alkyl triflate derived from alcohol (-)-(R)-116 may provide 
dearomatized adduct (+)-(S,S)-168A.16n   Finally, our laboratory has previously shown 
that compound 115 is conveniently derived from the commercially available compound 
monomethylphloroglucinol 140 via Friedel-Crafts acylation (Figure 4.2).16n   
 
4.2  Results 
 
Scheme 4.1 A) Gram Scale Synthesis of Racemic Alcohol 116 in one pot.  B) Gram Scale 
Synthesis of (-)-(R)-116 in Three Steps. 
 
     At the outset of our investigation, racemic alcohol (±)-116 was prepared in the same 
manner previously described in a single step from commercially available starting 









A Synthesis of Racemic Alcohol 116
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regioselective bis-alkylation of acylphloroglucinol 115 in the presence of LiHMDS 
providing the dearomatized enols (±)-168A, (meso)-168B, and (meso)-168C in 53 % 
yield (Scheme 4.2).  The (R) and (S) alkyl substituents of (meso)-168B and (meso)-168C 
create a mirror plane of symmetry in each structure rendering them achiral/meso (Figure 
4.3).  Alternatively, compound (+)-(S,S)-168A could be produced as a single, enantiopure 
diastereomer via bis-alkylation of acylphloroglucinol 115 utilizing the enantioenriched 
triflate derived from alcohol (-)-(R)-116 (Scheme 4.2).  We developed a multigram scale 
synthesis of alcohol (-)-(R)-116 by a modified and improved 3-step protocol starting from 
(R)-4-benzyl-2-oxazolidinone (Scheme 4.1B).  Due to the tendency of dearomatized 
enols to form calcium salts on silica gel,16n enol (+)-(S,S)-168A and racemic variants (±)-
168A, (meso)-168B, and (meso)-168C were conveniently purified by potassium salt 
formation without the need for column chromatography.  The structure of (meso)-168C 
was confirmed by X-ray crystal structure analysis.   
     The observed regioselectivity may be explained, in part, by relief of A1,3-strain when 
the anion of monoalkylated dianion intermediate 115i resides at C5 bearing the alkyl 
substituent (Scheme 4.2).17   Moreover, the trisubstituted anion at C5 should be less 
stable and more reactive than the corresponding disubstituted anion at C3 resulting in the 
production of gem-dialkylation products 168 in good yield.  DFT calculations (BL3LYP, 
6-31G*) were carried out in order to investigate the potential for pyramidalization at C5 
of 115i and to examine the difference between the HOMO at C5 and that at C3.  
However, the difference between the orbital co-efficients at both C3 and C5 were not 
significant, and pyramidalization at either position was not apparent.  
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Scheme 4.2 Regioselective bis-Alkylation of Acylphloroglucinol 115: Racemic and 
Enantioenriched Variants.  
 




















































Regioselective bis-Alkylation Utilizing (-)-(R)-116:
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(meso)-168C(meso)-168B X-ray of (meso)-168C
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     We next evaluated the possibility for diastereoselective oxycyclization of (+)-(S,S)-
168A to provide the enantiopure pyranodienones (-)-167 and (+)-169 (Table 4.1).  The 
diastereoselectivity in this case would result if the two 1,1-disubstituted alkenes of (+)-
(S,S)-168A undergo protonation at different kinetic rates.  A number of acidic conditions 
were evaluated for cyclization including HCl in CH2Cl2 which provided (-)-167 and (+)-
169 in 1:1.1 d.r. (Table 4.1, entry 1).  After considerable experimentation, we discovered 
that binary acid combinations70 of LiBr with either chiral or achiral phosphoric acids 
provided high yields of (-)-167 and (+)-169 in roughly 1:2 d.r. in favor of (+)-169 (Table 
4.1, entries 2 – 8).  In the absence of LiBr, the reaction did not proceed as the acidity of 
the phosphoric acid was presumably enhanced through lithium coordination (Table 4.1, 
entry 10). Since both chiral (171 – 174) and achiral phosphoric acids (175 – 176) 
provided similar outcomes with LiBr (Table 4.1, entries 2-8), we anticipated that the 
observed diastereoselectivity may be the result of Lewis acid coordination to enol (+)-
(S,S)-168A which was supported by the fact that LiBr alone favored (+)-169 in 1:1.6 d.r. 
(Table 4.1, entry 11).   
     Since it is known that Lewis acid coordination to Brønsted acid restricts the 
orientational flexibility of protons,71,72 metal coordination to the β-keto enol functionality 
of (+)-(S,S)-168A may restrict the orientation of its enol proton in addition to making it 
more acidic and prone to react with the proximal 1,1-disubstituted olefin.71  Indeed, we 
discovered that stronger Lewis acids (e.g. SbCl5 and SnCl4) improved the overall 
diastereoselectivity. For example, evaluation of the Lewis acid-assisted Brønsted acid 
(LBA) system developed by Corey,73 SbCl5 with 2,2’- dichloro-(S)-BINOL (S)-174 in 
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Table 4.1 Diastereoselective Oxycyclization and Chelation Studies. 
 
Entry Brønsted Acid Lewis Acid Conditions Yielda d.r. (167:169)b 
1 HClc none -10 °C to r.t., 72h 25%b 1:1.1 
2 176 (10 equiv) LiBr (10 equiv) 0 oC, 48 h 99% 1:1.8 
3 175 (5 equiv) LiBr (5 equiv) r.t., 1.5 h 79% 1:1.8 
4 (R)-171 (10 equiv) LiBr (10 equiv) 0 °C, 48 h 91% 1:2 
5 (S)-171 (10 equiv) LiBr (10 equiv) 0 °C, 48 h 91% 1:3 
6 (R)-172 (5 equiv) LiBr (5 equiv) r.t., 48 h 89% 1:2.2 
7 (S)-172 (5 equiv) LiBr (5 equiv) r.t., 48 h 86% 1:1.8 
8 (S)-173 (10 equiv) LiBr (10 equiv) 0 °C, 48 h 99% 1:1.5 
9 (S)-174 (1 equiv) SbCl5 (1 equiv) -78 oC, 2 h 18% 9:1 
10 (S)-171  (5 equiv) none -5 to 10 °C,  48 h 0% none 
11 none LiBr (10 equiv) r.t., 5 d 19% 1:1.6 
12 none SnCl4 (2 equiv) -78 to -20 °C, 48 h 36% 7:1 
13d (±)-171 (2 equiv) SnCl4 (1 equiv) -78 to 50 °C, 36 h 58% 1:1.1 
14 pTsOH (10 equiv) BF3OEt2 (79 equiv) -78 to -5 °C, 1 h 32% (57% brsm)e 1:2 
a Isolated yields after column chromatography. b Determined by 1H NMR analysis of the crude reaction mixture. c CH2Cl2/4 M HCl in dioxane 
(1:1). d SnCl4 saturated with (±)-171 prior to addition of substrate (+)-(S,S)-168A. e 54 % starting material also recovered. 
 
CH2Cl2 at -78 oC, led to the production of (-)-167 in 18 % yield and 9:1 d.r. (Table 4.1, 
entry 9). 
     The effect of chelation on diastereoselectivity was also evaluated by saturating the 













































prevent substrate chelation. 74   In this case, reaction was not observed until the 
temperature reached 50 oC providing clean formation of products (-)-167 and (+)-169 in 
58 % yield and 1:1.1 d.r (Table 4.1, entry 13).      








1 (S)-171 (2 equiv) SnCl4 (2 equiv) -78 to -30 °C, 6 d 68 % 14:1 
2 (R)-171 (2 equiv) SnCl4 (2 equiv) -78 to -30 °C, 6 d 9 % 1:0 
3c (±)-171 (2 equiv) SnCl4 (2 equiv) -78 to -20 °C, 17 h 52 % 14:1 
4 175 (2 equiv) SnCl4 (2 equiv) -78 to 0 °C, 19 h 47 % 10:1 
5 175 (10 equiv) InCl3 (10 equiv) r.t., 1 h 99 % 5.4:1 
6 pTsOH (10 equiv) BF3OEt2 (79 equiv) 
-15 to -5 °C, 2 h; 
-40 to -5 °C, 2 h 
42 % 1:5 
a Isolated yields after column chromatography. b Determined by 1H NMR analysis. c Substrate (±)-168A was used. 
 
     After screening an array of Lewis acids with variations in size and coordination ability 
along with different phosphoric acid promoters, optimized conditions for 
diastereoselective cyclization to (-)-167 or (+)-169 were identified (Table 4.2).  The 
combination of SnCl4 with the inexpensive, achiral diphenylphosphoric acid 175 
($3.18/gram) required lower reaction times and provided a cost-effective approach for the 











































Figure 4.4A  Relative Transition State Energies for Intramolecular Protonation of SnCl4-
168A. 
 










































Figure 4.5   BF2- and SnCl4- Complexes of Substrates Analogous to (+)-(S,S)-168A that 
Coordinate to the Metal in a Bidentate Fashion. 
selectivity for cyclization was highly favored only in the case of BF3-OEt2 and p-TsOH 
which provided (+)-169 in 42 % yield and 1:5 d.r. (Table 4.2, entry 6). 
     It has been reported that SnCl4 and BF3-OEt2 can bind in a bidentate fashion to β-keto 
enol substrates resulting in the formation of hexacoordinate Sn- and tetrahedral BF2-
complexes (Figure 4.5).71a,75,76 The BF2-salt shown in Figure 4.5 was reported to form 
by subjecting ethyl benzoylacetate to BF3 -OEt2 in toluene for 24 h.76b  We hypothesized 
that the observed diastereoselectivity may be governed by an intramolecular protonation 
event following complex formation wherein the proximal olefin approach is 
perpendicular to the acidic enol proton.71a,72e  As SnCl4 alone provided (-)-167 in 7:1 d.r. 
and 36 % yield (Table 4.1, entry 12), we simplified our transition state analysis by 
examining bidentate complexes without Brønsted acid ligand (Figures 4.4A and B).  
Indeed, analysis of transition states (done in collaboration with Dr. Vincent 
Eschenbrenner-Lux) indicated that complex SnCl4-168A-TS1 appears to favor 
cyclization to (-)-167 by an energy difference of 5.3 kcal/mol in comparison with 
transition state SnCl4-168A-TS2 leading to (+)-169 (Figure 4.4A). This discrimination 













of two chlorine ligands to the acidic enol proton and to the emerging carbocation.72a,77  In 
contrast, complex BF2-168A-TS2 favors the formation of (+)-169 by an energy difference 
of 3.8 kcal/mol relative to BF2-168A-TS1 leading to (-)-167 which correlates with our 
experimental results (Figure 4.4B). Furthermore, it should be noted that preliminary 
conformational calculations on monodentate BF3 complexes of 168A with Spartan 14’ 
did not rationalize the observed diastereoselectivity.  To the best of our knowledge, this 
represents the first example of a SnCl4- or BF3-OEt2-phosphoric acid LBA system and the 
first Lewis acid-controlled diastereoselective oxycyclization of dearomatized 
acylphloroglucinols.   
      With optimized methods for accessing either (-)-167 or (+)-169 from (+)-(S,S)-168A 
(Scheme 4.3A), oxycyclization of meso-168B and meso-168C was also achieved in short 
reaction times and reasonable yield with the use of LiBr and diphenyl phosphate 175 
(Scheme 4.3B).  Vinylic allylation of pyranodienones (-)-167, (+)-169, 179, and 182 
proceeded smoothly utilizing lithium 2-thienylcyanocuprate to provide the cyclization 
precursors (-)-166, (+)-170, 180, and 183 respectively in good yields (Schemes 4.3A and 
4.3B).32 
     In our efforts to cyclize compound (-)-166 to the PPAP core (-)-177, we observed 
undesired conversion to product 181 in dry TFA.  However, we discovered that 
isomerization could be completely avoided in the presence of water allowing for efficient 
cyclization to cycloadduct (-)-177 with 1:1 H2O/TFA (Scheme 4.3A).  Compound 180 
seamlessly cyclized at 60 oC after 1.5 h in dry TFA to its respective [3.3.1]-bicyclic core 
181 in good yield (Scheme 4.3B).  The relative stereochemical assignments of compound 
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Scheme 4.3  A. Asymmetric Syntheses of (-)-6-epi-13,14-didehydroxyisogarcinol, (+)-
30-epi-13,14-didehydroxyisogarcinol and B. Racemic Syntheses of (±)-6,30-epi-13,14-
didehydroxyisogarcinol, and (±)-6,30-epi-garcimultiflorone A. 
 
181 were determined by detailed NOE studies and were later confirmed by X-ray crystal 
structure analysis (Scheme 4.5B). 
     The cyclization of compound (+)-170 to (+)-178 proved more challenging which may 
be due to unfavorable steric interactions shown in transition state 185 (Figure 4.4).  The 
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axially-oriented allyl group at C6 likely experiences destabilizing interactions with the 
proximal benzoyl or cyclohexadienone functionalities disfavoring cyclization to product 
(+)-178.16n  In contrast, the C6 allyl group in transition state 186 is equatorially oriented 
and avoids steric influences that would deter cyclization to desired stereoisomer 181.  
 
Scheme 4.4  Comparison of Transition State Models for Cyclization of 180 to (+)-178 
and 181. 
 
     After considerable experimentation, we discovered that the formation of the C-
cyclization adduct (+)-178 could only be achieved in the presence of water, where 1 % 
H2O/TFA provided an optimized yield of 14 % (Scheme 4.3A) along with 69 % of 
byproduct (+)-187 (cf. Scheme 4.5A).  The relative stereochemical assignment of 
compound 178 was determined by X-ray crystal structure analysis (Scheme 4.5A).  
Formation of the undesired O-cyclization product (+)-187 may result from hydrolysis of 
methyl enol ether (+)-170 in H2O/TFA as further increasing the water content provided 
higher yields of byproduct (+)-187.  It is also notable that compound (+)-170 did not 
cyclize in dry TFA even after stirring for 24 h at room temperature.  Furthermore, in the 
















































   Pyranodienone 183, shown in Scheme 4.3B, proved unsuitable for cyclization to its 
corresponding type B PPAP core which was likely impeded by undesired steric 
interactions in the transition state analogous to those noted in Figure 4.4.  Surprisingly, 
we discovered that 1:1 H2O/TFA induced unexpected cyclization at C2 of compound 183 
cleanly furnishing type A PPAP core 184 in 79 % yield (Scheme 4.3B).  As one 
possibility, the cyclization of 183 may proceed through a cationic rearrangement wherein 
acid-induced pyran opening leads to cyclization at C2 and a formal 1,3-shift78 followed 
by an oxycyclization/demethylation sequence. Pleasingly, olefin metathesis proceeded 
efficiently for all stereoisomers providing type B PPAPs (-)-6-epi-3, (+)-30-epi-3, (±)- 
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Scheme 4.5  A. Scalable Strategy for Production of (-)-177 and (+)-178 and B. Gram 
Scale Synthesis of Chiral, Racemic Stereoisomers 177, 178, 181, and 184 in a Single 
Synthetic Sequence. 
6,30-epi-3, and type A PPAP (±)-6,30-epi-4 in excellent yields (Schemes 4.3A and B).        
     Finally, a convenient strategy for large scale production of all stereoisomers was 
developed by enabling diastereomer separation at a later stage in the synthesis which 
minimized the number of necessary synthetic operations (Scheme 4.5).  A scalable 
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demonstrated in Scheme 4.5A.  Gram scale oxycyclization of enol (+)-(S,S)-168A with 
LiBr and diphenyl phosphate 175 provided (-)-167 and (+)-169 in 79 % yield (1:1.8 d.r. 
as determined by 1H NMR analysis).  Furthermore, phosphoric acid 175 could be 
recovered after work-up.  Vinylic allylation served as the most convenient stage for 
diastereomer separation where column chromatography was sufficient to provide ample  
quantities of products (+)-170 and (-)-166 for subsequent cyclization.   
     Our strategy for gram scale synthesis of racemic stereoisomers 177, 178, 181, and 184 
is shown in Scheme 4.5B (demonstrated on 1.08 gram scale in Experimental Section 
4.4).  In comparison, their synthesis would require a total of 13 steps (4 steps for each 
isomer) by the strategy presented in Schemes 4.2 and 4.3.  Hence, our improved gram 
scale sequence in Scheme 4.5B accomplishes the same goal in nine fewer steps providing 
a superior alternative for the synthesis of (±)-6-epi-3, (±)-30-epi-3, (±)-6,30-epi-3, and 
(±)-6-epi-4. To produce modest yields of each diastereomer in the final cyclization step of 
Scheme 4.5B, it was necessary to use 10 % H2O/TFA as 1 % H2O/TFA would improve 
the yield of stereoisomer 178 but minimize formation of 184 (Scheme 4.5B).  Moreover, 
substantially raising the water content employing 1:1 H2O/TFA as solvent would prevent 
synthesis of product 178 and maximize formation of the type A PPAP core 184.  This 
gram scale strategy demonstrated that all stereoisomers 177, 178, 181, and 184 could be 
achieved in only 4 synthetic operations from acylphloroglucinol 115 in a timeframe of 72 
h (Scheme 4.5B).  It should be noted that compounds 177 and 181 were isolated as a 
mixture by column chromatography and could be further separated for characterization 




     In conclusion, three non-natural diastereomers of 13,14-didehydroxyisogarcinol (3) 
and one diastereomer of garcimultiflorone A (4) were synthesized for the first time by an 
efficient six-step strategy from the commercially available phloroglucinol 140 using 
regioselective bis-alkylation, Lewis acid-controlled oxycyclization, and cationic C-
cyclization as key steps.  Type B stereoisomers (-)-6-epi-3, (+)-30-epi-3, and (±)-6,30-
epi-3 were obtained in up to 22 %, 2 %, and 16 % respective overall yields from 
acylphloroglucinol 115. Notably, the synthesis also provided the type A PPAP (±)-6,30-
epi-garcimultiflorone A ((±)-6,30-epi-4) in 8.4 % overall yield from 115.  Moreover, 
diastereoselective oxycyclization of (+)-(S,S)-168A utilized novel SnCl4 and BF3-OEt2 
LBA systems to induce stereoselective, intramolecular protonation resulting in selective 
formation of either pyranodienone (-)-167 or (+)-169.  Finally, a gram scale strategy was 
developed to allow for production of useful quantities of each isomer in a single synthetic 
sequence which minimized step count and purification events. Notably, a synthesis of 
bicyclo[3.3.1]nonanes (-)-177 and (+)-178 was achieved without the need for preparative 
TLC and the production of stereoisomers 177, 178, 181, and 184 could be accomplished 






4.4  Experimental Section 
General Information 
A. Instrumentation and Methods 
1H NMR spectra were recorded at 400 MHz or 500 MHz at ambient temperature with 
CDCl3, MeOD, or CD3CN (Cambridge Isotope Laboratories, Inc.) as solvents unless 
otherwise stated.  Data for 1H NMR are reported as follows: chemical shift, integration, 
multiplicity (app = apparent, br = broad, par obsc = partially obscure, ovrlp = overlapping, 
s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet) and coupling constants.  
13C NMR were recorded at 100 MHz or 125.0 MHz at ambient temperature with the same 
solvents unless otherwise stated.  Chemical shifts are reported in parts per million relative 
to CDCl3 (1H, δ 7.26; 13C, δ 77.0), C6D6 (1H, δ 7.16), DMSO-D6 (1H, δ 2.50; 13C δ 39.4), 
CD3OD (1H, δ 3.31, 4.78; 13C, δ 49.3) or CD2O2 (1H, δ 10.35; 13C δ 165.5).  All 13C NMR 
spectra were recorded with complete proton decoupling.  Infrared spectra were recorded 
on a Nicolet Nexus 670 FT-IR spectrophotometer.  High-resolution mass spectra were 
obtained in the Boston University Chemical Instrumentation Center using a Waters Q-
TOF mass spectrometer.  Melting points were recorded on a Mel-temp (Laboratory 
Devices).  Analytical thin layer chromatography was performed using 200-400 mesh 
silica gel (Scientific Absorbents, Inc.).  Yields refer to chromatographically and 
spectroscopically pure materials, unless otherwise stated.  All reactions were carried out 
in oven-dried glassware under an argon atmosphere unless otherwise noted.  Analytical 
LC-MS experiments were performed using a Waters Acquity UPLC (Ultra Performance 
Liquid Chromatography) with a Binary solvent manager, SQ mass spectrometer, Water 
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2996 PDA (PhotoDiode Array) detector, and Evaporative Light Scattering Detector 
(ELSD).  An Acquity UPLC BEH C18 1.7 µm column was used for analytical UPLC-MS. 
Preparative HPLC purification was performed on a Gilson PLC 2020 Personal 
Purification System.  Optical rotations were recorded on an AUTOPUL III digital 
polarimeter at 589 nm and are recorded as [α]22D  (concentration in grams/100 mL 
solvent).  A CHIRALPAK® AD-H [Chiral Technologies Inc., 150 x 4.60 mm (L x I.D.)] 
column was used for enantiomeric excess determination.  The Scilligence Electronic 
Laboratory Notebook (ELN) was used for experimental procedure planning.   
 
B.  Reagents and Solvents 
HPLC grade tetrahydrofuran, methylene chloride, diethyl ether, toluene, acetonitrile, and 
benzene were purchased from Fisher and VWR and were purified and dried by passing 
through a PURE SOLV® solvent purification system (Innovative Technology, Inc.).  
Other ACS grade solvents for chromatography were purchased from Clean Harbors. All 
other reagents and relevant catalysts were purchased from Sigma-Aldrich, Acros, Alfa 
Aesar, and Strem Chemicals. Diisopropylamine was distilled over KOH before use. 
Phloroglucinol was purchased from Sigma-Aldrich.  3,3-Dimethylacrylate was purchased 






Experimental Procedures and Compound Characterization 
 
2-(Prop-1-en-2-yl)pent-4-en-1-ol (±)-116:  Chiral, racemic alcohol (±)-116 was 
prepared according to a known protocol;16n spectroscopic data for (±)-116 were found to 
be identical with those reported in the literature.16n  
 
 
(-)-(R)-2-(Prop-1-en-2-yl)pent-4-en-1-ol (-)-(R)-116:16n,40   To a flame-dried, 3-L round-
bottom flask was added oxazolidinone 188 (34.9 g, 197 mmol) and THF (643 mL).  The 
solution was cooled to -78 oC, and n-butyllithium (82.7 mL, 2.5 M in THF) was then 
added dropwise.  The orange reaction mixture was stirred for 10 min which was followed 
by dropwise addition of 3,3-dimethylacryloylchloride (23.7 mL, 213 mmol).  The 
reaction mixture [now yellow in color] was warmed to 0 oC and then stirred for 30 min at 
which point TLC analysis indicated completion.  Excess acid chloride was hydrolyzed by 
the addition of aqueous 1 M K2CO3 (125 mL).  The reaction was then warmed to room 
temperature and allowed to stir for 1.5 h.  Water (100 mL) was added and THF was 



































37 % 46 %
over 3 steps
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extracted with CH2Cl2 (3 x 250 mL).  The combined organic layers were washed with 
water (1 x 200 mL) and brine (1 x 200 mL), dried (MgSO4), filtered, and concentrated in 
vacuo to afford intermediate 189 (51.1 g, >98 % purity by 1H NMR analysis) as a white 
solid.  Compound 189 was then dissolved in THF (656 mL), and the solution was cooled 
to -78 oC.  A solution of NaHMDS (200 mL, 1.0 M in THF) was added dropwise via 
cannula, and the reaction mixture was then stirred for 45 min.  Allyl iodide (18 mL, 197 
mmol) was added via syringe, and the reaction mixture was stirred for an additional 3 h.  
The reaction was then quenched with a saturated aqueous solution of NH4Cl (500 mL), 
warmed to room temperature, and extracted with Et2O (3 x 500 mL).  The combined 
organic extracts were washed with water (1 x 500 mL) and brine (1 x 500 mL), dried 
(MgSO4), and concentrated in vacuo to provide a crude oil (50 g). Purification by column 
chromatography (silica gel, 2-9 % EtOAc/hexanes) afforded allylation adduct 190 as a 
crude oil (45.5 g, >65 % purity as determined by 1H NMR analysis, product 190 Rf = 
0.54 and byproduct Rf  = 0.36 in 10 % EtOAc/pentane). Crude allylation adduct 190 was 
dissolved in Et2O (560 mL), and the solution was cooled to 0 oC.  A solution of LiBH4 
(169 mL, 2.0 M in Et2O) was then added dropwise followed by EtOH (17.8 mL), and the 
reaction mixture was stirred at 0 oC for 1 h.  The reaction was quenched with saturated 
aqueous NH4Cl (500 mL), poured into a separatory funnel, and extracted with Et2O (3 x 
500 mL).  The combined organic layers were then dried over MgSO4, filtered, and 
concentrated in vacuo to afford (-)-(R)-116 as a crude oil.  Purification by column 
chromatography (silica gel, 2-12 % EtOAc/hexanes) provided alcohol (-)-(R)-116 (9.22 
g, 37 % over three steps, >98 % purity as determined by 1H NMR analysis) as a clear oil 
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in >99 % ee as determined by chiral HPLC analysis of its benzoylated derivative (100 % 
hexanes using a Lux® 5u Cellulose-2 column).16n Oxazolidinone 188 (16.0 g, 46 %) was 
also recovered and stored for future use. Spectroscopic data for (-)-(R)-116 were found to 
be identical with those reported in the literature.16n Alcohol (-)-(R)-116 was further dried 
by vacuum distillation (12.3 mm Hg, oil bath temperature: 95 oC, b.p. 61 oC) before use 





Triflate (-)-(R)-114:  To a flame-dried, 250-mL round-bottom flask under argon 
containing alcohol (-)-(R)-116 (3.9 mL, 27.4 mmol) was added toluene (21.6 mL), 
hexane (48 mL), and diisopropylethylamine (6.0 mL, 34.5 mmol).  The solution was 
cooled to -10 oC, and trifluoromethansulfonic anhydride (4.19 mL, 24.9 mmol) was 
added dropwise over the course of 20 seconds.  The reaction mixture was allowed to stir 
for 5 min before being filtered under argon into a 250-mL round-bottom flask using a 
custom-made 150-mL ChemGlass Büchner funnel with a 24/40 joint pictured in Figure 









balloon.  The clear solution of triflate (-)-(R)-114 was then used immediately in the next 
reaction (vide infra). 





















Regioselective Alkylative Dearomatization  
 
(+)-2-Benzoyl-3-hydroxy-5-methoxy-6,6-bis((S)-2-(prop-1-en-2-yl)pent-4-en-1-
yl)cyclohexa-2,4-dien-1-one (+)-(S,S)-168A: To a flame-dried, round-bottom flask fitted 
with a stir bar was added acylphloroglucinol 115 (1.5 g, 6.14 mmol).  The flask was 
charged with argon, THF (20.4 mL), and toluene (6.6 mL), and the solution was then 
cooled to 0 oC in an ice-water bath.  LiHMDS (39 mL, 1.0 M in THF) was added over the 
course of 5 min, and the reaction mixture was allowed to stir until a homogeneous 
solution was formed.  The solution of triflate (-)-(R)-114 (7.07 g, 27.4 mmol) was then 
added to the reaction mixture via syringe over the course of 3 min.  The reaction mixture 
was warmed to 20 oC in a water bath and stirred for 20 min.  The water bath was removed 
and the reaction was warmed to room temperature and stirred for 4.5 h.  The reaction 
mixture was quenched with 1 M HCl (300 mL), diluted with water (600 mL), and 
extracted into Et2O (3 x 300 mL).  The combined organic layers were washed with 1 M 
HCl (1 x 400 mL), water (1 x 400 mL), and brine (1 x 300 mL), dried (Na2SO4), filtered, 
and concentrated in vacuo to provide a crude orange oil.  Purification by the General 
Purification Procedure for Dearomatized Phloroglucinols and PPAP Derivatives (see 

















Crops 2 and 3 provided impure potassium salt (+)-(S,S)-168A-K (134.6 mg, 4 %), which 
was further purified by dissolving in Et2O and triturating with pentane.  The potassium 
salt (+)-(S,S)-168A-K was converted to enol (+)-(S,S)-168A with 97 % recovery via 
extraction with 1M HCl (vide infra). 
 
2-Benzoyl-3-hydroxy-5-methoxy-6,6-bis(2-(prop-1-en-2-yl)pent-4-en-1-yl)cyclohexa-
2,4-dien-1-one (±)-168A, (meso)-168B, and (meso)-168C:[single enantiomer drawn for 
clarity] Potassium salts (±)-168A-K, (meso)-168B-K, and (meso)-168C-K were prepared 
from acylphloroglucinol 115 (1.5 g, 6.14 mmol), LiHMDS (39 mL, 1.0 M in THF), and 
racemic triflate 114 (7.07 g, 27.4 mmol) in the same manner described above for the 
preparation of potassium salt (+)-(S,S)-168A-K. Purification of the resulting crude oil by 
the General Purification Procedure for Dearomatized Phloroglucinols and PPAP 
Derivatives (see below) provided potassium salts (±)-168A-K, (meso)-168B-K, and 
(meso)-168C-K (1.62 g, 53 %, 1.9:1.4:1 d.r. as determined by 1H NMR analysis).  The 
potassium salts were converted to enols (±)-168A, (meso)-168B, and (meso)-168C with 




























General Purification Procedure for Dearomatized Phloroglucinols and PPAP 
Derivatives:16n,54 
Pentane (150 mL) was added to the crude oil containing enol (+)-(S,S)-168A or enols (±)-
168A, (meso)-168B,  and (meso)-168C and was stirred vigorously for 30 min.  The 
resulting solution was decanted to a separatory funnel and vigorously mixed with 
saturated aqueous K2CO3 (40 mL).  Water (10 mL) was then added to the biphasic 
mixture, and upon shaking vigorously, a precipitate crashed out of solution (Figure 4.7).  
The layers were separated, and the precipitate remained in the separatory funnel. The 
precipitate was rinsed with pentane to remove impurities and was then dissolved in 
acetone.  Additional precipitate was obtained by repeating the extraction process with the 
initial crude pentane solution two additional times.  The acetone solutions of precipitate 
were dried (Na2SO4), filtered, and concentrated in vacuo to provide potassium salt (+)-
(S,S)-168A-K (1.53 g, 50 % from the first extraction) or potassium salts (±)-168A-K, 
(meso)-168B-K, and (meso)-168C-K (1.62 g, 53 %, 1.9:1.4:1 d.r. as determined by 1H 
NMR analysis).  If the 2nd and 3rd crops proved impure, the impure precipitates were 








Figure 4.7  Potassium salts (±)-168A-K, (meso)-168B-K, and (meso)-168C-K Formed as 
Precipitates in the General Purification Procedure for Dearomatized Phloroglucinols 




















General Procedure to Convert Potassium Salts to Enols with up to 97 % Recovery: 
A solution of (+)-(S,S)-168A-K (510.1 mg) in EtOAc (30 mL) was extracted with 1M 
HCl (1 x 20 mL), washed with H2O (1 x 20 mL) and brine (1 x 20 mL), dried (Na2SO4), 
filtered, and concentrated in vacuo to provide enol (+)-(S,S)-168A (454.9 mg, 97 % yield) 
as a red solid.   
 [Enols (±)-168A (red solid), (meso)-168B (pink solid), and (meso)-168C (yellow oil) can 
be separated via preparative thin layer chromatography (silica gel, 3 elutions in 7 % 
EtOAc/hexanes with 1 % AcOH, Elution 1: 12 hours; Elution 2: 1 h, and Elution 3: 1 h).]   
 
(+)-2-Benzoyl-3-hydroxy-5-methoxy-6,6-bis((S)-2-(prop-1-en-
2-yl)pent-4-en-1-yl)cyclohexa-2,4-dien-1-one (+)-(S,S)-168A:  
Rf = 0.20 (10 % EtOAc/hexanes); m.p. 79 – 84 oC (CH2Cl2);  IR 
νmax 3074, 2978, 2932, 2851, 1661, 1645, 1621, 1593, 1519, 
1447, 1374, 1218, 1176, 913, 893, 835 cm-1; 1H NMR (400 
MHz, CDCl3, ~ 3:1 mixture of enol tautomers as determined by 1H NMR analysis) δ 
17.95 (s, 0.6H)*, 17.28 (s, 0.2H)**, 7.56 – 7.33 (m, 5H), 5.67 – 5.48 (m, 3H), 5.05 – 4.85 























2.25H)*, 3.69 (s, 0.75H)**, 2.30 – 1.85 (m, 9H), 1.73 (dd, J = 13.3, 2.4 Hz, 1H), 1.62 – 
1.55 (m, 4H), 1.48 (s, 2H); 
*denotes conjugated enol tautomer (major) 
** denotes cross-conjugated enol tautomer (minor) 
13C NMR (100 MHz, CDCl3, 3:1 mixture of enol tautomers as determined by 1H NMR 
analysis) δ 197.0*, 194.9**, 193.5*, 189.1*, 188.1**, 183.9**, 178.3*, 170.4**, 146.6, 
146.4, 146.2, 146.0, 139.3, 138.1, 136.6, 136.4, 136.4, 136.2, 131.6, 130.6, 128.3, 127.5, 
127.4, 127.3, 127.3, 116.1, 115.9, 115.7, 113.3, 113.1, 112.1, 112.1, 108.6, 104.8, 98.3, 
98.0, 56.6, 56.6, 55.7, 55.1, 52.1, 44.3, 43.9, 43.8, 43.5, 43.4, 42.6, 41.3, 40.4, 39.7, 39.4, 
39.1, 18.3**, 18.1*, 17.7**, 17.5*; HR-MS: m/z Calcd. for C30H36O4 [M+H+]: 461.2692, 
Found 461.2693; [a]25𝐷  = +28.1 (c. 0.250, CHCl3). 
 [meso]-(r)-2-Benzoyl-3-hydroxy-5-methoxy-6-((R)-2-(prop-1-
en-2-yl)pent-4-en-1-yl)-6-((S)-2-(prop-1-en-2-yl)pent-4-en-1-
yl)cyclohexa-2,4-dien-1-one (meso)-168B:  Rf = 0.23 (10 % 
EtOAc/hexanes); m.p. 81 – 84 oC (CH2Cl2); IR nmax 3072, 2977, 
2934, 1658, 1644, 1618, 1590, 1519, 1446, 1373, 1288, 1218, 
1177, 1114, 992, 912, 893, 831 cm-1; 1H NMR (400 MHz, CDCl3, ~ 5:1 mixture of enol 
tautomers as determined by 1H NMR analysis) δ 17.70 (s, 0.8H)*, 17.04 (s, 0.1H)**, 7.62 
– 7.34 (m, 5H), 5.65 – 5.50 (m, 2H), 5.41 (s, 0.8H)*, 5.35 (s, 0.2H)**, 4.99 – 4.88 (m, 
4H), 4.66 (app dd, J = 1.8, 1.4 Hz, 2H), 4.57 (app d, J = 2.2 Hz, 2H), 3.68 (s, 2.5H)*, 
3.57 (s, 0.5H)**, 2.23 – 1.87 (m, 10H), 1.64 – 1.55 (m, 6H); 








** denotes cross-conjugated enol tautomer (minor) 
13C NMR (100 MHz, CDCl3, ~ 5:1 mixture of enol tautomers as determined by 1H NMR 
analysis) δ 198.3**, 197.6*, 194.6*, 193.6**, 188.6*, 183.7**, 178.8*, 170.6**, 146.3, 
146.2, 139.2, 138.3, 136.4, 136.2, 131.9, 131.1, 128.5, 127.7, 127.6, 127.6, 116.1, 115.7, 
112.2, 112.0, 107.9, 104.6, 98.0, 57.0, 55.0, 54.5, 52.1, 44.2, 43.7, 42.9, 41.0, 39.6, 39.4, 
18.3, 17.9; HR-MS: m/z Calcd. for C30H36O4 461.2692 [M+H+]: Found 461.2686. 
 [meso]-(s)-2-Benzoyl-3-hydroxy-5-methoxy-6-((R)-2-(prop-1-
en-2-yl)pent-4-en-1-yl)-6-((S)-2-(prop-1-en-2-yl)pent-4-en-1-
yl)cyclohexa-2,4-dien-1-one (meso)-168C:  Rf = 0.33 (14 % 
EtOAc/hexanes); IR nmax 3072, 2979, 2929, 2848, 1661 1644, 
1621, 1517, 1448, 1373, 1216, 1174, 1111, 992, 912, 890, 836 cm-
1; 1H NMR (400 MHz, CDCl3, ~1.7:1 mixture of enol tautomers as determined by 1H 
NMR analysis) δ 18.11 (s, 0.5H)*, 17.38 (s, 0.3H)**, 7.54 – 7.32 (m, 5H), 5.74 (s, 
0.6H)*, 5.66 (s, 0.4H)**, 5.65 – 5.52 (m, 2H), 5.03 – 4.90 (m, 4H), 4.62 (dd, J = 1.7, 1.7 
Hz, 1.3H), 4.57 (dd, J = 1.6, 1.6 Hz, 2.7H), 3.91 (s, 1.9H)*, 3.80 (s, 1.1H)**, 2.25 (dd, J 
= 13.5, 7.9 Hz, 1H), 2.18 – 1.88 (m, 8H), 1.72 (dd, J = 13.4, 2.4 Hz, 1H), 1.59 (br s, 3H), 
1.47 (br s, 3H);  
*denotes conjugated enol tautomer (major) 
** denotes cross-conjugated enol tautomer (minor) 
13C NMR (100 MHz, CDCl3; ~1.7:1 mixture of enol tautomers as determined by 1H 
NMR analysis) δ 196.4, 195.9, 195.7, 192.4, 189.2, 183.9, 177.8, 170.3, 146.7, 146.1, 








115.9, 115.7, 113.1, 113.0, 109.5, 104.9, 98.7, 98.4, 65.8, 56.6, 56.3, 55.7, 52.3, 44.5, 
44.0, 43.3, 40.8, 39.4, 39.2, 17.7, 17.6, 15.3; HR-MS: m/z Calcd. for C30H36O4 [M+H+]: 





















Diastereoselective Oxycyclization Studies (Tables 4.1 and 4.2): 
Table 4.1  Diastereoselective Oxycyclization and Chelation Studies. 
 
Entry Brønsted Acid Lewis Acid Conditions Yielda d.r. (167:169)b 
1 HClc none -10 °C to r.t., 72h 25%b 1:1.1 
2 176 (10 equiv) LiBr (10 equiv) 0 oC, 48 h 99% 1:1.8 
3 175 (5 equiv) LiBr (5 equiv) r.t., 1.5 h 79% 1:1.8 
4 (R)-171 (10 equiv) LiBr (10 equiv) 0 °C, 48 h 91% 1:2 
5 (S)-171 (10 equiv) LiBr (10 equiv) 0 °C, 48 h 91% 1:3 
6 (R)-172 (5 equiv) LiBr (5 equiv) r.t., 48 h 89% 1:2.2 
7 (S)-172 (5 equiv) LiBr (5 equiv) r.t., 48 h 86% 1:1.8 
8 (S)-173 (10 equiv) LiBr (10 equiv) 0 °C, 48 h 99% 1:1.5 
9 (S)-174 (1 equiv) SbCl5 (1 equiv) -78 oC, 2 h 18% 9:1 
10 (S)-171  (5 equiv) none -5 to 10 °C, 48 h 0% none 
11 none LiBr (10 equiv) r.t., 5 d 19% 1:1.6 
12 none SnCl4 (2 equiv) -78 to -20 °C, 48 h 36% 7:1 
13d (±)-171 (2 equiv) SnCl (1 equiv) -78 to 50 °C, 36 h 58% 1:1.1 
14 pTsOH (10 equiv) BF3OEt2 (79 equiv) -78 to -5 °C, 1 h 32% (57% brsm)e 1:2 
a Isolated yields after column chromatography. b Determined by 1H NMR analysis of the crude reaction mixture. c CH2Cl2/4M HCl in dioxane 














































Table 4.2  Optimized Lewis/Brønsted Acid Combinations for Diastereoselective 
Cyclization. 
 
Entry Brønsted Acid Lewis Acid Conditions Yielda d.r. (167:169)b 
1 (S)-171 (2 equiv) SnCl4 (2 equiv) -78 to -30 °C, 6 d 68 % 14:1 
2 (R)-171 (2 equiv) SnCl4 (2 equiv) -78 to -30 °C, 6 d 9 % 1:0 
3c (±)-171 (2 equiv) SnCl4 (2 equiv) -78 to -20 °C, 17 h 52 % 14:1 
4 175 (2 equiv) SnCl4 (2 equiv) -78 to 0 °C, 19 h 47 % 10:1 
5 175 (10 equiv) InCl3 (10 equiv) r.t., 1 h 99 % 5.4:1 
6 pTsOH (10 equiv) BF3OEt2 (79 equiv) 
-15 to -5 °C, 2 h; 
-40 to -5 °C, 2 h 
42 % 1:5 
a Isolated yields after column chromatography. b Determined by 1H NMR analysis. c Substrate (±)-168A was used. 
 
 (Table 4.1, entry 1)  To a flame-dried 10-mL round-bottom flask under an argon 
atmosphere containing enol (+)-(S,S)-168A (2.3 mg, 0.00499 mmol) was added CH2Cl2 
(0.33 mL).  The solution was cooled to -10 oC, and 4 M HCl in dioxane (0.3 mL) was 
added.  The reaction mixture was allowed to slowly warm to room temperature and was 
stirred for 72 h.  The reaction was then quenched with saturated aqueous NaHCO3 (2 
mL), poured into water (2 mL), and extracted into CH2Cl2 (3 x 4 mL).  The combined 
organic layers were washed with water (1 x 5 mL) and brine (1 x 5 mL), dried (Na2SO4), 
filtered, and concentrated in vacuo to afford the oxycyclization products (+)-169 and (-)-























General Procedure A  
(+)-
(3S,4aR)-3-Allyl-8-benzoyl-5-methoxy-2,2-dimethyl-4a-((S)-2-(prop-1-en-2-yl)pent-
4-en-1-yl)-2,3,4,4a-tetrahydro-7H-chromen-7-one (+)-169 and (-)-(3S,4aS)-3-Allyl-8-
benzoyl-5-methoxy-2,2-dimethyl-4a-((S)-2-(prop-1-en-2-yl)pent-4-en-1-yl)-2,3,4,4a-
tetrahydro-7H-chromen-7-one (-)-167:  (Table 4.1, entry 3)  To a 250-mL round-
bottom flask containing a solution of enol (+)-(S,S)-168A (1.39 g, 3.02 mmol) in CH2Cl2 
(101 mL) was added LiBr (1.31 g, 15.1 mmol) in a single portion.  After the suspension 
was stirred for one minute, diphenyl phosphate 175 (3.79 g, 15.1 mmol) was added in a 
single portion.  The reaction mixture was allowed to stir vigorously for 1.5 h and was 
then quenched with saturated aqueous NaHCO3 (100 mL), poured into water (20 mL), 
and extracted with CH2Cl2 (3 x 100 mL).  The combined organic layers were washed 
with water (1 x 100 mL) and brine (1 x 100 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo.  Purification by column chromatography (silica gel, 10 – 40 % 






























(Table 1 , entry 3)
majorminor
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1:1.8 d.r. as determined by 1H NMR analysis) as a red oil.  Diphenyl phosphate 175 was 
re-isolated following extraction of the combined aqueous layers (pH<7) with EtOAc. 
 
(Table 4.1, entries 2-8, entry 11) All reactions in Table 4.1 using LiBr were carried out 
according to general procedure A to provide oxycyclization products (-)-167 and (+)-169.   
 
(Table 4.2, entry 5)  Oxycyclization product (-)-167 (3.6 mg, 99 %, 5.4:1 d.r. as 
determined by 1H NMR analysis) was prepared according to general procedure A from a 
solution of enol (+)-(S,S)-168A (3.6 mg, 0.00782 mmol) in CH2Cl2 (0.53 mL) using InCl3 
(17.3 mg, 0.0782 mmol) and phosphoric acid 175 (19.6 mg, 0.0782 mmol).  After 1 h, the 
reaction was quenched with saturated aqueous NaHCO3 and extracted into Et2O (3 x 3 
mL).  The combined organic layers were washed with H2O (1 x 3 mL) and brine (1 x 3 
mL), dried (Na2SO4), filtered, and concentrated.  Purification by column chromatography 
(silica gel, 10 – 40 % EtOAc/hexanes) provided the oxycyclization product (-)-167 (3.6 

































(Table 4.2, entry 5)
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General Procedure B  
 
(-)-(3S,4aS)-3-Allyl-8-benzoyl-5-methoxy-2,2-dimethyl-4a-((S)-2-(prop-1-en-2-
yl)pent-4-en-1-yl)-2,3,4,4a-tetrahydro-7H-chromen-7-one (-)-167: (Table 4.2, entry 4)  
To a flame-dried, round-bottom flask was added diphenyl phosphate 175 (10.2 mg, 
0.0408 mmol) and the flask was then purged with argon.  Methylene chloride (0.29 mL) 
and SnCl4 (0.2 mL, 0.2 M in CH2Cl2, 0.0408 mmol) were then added sequentially at 
room temperature, and the clear solution was cooled to -78 oC.  A solution of enol (+)-
(S,S)-168A (9.4 mg, 0.0204 mmol) in CH2Cl2 (0.2 mL) was transferred to the SnCl-
4/diphenyl phosphate mixture via syringe over the course of 2 min, and the reaction 
mixture was allowed to stir for 19 h at 0 oC (temperature controlled by a Cryocool™).  
The reaction was quenched with saturated aqueous NaHCO3 (3 mL), poured into water (2 
mL), and extracted with CH2Cl2 (3 x 5 mL).  The combined organic layers were washed 
with water (1 x 5 mL) and brine (1 x 5 mL), dried (Na2SO4), filtered, and concentrated in 
vacuo.  Purification by silica gel chromatography (10 – 40 % EtOAc/hexanes) afforded 
oxycyclization product (-)-167 (4.4 mg, 47 %, 10:1 d.r. as determined by 1H NMR 
analysis) as a white amorphous solid.  [Compounds (-)-167 and (+)-169 were separated 






























(Table 4.2, entry 4)
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Rf = 0.24 (35 % EtOAc/hexanes); IR νmax 3074, 2980, 2941, 1677, 1650, 1621, 1598, 
1448, 1387, 1374, 1350, 1265, 1225, 1170, 1137, 1129, 1084, 994, 914, 839, 782, 732 
cm-1; 1H NMR (500 MHz, CDCl3) δ 7.92 – 7.86 (m, 2H), 7.55 – 7.50 (m, 1H), 7.45 – 
7.39 (m, 2H), 5.72 – 5.58 (m, 2H), 5.49 (s, 1H), 5.09 – 4.95 (m, 4H), 4.69 (br s, 1H), 4.63 
(br s, 1H), 3.64 (s, 3H), 2.45 (dd, J = 14.3, 4.4 Hz, 1H), 2.23 – 2.12 (m, 2H), 2.11 – 1.94 
(m, 4H), 1.80 – 1.69 (m, 1H), 1.68 – 1.60 (m, 1H), 1.62 (s, 3H), 1.55 (t, J = 13.3 Hz, 2H), 
1.26 (s, 3H), 1.10 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 194.4, 186.0, 174.8, 169.6, 
146.7, 137.7, 136.5, 135.8, 133.1, 129.2, 128.4, 126.3, 117.3, 116.3, 111.6, 103.1, 88.4, 
55.3, 47.6, 44.6, 42.4, 42.3, 39.8, 36.1, 35.6, 28.8, 21.7, 19.1; HR-MS: m/z Calcd. for 
C30H36O4 [M+H+]: 461.2692, Found 461.2701; [α]25𝐷  = -79.1 (c. 0.250, CHCl3).  
 
 (Table 4.1, entry 9)73 Oxycyclization product (-)-167 was prepared according to general 
procedure B from a solution of enol (+)-(S,S)-168A (9.5 mg, 0.0206 mmol) in CH2Cl2 
(0.05 mL) which was added to a solution of (S)-ο,ο’-dichloro-BINOL (S)-174 (7.3 mg, 
0.0206 mmol) and SbCl5 (21 µL, 1.0 M in CH2Cl2) in CH2Cl2 (0.1 mL) at -78 oC.  The 
reaction mixture was stirred at this temperature for 4 h and was then quenched with 































layers were washed with water (1 x 5 mL) and brine (1 x 5 mL), dried (Na2SO4), filtered, 
and concentrated in vacuo.  Purification by preparative thin layer chromatography (silica 
gel, 19 % EtOAc/hexanes with 3 % AcOH) provided the oxycyclization product (-)-167 
(1.7 mg, 18 %, 9:1 d.r. as determined by 1H NMR analysis). 
(Table 4.1, entry 12)  To a solution enol (+)-(S,S)-168A (11.8 mg, 0.0256 mmol) in 
CH2Cl2 (0.56 mL) in a flame-dried, round-bottom flask at -78 oC was added SnCl4 (0.25 
mL, 0.2 M in CH2Cl2).  The reaction mixture was warmed to -20 oC for 48 h and then 
quenched and purified according to general procedure B to provide oxycyclization 
product (-)-167 (4.3 mg, 36 %, 7:1 d.r. as determined by 1H NMR analysis).  
 
 
(Table 4.1, entry 13) Oxycyclization products (+)-169 and (-)-167 were prepared 























































(Table 4.1, entry 13)
(2 equiv)
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0.00868 mmol) in CH2Cl2 (0.09 mL) which was added to a solution of phosphoric acid 
(±)-171 (6.0 mg, 0.0174 mmol) and  SnCl4 (40 µL, 0.2 M in CH2Cl2) in CH2Cl2 (0.12 
mL) at -78 oC.  The reaction mixture was warmed to -20 oC for 24 h and then heated to 
50 oC for 12 h. The reaction was quenched with 1M HCl and extracted into CH2Cl2 (3 x 4 
mL). The combined organic layers were washed with water (1 x 3 mL) and brine (1 x 3 
mL), dried (Na2SO4), filtered, and concentrated in vacuo.  Purification by silica gel 
chromatography (10 – 40 % EtOAc/hexanes) provided the oxycyclization products (+)-
169 and (-)-167 (2.3 mg, 58 %, 1:1.1 d.r. as determined by 1H NMR analysis). 
 
 
(Table 4.2, entry 1)  Oxycyclization product (-)-167 was prepared according to general 
procedure B from a solution of (+)-(S,S)-168A (3.7 mg, 0.00803 mmol) in CH2Cl2 (0.15 
mL) which was added to a solution of (S)-171 (5.6 mg, 0.0161 mmol) and SnCl4 (0.08 
mL, 0.2 M in CH2Cl2) in CH2Cl2 (0.11 mL) at -78 oC.  The reaction mixture was warmed 
to -45 oC for 3 h and then allowed to stir for 6 d at -30 oC.  The reaction was quenched 
with pyridine (1.3 µL) and saturated aqueous NaHCO3 (2 mL), poured into water (2 mL), 
and extracted with CH2Cl2 (3 x 3 mL).  The combined organic layers were washed with 































(Table 4.2, entry 1)
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filtered, and concentrated in vacuo.  Purification by column chromatography (silica gel, 
10 – 40 % EtOAc/hexanes) afforded oxycyclization product (-)-167 (2.5 mg, 68 %, 14:1 
d.r. as determined by 1H NMR analysis).  
 
(Table 4.2, entry 2)  Oxycyclization product (-)-167 was prepared according to general 
procedure B from a solution of enol (+)-(S,S)-168A (3.4 mg, 0.00738 mmol) in CH2Cl2 
(0.15 mL) which was added to a solution of phosphoric acid (R)-171 (5.7 mg, 0.0162 
mmol) and SnCl4 (0.07 mL, 0.2 M in CH2Cl2) in CH2Cl2 (0.11 mL) at -78 oC.  The 
reaction mixture was warmed to -45 oC for 3 h and then allowed to stir for 6 d at -30 oC.  
The reaction was quenched with pyridine (1.2 µL) and saturated aqueous NaHCO3 (2 
mL), poured into water (2 mL), and extracted with CH2Cl2 (3 x 3 mL).  The combined 
organic layers were washed with water (1 x 3 mL) and brine (1 x 3 mL).  The organic 
solution was dried over Na2SO4, filtered, and concentrated in vacuo.  Purification by 
column chromatography (silica gel, 10 – 40 % EtOAc/hexanes) afforded oxycyclization 























-78 to -30 oC, 6 d
 (Table 4.2, entry 2)
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(Table 4.2, entry 3) Oxycyclization product (±)-167 was prepared according to general 
procedure B from a solution of enol (±)-168A (6.0 mg, 0.013 mmol) in CH2Cl2 (0.13 mL) 
which was added to a solution of phosphoric acid (±)-171 (9.1 mg, 0.0261 mmol) and 
SnCl4 (0.13 mL, 0.2 M in CH2Cl2) in CH2Cl2 (0.19 mL) at -78 oC. The reaction mixture 
was then warmed to -20 oC and was stirred at this temperature for 17 h. The reaction 
mixture was then warmed to room temperature for 5 minutes before it was quenched and 
purified according to general procedure B to afford (±)-167 (3.1 mg, 52 %, 14:1 d.r. as 







































(Table 4.2, entry 3)
(2 equiv)
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General Procedure C 
 
(+)-(3S,4aR)-3-Allyl-8-benzoyl-5-methoxy-2,2-dimethyl-4a-((S)-2-(prop-1-en-2-
yl)pent-4-en-1-yl)-2,3,4,4a-tetrahydro-7H-chromen-7-one (+)-169: (Table 4.2, entry 
6) To a 100-mL flame-dried round-bottom flask under an argon atmosphere containing a 
solution of enol (+)-(S,S)-168A (107 mg, 0.232 mmol) in CH2Cl2 (23 mL) at -15 oC was 
added BF3OEt2 (2.3 mL, 18.5 mmol). The reaction was stirred and allowed to warm to -
10 oC over 10 min.  p-TsOH (444 mg, 2.33 mmol) was then added to the reaction mixture 
in a single portion and the reaction mixture was allowed to warm to -5 oC until the 
pTsOH completely dissolved.  The reaction vessel was then transferred to an acetone bath 
at -5 oC (the temperature was controlled by Cryocool™) and stirred at this temperature 
for 2 h.  The reaction mixture was cooled to -40 oC and then allowed to warm to -5 oC 
over the course of 2 h. The reaction was quenched with 1 M HCl (30 mL) and stirred 
vigorously for 1 h.  The biphasic mixture was then poured into H2O (10 mL) and 
extracted into CH2Cl2 (3 x 30 mL). The combined organic layers were washed with 
saturated aqueous NaHCO3 (1 x 20 mL), water (1 x 20 mL) and brine (1 x 20 mL), dried 
(Na2SO4), filtered, and concentrated in vacuo.  Purification by column chromatography 















-15 to -5 oC, 2h;











(Table 4.2, entry 6)
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(+)-169 (45.4 mg, 42 %, 1:5 d.r. as determined by 1H NMR analysis) as a solid.  (+)-169: 
Rf = 0.21 (35 % EtOAc/hexanes); m.p. 154 – 156 oC (CH2Cl2); IR νmax 3073, 2979, 
2926, 2851, 1677, 1653, 1624, 1599, 1449, 1384, 1375, 1225, 1174, 1132, 1082, 1015, 
993, 913, 840, 733 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.89 – 7.85 (m, 2H), 7.53 – 7.48 
(m, 1H), 7.42 – 7.37 (m, 2H), 5.74 (dddd, J = 17.3, 10.0, 7.8, 5.7 Hz, 1H), 5.68 – 5.59 
(m, 1H), 5.61 (s, 1H), 5.13 – 5.03 (m, 2H), 5.01 – 4.94 (m, 2H), 4.76 (br s, 1H), 4.67 (br 
s, 1H), 3.73 (s, 3H), 2.32 (dd, J = 13.7, 6.8 Hz, 1H), 2.23 (dd, J = 13.9, 3.8 Hz, 1H), 2.18 
– 2.11 (m, 2H), 2.10 – 1.94 (m, 3H), 1.80 (dd, J = 13.8, 3.3 Hz, 1H), 1.71 – 1.62 (m, 1H), 
1.66 (s, 3H), 1.49 (t, J = 13.2 Hz, 1H), 1.29 (s, 3H), 0.92 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 193.9, 186.4, 175.0, 168.5, 146.0, 137.6, 136.6, 135.8, 133.0, 129.3, 128.1, 
125.8, 117.3, 116.0, 112.1, 102.5, 87.4, 55.8, 45.3, 43.2, 39.7, 39.6, 39.5, 36.0, 35.8, 28.2, 
20.7, 19.3; HR-MS: m/z Calcd. for C30H36O4 [M+H+]: 461.2692, Found 461.2681; [a]25𝐷  
= +34.1 (c. 0.250, CHCl3).  
 
 
(Table 4.1, entry 14)  Oxycyclization products (-)-167 and (+)-169 were prepared 
according to general procedure C from a solution of (+)-(S,S)-168A (50.7 mg, 0.11 































1.1 mmol).  After the pTsOH completely dissolved, the reaction mixture was allowed to 
stir vigorously for 1 h.  The reaction mixture was then quenched and purified according 
to general procedure C to provide oxycyclization products (-)-167 and (+)-169 (16.4 mg, 
32 %, 1:2 d.r. as determined by 1H NMR analysis) and starting enol (+)-(S,S)-168A (27.4 


















Total Synthesis of (-)-6-epi-, (+)-30-epi-, (±)-6,30-epi-13,14-Didehydroxyisogarcinol 
and (±)-6,30-epi-Garcimultiflorone A (Schemes 4.3 and 4.5). 
 
 
Scheme 4.3 A. Asymmetric Syntheses of (-)-6-epi-13,14-Didehydroxyisogarcinol and 
(+)-30-epi-13,14-Didehydroxyisogarcinol and B. Racemic Syntheses of (±)-6,30-epi-






-15 oC to -5 oC, 2 h;
-40 to -5 oC, 2h
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-78 to 0 oC, 19 h
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Scheme 4.5B. Gram Scale Synthesis of Racemic Stereoisomers 177, 178, 181, and 184 in 









        1 : 1.8 d.r.
CH2Cl2, r.t., 1.5 h



































































































































yl)pent-4-en-1-yl)-2,3,4,4a-tetrahydro-7H-chromen-7-one 179:  Oxycyclization 
product 179 (167 mg, 83 %) was provided as an amorphous solid and was prepared 
according to general procedure A from enol (meso)-168B (201 mg, 0.436 mmol) using 
LiBr (379 mg, 4.36 mmol) and diphenyl phosphate 175 (1.09 g, 4.36 mmol) in CH2Cl2 
(30 mL).  179:  Rf = 0.23 (30 % EtOAc/hexanes); IR nmax 3073, 2977, 2940, 2845, 1677, 
1652, 1622, 1598, 1449, 1389, 1374, 1262, 1226, 1174, 1133, 1078, 994, 914, 839, 778, 
731 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.95 – 7.82 (m, 2H), 7.58 – 7.47 (m, 1H), 7.47 – 
7.37 (m, 2H), 5.83 – 5.59 (m, 2H), 5.51 (s, 1H), 5.18 – 4.94 (m, 4H), 3.64 (s, 3H), 2.30 – 
2.05 (m, 7H), 2.00 (dd, J = 13.3, 6.3 Hz, 1H), 1.72 (ddd, J = 13.6, 9.4, 9.4 Hz, 1H), 1.67 
(s, 3H), 1.52 (dd, J = 13.0, 13.0 Hz, 1H), 1.33 (s, 3H), 1.03 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 194.1, 186.2, 174.9, 168.2, 146.8, 137.6, 136.6, 135.8, 133.1, 129.2, 128.3, 
126.1, 117.3, 116.2, 111.7, 102.9, 87.4, 55.2, 45.4, 42.6, 39.9, 39.8, 39.4, 36.1, 35.1, 28.2, 


























yl)pent-4-en-1-yl)-2,3,4,4a-tetrahydro-7H-chromen-7-one 182: Oxycyclization 
product 182 (63.6 mg,  66 %) was synthesized as an amorphous solid and was prepared 
according to general procedure A from enol (meso)-168C (95.8 mg, 0.208 mmol), LiBr 
(182 mg, 2.1 mmol), diphenyl phosphate 175 (525 mg, 2.1 mmol) in CH2Cl2 (14 mL).  
182:  Rf = 0.31 (35 % EtOAc/hexanes); IR nmax 3075, 2979, 2933, 2920, 2857, 1678, 
1650, 1622, 1598, 1449, 1374, 1349, 1259, 1226, 1169, 1126, 1075, 1006, 915, 839, 781, 
733 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.91 – 7.82 (m, 2H), 7.55 – 7.48 (m, 1H), 7.44 – 
7.37 (m, 2H), 5.67 (dddd, J = 16.4, 10.0, 8.0, 5.8 Hz, 1H), 5.65 – 5.57 (m, 1H), 5.60 (s, 
1H), 5.14 – 4.91 (m, 4H), 4.76 (t, J = 1.5 Hz, 1H), 4.67 (s, 1H), 3.75 (s, 3H), 2.48 (dd, J = 
13.7, 3.7 Hz, 1H), 2.24 – 2.09 (m, 2H), 2.08 – 1.88 (m, 4H), 1.74 (ddd, J = 13.9, 8.8, 8.8 
Hz, 1H), 1.66 (s, 3H), 1.64 – 1.57 (m, 1H), 1.54 (dd, J = 13.3 Hz, 1H), 1.27 (s, 3H), 1.02 
(s, 3H); 13C NMR (125 MHz, CDCl3) δ 194.1, 186.0, 175.1, 170.0, 146.1, 137.7, 136.5, 
135.8, 133.0, 129.3, 128.3, 126.0, 117.3, 116.1, 111.7, 102.5, 88.3, 55.8, 47.6, 45.3, 42.7, 
42.4, 39.5, 36.0, 35.5, 28.8, 21.6, 19.9; HR-MS: m/z Calcd. for C30H36O4 [M+H+]: 























2,3,4,4a-tetrahydro-7H-chromen-7-one 169:179:167:182:  Oxycyclization products 
169:179:167:182 (1.7 g, 3:3:1:1 d.r. as determined by 1H NMR analysis) were prepared 
according to general procedure A from enols (±)-168A:(meso)-168B:(meso)-168C (2.0 g, 
4.34 mmol, 2.5:2.4:1 d.r. as determined by 1H NMR analysis), LiBr (3.77 g, 43.4 mmol), 
diphenyl phosphate 175 (10.9 g, 43.4 mmol) in CH2Cl2 (289 mL).    
Vinylic Allylation: 
General Procedure D 
 
(Lithium Tetramethylpiperidine [LTMP] Preparation): To a flame-dried 10-mL round-
bottom flask under an argon atmosphere containing a solution of 2,2,6,6-








































(4.96 mL, 2.5 M in THF) in a dropwise fashion over the course of 15 min.  The LTMP 
solution was allowed to stir for 15 min at -78 oC prior to use.  
(±)-3,6-Diallyl-8-benzoyl-5-methoxy-2,2-dimethyl-4a-(2-(prop-1-en-2-yl)pent-4-en-1-
yl)-2,3,4,4a-tetrahydro-7H-chromen-7-one 170:180:166:183: To a flame-dried 1-L 
round-bottom flask under an argon atmosphere containing pyranodienones 
169:179:167:182 (1.04 g, 2.27 mmol, 3:3:1:1 d.r. as determined by 1H NMR analysis) 
was added THF (86.4 mL).  The solution was cooled to -78 oC, and a freshly prepared 
solution (at -78 oC) of LTMP (22.7 mL, 0.5 M in THF) was added along the side of the 
flask in a dropwise fashion over the course of an hour.  Lithium 2-thienylcyanocuprate 
(49.9 mL, 0.25 M in THF) was then added in a dropwise manner along the side of the 
flask over the course of an hour.  [Note:  Lithium 2-thienylcyanocuprate should be bright 
yellow in color and should not contain any visible copper salts for optimal yields.] Allyl 
bromide (0.98 mL, 11.3 mmol) was added dropwise into the center of the reaction 
mixture over the course of 10 min.  [Note:  Allyl bromide was filtered through a pad of 
basic Al2O3 under an argon atmosphere prior to use.]  The reaction was allowed to stir for 
1 h and was then quenched with 30 % NH4OH (432 mL), diluted with Et2O (200 mL), 
and vigorously stirred for 5 min at room temperature. The mixture was poured into a 
separatory funnel and extracted into Et2O (3 x 400 mL).  The combined organic extracts 
were washed with water (1 x 400 mL) and brine (1 x 400 mL), dried (Na2SO4), filtered, 
and concentrated in vacuo.  Purification by column chromatography (silica gel, 2 – 10 % 
EtOAc/hexanes) provided vinylic allylation products 170:180:166:183 (853 mg, 75 %, 




yl)pent-4-en-1-yl)-2,3,4,4a-tetrahydro-7H-chromen-7-one (-)-166: Vinylic allylation 
product (-)-166 (17.4 mg, 79 %) was prepared according to general procedure D from a 
solution of pyranodineone (-)-167 (20.3 mg, 0.0441 mmol) in THF (1.68 mL) at -78 oC 
using LTMP (0.44 mL, 0.5 M in THF), lithium 2-thienylcyanocuprate (0.97 mL, 0.25 M 
in THF), and allyl bromide (19 µL, 0.22 mmol).  (-)-166:  Rf = 0.38 (20 % 
EtOAc/hexanes); IR nmax 2982, 2917, 2848, 1677, 1656, 1618, 1598, 1449, 1373, 1229, 
1174, 1129, 998, 916, 739 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.87 – 7.82 (m, 2H), 7.55 
– 7.48 (m, 1H), 7.41 (m, 2H), 5.93 (dddd, J = 16.5, 10.2, 6.3, 6.1 Hz, 1H), 5.69 (dddd, J = 
16.4, 10.4, 8.3, 5.8 Hz, 1H), 5.62 (dddd, J = 17.1, 10.2, 6.8, 6.6 Hz, 1H), 5.12 – 4.90 (m, 
6H), 4.68 (t, J = 1.4 Hz, 1H), 4.54 (br s, 1H), 3.93 (s, 3H), 3.26 (dddd, J = 15.6, 5.7, 1.8, 
1.8 Hz, 1H), 3.06 (dddd, J = 15.7, 6.4, 1.6, 1.6 Hz, 1H), 2.44 (dd, J = 14.5, 4.5 Hz, 1H), 
2.22 (dd, J = 13.5, 5.8 Hz, 1H), 2.19 – 1.95 (m, 4H), 1.92 (dd, J = 13.5, 3.4 Hz, 1H), 1.74 
(ddd, J = 13.8, 10.2, 9.6 Hz, 1H), 1.66 – 1.59 (m, 1H), 1.60 (br s, 3H), 1.49 (dd, J = 14.6, 
13.0 Hz, 1H), 1.27 (s, 3H), 1.12 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 194.4, 186.4, 
171.8, 169.9, 146.7, 137.7, 136.6, 136.5, 135.9, 133.0, 129.1, 128.4, 126.0, 119.9, 117.2, 

















HR-MS: m/z Calcd. for C33H40O4 [M+H+]: 501.3005, Found 501.3013; [α]27𝐷  = -140.6 
(c. 0.250, CHCl3). 
 
(+)-(3S,4aS)-3,6-Diallyl-8-benzoyl-5-methoxy-2,2-dimethyl-4a-((S)-2-(prop-1-en-2-
yl)pent-4-en-1-yl)-2,3,4,4a-tetrahydro-7H-chromen-7-one (+)-170: Vinylic allylation 
product (+)-21 (93.8 mg, 87 %) was prepared according to general procedure D from a 
solution of pyranodineone (+)-169 (98.7 mg, 0.2143 mmol) in THF (8.2 mL) at -78 oC 
using LTMP (2.14 mL, 0.5 M in THF), lithium 2-thienylcyanocuprate (4.7 mL, 0.25 M in 
THF), and allyl bromide (0.1 mL, 1.16 mmol). (+)-170: Rf = 0.28 (15 % 
EtOAc/hexanes); IR nmax 3072, 2976, 2928, 2848, 1678, 1656, 1622, 1449, 1387, 1372, 
1229, 1178, 1130, 995, 912, 740 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.87 – 7.80 (m, 
2H), 7.53 – 7.47 (m, 1H), 7.42 – 7.35 (m, 2H), 5.95 (dddd, J = 16.7, 10.1, 6.0, 6.0 Hz, 
1H), 5.80 – 5.69 (m, 1H), 5.67 – 5.56 (m, 1H), 5.15 – 4.91 (m, 6H), 4.73 (qd, J = 1.5, 1.4 
Hz, 1H), 4.59 (br s, 1H), 3.97 (s, 3H), 3.27 (dddd, J = 15.4, 5.7, 1.6, 1.6 Hz, 1H), 3.20 
(dddd, J = 15.7, 6.4, 1.6, 1.6 Hz, 1H), 2.34 – 2.27 (m, 1H), 2.23 (dd, J = 13.5, 3.8 Hz, 
1H), 2.20 – 2.12 (m, 2H), 2.11 – 1.97 (m, 3H), 1.79 – 1.72 (m, 1H), 1.72 – 1.63 (m, 1H), 
1.62 (s, 3H), 1.47 (dd, J = 12.9, 12.9 Hz, 1H), 1.31 (s, 3H), 0.95 (s, 3H); 13C NMR (125 

















129.3, 128.1, 125.9, 121.4, 117.2, 115.7, 115.3, 112.3, 87.3, 62.4, 46.8, 43.5, 39.7, 39.5, 
39.3, 36.6, 36.1, 28.2, 28.2, 20.7, 18.8; HR-MS: m/z Calcd. for C33H40O4 [M+H+]: 
501.3005, Found 501.3006; [α]27𝐷  = +41.1 (c. 0.250, CHCl3). 
 
(+)-(3S,4aS)-3,6-Diallyl-8-benzoyl-5-methoxy-2,2-dimethyl-4a-((S)-2-(prop-1-en-2-
yl)pent-4-en-1-yl)-2,3,4,4a-tetrahydro-7H-chromen-7-one (+)-170 and (-)-(3S,4aR)-
3,6-Diallyl-8-benzoyl-5-methoxy-2,2-dimethyl-4a-((S)-2-(prop-1-en-2-yl)pent-4-en-1-
yl)-2,3,4,4a-tetrahydro-7H-chromen-7-one (-)-166:  Vinylic allylation products (+)-170 
(621 mg, 52 %) and (-)-166 (323 mg, 27 %) were prepared according to general 
procedure D from a solution of pyranodineones (+)-169:(-)-167 (1.1 g, 2.39 mmol) in 
THF (91 mL) at -78 oC using LTMP (23.9 mL, 0.5 M in THF), lithium 2-
thienylcyanocuprate (52.5 mL, 0.25 M in THF), and allyl bromide (1.03 mL, 11.9 mmol).  
Purification by column chromatography (silica gel, 2 – 14 % EtOAc/hexanes) provided 
306 mg of (+)-170 and 159 mg of (-)-166.  Purification of remaining impure fractions by 
preparative thin layer chromatography (silica gel, 4 elutions in 15 % EtOAc/hexanes) 
afforded an additional 315 mg of (+)-170 and 164 mg of (-)-166.  Reaction yield:[(+)-170 



























yl)pent-4-en-1-yl)-2,3,4,4a-tetrahydro-7H-chromen-7-one 180: Vinylic allylation 
product 180 (19.3 mg, 89 %) was prepared as a yellow oil according to general procedure 
D from a solution of pyranodienone 179 (20.0 mg, 0.0434 mmol) in THF (1.65 mL) at -
78 oC using LTMP (0.43 mL, 0.5 M in THF), lithium 2-thienylcyanocuprate (0.96 mL, 
0.25 M in THF), and allyl bromide (20 µL, 0.231 mmol). 180:  Rf = 0.26 (14 % 
EtOAc/hexanes); IR nmax 3075, 2977, 2924, 2852, 1678, 1656, 1621, 1449, 1372, 1229, 
1175, 1130, 1074, 995, 912, 741 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.87 – 7.80 (m, 
2H), 7.55 – 7.48 (m, 1H), 7.45 – 7.37 (m, 2H), 5.93 (dddd, J = 16.7, 10.0, 6.1, 6.1 Hz, 
1H), 5.81 – 5.69 (m, 1H), 5.64 (dddd, J = 17.0, 10.1, 6.6, 6.6 Hz, 1H), 5.14 – 4.92 (m, 
6H), 4.68 (dd, J = 1.3, 1.3 Hz, 1H), 4.56 (s, 1H), 3.91 (s, 3H), 3.25 (dddd, J = 15.5, 5.5, 
2.0, 2.0 Hz, 1H), 3.06 (dddd, J = 15.9, 6.8, 1.7, 1.7 Hz, 1H), 2.27 – 2.00 (m, 7H), 1.97 
(dd, J = 13.3, 6.0 Hz, 1H), 1.69 (ddd, J = 14.0, 9.6, 9.6 Hz, 1H), 1.61 (s, 3H), 1.47 (dd, J 
= 13.2, 13.2 Hz, 1H), 1.31 (s, 3H), 0.99 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 194.2, 
186.6, 172.1, 168.6, 146.9, 137.6, 136.7, 136.5, 135.9, 133.0, 129.1, 128.3, 125.9, 120.3, 
117.2, 116.1, 115.0, 111.8, 87.1, 62.0, 46.8, 42.6, 39.9, 39.5, 39.4, 36.2, 35.0, 28.2, 28.2, 




















yl)pent-4-en-1-yl)-2,3,4,4a-tetrahydro-7H-chromen-7-one 183:  Vinylic allylation 
product 183 (48.9 mg, 71 %) was prepared according to general procedure D from a 
solution of pyranodienone 182 (63.6 mg, 0.138 mmol) in THF (5.3 mL) at -78 oC using 
LTMP (1.4 mL, 0.5 M in THF), lithium 2-thienylcyanocuprate (3.0 mL, 0.25 M in THF), 
and allyl bromide (60 µL, 0.691 mmol). 183: Rf = 0.42 (25 % EtOAc/hexanes); IR nmax 
3082, 2978, 2935, 2849, 1679, 1654, 1620, 1449, 1373, 1229, 1172, 1123, 1068, 996, 
913, 740 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.86 – 7.81 (m, 2H), 7.54 – 7.48 (m, 1H), 
7.43 – 7.37 (m, 2H), 5.95 (dddd, J = 16.5, 10.4, 6.1, 6.1 Hz, 1H), 5.69 (dddd, J = 16.7, 
10.3, 8.6, 5.6 Hz, 1H), 5.60 (dddd, J = 16.0, 12.0, 6.9, 6.7 Hz, 1H), 5.14 – 4.90 (m, 6H), 
4.74 (br s, 1H), 4.62 (br s, 1H), 4.01 (s, 3H), 3.24 (ddd, J = 37.9, 15.8, 5.9 Hz, 2H), 2.45 
(dd, J = 14.1, 4.2 Hz, 1H), 2.16 (dddd, J = 31.6, 13.8, 8.6, 8.6 Hz, 2H), 2.06 – 1.95 (m, 
4H), 1.74 (ddd, J = 14.2, 9.4, 9.4 Hz, 1H), 1.63 (s, 3H), 1.61 – 1.55 (m, 1H), 1.51 (dd, J = 
14.1 Hz, 1H), 1.27 (s, 3H), 1.07 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 194.2, 186.3, 
171.9, 170.0, 146.1, 137.8, 136.7, 136.4, 135.9, 132.9, 129.2, 128.2, 126.3, 120.7, 117.3, 
115.8, 115.2, 112.0, 88.2, 62.4, 49.1, 45.2, 42.9, 42.3, 39.1, 36.2, 35.4, 28.7, 28.5, 21.7, 















THF, -78 oC, 1 h
71 %
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hexahydro-2H,9H-4a,8-methanocycloocta[b]pyran-9,11-dione (-)-177: Trifluoroacetic 
acid (1.0 mL) and water (1.0 mL) were added to a 20-mL scintillation vial.  After the 
mixture cooled to room temperature, the TFA/H2O (2.0 mL) mixture was added to a 20-
mL scintillation vial containing pyranodienone (-)-166 (7.1 mg, 0.0141 mmol).  The 
reaction mixture was then heated to 50 oC for 2 h, cooled to room temperature, and 
concentrated in vacuo.  Purification by column chromatography provided C-cyclization 
product (-)-177 (5.8 mg, 84 %) as a white amorphous solid. (-)-177:  Rf = 0.43 (20 % 
EtOAc/hexanes); IR νmax 3078, 2978, 2935, 1728, 1682, 1641, 1600, 1449, 1391, 1374, 
1351, 1305, 1120, 993, 917, 733 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.78 – 7.70 (m, 
2H), 7.55 – 7.48 (m, 1H), 7.42 – 7.35 (m, 2H), 5.85 – 5.77 (m, 1H), 5.73 (dddd, J = 16.5, 
9.8, 8.8, 5.2 Hz, 1H), 5.64 (dddd, J = 16.6, 10.2, 7.6, 6.2 Hz, 1H), 5.17 – 4.98 (m, 6H), 
3.02 (dd, J = 14.2, 3.6 Hz, 1H), 2.69 (dddd, J = 13.1, 7.5, 1.2, 1.2 Hz, 1H), 2.58 (dddd, J 
= 12.9, 6.3, 1.3, 1.3 Hz, 1H), 2.44 – 2.37 (m, 1H), 2.18 (dd, J = 13.9, 4.7 Hz, 1H), 2.21 – 
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1H), 1.53 – 1.42 (m, 2H), 1.21 (s, 3H), 1.09 (s, 3H), 1.00 (dd, J = 13.9, 13.9 Hz 1H), 0.93 
(s, 3H), 0.74 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 205.9, 193.7, 193.2, 171.0, 137.3, 
136.8, 135.5, 134.4, 133.1, 129.0, 128.3, 127.1, 119.2, 117.4, 116.8, 87.0, 70.7, 52.9, 
46.1, 42.0, 41.9, 39.7, 35.5, 33.7, 30.0, 28.4, 27.3, 22.0, 21.3, 16.1; HR-MS: m/z Calcd. 
for C32H38O4 [M+Na+]: 509.2668, Found 509.2674; [α]





hexahydro-2H,9H-4a,8-methanocycloocta[b]pyran-9,11-dione (+)-178:  To a 25-mL 
round-bottom flask containing pyranodienone (+)-170 (10.0 mg, 0.01997 mmol) and a 
stir bar was added TFA (5.0 mL) and the solution was allowed to stir at room temperature 
for 1 h.  Water (0.05 mL) was then added and the reaction mixture was allowed to stir for 
24 hours. The solvent was removed in vacuo.  This process was repeated 5x before 
purification by column chromatography (silica gel, 2 – 12 % EtOAc/hexanes) to provide 
C-cyclization product (+)-178 (1.4 mg, 14 %) as a yellow solid and O-cyclization product 
(+)-187 (6.7 mg, 69 %) as a white amorphous solid. (+)-178:  Rf = 0.31 (15 % 





















1682, 1640, 1607, 1449, 1390, 1353, 1230, 1173, 1137, 1120, 1002, 922, 731 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 7.76 – 7.69 (m, 2H), 7.54 – 7.48 (m, 1H), 7.37 (m, J = 7.7 
Hz, 2H), 5.77 – 5.55 (m, 3H), 5.27 (ddd, J = 17.0, 2.0 Hz, 1H), 5.13 – 5.05 (m, 4H), 5.02 
(dd, J = 10.2, 2.1 Hz, 1H), 2.73 – 2.64 (m, 3H), 2.60 (dd, J = 12.9, 6.6 Hz, 1H), 2.36 
(ddd, J = 14.4, 4.3 Hz, 1H), 2.20 (br dd, J = 14.2, 5.7 Hz, 1H), 1.98 – 1.87 (m, 2H), 1.80 
– 1.66 (m, 3H), 1.65 – 1.57 (m, 1H), 1.30 (s, 3H), 1.15 (s, 3H), 1.03 (s, 3H), 0.77 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 208.9, 193.7, 193.2, 170.5, 138.1, 137.4, 135.2, 134.2, 
133.2, 128.9, 128.2, 123.6, 119.3, 117.8, 117.8, 85.4, 69.7, 48.2, 46.6, 44.4, 38.6, 36.2, 
35.9, 34.7, 30.3, 28.7, 27.9, 26.7, 22.1, 21.4; HR-MS: m/z Calcd. for C32H38O4 [M+H+]: 
487.2770, Found 487.2762; [α]24.6𝐷  = +24.4 (c. 0.250, CHCl3). 
 (+)-(3S,4aS,6S)-3,6,9-Triallyl-11-benzoyl-2,2,7,7-
tetramethyl-3,4,6,7-tetrahydro-2H,5H,10H-pyrano[3,2-
e]chromen-10-one (+)-187:  Rf = 0.16 (15 % EtOAc/hexanes); 
IR νmax 3077, 2979, 2932, 2851, 1686, 1659, 1622, 1449, 1396, 
1374, 1270, 1226, 1195, 1123, 995, 914, 841, 734 cm-1;  1H 
NMR (500 MHz, CDCl3) δ 7.86 – 7.80 (m, 2H), 7.56 – 7.48 (m, 1H), 7.46 – 7.38 (m, 
2H), 5.85 (dddd, J = 16.7, 10.0, 6.5 Hz, 1H), 5.78 – 5.64 (m, 2H), 5.19 – 4.89 (m, 6H), 
3.18 (dddd, J = 14.2, 6.7, 1.4 Hz, 1H), 3.08 (dddd, J = 14.2, 6.3, 1.6 Hz, 1H), 2.49 (ddd, J 
= 14.5, 11.3, 3.7 Hz, 2H), 2.02 – 1.89 (m, 2H), 1.76 – 1.62 (m, 2H), 1.54 (s, 3H), 1.36 (d, 
J = 13.7 Hz, 1H), 1.33 (s, 3H), 1.30 (d, J = 14.0 Hz, 1H), 1.14 (s, 3H), 0.98 (s, 3H); 13C 
NMR (125 MHz, CDCl3) δ 194.0, 185.7, 170.4, 168.3, 137.5, 136.0, 135.6, 135.6, 133.0, 







33.4, 32.7, 28.5, 28.2, 27.1, 20.6, 20.2; HR-MS: m/z Calcd. for C32H38O4 [M+H+]: 




hexahydro-2H,9H-4a,8-methanocycloocta[b]pyran-9,11-dione 181: To a 20-mL 
scintillation vial containing pyranodienone 180 (55.1 mg, 0.110 mmol) was added TFA 
(4 mL). The vessel was then sealed and placed in an oil bath at 60 oC and stirred 
vigorously for 1.5 h.  After cooling to room temperature, the reaction mixture was 
concentrated in vacuo and purified by column chromatography (silica gel, 2-10 % 
EtOAc/hexanes) to provide 37.4 mg (70 %) of C-cyclization product 181 as a white solid. 
181:  Rf = 0.29 (14 % EtOAc/hexanes); m.p. 137 – 139 oC (CH2Cl2); IR νmax 2975, 2922, 
2857, 1727, 1683, 1641, 1606, 1449, 1390, 1353, 1137, 1121, 915, 732 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 7.77 – 7.70 (m, 2H), 7.55 – 7.48 (m, 1H), 7.42 – 7.34 (m, 2H), 5.83 
– 5.66 (m, 2H), 5.61 (dddd, J = 17.1, 10.2, 6.9, 6.9 Hz, 1H), 5.16 – 4.96 (m, 6H), 2.68 
(dd, J = 13.1, 7.2 Hz, 1H), 2.58 (dd, J = 12.8, 6.5 Hz, 1H), 2.44 – 2.35 (m, 1H), 2.41 (dd, 
J = 13.8, 4.5 Hz, 1H), 2.26 – 2.19 (m, 1H), 2.02 (dd, J = 14.0 Hz, 2H), 2.08 – 2.00 (m, 
1H), 1.87 (dddd, J = 13.4, 10.3, 2.9, 2.9 Hz, 1H), 1.72 (dd, J = 14.6, 3.4 Hz, 1H) 1.80 – 
neat TFA, 












1.68 (m, 2H), 1.31 – 1.23 (m, 1H), 1.27 (s, 3H), 1.09 (s, 3H), 0.84 (s, 3H), 0.75 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ 207.9, 193.7, 193.0, 169.8, 137.4, 136.8, 135.2, 134.4, 
133.1, 128.9, 128.3, 126.1, 119.1, 117.8, 116.8, 85.4, 71.5, 49.7, 46.3, 40.3, 40.1, 38.6, 
35.9, 33.7, 29.6, 28.4, 27.9, 22.2, 21.2, 15.9; HR-MS: m/z Calcd. for C32H38O4 [M+Na+]: 
487.2848, Found 487.2849. 
 
(±)-(3R,4aS,6S,8R)-3,6,10-Triallyl-8-benzoyl-2,2,7,7-tetramethyl-3,4,5,6,7,8-
hexahydro-2H,9H-4a,8-methanocycloocta[b]pyran-9,11-dione 184:  To a 20-mL 
scintillation vial containing pyranodienone 183 (5.1 mg, 0.0102 mmol) was added water 
(4.5 mL) and TFA (4.5 mL). The reaction mixture was allowed to stir for 17 h before 
concentrating in vacuo to provide C-cyclization product 184 (3.9 mg, 79 %) as a clear oil. 
184: Rf = 0.33 (15 % EtOAc/hexanes); IR νmax 3078, 2978, 2927, 2854, 1722, 1698, 
1641, 1604, 1448, 1392, 1374, 1348, 1243, 1224, 1186, 1134, 1115, 995, 915, 732 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.52 – 7.46 (m, 2H), 7.41 – 7.35 (m, 1H), 7.26 – 7.21 (m, 
2H), 5.81 – 5.61 (m, 3H), 5.15 – 4.91 (m, 6H), 3.17 (dd, J = 13.5, 6.4 Hz, 1H), 3.12 (dd, J 
= 13.5, 7.4 Hz, 1H), 2.42 – 2.28 (m, 3H), 2.01 (dd, J = 13.9 Hz, 1H), 1.97 – 1.90 (m, 1H), 
1.80 (ddd, J = 13.9, 9.2 Hz, 1H), 1.77 – 1.70 (m, 3H), 1.54 (s, 3H), 1.34 (s, 3H), 1.30 – 
1.24 (m, 1H), 1.20 (s, 3H), 1.14 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 207.7, 193.5, 















84.1, 79.1, 50.9, 47.7, 41.4, 40.1, 38.8, 36.0, 32.6, 28.9, 28.2, 27.1, 23.0, 21.5, 16.1;  HR-
MS: m/z Calcd. for C32H38O4 [M+H+]: 487.2848, Found 487.2853. 
 
 
Cyclization Products 177:181:178:184:187:  To a 500-mL round-bottom flask 
containing pyranodienones 170:180:166:183 (1.08 g, 2.16 mmol, 3:3:1:1 d.r. as 
determined by 1H NMR analysis), was added TFA (120 mL).  After 10 min, compounds 
170:180:166:183 were fully dissolved in TFA, and water (12 mL) was then added 
dropwise over the course of 10 min.  The reaction mixture stirred at room temperature for 
24 h and was then concentrated in vacuo.  Purification by column chromatography (silica 
gel, 0 – 12 % EtOAc/hexanes) provided 30-epi-13,14-didehydroxyisogarcinol core 178 
(47 mg, 5 %) as a yellow solid, O-cyclization product 187 (319 mg, 30 %) as a white 
amorphous solid, and a mixture of cyclization products 177 and 181 (321 mg, 31 %, 1:3.7 
mixture as determined by 1H NMR analysis) as a white crystalline solid.  Type A 
cyclization product 184 (90.5 mg, 41 % purity) was further purified by preparative thin 
layer chromatography (silica gel, ~2 elutions in 15 % EtOAc/hexanes) to provide 37 mg 
(4 %, 100 % purity) of 184 as a yellow oil. [Cyclization products 181 and 177 were 

















































EtOAc/hexanes;  A single spot was cut into five sections, with the bottom two sections 
(compound 181) and top two sections (compound 177) in most cases 100 % pure)]. 
 
Olefin Metathesis:  
General Procedure E 
 
(-)-6-epi-13,14-Didehydroxyisogarcinol (-)-6-epi-3:  To a flame-dried 30-mL glass 
pressure tube containing (-)-177 (16.8 mg, 0.0345 mmol) was added Grubbs 2nd 
generation catalyst (5.9 mg, 0.0069 mmol).  The vessel was purged with argon, cooled to 
-78 oC, and filled with isobutylene (7 mL) which was condensed along the side of the 
tube.  The reaction vessel was then sealed and warmed to 60 oC with vigorous stirring for 
12 h.  The reaction mixture was then re-cooled to -78 oC and opened to the air. The dry 
ice bath was then removed which allowed for the evaporation of isobutylene.  
Purification by column chromatography (silica gel, 2 – 10 % EtOAc/hexanes) provided 
19.3 mg (98 %) of (-)-6-epi-13,14-didehyroxyisogarcinol [(-)-6-epi-3] as a clear oil. (-)-6-
epi-3: Rf = 0.24 (9 % EtOAc/hexanes); IR νmax 2973, 2928, 2858, 1728, 1683, 1643, 
1605, 1449, 1374, 1348, 1308, 1231, 1172, 1125, 1095, 984, 955, 831, 755 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 7.81 – 7.66 (m, 2H), 7.56 – 7.46 (m, 1H), 7.43 – 7.32 (m, 
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Hz, 1H), 3.03 (dd, J = 14.2, 3.7 Hz, 1H), 2.68 (dd, J = 13.8, 8.0 Hz, 1H), 2.52 – 2.31 (m, 
1H), 2.23 – 2.15 (m, 1H), 2.15 (dd, J = 14.0, 4.7 Hz, 1H), 2.06 – 1.97 (m, 2H), 1.84 – 
1.67 (m, 2H), 1.77 (s, 3H), 1.70 (s, 3H), 1.64 (s, 3H), 1.60 (s, 6H), 1.58 (s, 3H), 1.47 (dd, 
J = 13.9, 12.4 Hz, 1H), 1.41 (dddd, J = 9.9, 9.9, 3.7, 3.7 Hz, 1H), 1.21 (s, 3H), 1.11 (s, 
3H), 0.96 (dd, J = 14.2, 13.0 Hz, 1H), 0.89 (s, 3H), 0.75 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 206.4, 194.0, 193.6, 170.9, 137.5, 134.3, 133.6, 133.2, 132.9, 128.8, 128.3, 
126.8, 122.5, 121.4, 120.1, 86.8, 70.4, 52.8, 46.1, 42.9, 42.4, 40.8, 29.7, 28.5, 27.7, 27.7, 
26.1, 25.8, 25.8, 24.8, 22.1, 21.3, 18.1, 18.0, 18.0, 16.2; HR-MS: m/z Calcd. for 
C38H50O4 [M+Na+]: 593.3607, Found 593.3607; [α]
26𝐷  = -144.59 (c. 0.250, CHCl3).  
 
(+)-30-epi-13,14-Didehydroxyisogarcinol (+)-30-epi-3: Polyprenylated product (+)-30-
epi-3 (21.4 mg, 70 %) was afforded as a yellow oil and prepared according to general 
procedure E from Type B PPAP core (+)-178 (26.0 mg, 0.0534 mmol) using Grubbs 2nd 
generation catalyst (18.2 mg, 0.0214 mmol) and isobutylene (10 mL) in a sealed pressure 
tube.  (+)-30-epi-3: Rf = 0.29 (12 % EtOAc/hexanes); IR νmax 2975, 2924, 2892, 2851, 
1728, 1685, 1642, 1607, 1448, 1393, 1347, 1229, 1169, 1124, 959, 842, 756 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 7.75 – 7.68 (m, 2H), 7.52 – 7.45 (m, 1H), 7.38 – 7.30 (m, 
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2.09 – 2.01 (m, 1H), 1.97 (dd, J = 14.4, 13.8 Hz, 1H), 1.88 – 1.74 (m, 3H), 1.72 (s, 3H), 
1.70 (s, 6H), 1.70 (s, 3H), 1.69 (s, 3H), 1.65 (dd, J = 14.5, 3.0 Hz, 1H), 1.61 (s, 6H), 1.60 
(s, 3H), 1.52 – 1.46 (m, 1H), 1.30 (s, 3H), 1.16 (s, 3H), 1.00 (s, 3H), 0.78 (s, 3H); 13C 
NMR (126 MHz, CDCl3) δ 209.5, 193.8, 193.6, 170.4, 137.6, 134.5, 134.3, 133.1, 133.0, 
128.7, 128.3, 125.0, 123.9, 121.2, 119.8, 85.4, 69.2, 48.4, 46.7, 46.4, 39.7, 38.0, 30.0, 
29.2, 29.1, 28.0, 26.8, 26.1, 26.0, 25.8, 25.2, 22.3, 21.5, 18.2, 18.1, 17.9; HR-MS: m/z 
Calcd. for C38H50O4 [M+H+]: 571.3787, Found 571.3787; [α]
26𝐷  = -144.59 (c. 0.250, 
CHCl3). 
 
(±)-6,30-epi-13,14-didehydroxyisogarcinol (±)-6,30-epi-3:  Polyprenylated product (±)-
6,30-epi-3 (10.7 mg, 91 %) was prepared according to general procedure E from Type B 
PPAP core 181 (10.0 mg, 0.0206 mmol) using Grubbs 2nd generation catalyst (3.5 mg, 
0.00411 mmol) and isobutylene (5 mL) in a sealed pressure tube. (±)-6,30-epi-3: Rf = 
0.28 (15 % EtOAc/hexanes); IR νmax 2977, 2929, 2857, 1726, 1683, 1644, 1609, 1449, 
1377, 1347, 1310, 1226, 1173, 1124, 964, 917, 839, 763, 733 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.83 – 7.65 (m, 2H), 7.57 – 7.45 (m, 1H), 7.42 – 7.32 (m, 2H), 5.17 – 5.02 (m, 
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Hz, 1H), 2.41 (dd, J = 13.6, 4.5 Hz, 1H), 2.31 – 2.19 (m, 1H), 2.18 – 2.02 (m, 2H), 2.02 – 
1.92 (m, 1H), 1.90 – 1.61 (m, 13H), 1.77 (s, 6H), 1.64 (s, 3H), 1.36 – 1.25 (m, 1H), 1.32 
(s, 3H), 1.15 (s, 3H), 0.89 (s, 3H), 0.81 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 208.6, 
193.9, 193.5, 169.8, 137.6, 134.2, 134.1, 133.3, 133.0, 128.8, 128.3, 125.8, 122.6, 121.2, 
120.1, 85.4, 71.3, 49.8, 46.3, 41.5, 40.5, 39.6, 29.9, 28.6, 28.0, 27.8, 26.1, 25.8, 25.8, 
24.4, 22.3, 21.3, 18.1, 18.0, 17.9, 16.0; HR-MS: m/z Calcd. for C38H50O4 [M+Na+]: 
593.3607, Found 593.3611. 
 
(±)-6,30-epi-garcimultiflorone A 6,30-epi-4:  Polyprenylated product (±)-6,30-epi-4 
(18.9 mg, 99 %) was afforded as a white amorphous solid and was prepared according to 
general procedure E from 184 (16.3 mg, 0.0335 mmol) with Grubbs 2nd generation 
catalyst (5.7 mg, 0.0067 mmol), and isobutylene (5 mL). 6,30-epi-4: Rf = 0.51 (10 % 
EtOAc/hexanes); IR νmax 2973, 2923, 2857, 1721, 1697, 1643, 1604, 1447, 1389, 1373, 
1344, 1243, 1222, 1125, 1065, 1024, 850 cm-1;  1H NMR (500 MHz, CDCl3) δ 7.53 – 
7.48 (m, 2H), 7.40 – 7.35 (m, 1H), 7.25 – 7.20 (m, 2H), 5.11 – 5.06 (m, 1H), 5.06 – 4.95 
(m, 1H), 3.12 (dd, J = 13.6, 7.2 Hz, 1H), 3.07 (dd, J = 13.6, 7.7 Hz, 1H), 2.27 (dd, J = 
13.5, 4.3 Hz, 1H), 2.24 – 2.12 (m, 2H), 1.98 (dd, J = 14.3, 13.2 Hz, 1H), 1.90 – 1.76 (m, 
2H), 1.73 (s, 3H), 1.71 (s, 3H), 1.70 – 1.55 (unresolved m, 3H), 1.66 (br d, J = 1.4 Hz, 
184
   Grubbs II, 
   Isobutylene













3H), 1.64 (br d, J = 1.3 Hz, 3H), 1.62 (s, 3H), 1.58 (s, 3H), 1.54 (s, 3H), 1.35 (s, 3H), 
1.27 (dd, J = 13.6, 12.5 Hz, 1H), 1.19 (s, 3H), 1.15 (s, 3H); 13C NMR (125 MHz, CDCl3) 
δ 208.2, 193.6, 192.8, 167.0, 136.8, 134.2, 133.2, 131.9, 131.8, 128.2, 127.8, 124.5, 
122.6, 121.3, 121.3, 84.0, 79.1, 51.0, 47.8, 42.7, 40.5, 39.8, 30.0, 29.0, 28.2, 26.7, 25.9, 
25.8, 25.8, 23.0, 21.8, 21.2, 18.0, 17.9, 17.9, 16.1; HR-MS: m/z Calcd. for C38H50O4 




X-Ray Crystallographic Data 
  









     Crystals of compound (meso)-168C suitable for X-ray analysis were obtained in 
isooctane at -20 oC over the course of 48 h.  Crystallographic data have been deposited 
with the Cambridge Crystallographic Data Centre (CCDC # 1508478). Copies of the data 
can be obtained free of charge on application to the CCDC, 12 Union Road, Cambridge 
CB21EZ, UK (fax: (+44)-1223-336-033; e-mail: deposit@ccdc.cam.ac.uk ). 
 
Crystal data 
  C30H36O4 F(000) = 1984 
Mr = 460.59 Dx = 1.151 Mg m-3 
Monoclinic, P21/n Cu Ka radiation, l = 1.54178 Å 
Hall symbol:  -P 2yn Cell parameters from 9698 reflections 
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a = 14.1854 (2) Å q = 3.2–66.5° 
b = 19.4283 (3) Å m = 0.59 mm-1 
c = 19.7516 (3) Å T = 100 K 
b = 102.419 (1)° Block, colorless 
V = 5316.13 (14)  Å3 0.24 × 0.20 × 0.15 mm 
Z = 8  
 
Data collection 
  Bruker Proteum-R  
diffractometer 
9331 independent reflections 
Radiation source: rotating anode 8667 reflections with I > 2s(I) 
Montel Rint = 0.040 
ω and φ scans θmax = 66.6°, θmin = 3.2° 
Absorption correction: multi-scan  
SADABS (Sheldrick, 2015) 
h = -16→16 
Tmin = 0.702, Tmax = 0.753 k = -23→23 
53021 measured reflections l = -23→23 
 
Refinement 
  Refinement on F2 8 restraints 
Least-squares matrix: full Hydrogen site location: mixed 
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R[F2 > 2σ(F2)] = 0.041 H atoms treated by a mixture of 
independent and constrained refinement 
wR(F2) = 0.109  w = 1/[σ2(Fo2) + (0.049P)2 + 2.449P]   
where P = (Fo2 + 2Fc2)/3 
S = 1.04 (Δ/σ)max = 0.001 
9331 reflections Δ〉max = 0.43 e Å-3 
645 parameters Δ〉min = -0.23 e Å-3 
Special details 
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are 
estimated using the full covariance matrix.  The cell esds are taken into account 
individually in the estimation of esds in distances, angles and torsion angles; correlations 
between esds in cell parameters are only used when they are defined by crystal 
symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds 
involving l.s. planes. 
Refinement. A two component disorder was refined on one of the two independent   
residues.  The conformation of the minor component is a close match with the 
conformation of the second (non-disordered) residue.  Pseudo-symmetry between the two 
residues is evident, with slight conformational variability seen in the pendant -
C(=CH2)Me groups, leading to elongated atomic displacement ellipsoids.  Refinement of 
these slight distortions as disorders would not improve the model significantly with 
regard to the goals of the study – unequivocal identification of the bonding and 
determination of the relative stereochemistry. 
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 CheckCIF Alerts and Discussion: 
 PLAT220_ALERT_2_C Non-Solvent Resd 1 C Ueq(max)/Ueq(min) Range 3.2 
Ratio   PLAT220_ALERT_2_C Non-Solvent Resd 2 C Ueq(max)/Ueq(min) Range 3.1 
Ratio  
 The pseudosymmetric distortion of the -C(=CH2)Me group ADPs, discussed above, 
give rise to these PLAT220 alerts. 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 
 x y z Uiso*/Ueq Occ. (<1) 
O4 1.09297 (6) 0.15715 (4) 0.20805 (4) 0.01925 
(19) 
 
O104 0.64233 (6) 0.32305 (5) 0.35483 (4) 0.02131 
(19) 
 
O103 0.35885 (6) 0.24222 (5) 0.20792 (5) 0.0232 (2)  
O3 0.88681 (6) 0.32151 (5) 0.27426 (5) 0.0232 (2)  
O1 1.12602 (7) 0.42870 (6) 0.38743 (6) 0.0372 (3)  
O101 0.51998 (7) 0.16489 (6) 0.06906 (6) 0.0398 (3)  
O2 1.22521 (7) 0.34941 (6) 0.33734 (6) 0.0372 (3)  
H2 1.2010 (15) 0.3822 (10) 0.3624 (10) 0.056*  
O102 0.65948 (7) 0.21588 (6) 0.14434 (6) 0.0378 (3)  
H102 0.6157 (14) 0.1927 (10) 0.1111 (10) 0.057*  
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C19 1.08626 (9) 0.21714 (6) 0.23984 (6) 0.0169 (2)  
C109 0.44664 (9) 0.24816 (6) 0.21797 (7) 0.0182 (3)  
C119 0.60427 (9) 0.29128 (6) 0.29524 (6) 0.0180 (2)  
C10 0.98338 (8) 0.23316 (6) 0.24247 (6) 0.0173 (2)  
C108 0.50429 (9) 0.22348 (6) 0.16996 (7) 0.0211 (3)  
C8 1.05439 (9) 0.34271 (7) 0.30989 (7) 0.0208 (3)  
C123 0.45015 (9) 0.35309 (6) 0.29421 (6) 0.0188 (3)  
H12A 0.3792 0.3470 0.2836 0.023*  
H12B 0.4695 0.3676 0.3433 0.023*  
C121 0.65401 (9) 0.27063 (7) 0.24785 (7) 0.0220 (3)  
H121 0.7214 0.2790 0.2554 0.026*  
C122 0.60532 
(10) 
0.23608 (7) 0.18619 (7) 0.0245 (3)  
C22 1.14657 (9) 0.31777 (7) 0.30554 (7) 0.0240 (3)  
C110 0.49696 (9) 0.28217 (6) 0.28684 (6) 0.0175 (2)  
C5 0.94034 
(10) 
0.46233 (7) 0.41489 (7) 0.0248 (3)  
H5 0.9784 0.4444 0.4567 0.030*  
C107 0.46492 
(10) 
0.18645 (7) 0.10778 (7) 0.0251 (3)  
C106 0.36103 (9) 0.16794 (7) 0.08309 (6) 0.0209 (3)  
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C20 1.18870 (9) 0.13223 (7) 0.20766 (7) 0.0216 (3)  
H20A 1.1841 0.0880 0.1833 0.032*  
H20B 1.2249 0.1262 0.2555 0.032*  
H20C 1.2221 0.1656 0.1839 0.032*  
C9 0.96987 (9) 0.30364 (6) 0.27532 (6) 0.0182 (3)  
C21 1.16168 (9) 0.25772 (7) 0.26770 (6) 0.0209 (3)  
H21 1.2247 0.2464 0.2622 0.025*  
C113 0.43687 
(10) 
0.10766 (7) 0.33501 (7) 0.0250 (3)  
C101 0.28868 
(10) 
0.21723 (7) 0.06578 (7) 0.0237 (3)  
H101 0.3036 0.2646 0.0735 0.028*  
C112 0.51596 (9) 0.16169 (6) 0.34855 (7) 0.0218 (3)  
H112 0.5531 0.1576 0.3110 0.026*  
C7 1.04977 (9) 0.40372 (7) 0.35035 (7) 0.0246 (3)  
C11 0.91784 (9) 0.22771 (6) 0.16877 (6) 0.0194 (3)  
H11A 0.9117 0.1784 0.1558 0.023*  
H11B 0.8527 0.2443 0.1712 0.023*  
C124 0.47444 (9) 0.41173 (6) 0.24891 (7) 0.0223 (3)  
H124 0.5461 0.4123 0.2537 0.027*  




0.46971 (7) 0.29041 (7) 0.0293 (3)  
H1 0.9164 0.4562 0.2469 0.035*  
C4 0.86474 
(10) 
0.50724 (7) 0.41709 (8) 0.0295 (3)  
H4 0.8504 0.5193 0.4604 0.035*  
C111 0.47551 (9) 0.23594 (6) 0.34615 (7) 0.0207 (3)  
H11C 0.5026 0.2586 0.3910 0.025*  
H11D 0.4047 0.2333 0.3413 0.025*  
C105 0.33829 
(10) 
0.09856 (7) 0.07217 (7) 0.0246 (3)  
H105 0.3875 0.0647 0.0833 0.030*  
C12 0.95032 
(10) 
0.26691 (7) 0.11027 (7) 0.0237 (3)  
H12 1.0173 0.2516 0.1092 0.028*  
C23 0.94394 (9) 0.17787 (6) 0.28671 (6) 0.0203 (3)  
H23A 0.8737 0.1857 0.2812 0.024*  
H23B 0.9520 0.1322 0.2665 0.024*  
C117 0.62860 
(10) 
0.07897 (7) 0.42745 (8) 0.0288 (3)  




0.19705 (8) 0.03718 (7) 0.0283 (3)  
H10A 0.1457 0.2308 0.0245 0.034*  
C116 0.58725 
(10) 
0.14998 (7) 0.41830 (7) 0.0264 (3)  
H11E 0.6409 0.1834 0.4224 0.032*  
H11F 0.5537 0.1595 0.4564 0.032*  
C114 0.42338 
(11) 
0.06856 (7) 0.27879 (8) 0.0346 (3)  
H11G 0.3736 0.0349 0.2709 0.042*  
H11H 0.4635 0.0742 0.2464 0.042*  
C120 0.74388 (9) 0.33981 (8) 0.36805 (7) 0.0263 (3)  
H12C 0.7562 0.3707 0.3317 0.039*  
H12D 0.7816 0.2975 0.3682 0.039*  
H12E 0.7628 0.3626 0.4132 0.039*  
C104 0.24385 
(11) 
0.07889 (8) 0.04513 (7) 0.0299 (3)  
H104 0.2282 0.0314 0.0390 0.036*  
C125 0.44502 
(11) 
0.48058 (7) 0.27786 (7) 0.0292 (3)  
H12F 0.4450 0.5173 0.2431 0.035*  
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H12G 0.3785 0.4764 0.2855 0.035*  
C16 0.88347 
(11) 
0.24729 (8) 0.04002 (7) 0.0298 (3)  
H16A 0.8165 0.2608 0.0410 0.036*  
H16B 0.9033 0.2739 0.0026 0.036*  
C118 0.63140 
(12) 
0.04026 (8) 0.48258 (8) 0.0376 (4)  
H11I 0.6060 0.0571 0.5201 0.045*  
H11J 0.6589 -0.0045 0.4848 0.045*  
C13 0.95213 
(12) 
0.34425 (8) 0.12025 (7) 0.0341 (3)  
C115 0.37547 
(11) 
0.10088 (8) 0.38799 (8) 0.0342 (3)  
H11K 0.4165 0.0893 0.4331 0.051*  
H11L 0.3276 0.0644 0.3738 0.051*  
H11M 0.3423 0.1445 0.3916 0.051*  
C128 0.42852 
(11) 
0.40433 (7) 0.17257 (7) 0.0295 (3)  
C2 0.83020 
(12) 
0.51563 (8) 0.29312 (9) 0.0368 (3)  




0.12788 (8) 0.02709 (7) 0.0316 (3)  
H103 0.1080 0.1142 0.0078 0.038*  
C3 0.81042 
(11) 
0.53434 (8) 0.35642 (9) 0.0350 (3)  
H3 0.7596 0.5657 0.3580 0.042*  
C24 0.98847 
(11) 
0.17426 (7) 0.36466 (7) 0.0286 (3)  
H24 1.0013 0.2224 0.3823 0.034* 0.882 (2) 
H24A 1.0321 0.2153 0.3710 0.034* 0.118 (2) 
C17 0.88491 
(12) 
0.17269 (8) 0.02320 (8) 0.0368 (4)  
H17 0.9454 0.1525 0.0216 0.044*  
C130 0.32064 
(13) 
0.40750 (9) 0.15178 (9) 0.0412 (4)  
H13A 0.2927 0.3702 0.1746 0.062*  
H13B 0.3004 0.4024 0.1014 0.062*  
H13C 0.2982 0.4519 0.1658 0.062*  
C126 0.51127 
(13) 
0.50079 (7) 0.34441 (9) 0.0396 (4)  






0.40038 (9) 0.0301 (4) 0.882 (2) 
C127 0.48875 
(17) 
0.50156 (9) 0.40542 (9) 0.0536 (5)  
H12H 0.4258 0.4885 0.4098 0.064*  
H12I 0.5354 0.5151 0.4452 0.064*  
C26B 1.1339 (16) 0.1081 (11) 0.4460 (9) 0.0387 (6) 0.118 (2) 







0.0480 (5) 0.882 (2) 
H30A 0.8279 0.1534 0.4660 0.058* 0.882 (2) 
H30B 0.8921 0.2219 0.4564 0.058* 0.882 (2) 
C14 1.03420 
(16) 
0.37891 (9) 0.13193 (8) 0.0503 (5)  
H14A 1.0339 0.4275 0.1374 0.060*  







0.0353 (5) 0.882 (2) 
H25A 1.0729 0.0883 0.3604 0.042* 0.882 (2) 
H25B 1.1319 0.1587 0.3622 0.042* 0.882 (2) 
C27A 1.13524 0.06682 0.49160 0.0400 (6) 0.882 (2) 
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(18) (14) (14) 
H27A 1.1224 0.0249 0.4665 0.048* 0.882 (2) 
H27B 1.1590 0.0660 0.5404 0.048* 0.882 (2) 
C15 0.85652 
(15) 
0.37957 (9) 0.11521 (9) 0.0483 (5)  
H15A 0.8177 0.3747 0.0680 0.072*  
H15B 0.8672 0.4285 0.1263 0.072*  
H15C 0.8223 0.3585 0.1481 0.072*  
C129 0.48330 
(15) 
0.39616 (8) 0.12619 (8) 0.0424 (4)  
H12J 0.4541 0.3921 0.0783 0.051*  







0.0542 (5)  
H18A 0.7465 0.1511 0.0115 0.065*  







0.0436 (5) 0.882 (2) 
H2168A 0.8644 0.0645 0.3311 0.065* 0.882 (2) 
H2168B 0.8319 0.0549 0.4032 0.065* 0.882 (2) 
H2168C 0.9407 0.0386 0.3981 0.065* 0.882 (2) 
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C30B 0.9546 (11) 0.2325 (8) 0.4587 (7) 0.0480 (5) 0.118 (2) 
H30C 0.9941 0.2702 0.4518 0.058* 0.118 (2) 
H30D 0.9216 0.2333 0.4958 0.058* 0.118 (2) 
C28B 0.9457 (9) 0.1809 (7) 0.4182 (6) 0.0301 (4) 0.118 (2) 
C2168B 0.8756 (11) 0.1212 (8) 0.4126 (9) 0.0436 (5) 0.118 (2) 
H29D 0.8419 0.1155 0.3641 0.065* 0.118 (2) 
H29E 0.8284 0.1306 0.4411 0.065* 0.118 (2) 
H29F 0.9111 0.0790 0.4289 0.065* 0.118 (2) 
C25B 1.0652 (12) 0.1121 (9) 0.3762 (9) 0.0353 (5) 0.118 (2) 
H25C 1.0289 0.0682 0.3684 0.042* 0.118 (2) 







0.0387 (6) 0.882 (2) 
H26A 1.1338 0.1669 0.4856 0.046* 0.882 (2) 
C27B 1.1535 (18) 0.0528 (12) 0.4818 (13) 0.0400 (6) 0.118 (2) 
H27C 1.1240 0.0105 0.4646 0.048* 0.118 (2) 
















Crystals of compound 181 suitable for X-ray analysis were obtained by slow evaporation 
from isooctane.  Crystallographic data have been deposited with the Cambridge 
Crystallographic Data Centre (CCDC # 1508479). Copies of the data can be obtained free 
of charge on application to the CCDC, 12 Union Road, Cambridge CB21EZ, UK (fax: 
(+44)-1223-336-033; e-mail: deposit@ccdc.cam.ac.uk ). 
 
Crystal data 
  C32H38O4 F(000) = 1048 
Mr = 486.62 Dx = 1.172 Mg m-3 
Orthorhombic, Pca21 Cu Kα radiation, λ = 1.54178 Å 
Hall symbol:  P 2c -2ac Cell parameters from 9398 reflections 
a = 23.1187 (4) Å θ = 3.8–66.5° 
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b = 7.8379 (2) Å µ = 0.60 mm-1 
c = 15.2175 (3) Å T = 100 K 
V = 2757.44 (10)  Å3 Prism, colorless 
Z = 4 0.19 × 0.14 × 0.08 mm 
 
Data collection 
  Bruker Proteum-R  
diffractometer 
4823 independent reflections 
Radiation source: rotating anode 4762 reflections with I > 2σ(I) 
Montel Rint = 0.049 
w and f scans θmax = 66.7°, θmin = 3.8° 
Absorption correction: multi-scan  
SADABS (Sheldrick, 2015) 
h = -27→27 
Tmin = 0.793, Tmax = 0.864 k = -9→9 
71181 measured reflections l = -18→17 
 
Refinement 
  Refinement on F2 Hydrogen site location: inferred from 
neighbouring sites 
Least-squares matrix: full H-atom parameters constrained 
R[F2 > 2σ(F2)] = 0.029  w = 1/[σ2(Fo2) + (0.039P)2 + 0.691P]   
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where P = (Fo2 + 2Fc2)/3 
wR(F2) = 0.077 (Δ/σ)max < 0.001 
S = 1.04 Δ〉max = 0.19 e Å-3 
4823 reflections Δ〉min = -0.13 e Å-3 
330 parameters Absolute structure:  Refined as an 
inversion twin. 
1 restraint Flack parameter: 0.49 (19) 
 
Special Details 
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are 
estimated using the full covariance matrix. The cell esds are taken into account 
individually in the estimation of esds in distances, angles and torsion angles; correlations 
between esds in cell parameters are only used when they are defined by crystal 
symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds 
involving l.s. planes. 
Refinement. Refined as a 2-component inversion twin. 
 CheckCIF Alert and Discussion: 
 Alert level C STRVA01_ALERT_4_C Flack test results are ambiguous.  From the 
CIF: _refine_ls_abs_structure_Flack 0.490 From the CIF: 
_refine_ls_abs_structure_Flack_su 0.190 
 Discussion:  Since the structure is composed of only light atoms, the anomalous 
dispersion 'signal' is weak, resulting in the relatively large s.u. for the Flack parameter.  
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Nonetheless, refinement of the structure as an inversion twin significantly improved all of 
the relevant metrics for model quality including R1, wR2 and the GOOF.  Despite high 
s.u.'s, the Flack parameter, the Hooft y and the refined twin fraction all agree fairly well.  
Since the structure is racemic, identification of the absolute structure has no relevance to 
the results. 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 
 x y z Uiso*/Ueq 
O2 0.41587 (6) 0.57164 (18) 0.63038 (9) 0.0228 (3) 
O4 0.26372 (5) 0.55694 (18) 0.44008 (10) 0.0276 (3) 
O3 0.41522 (6) 0.19463 (18) 0.39632 (11) 0.0306 (3) 
O1 0.43755 (7) 0.1629 (2) 0.61676 (13) 0.0416 (4) 
C10 0.35369 (8) 0.6453 (2) 0.50397 (13) 0.0189 (4) 
C19 0.31561 (8) 0.5411 (2) 0.44236 (13) 0.0197 (4) 
C9 0.39375 (7) 0.5256 (2) 0.55223 (13) 0.0189 (4) 
C21 0.39550 (8) 0.3256 (2) 0.42847 (14) 0.0213 (4) 
C8 0.41377 (7) 0.3805 (2) 0.51564 (13) 0.0194 (4) 
C26 0.42174 (8) 0.6715 (2) 0.36698 (13) 0.0217 (4) 
H26 0.4508 0.5930 0.3940 0.026* 
C7 0.45546 (8) 0.2645 (2) 0.56343 (13) 0.0230 (4) 
C16 0.38173 (8) 0.6750 (3) 0.69382 (13) 0.0238 (4) 
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C6 0.51833 (8) 0.2759 (3) 0.54256 (13) 0.0254 (4) 
C12 0.35278 (9) 0.8211 (3) 0.64295 (14) 0.0228 (4) 
H12 0.3843 0.8925 0.6169 0.027* 
C25 0.39072 (8) 0.7628 (2) 0.44318 (13) 0.0225 (4) 
H25A 0.3652 0.8519 0.4182 0.027* 
H25B 0.4202 0.8210 0.4797 0.027* 
C11 0.31685 (8) 0.7515 (2) 0.56749 (13) 0.0213 (4) 
H11A 0.2990 0.8476 0.5351 0.026* 
H11B 0.2853 0.6797 0.5913 0.026* 
C20 0.34878 (8) 0.4285 (2) 0.37886 (13) 0.0207 (4) 
C17 0.33976 (9) 0.5523 (3) 0.73804 (15) 0.0291 (5) 
H17A 0.3128 0.5071 0.6942 0.044* 
H17B 0.3181 0.6129 0.7838 0.044* 
H17C 0.3614 0.4580 0.7646 0.044* 
C13 0.31620 (9) 0.9380 (3) 0.70229 (14) 0.0283 (5) 
H13A 0.2826 0.8733 0.7249 0.034* 
H13B 0.3397 0.9748 0.7532 0.034* 
C22 0.30803 (9) 0.3014 (3) 0.33305 (14) 0.0250 (4) 
H22A 0.2779 0.3660 0.3011 0.030* 
H22B 0.3304 0.2355 0.2892 0.030* 
C23 0.27924 (10) 0.1793 (3) 0.39519 (15) 0.0292 (5) 
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H23 0.3032 0.1185 0.4351 0.035* 
C14 0.29518 (10) 1.0924 (3) 0.65330 (15) 0.0326 (5) 
H14 0.3236 1.1666 0.6292 0.039* 
C28 0.50541 (9) 0.8776 (3) 0.36545 (15) 0.0286 (5) 
H28 0.4967 0.9610 0.4087 0.034* 
C30 0.37978 (9) 0.5584 (3) 0.31189 (14) 0.0239 (4) 
C5 0.55341 (9) 0.1354 (3) 0.56228 (15) 0.0342 (5) 
H5 0.5370 0.0359 0.5878 0.041* 
C1 0.54274 (9) 0.4214 (3) 0.50662 (14) 0.0334 (5) 
H1 0.5192 0.5173 0.4931 0.040* 
C27 0.45603 (10) 0.8054 (3) 0.31318 (14) 0.0275 (5) 
H27A 0.4712 0.7515 0.2591 0.033* 
H27B 0.4297 0.8990 0.2955 0.033* 
C31 0.33416 (10) 0.6675 (3) 0.26447 (15) 0.0319 (5) 
H31A 0.3110 0.7295 0.3080 0.048* 
H31B 0.3089 0.5934 0.2296 0.048* 
H31C 0.3535 0.7492 0.2256 0.048* 
C32 0.41365 (10) 0.4580 (3) 0.24271 (15) 0.0328 (5) 
H32A 0.4321 0.5376 0.2017 0.049* 
H32B 0.3872 0.3830 0.2105 0.049* 
H32C 0.4434 0.3890 0.2717 0.049* 
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C18 0.42750 (10) 0.7368 (3) 0.75764 (15) 0.0332 (5) 
H18A 0.4494 0.6389 0.7799 0.050* 
H18B 0.4089 0.7959 0.8068 0.050* 
H18C 0.4538 0.8154 0.7274 0.050* 
C15 0.24075 (11) 1.1329 (3) 0.64120 (16) 0.0389 (6) 
H15A 0.2111 1.0620 0.6643 0.047* 
H15B 0.2310 1.2331 0.6094 0.047* 
C24 0.22383 (10) 0.1505 (3) 0.39844 (17) 0.0372 (5) 
H24A 0.1985 0.2090 0.3596 0.045* 
H24B 0.2087 0.0712 0.4397 0.045* 
C4 0.61223 (10) 0.1417 (4) 0.54450 (17) 0.0475 (7) 
H4 0.6360 0.0457 0.5569 0.057* 
C29 0.55912 (11) 0.8339 (3) 0.3556 (2) 0.0468 (7) 
H2168A 0.5694 0.7508 0.3129 0.056* 
H2168B 0.5882 0.8850 0.3911 0.056* 
C2 0.60231 (11) 0.4264 (4) 0.49030 (17) 0.0467 (7) 
H2 0.6193 0.5264 0.4663 0.056* 
C3 0.63625 (11) 0.2871 (5) 0.50889 (17) 0.0525 (8) 














Crystals of compound (±)-178 suitable for X-ray analysis were obtained by slow 
evaporation from isooctane.  Crystallographic data have been deposited with the 
Cambridge Crystallographic Data Centre (CCDC # 1508480). Copies of the data can be 
obtained free of charge on application to the CCDC, 12 Union Road, Cambridge 
CB21EZ, UK (fax: (+44)-1223-336-033; e-mail: deposit@ccdc.cam.ac.uk ). 
Crystal data 
 C32H38O4 V = 2727.8 (4)  Å3 
Mr = 486.62 Z = 4 
Monoclinic, P21/n Cu Ka radiation, l = 1.54178 Å 
a = 10.9732 (10) Å m = 0.60 mm-1 
b = 16.0101 (14) Å T = 100 K 
 341 
c = 15.5863 (14) Å 0.4 × 0.3 × 0.25 mm 
b = 94.993 (3)°  
 
Data collection 
 Bruker Proteum-R  diffractometer 4803 independent reflections 
Absorption correction: multi-scan 
 SADABS (Sheldrick, 2015) 
4745 reflections with I > 2s(I) 
Tmin = 0.829, Tmax = 0.861 Rint = 0.049 




 R[F2 > 2s(F2)] = 0.039 0 restraints 
wR(F2) = 0.096 H-atom parameters constrained 
S = 1.05 Dρmax = 0.25 e Å-3 
4803 reflections Dρmin = -0.22 e Å-3 
348 parameters  
 
Data collection: APEX2 (Bruker, 2006); cell refinement: SAINT (Bruker, 2006); data 
reduction: SAINT (Bruker, 2006); program(s) used to solve structure: SHELXT 
(Sheldrick, 2015); program(s) used to refine structure: SHELXL2014/7 (Sheldrick, 
 342 
2014); molecular graphics: Olex2 (Dolomanov et al., 2009); software used to prepare 
material for publication: Olex2 (Dolomanov et al., 2009). 
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S2.2. Refinement 
Crystal data, data collection and structure refinement details are summarized in Table 4.1. 
S3. Results and discussion 
(boyce6_0m) 
Crystal data 
 C32H38O4 F(000) = 1048 
Mr = 486.62 Dx = 1.185 Mg m-3 
Monoclinic, P21/n Cu Ka radiation, l = 1.54178 Å 
a = 10.9732 (10) Å Cell parameters from 9577 reflections 
b = 16.0101 (14) Å q = 2.8–66.3° 
c = 15.5863 (14) Å m = 0.60 mm-1 
b = 94.993 (3)° T = 100 K 
V = 2727.8 (4)  Å3 Prism, colorless 




 Bruker Proteum-R  diffractometer 4803 independent reflections 
Radiation source: rotating anode 4745 reflections with I > 2s(I) 
Montel monochromator Rint = 0.049 
/w and /f scans qmax = 66.7°, qmin = 4.9° 
 344 
Absorption correction: multi-scan 
 SADABS (Sheldrick, 2015) 
h = -13®13 
Tmin = 0.829, Tmax = 0.861 k = -17®18 
88704 measured reflections l = -18®18 
 
Refinement 
 Refinement on F2 0 restraints 
Least-squares matrix: full 
Hydrogen site location: inferred from 
neighbouring sites 
R[F2 > 2s(F2)] = 0.039 H-atom parameters constrained 
wR(F2) = 0.096 
 w = 1/[s2(Fo2) + (0.042P)2 + 1.182P]  
 where P = (Fo2 + 2Fc2)/3 
S = 1.05 (D/s)max = 0.001 
4803 reflections Dρmax = 0.25 e Å-3 
348 parameters Dρmin = -0.22 e Å-3 
 
Special details 
 Geometry. All esds (except the esd in the dihedral angle between two l.s. planes)  are 
estimated using the full covariance matrix.  The cell esds are taken into account 
individually in the estimation of esds in distances, angles  and torsion angles; 
correlations between esds in cell parameters are only  used when they are defined by 
 345 
crystal symmetry.  An approximate (isotropic) treatment of cell esds is used for 
estimating esds involving l.s. planes. 
Refinement. CheckCIF Alert and Discussion: 
 PLAT230_ALERT_2_C Hirshfeld Test Diff for C2 – C3 . 5.4 s.u.   
 Discussion:  The disorder at C31—C32 most likely creates two slightly different 
orientations of the phenyl ring containing C2—C3.  Refinement of this disorder would 
only increase the number of parameters without any significant effect on   either model 
quality or on the structural information needed for this study. 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) for (boyce6_0m) 
 x y z Uiso*/Ueq Occ. (<1) 




O34 0.20176 (8) 0.61749 (5) 0.48014 (5) 0.0258 (2)  
O31 0.33969 (8) 0.78687 (6) 0.83505 (5) 0.0263 (2)  
O33 0.14828 (8) 0.83476 (5) 0.66303 (6) 0.0326 (2)  

















0.52147 (7) 0.60060 (7) 0.0187 (2)  
H11A 0.2907 0.4783 0.5659 0.022*  












0.47981 (7) 0.67707 (7) 0.0201 (2)  




0.54612 (7) 0.67000 (7) 0.0196 (2)  
H1168A 0.1021 0.5030 0.6296 0.024*  








0.86663 (8) 0.78825 (8) 0.0248 (3)  
 347 












0.60604 (8) 0.69144 (8) 0.0234 (3)  








0.83864 (8) 0.64078 (8) 0.0267 (3)  




0.41234 (8) 0.64639 (9) 0.0263 (3)  
H16A 0.5530 0.4384 0.6085 0.032*  




0.34324 (7) 0.59842 (8) 0.0273 (3)  
H17 0.3547 0.3240 0.6202 0.033*  
C30 0.07728 0.76840 (8) 0.50066 (9) 0.0303 (3)  
 348 
(12) 
H30A 0.0205 0.7387 0.4583 0.036* 0.691 (6) 
H30B 0.0341 0.8181 0.5206 0.036* 0.691 (6) 
H30C 0.0539 0.7339 0.4491 0.036* 0.309 (6) 




0.61515 (8) 0.54294 (9) 0.0305 (3)  
H26A -0.1055 0.6524 0.4960 0.046*  
H26B -0.1440 0.5862 0.5657 0.046*  




0.64684 (8) 0.78203 (8) 0.0275 (3)  
H21A 0.1166 0.6916 0.7803 0.033*  







0.0357 (3)  







0.0344 (3)  
H14A 0.5700 0.6012 0.6406 0.052*  
H14B 0.6558 0.5388 0.6989 0.052*  
 349 







0.0386 (3)  




0.51033 (8) 0.82657 (9) 0.0356 (3)  
H15A 0.5505 0.5532 0.8627 0.053*  
H15B 0.5600 0.4608 0.8247 0.053*  




0.58548 (9) 0.85049 (9) 0.0366 (3)  







0.0364 (3)  
H25A -0.0528 0.7715 0.6846 0.055*  
H25B -0.1625 0.7057 0.6705 0.055*  







0.0425 (4)  
H3 0.7311 0.9471 0.6542 0.051*  
C23 0.19857 0.59254 0.90143 (9) 0.0453 (4)  
 350 
(16) (11) 
H23A 0.2509 0.6391 0.8958 0.054*  







0.0405 (4)  
H18A 0.5343 0.3245 0.5050 0.049*  
H18B 0.4133 0.2635 0.5020 0.049*  
C31A 0.1896 (4) 0.7971 (2) 0.4562 (2) 0.0323 (9) 0.691 (6) 
H31A 0.2245 0.7592 0.4183 0.039* 0.691 (6) 





0.0446 (9) 0.691 (6) 
H32A 0.2074 0.9105 0.5054 0.054* 0.691 (6) 
H32B 0.3098 0.8858 0.4386 0.054* 0.691 (6) 
C32B 0.2431 (6) 0.8101 (3) 0.4155 (5) 0.0420 (18) 0.309 (6) 
H32C 0.2235 0.7639 0.3786 0.050* 0.309 (6) 
H32D 0.3085 0.8463 0.4045 0.050* 0.309 (6) 
C31B 0.1792 (8) 0.8239 (5) 0.4825 (5) 0.032 (2) 0.309 (6) 
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VI. Computational Studies 
Figure 4.4: Energy profiles for the transformation of 168A to (-)-167 and (+)-169, in 







































































All structures were fully optimized by using Density Functional Theory (DFT) in Jaguar 
9.2 (Schrodinger 2016-2) with the B3LYP functional. All calculations were carried out 
with the Los Alamos Effective Core Potentials Double Zeta (LACV3P) pseudospectral 
basis set for all atoms. Structures were evaluated by optimized energy values at the same 
level of theory. Transition state searches were performed using the QST method on 
Jaguar Version 9.2 (Schrodinger Maestro) using the same function and basis set. 
 
 SnCl4-­‐168A	  
C1      0.1161780000000  -1.2742290000000  -1.0971500000000 
C2     -0.3409010000000  -2.5455230000000  -1.0322000000000 
C3     -1.0892830000000  -3.0214930000000   0.1332210000000 
C4     -1.4869090000000  -2.0285350000000   1.1605750000000 
C5     -1.0178870000000  -0.7547140000000   1.0934660000000 
C6     -0.1034970000000  -0.1996940000000  -0.0201550000000 
O7     -1.3206260000000  -4.2112050000000   0.2932430000000 
H8     -0.1650780000000  -3.2698560000000  -1.8152260000000 
O9      0.8263810000000  -0.7628250000000  -2.1590520000000 
C10     1.1009160000000  -1.6127780000000  -3.2693340000000 
C11    -2.3151960000000  -2.4900340000000   2.3201830000000 
O12    -2.0035710000000  -2.1614420000000   3.4590540000000 
C13    -3.5729670000000  -3.2611400000000   2.1019820000000 
C14    -4.0787250000000  -4.0746580000000   3.1472280000000 
C15    -5.2710030000000  -4.8012470000000   2.9727080000000 
C16    -5.9735390000000  -4.7251010000000   1.7579470000000 
C17    -5.4809450000000  -3.9247400000000   0.7129550000000 
C18    -4.2879590000000  -3.1981520000000   0.8817960000000 
O19    -1.3297970000000   0.1847820000000   2.0149790000000 
C20     1.2890030000000   0.2260890000000   0.5555620000000 
C21    -0.7183780000000   1.0716860000000  -0.7031860000000 
C22    -1.9362360000000   0.8936500000000  -1.6521340000000 
C23    -3.2484770000000   0.4976890000000  -0.9812250000000 
C24    -4.0378580000000  -0.5679420000000  -1.7141380000000 
C25    -3.7142740000000   1.0625670000000   0.1464140000000 
C26    -2.1292600000000   2.1320470000000  -2.5547540000000 
C27    -2.4412670000000   3.4133500000000  -1.8021730000000 
C28    -1.5888210000000   4.4407760000000  -1.6670190000000 









C30     2.3041840000000  -2.0562270000000   1.2804690000000 
C31     2.8629660000000  -2.3774210000000   0.1016930000000 
C32     2.0091970000000  -3.1162320000000   2.3257740000000 
C33     3.2174660000000   0.0688390000000   2.2183810000000 
C34     2.9367570000000   1.3384760000000   3.0007170000000 
C35     3.1285120000000   2.5775860000000   2.5237590000000 
H36     1.6645760000000  -1.0539130000000  -4.0172020000000 
H37     1.7081290000000  -2.4718850000000  -2.9794410000000 
H38     0.1835790000000  -1.9610300000000  -3.7468570000000 
H39    -3.5740030000000  -4.1887410000000   4.0967700000000 
H40    -5.6513560000000  -5.4316110000000   3.7665250000000 
H41    -6.8870780000000  -5.2900730000000   1.6238910000000 
H42    -6.0226330000000  -3.8806100000000  -0.2230750000000 
H43    -3.9483600000000  -2.6081740000000   0.0467170000000 
H44    -0.7994020000000   0.9674860000000   2.0183700000000 
H45     1.2076890000000   1.2475250000000   0.9274920000000 
H46     2.0020010000000   0.3384230000000  -0.2646750000000 
H47     0.0713020000000   1.4973850000000  -1.3281750000000 
H48    -0.9221490000000   1.8756100000000   0.0021190000000 
H49    -1.6930140000000   0.0921930000000  -2.3511370000000 
H50    -4.3243280000000  -0.1987310000000  -2.7006440000000 
H51    -3.4454420000000  -1.4706080000000  -1.8642850000000 
H52    -4.9574000000000  -0.8338680000000  -1.1908100000000 
H53    -4.6639340000000   0.7579740000000   0.5685170000000 
H54    -3.1868620000000   1.8633390000000   0.6415350000000 
H55    -2.9352950000000   1.9575330000000  -3.2701160000000 
H56    -1.2343710000000   2.2871390000000  -3.1606110000000 
H57    -3.4266250000000   3.4885380000000  -1.3634080000000 
H58    -1.8724150000000   5.3355060000000  -1.1294980000000 
H59    -0.5978000000000   4.4155380000000  -2.0985690000000 
H60     1.2718070000000  -0.7046960000000   2.5154050000000 
H61     3.1119600000000  -3.4010230000000  -0.1452540000000 
H62     3.0981000000000  -1.6316160000000  -0.6450020000000 
H63     0.9476590000000  -3.1874330000000   2.5468600000000 
H64     2.3412140000000  -4.1004610000000   1.9885890000000 
H65     2.5486590000000  -2.8963490000000   3.2487460000000 
H66     3.9001490000000   0.2915380000000   1.3951540000000 
H67     3.7717070000000  -0.5991490000000   2.8812070000000 
H68     2.5808280000000   1.2217850000000   4.0141160000000 
H69     2.9319520000000   3.4509690000000   3.1315160000000 
H70     3.5004360000000   2.7477660000000   1.5218290000000 
Sn71   -1.5586980000000  -0.2966440000000   3.9337700000000 









Cl73   -2.5005390000000  -1.0310690000000   6.0862560000000 
Cl74   -1.2091420000000   2.0880850000000   4.3564170000000 
Cl75   -3.8663200000000   0.3278560000000   3.5059650000000 



























H60	  	  	  	  	  0.9492420000000	  	  -­‐0.1526280000000	  	  	  2.3036810000000	  H61	  	  	  	  	  2.1519790000000	  	  -­‐0.5212890000000	  	  	  4.5689820000000	  H62	  	  	  	  	  2.7866570000000	  	  -­‐2.1373170000000	  	  	  4.9131660000000	  H63	  	  	  	  	  3.7628160000000	  	  -­‐0.9558180000000	  	  	  4.1015380000000	  H64	  	  	  	  	  2.6438690000000	  	  	  0.9608490000000	  	  	  0.6950730000000	  H65	  	  	  	  	  3.8439060000000	  	  -­‐0.0731360000000	  	  	  1.4139980000000	  H66	  	  	  	  	  2.0683950000000	  	  	  1.9808630000000	  	  	  2.9206400000000	  H67	  	  	  	  	  4.1181280000000	  	  	  2.5197670000000	  	  	  4.0892620000000	  H68	  	  	  	  	  5.0301080000000	  	  	  1.2317480000000	  	  	  3.1334200000000	  Sn69	  	  	  -­‐1.5833050000000	  	  -­‐2.5825750000000	  	  	  4.3834160000000	  Cl72	  	  	  -­‐0.5926150000000	  	  -­‐4.6482380000000	  	  	  4.9418960000000	  Cl73	  	  	  -­‐3.5326960000000	  	  -­‐2.5499300000000	  	  	  5.7657450000000	  Cl74	  	  	  -­‐0.2741900000000	  	  -­‐0.9250970000000	  	  	  5.4552850000000	  Cl75	  	  	  -­‐3.1100630000000	  	  -­‐1.1801720000000	  	  	  3.0972080000000	  H74	  	  	  	  	  2.3107560000000	  	  -­‐3.3643670000000	  	  	  3.9603300000000	  H75	  	  	  	  	  2.0696200000000	  	  -­‐3.3301130000000	  	  	  2.2873730000000	  	  








































































H51	  	  	  	  -­‐4.2729240000000	  	  -­‐1.3138370000000	  	  	  0.8090180000000	  H52	  	  	  	  -­‐5.1432180000000	  	  	  0.1099820000000	  	  	  1.4873540000000	  H53	  	  	  	  -­‐3.7270320000000	  	  	  1.8197950000000	  	  	  2.2152000000000	  H54	  	  	  	  -­‐2.0688660000000	  	  	  2.1437510000000	  	  	  1.4510290000000	  H55	  	  	  	  -­‐3.2704890000000	  	  	  1.1216350000000	  	  -­‐2.0423220000000	  H56	  	  	  	  -­‐1.6150700000000	  	  	  0.6406980000000	  	  -­‐2.4876180000000	  H57	  	  	  	  -­‐2.4099510000000	  	  	  3.1412830000000	  	  -­‐0.7873830000000	  H58	  	  	  	  -­‐0.3803200000000	  	  	  4.0304630000000	  	  -­‐1.7172070000000	  H59	  	  	  	  	  0.0034870000000	  	  	  2.3887270000000	  	  -­‐2.5225460000000	  H60	  	  	  	  	  1.0350230000000	  	  -­‐0.3158900000000	  	  	  2.2153890000000	  H61	  	  	  	  	  1.9171420000000	  	  -­‐0.6401760000000	  	  	  4.5400350000000	  H62	  	  	  	  	  2.7193890000000	  	  -­‐2.1937480000000	  	  	  4.9850220000000	  H63	  	  	  	  	  3.6559680000000	  	  -­‐0.9643580000000	  	  	  4.1228930000000	  H64	  	  	  	  	  2.8931990000000	  	  	  0.5710700000000	  	  	  0.5371120000000	  H65	  	  	  	  	  3.9923350000000	  	  -­‐0.5046910000000	  	  	  1.4483470000000	  H66	  	  	  	  	  2.2109940000000	  	  	  1.7574810000000	  	  	  2.7296840000000	  H67	  	  	  	  	  4.2553870000000	  	  	  2.3068260000000	  	  	  3.8675800000000	  H68	  	  	  	  	  5.1576490000000	  	  	  0.9410390000000	  	  	  2.9648840000000	  H69	  	  	  	  	  0.9506430000000	  	  -­‐3.3330440000000	  	  	  4.1298610000000	  H70	  	  	  	  	  1.1633120000000	  	  -­‐3.8853210000000	  	  	  2.4421100000000	  H71	  	  	  	  	  3.0747800000000	  	  -­‐2.6108940000000	  	  	  2.4756650000000	  B72	  	  	  	  -­‐1.9308590000000	  	  -­‐2.4089960000000	  	  	  3.2888770000000	  F73	  	  	  	  -­‐1.6071860000000	  	  -­‐2.2731500000000	  	  	  4.6572430000000	  F74	  	  	  	  -­‐3.0102760000000	  	  -­‐1.5263620000000	  	  	  3.0726410000000	  	  


















H69	  	  	  	  	  0.9652330109511	  	  -­‐1.8009512264954	  	  -­‐4.8238139253844	  H70	  	  	  	  -­‐0.1625949812531	  	  -­‐3.5865557496855	  	  -­‐3.7517805007502	  H71	  	  	  	  -­‐0.4587455857235	  	  -­‐3.5947589412192	  	  -­‐1.9331794654028	  H72	  	  	  	  -­‐2.0880316196474	  	  	  0.4318444896317	  	  -­‐5.6107696854193	  H73	  	  	  	  -­‐1.9615281790418	  	  -­‐1.1843320922578	  	  -­‐4.9311105991974	  H74	  	  	  	  -­‐3.4685015473557	  	  -­‐0.2496427910009	  	  -­‐4.7601153158664	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          Chapter 5 
 
        Rearrangements and Diastereoselective 
Cyclizations to Access Novel PPAP Frameworks in 
Formic Acid: Mechanistic Studies 
5.1 Introduction to Formic Acid-Mediated Rearrangements and Cyclizations.   
 
Scheme 5.1 Biosynthesis of PPAPs Resulting from Dearomative Prenylation of 


















































     PPAP natural products and their analogs are important targets for isolation, chemical 
synthesis, and biological studies as minor structural differences lead to significant 
variations in bioactivity.2,3  The representative set of PPAPs shown in Scheme 5.1 are 
thought to derive biosynthetically from acylphloroglucinol scaffold 26 via a series of 
reactions including prenylations, proton transfers, double bond isomerizations, and 
oxidations initiated by prenyl pyrophosphate.11a,17  If Nature’s bio-synthetic routes could 
be replicated in a laboratory setting, it may represent the most efficient means to access 
these molecules.  Thus, it is not surprising that several synthetic groups have utilized 
biomimetic strategies to access these natural products.16c-n,18-21,31a  In chapter 2, we 
described a biomimetic, cationic cyclization in formic acid to the type B core of 
clusianone; the type A variant was not observed.16n  Surprisingly, neat formic acid was 
the only condition out of > 70 others that led to C-cyclization of (-)-(S,S)-113 to the type 
B bicyclo[3.3.1]nonane (-)-112 (Scheme 5.2).     In comparison to other Brønsted acids, 
formic acid has unique properties,42 including the ability to add to 1,1-disubstituted 
double bonds as well as to electron deficient and strained ketones.43  In chapter 2, we  
 
 





















































also described how the properties of formic acid may explain the selectivity for C-
cyclization to (-)-allyl clusianone (-)-112 (Scheme 5.2). Additionally, reactions in formic 
acid are often governed by thermodynamic equilibria that may favor the formation of the 
more stable product due to its unique ability to stabilize carbocation intermediates 
(Scheme 5.3).79,80  For example, George and coworkers demonstrated that the trans-
lactone 191 rapidly converts to the more stable cis-lactone 192 in the presence of formic 
acid,80 while Della and coworkers showed that formic acid-mediated Wagner-Meerwein 
shifts of esters, including 193, were exclusively converted to the thermodynamically 
more stable formate adduct 196 via the intermediacy of 194 and 195.80  
































     There are a number of biomimetic syntheses involving cyclizations that are 
exclusively mediated by formic acid, some of which were discussed in Chapter 2.41  In 
his seminal work, Johnson discovered that the cyclization of polyene 197 in formic acid 
led to the production of 198 and 199 in 94 % yield en route to (±)-fichtelite (200) 
(Scheme 5.4). 41c-g,81   Heathcock and coworkers also reported a unique cyclization of 
allylic alcohol 201 in 98 % formic acid providing exclusive formation of the bicyclic enol 
formate adduct 202 in up to 84 % yield (Scheme 5.4).41h As previously described in 
Chapter 2, Trost and coworkers showed that formic acid was unique in its ability to  
 
Scheme 5.4 Formic Acid-Mediated Biomimetic Polyene Cyclizations and the Cyclization 



























cyclize alcohol 135a to furan 137c en route to allamandin as they noted that all other 
conditions failed.41a Furthermore, Andersen and coworkers described a biomimetic 
cyclization in their synthesis of liphagal that was exclusively mediated by formic acid.41b  
Interestingly, after initial cyclization to cyclohexene isomers 139e, further cyclization to 
the desired 8/6-fused tetracycle 140f occurred after stirring for four weeks in formic acid  
 
Scheme 5.5  Biomimetic Cyclizations in Formic Acid. 
 
(Scheme 5.5).  Additionally, cyclization rates in formic acid are known to depend on its 
water content, such that the rates of polyene cyclizations of farnesol at 0 oC in 90 %, 98 
















































Key Intermediate en route
to Allamandin







     Herein, we demonstrate diastereoselective cyclizations of O-alkylated dearomatized 
acylphloroglucinols to access a novel type A PPAP scaffold in 98 % formic acid. In 
addition to type A-selective cyclizations, novel rearrangements to bicyclo[3.3.1]lactones 
were observed in formic acid, and our mechanistic hypothesis suggests that formic acid 
may render these transformations more efficient by acting as a nucleophile.16n,43   
5.2 Results 
5.2.1  Selective Cyclizations to Type A PPAPs  
 



















































Figure 5.1  Symmetry of meso-168B and meso-168C as Represented by 3D-Models. 
     As part of a program to generate diverse PPAP natural products, we sought to extend 
the application of our biomimetic cyclization conditions in 98 % formic acid to O-
alkylated conjugated isomers (±)-203 as potential cyclization substrates (Scheme 5.6).  
We anticipated that these substrates may cyclize differently than enols (±)-168 and aimed 
to investigate a variety of substrates with varying substituents at the C2-enol to evaluate 
the impact of different alkyl groups (R groups) on the cyclization outcome.  




Scheme 5.7 A. Synthesis and Isolation of (±)-206 as a Diastereomeric Mixture.   B. 
Cyclization of the Diastereomeric Mixture (±)-206 Provided Type A (±)-208 and Type B 
(±)-209 scaffolds. 
 
     Early experiments for the synthesis (±)-168 from acylphloroglucinol 115 and racemic 
triflate (±)-114 unexpectedly provided O-alkylated dearomatized acylphloroglucinol (±)-
206 as a diastereomeric mixture that was purified by basic extraction without the need for 






5 oC to r.t. (1h 45 min)
then



















































room temperature for 48 h, the reaction had not progressed and was therefore heated to 
75 oC for 12 h (Scheme 5.8B).  This increase in temperature led to the production of 
novel type A PPAP (±)-208 and type B scaffold (±)-209 along with full consumption of 
starting material (±)-206.  The relative stereochemistry of bicyclo[3.3.1]nonane (±)-208 
was unambiguously determined by X-ray crystal structure analysis.   
 
Scheme 5.8  One-Pot Triflation/Alkylative Dearomatization of 115 Followed by O-
Alkylation of (+)-(S,S)-168A to Provide (+)-210A. 
 
     In order to optimize the synthesis of this type A PPAP, we utilized a one-pot protocol 
to access (+)-(S,S)-168A as a single diastereomer from the reaction of acylphloroglucinol 
115 and an in situ-generated, enantioenriched triflate.16m Product (+)-(S,S)-168 was 
purified by potassium salt formation without the need for column chromatography.  
Subsequent alkylation with triflate (-)-(R)-114 provided enantioenriched alkyl enol ether 
(+)-210A in 45 % yield (75% brsm, Scheme 5.8). Pleasingly, we discovered a 
diastereoselective cyclization to novel type A PPAP scaffold (-)-216 upon treating (+)-
210A with formic acid at 75 oC (Scheme 5.9).   
     One possible mechanism for the formation of product (-)-216 is shown in Scheme 



















-10 to 0 oC, 10 min;
OTf
(-)-(R)-114 (1.5 equiv)
43 %, 75 % brsm











Scheme 5.9 Cyclization to Type A PPAP (-)-216 in 98 % Formic Acid. 
  














































































reactivity.  Presumably, intramolecular cyclization of proposed carbocation 212 to 
bicyclic oxonium intermediate 213 occurs prior to hydrolytic cleavage of the O-alkyl 
group.  In contrast, in the absence of this R-group, type B PPAPs (±)-217 and (±)-218 are 
formed (Scheme 5.11).  Furthermore, it is reasonable to suggest that the π* of proposed 
oxonium intermediate 213 might induce the unexpected conjugate alkene addition83   
 
Scheme 5.11 Type B PPAPs Result in the Absence of a O-Alkyl Substituent at C2. 
 
leading to the formation of a conjugated oxonium ion 215 that would be quenched by 
hydrolysis of the O-alkyl group to provide type A PPAP (-)-216.  Finally, we note that 
the stereochemistry at C7 in (-)-216 is undetermined as isomerization at C7 may occur 
under the reaction conditions.  Moreover, 1H NMR analysis suggests that the structures of 
(-)-216 and 208 may be identical.  Investigations to determine the C7 stereochemistry of 
(-)-216 by X-ray crystal structure analysis are underway and will be reported in due 
course.    
     With the discovery of this novel cyclization, we wished to develop a platform for type 
A PPAP synthesis utilizing a simple and readily available O-alkyl group to bring about 
the desired transformation.  Moreover, the steric and electronic properties of the R-group 


























Scheme 5.12 Preparation of Substrates to Evaluate Optimal R-group for Cyclization. 
 
identifying an optimal R-group, we could then investigate type A-selective cyclizations 
of O-alkylated meso-168B and meso-168C. 
     Initial experiments focused on the synthesis of more labile R-groups including allyl 
and benzyl prepared by Method 1 (Scheme 5.12).  Allylation of 168A with allyl bromide 
and tetrabutylammonium iodide in acetone provided conjugated isomer 225 (81 %).  
When conjugated isomer 225 was heated in 98 % formic acid to 75 oC, the type A 
scaffold 216 was produced in 16 % yield along with undesired O-cyclization products 
(Scheme 5.13).  In contrast, when TFA was used for the cyclization of substrate (±)-225, 
only O-cyclization products were observed. Other labile R-groups such as the conjugated 





















Prepared by Method 1a
a Method 1: allyl or benzyl bromide (1.33 equiv), K2CO3 (1.5 equiv), TBAI (0.38 equiv), Acetone (1.13 M), 70 
oC, 3 h.  b Method 2: alkyl triflate (6.0 equiv) in hexanes/toluene (2.1:1), KHMDS (1.5 equiv), THF, 0 oC to r.t., 





































of 216 along with type B PPAPs (217 and 218) and oxycyclization products.  Further 
studies on the chemistry of substrates in Scheme 5.12 will be performed to determine the 
optimal R group for type A-selective cyclizations. 
 
Scheme 5.13 Cyclization of O-Alkyl Substrate 225 in 98 % Formic Acid. 
5.2.2  Formic Acid-Mediated Rearrangements Provide [3.3.1]-Bicyclic Lactones 
          As part of a program aimed at diversity-oriented synthesis (DOS) of PPAP analogs, 
we now report rearrangements of dearomatized acylphlorogluinols and pyranodienones in 
formic acid. We first examined substrate (±)-170 that previously provided type B PPAP 
178 in TFA and H2O (Scheme 5.14)16m and discovered a diastereoselective 
rearrangement in 98 % formic acid that provided [3.3.1]-bicyclic lactone (±)-243 in 27 % 
yield (Scheme 5.15).  The structure and relative stereochemistry of (±)-243 was 
unambiguously confirmed by X-ray crystal structure analysis.  
 
























































Scheme 5.15  Proposed Mechanism for Rearrangement of Pyranodienone (±)-170. 
 
Scheme 5.16  The Hydroxyl Lone Pair is ~2.3 Å from the π* of the Vinylogous Ester 
Carbonyl which may Enable Intramolecular Attack and Oxetane Formation. 
 
 



















































































     Since the efficiency of the rearrangement decreased dramatically upon changing the 
Brønsted acid, we suspected that formic acid may play an important role in the 
mechanism of this transformation.  We propose a mechanism for the diastereoselective 
formation of enol ester (±)-243 employing formic acid as a nucleophile which may add to 
bridgehead ketone 244 to generate hemiketal 245 (Scheme 5.15).  A DFT-optimized 
model of 245 shows that its non-bonding hydroxyl lone pair (nb(OH)) is ~2.3Å from the 
π*C=O antibonding LUMO of its vinylogous methyl ester carbonyl  (LUMO shaded in 
blue, Scheme 5.16).  Thus, the hydroxyl lone pair may be well-suited for intramolecular 
attack and formation of the resulting oxetane intermediate 246. 84   Grob-type 
fragmentation of oxetane 246 may proceed either in a concerted or stepwise fashion 
(Scheme 5.17),85 and proper alignment of its bonding and antibonding orbitals may 
facilitate the reaction in the following sequence: 1) donation of the oxygen lone pair 
(nb(OH)) into the σ* (C-C) of the oxetane may enable oxonium ion formation and C-C 
bond cleavage, and 2) σb (C-C) donation into σ* (C-O) of the formate may lead to 
extrusion of formic acid and formation of fused lactone 247 (Scheme 5.15).  The 
geometries (and orbitals) of intermediates 245 and 246 depicted in Schemes 5.16 and 
5.17 were DFT-optimized (ground state, B3LYP, 6-31G*) using Spartan16’. 
     Rearrangement of pyranodienone substrate (±)-183 was also observed in 98 % formic 
acid leading to the production of the fused lactones (±)-248, (±)-256, (±)-252, and (±)-
257 (Scheme 5.18A).  The [3.3.1]-bicyclic lactone (±)-248 was provided in 12 % yield 




Scheme 5.18 A. Rearrangment of Pyranodienone (±)-183 in 98 % Formic Acid and B. 
Proposed Mechanism for the Rearrangement of Pyranodienone (±)-183. 
 
Scheme 5.15. As in the case of pyranodienone substrate (±)-170, the rearrangement of 
(±)-183 did not proceed in neat TFA except for in the presence of 98 % formic acid. 
     The lower yield of (±)-248 compared to (±)-243 may be explained by the transition 
state for cyclization of (±)-252 relative to that of proposed intermediate 247 (Scheme 
5.19).  It was hardly surprising that proposed intermediate 247 was not isolated from the 
reaction mixture as the 7-allyl group is favorably positioned on the convex face of 
transition state 259, which should enable rapid cyclization to bicyclic lactone (±)-
243.16n,m In contrast, for the cyclization to (±)-248, the 7-allyl group is on the concave 
face of transition state 258 leading to unfavorable steric interactions and lower yields of 
PPAP (±)-248.  As a result, the formic acid-mediated cyclization of substrate (±)-183 also 
leads to the formation of fused lactone byproducts (±)-256, (±)-252, and (±)-257 
(Scheme 5.18A). 
A. Rearrangment of pyranodienone (±)-183 in 98 % formic acid.





















98 % formic acid,
r.t., 72 h
















































Scheme 5.19.  A Chair-Type Transition State Analysis Shows that the Cyclization to (±)-
248 may be Sterically Disfavored Compared with Cyclization to (±)-243. 
 
     The isolation and characterization of relevant rearrangement byproducts along with 
NMR studies further supported our proposed mechanism for the formation of PPAPs (±)-
243 and (±)-248.  For example, evidence for proposed intermediate 247 (Scheme 5.19) 
en route to bicyclic product (±)-243 was provided by the isolation of its stereoisomer (±)-
252 from the reaction of pyranodienone (±)-183 in formic acid (Scheme 5.18A).  
Additionally, sufficient evidence for the first step of the rearrangement involving 
conversion of pyranodienone (±)-170 to the proposed PPAP intermediate 244 was 
provided by X-ray crystal structure analysis of product (±)-243 as one of two possible 




















































Scheme 5.20  A.  Compound (±)-243 Results from C-Cyclization and Pyran Opening of 
(±)-170, and B. Compound (±)-254 could Result from a 1,3-Shift of (±)-170, which was 
not Observed. 
 
As product (±)-243 was produced with complete diastereoselectivity (Scheme 5.20A), we 
eliminated the possibility of a 1,3-shift that would lead to the formation of bicyclic 
product (±)-254 (Scheme 5.20B) which was not observed in the reaction mixture.  The 
tendency for pyranodienone (±)-170 to first cyclize to 244 may be due to unfavorable 
steric interactions in the transition state leading to (±)-254, which are analogous to those 
described in Scheme 5.19. 
     Additional mechanistic evidence for the first step of the rearrangement was provided 
by 1H NMR analysis.  When pyranodienone (±)-183 was subjected to formic acid-d2, we 
initially observed quantitative conversion to deuterated intermediate 249-dx which then 
























A.  The mechanism for the rearrangment of (±)-170 to intermediate 244 was determined by the stereochemistry of diastereomer (±)-243.
1
B. The alternative mechanism, a 1,3-shift,  would lead to formation of (±)-254, which was not observed.
observed
not observed













Schemes 5.15 and 5.18B
formic acid







Scheme 5.21.  Reaction Monitoring by 1H-NMR in Formic Acid-d2 Revealed the 
Formation of 249-dx before Cyclization to 184-dx. 
 
(Scheme 5.21). The formation of intermediate 249-dx suggests that substrate 249 may be 
initially formed in the cyclization to product (±)-248 as depicted in Scheme 5.18B.  In 
the case of formic acid-d2, hydrolysis may be rapid due to the presence of 5 % D2O as 
high yields of compound 184 have been achieved in TFA and H2O (Scheme 5.14).16m 
However, 98 % formic acid contains significantly less water and provides hydrolysis 
product 184 in lower yield. 
 
5.3  Conclusion and Future Outlook 
     In conclusion, we have described formic acid-promoted rearrangements of 
dearomatized acylphloroglucinols and pyranodienones that produce novel PPAP 
scaffolds. The tendency for formic acid to promote the rearrangement may be explained 
by our proposed mechanism, and mechanistic data suggests that formic acid may act as a 

















mixture of deuteroisomers 
with varying degrees of 
deutero-substitution at 
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proposed reaction intermediates, and X-ray crystal structure analyses. We have also 
demonstrated diastereoselective cyclizations in 98 % formic acid to access a novel type A 
PPAP scaffold from O-alkylated, dearomatized acylphloroglucinol substrates. Additional 
investigations into the biology of these compounds are underway and will be reported in 
due course.  
 
 
5.4 Experimental Section 
General Information 
A. Instrumentation and Methods 
1H NMR spectra were recorded at 400 MHz or 500 MHz at ambient temperature with 
CDCl3, MeOD, or CD3CN (Cambridge Isotope Laboratories, Inc.) as solvents unless 
otherwise stated.  Data for 1H NMR are reported as follows: chemical shift, integration, 
multiplicity (app = apparent, br = broad, par obsc = partially obscure, ovrlp = overlapping, 
s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet) and coupling constants.  
13C NMR were recorded at 100 MHz or 125.0 MHz at ambient temperature with the same 
solvents unless otherwise stated.  Chemical shifts are reported in parts per million relative 
to CDCl3 (1H, δ 7.26; 13C, δ 77.0), C6D6 (1H, δ 7.16), DMSO-D6 (1H, δ 2.50; 13C δ 39.4), 
CD3OD (1H, δ 3.31, 4.78; 13C, δ 49.3) or CD2O2 (1H, δ 10.35; 13C δ 165.5), DCO2D(1H, δ 
8.3, 10.6; 13C 165.5).  All 13C NMR spectra were recorded with complete proton 
decoupling.  Infrared spectra were recorded on a Nicolet Nexus 670 FT-IR 
spectrophotometer.  High-resolution mass spectra were obtained in the Boston University 
Chemical Instrumentation Center using a Waters Q-TOF mass spectrometer.  Melting 
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points were recorded on a Mel-temp (Laboratory Devices).  Analytical thin layer 
chromatography was performed using 200-400 mesh silica gel (Scientific Absorbents, 
Inc.).  Yields refer to chromatographically and spectroscopically pure materials, unless 
otherwise stated.  All reactions were carried out in oven-dried glassware under an argon 
atmosphere unless otherwise noted.  Analytical LC-MS experiments were performed 
using a Waters Acquity UPLC (Ultra Performance Liquid Chromatography) with a 
Binary solvent manager, SQ mass spectrometer, Water 2996 PDA (PhotoDiode Array) 
detector, and Evaporative Light Scattering Detector (ELSD).  An Acquity UPLC BEH 
C18 1.7 µm column was used for analytical UPLC-MS. Preparative HPLC purification 
was performed on a Gilson PLC 2020 Personal Purification System.  Optical rotations 
were recorded on an AUTOPUL III digital polarimeter at 589 nm and are recorded as 
[α]22D  (concentration in grams/100 mL solvent).  A CHIRALPAK® AD-H [Chiral 
Technologies Inc., 150 x 4.60 mm (L x I.D.)] column was used for enantiomeric excess 
determination.  The Scilligence Electronic Laboratory Notebook (ELN) was used for 
experimental procedure planning.   
 
B.  Reagents and Solvents 
HPLC grade tetrahydrofuran, methylene chloride, diethyl ether, toluene, acetonitrile, and 
benzene were purchased from Fisher and VWR and were purified and dried by passing 
through a PURE SOLV® solvent purification system (Innovative Technology, Inc.).  
Other ACS grade solvents for chromatography were purchased from Clean Harbors. All 
other reagents and relevant catalysts were purchased from Sigma-Aldrich, Acros, Alfa 
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Aesar, and Strem Chemicals. Diisopropylamine was distilled over KOH before use. 
Phloroglucinol was purchased from Sigma-Aldrich.  3,3-Dimethylacrylate was purchased 
from eNovation Chemicals and (R)-4-benzyl-2-oxazolidinone (188) was purchased from 
AK Scientific.  American Chemical Society (ACS) grade formic acid (98%) was 
purchased from EMD Millipore in 1L plastic bottles.  The density for alcohol 116 was 
determined to be 0.8858 g/mL. 
 
Experimental Procedures and Compound Characterization 
 
2-(Prop-1-en-2-yl)pent-4-en-1-ol (±)-116:  Chiral, racemic alcohol (±)-116 was 
prepared according to a known protocol;16n spectroscopic data for (±)-116 were found to 
be identical with those reported in the literature.16n  
 
(-)-(R)-2-(Prop-1-en-2-yl)pent-4-en-1-ol (-)-(R)-116:16m,40  Alcohol (-)-(R)-116 was 
prepared according to a known protocol;16m spectroscopic data for (-)-(R)-116 were found 








































Triflate (±)-114:16m,n [note: This prep is also described on a gram-scale in chapter 4] To 
a flame-dried, pear-shaped 10-mL flask under argon containing alcohol (±)-116 (0.28 
mL, 1.98 mmol) was added toluene (1.7 mL), hexane (4.0 mL), and 
diisopropylethylamine (0.52 mL, 2.98 mmol).  The solution was cooled to -10 oC, and 
trifluoromethanesulfonic anhydride (0.35 mL, 2.08 mmol) was added dropwise over the 
course of 20 seconds.  The reaction was allowed to stir for 5 minutes and was then taken 
forward without further purification as a solution (see below). 
(±)-(3R,4aR,6S,8S)-3,6-Diallyl-8-benzoyl-2,7,7-trimethyl-3,4,5,6,7,8-hexahydro-9H-
4a,8-methanobenzo[8]annulene-9,11-dione (±)-208 and (3R,4aS,6S,8R)-3,6-diallyl-
10-benzoyl-2,2,7,7-tetramethyl-3,4,5,6,7,8-hexahydro-2H,9H-4a,8-
methanocycloocta[b]pyran-9,11-dione (±)-209:  To a flame-dried, round-bottom flask 
fitted with a stir bar was added acylphloroglucinol 115 (231 mg, 0.945 mmol).  The flask 
was charged with argon, THF (12.4 mL), toluene (4.1 mL), and hexane (6.3 mL), and the 
solution was then cooled to 0 oC in an ice-water bath.  LiHMDS (2.9 mL, 1.0 M in THF) 
was added over the course of one minute giving a dark red solution.  The reaction was 
stirred for 3 minutes, and the solution of triflate 114 was then pulled into a luer lock 
syringe; the needle (3”, 22G) was quickly replaced with a wide needle (18G) fitted with a 






5 oC to r.t. (1h 45 min)
then


































course of 10 minutes.  The reaction was allowed to warm to 15 oC for 1 h, then was 
stirred at room temperature for 45 min, and was heated to 50 oC for 10 min.  After 
cooling to room temperature, water (20 mL) was added and the biphasic mixture was 
extracted with ether (3 x 20 mL).  The combined organic layers were then washed with 
water (1 x 40 mL), brine (1 x 40 mL), dried over Na2SO4, filtered, and concentrated in 
vacuo to provide the diastereomeric mixture (±)-206 (100 mg, 19 % yield).  To a 10-mL 
round-bottom flask containing the diastereomeric mixture (±)-206 (42.9 mg, 0.0754 
mmol) was added formic acid. The flask was sealed with a yellow cap (24/40), Teflon® 
tape, and Keck® clip, and the reaction mixture was allowed to stir at room temperature 
for 48 h followed by heating to 75 oC for 12 h.  After cooling the reaction mixture to 
room temperature, formic acid was removed in vacuo to provide a crude residue.  
Purification by preparative thin layer chromatography (silica gel, 20 % EtOAc/hexanes) 
provided 9.3 mg (28 %) of (±)-208 and 10.8 mg (32 %) of (±)-209.  
(±)-(3R,4aR,6S,8S)-3,6-Diallyl-8-benzoyl-2,7,7-trimethyl-
3,4,5,6,7,8-hexahydro-9H-4a,8-methanobenzo[8]annulene-9,11-
dione (±)-208: Rf = 0.54 (20 % EtOAc/hexanes); IR νmax 3078, 
2970, 2927, 2855, 1720, 1696, 1651, 1613, 1583, 1447, 1392, 1372, 
1268, 1226, 994, 914, 736 cm-1;  1H NMR (500 MHz, CDCl3) δ 
7.52 – 7.43 (m, 2H), 7.42 – 7.35 (m, 1H), 7.30 – 7.22 (m, 2H), 6.27 (s, 1H), 6.19 (br s, 
1H), 5.76 (dddd, J = 17.1, 10.1, 7.4, 6.9 Hz, 1H), 5.61 (dddd, J = 17.7, 9.6, 8.3, 5.6 Hz, 
1H), 5.19 – 5.09 (m, 2H), 5.03 – 4.95 (m, 2H), 2.62 – 2.55 (m, 1H), 2.52 – 2.43 (m, 1H), 









3H), 1.84 – 1.68 (m, 3H), 1.55 (s, 3H), 1.41 (dd, J = 13.7, 11.8 Hz, 1H), 1.37 (s, 3H), 
1.19 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 208.9, 196.1, 193.7, 155.1, 154.4, 136.9, 
136.7, 134.8, 132.1, 128.1, 128.1, 124.6, 124.0, 118.1, 116.7, 80.3, 50.3, 48.8, 40.5, 38.2, 
36.7, 35.8, 32.8, 32.6, 23.0, 22.3, 16.3; HR-MS: m/z Calcd. for C29H32O3 [M+H+]: 




9,11-dione (±)-209:  Rf = 0.33 (25 % EtOAc/hexanes); IR νmax 3081, 
2978, 2938, 2854, 1731, 1681, 1648, 1599, 1449, 1391, 1374, 1349, 
1316, 1182, 1134, 1118, 1056, 999, 917, 837, 732 cm-1; 1H NMR (500 
MHz, CDCl3) δ 7.83 – 7.74 (m, 2H), 7.57 – 7.51 (m, 1H), 7.44 – 7.39 
(m, 2H), 5.85 – 5.66 (m, 2H), 5.14 – 5.06 (m, 4H), 2.98 (s, 1H), 2.43 (dd, J = 13.6, 4.6 
Hz, 1H), 2.43 – 2.36 (m, 1H), 2.27 – 2.19 (m, 1H), 2.16 – 2.07 (m, 1H), 2.03 (dd, J = 
14.4, 14.4 Hz, 1H), 1.90 (dddd, J = 9.6, 9.6, 3.1, 3.1 Hz, 1H), 1.77 (ddd, J = 13.4, 9.6, 9.6 
Hz, 2H), 1.71 (dd, J = 14.4, 3.5 Hz, 1H), 1.29 (dd, J = 13.6, 13.6 Hz, 1H), 1.27 (s, 3H), 
1.16 (s, 3H), 0.88 (s, 3H), 0.88 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 206.1, 193.6, 
191.2, 171.2, 137.4, 136.6, 135.2, 133.3, 128.9, 128.4, 125.7, 117.9, 116.9, 86.1, 74.2, 
50.3, 42.7, 39.5, 39.2, 38.6, 35.9, 33.3, 27.9, 27.8, 26.5, 21.2, 20.4; HR-MS: m/z Calcd. 













yl)cyclohexa-2,4-dien-1-one (+)-(S,S)-168A:  Enantiopure enol (+)-(S,S)-168A was 
prepared according to a known protocol;16m spectroscopic data for (+)-(S,S)-168A were 
found to be identical with those reported in the literature.16m 
Triflate (-)-(R)-114:  Enantiopure triflate (-)-(R)-114 was prepared according to the 
protocol above for racemic triflate (±)-11416m from alcohol (-)-(R)-116 (0.06 mL, 0.166 
mmol) in a solution of toluene (0.15 mL) and hexane (0.33 mL) using iPr2NEt (0.04 mL, 
0.224 mmol) and Tf2O (0.030 mL, 0.174 mmol).  The reaction mixture was then used 
directly for the preparation of (+)-210A as described below. 
(+)-2-Benzoyl-5-methoxy-6,6-bis((S)-2-(prop-1-en-2-yl)pent-4-en-1-yl)-3-(((R)-2-
(prop-1-en-2-yl)pent-4-en-1-yl)oxy)cyclohexa-2,4-dien-1-one (+)-210A:  To a flame-
dried round-bottom flask containing (+)-(S,S)-168A (36.8 mg, 0.0799 mmol) under an 
argon atmosphere was added THF (0.29 mL), and the solution was cooled 0 oC in an ice-
water bath.   KHMDS (0.13 mL, 1.0 M in THF) was added in a single portion, and the 
reaction mixture was warmed to 5 oC.  The solution of triflate (-)-(R)-114 was then pulled 
into a luer lock syringe; the needle (3”, 22G) was quickly replaced with a wide needle 
(18G) fitted with a cotton plug, and the solution was filtered directly into the reaction 



















-10 to 0 oC, 10 min;
OTf
(-)-(R)-114 (1.5 equiv)
43 %, 75 % brsm










stirring 45 minutes in the ice-water bath, and a saturated aqueous solution of NaHCO3 (5 
mL) was added.  The biphasic mixture was then poured into water (10 mL) and extracted 
with Et2O (2 x 10 mL).  The combined organic layers were then washed with water (1 x 
10 mL), brine (1 x 10 mL), dried over Na2SO4, filtered, and concentrated in vacuo to 
provide a crude residue.  Purification by column chromatography (silica gel, 2 – 12 % 




1-yl)oxy)cyclohexa-2,4-dien-1-one (+)-210A:  Rf = 0.23 
(17 % EtOAc/hexanes); IR νmax 3075, 2976, 2925, 2845, 
1671, 1636, 1599, 1582, 1533, 1448, 1409, 1353, 1327, 
1241, 1202, 1172, 1122, 1021, 992, 975, 910, 893, 821 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 7.93 – 7.80 (m, 2H), 7.54 – 7.43 (m, 1H), 7.43 – 7.35 (m, 2H), 5.73 – 5.48 (m, 
3H), 5.02 – 4.83 (m, 6H), 4.76 – 4.52 (m, 6H), 3.97 – 3.81 (m, 2H), 3.74 (s, 3H), 2.28 
(dddd, J = 6.8, 6.8, 6.8, 6.8 Hz, 1H), 2.23 – 2.13 (m, 2H), 2.11 – 1.85 (m, 9H), 1.75 (dd, J 
= 13.6, 3.8 Hz, 1H), 1.61 (s, 3H), 1.54 (br s, 6H); 13C NMR (125 MHz, CDCl3) δ 196.0, 
194.6, 174.6, 171.0, 147.3, 146.6, 143.7, 139.0, 137.1, 136.7, 135.5, 132.4, 129.1, 128.1, 
116.6, 115.6, 115.4, 113.8, 112.8, 112.8, 111.4, 90.8, 71.3, 56.6, 55.0, 45.9, 44.6, 44.3, 
43.5, 43.1, 39.8, 39.0, 33.8, 20.4, 18.3, 18.0; HR-MS: m/z Calcd. for C38H48O4 [M+H+] 













4a,8-methanobenzo[8]annulene-9,11-dione (-)-216: To a 20-mL scintillation vial 
containing (+)-210A (7.5 mg, 0.0129 mmol) was added 98 % formic acid (2.0 mL).  The 
vial was capped and heated to 75 oC.  The reaction mixture was stirred at this temperature 
for 1 h.  After cooling the reaction mixture to room temperature, the formic acid was 
removed in vacuo to provide a crude residue.  Purification by column chromatography 
(silica gel, 5-20 % EtOAc/hexanes) provided 2.3 mg (42 %) of type A product (-)-216 
and 1.8 mg (30 %) of oxycyclization products (-)-167/(+)-169.   
(-)-(3S,4aR,6S,8S)-3,6-Diallyl-8-benzoyl-2,7,7-trimethyl-
3,4,5,6,7,8-hexahydro-9H-4a,8-methanobenzo[8]annulene-
9,11-dione (-)-216: Rf = 0.51 (29 % EtOAc/hexanes); IR νmax 
3074, 2976, 2948, 2919, 2854, 1720, 1695, 1650, 1612, 1583, 
1447, 1393, 1372, 1268, 1226, 1186, 994, 913, 733 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 7.51 – 7.45 (m, 2H), 7.42 – 7.35 (m, 1H), 7.31 – 7.24 (m, 




































(m, 2H), 5.04 – 4.95 (m, 2H), 2.64 – 2.55 (m, 1H), 2.52 – 2.43 (m, 1H), 2.42 – 2.35 (m, 
1H), 2.22 (ddd, J = 14.8, 7.8, 7.8 Hz, 1H), 2.09 – 1.97 (m, 2H), 2.03 (s, 3H), 1.84 – 1.67 
(m, 3H), 1.41 (dd, J = 13.0, 13.0 Hz, 1H), 1.36 (s, 3H), 1.19 (s, 3H); 13C NMR (125 
MHz, CDCl3) δ 208.9, 196.1, 193.7, 155.0, 154.4, 136.9, 136.7, 134.9, 132.1, 128.1, 
128.1, 124.6, 124.0, 118.1, 116.7, 80.3, 50.3, 48.8, 40.5, 38.2, 36.7, 35.8, 32.9, 32.7, 23.0, 
22.3, 16.3; HR-MS: m/z Calcd. for C29H32O3 [M+H+] 429.2430: Found 429.2442; 




2H,9H-4a,8-methanocycloocta[b]pyran-9,11-dione (±)-217 and (3S,4aR,6S,8S)-3,6-
diallyl-10-benzoyl-2,2,7,7-tetramethyl-3,4,5,6,7,8-hexahydro-2H,9H-4a,8-
methanocycloocta[b]pyran-9,11-dione (±)-218:  To a flame-dried 10-mL round-bottom 
flask containing (±)-168A (14.3 mg, 0.0311 mmol) was added 98 % formic acid (3 mL).  
The flask was sealed with a yellow cap (24/40), Teflon® tape, and a yellow Keck® clip.  
The reaction mixture was heated to 75 oC in an oil bath and stirred for 45 minutes.  After 
cooling the reaction mixture to room temperature, the formic acid was removed in vacuo 

























EtOAc/hexanes) provided 6.6 mg (47 %) of (±)-217 and (±)-218 (1.2:1 mixture of 
diastereomers as determined by 1H NMR analysis) as a white amorphous solid.  
Compounds (±)-217 and (±)-218 were separated for characterization by high performance 
liquid chromatography HPLC (0 to 100% CH3CN/H2O over 1 hour).    
(±)-(3S,4aS,6S,8R)-3,6-Diallyl-10-benzoyl-2,2,7,7-tetramethyl-
3,4,5,6,7,8-hexahydro-2H,9H-4a,8-methanocycloocta[b]pyran-9,11-
dione (±)-217: Rf = 0.14 (15 % EtOAc/hexanes); IR νmax 3076, 2977, 
2925, 2851, 1734, 1682, 1645, 1598, 1449, 1391, 1374, 1352, 1307, 
1181, 1118, 1001, 917 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.81 – 7.74 (m, 2H), 7.57 – 
7.49 (m, 1H), 7.45 – 7.39 (m, 2H), 5.84 – 5.70 (m, 2H), 5.19 – 5.01 (m, 4H), 3.02 (dd, J 
= 14.3, 3.8 Hz, 1H), 2.98 (s, 1H), 2.47 – 2.33 (m, 1H), 2.24 – 2.11 (m, 3H), 1.83 – 1.69 
(m, 2H), 1.59 – 1.45 (m, 2H), 1.22 (s, 3H), 1.16 (s, 3H), 1.01 (dd, J = 13.6, 13.6 Hz, 2H), 
0.96 (s, 3H), 0.87 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 204.3, 193.6, 191.1, 172.3, 
137.3, 136.6, 135.3, 133.3, 128.9, 128.5, 126.5, 117.5, 116.9, 87.6, 73.2, 53.4, 42.5, 42.1, 
41.4, 39.1, 35.4, 33.3, 28.3, 26.8, 26.4, 21.3, 20.3; HR-MS: m/z Calcd. for C29H34O4  




dione (±)-218: Rf = 0.16 (15 % EtOAc/hexanes); IR νmax 2967, 2927, 
2853, 1732, 1681, 1643, 1599, 1449, 1390, 1380, 1353, 1262, 1177, 















7.56 – 7.50 (m, 1H), 7.42 – 7.37 (m, 2H), 5.76 – 5.58 (m, 2H), 5.24 – 5.06 (m, 4H), 3.00 
(s, 1H), 2.70 (dd, J = 15.2, 2.6 Hz, 1H), 2.64 (ddd, J = 13.4, 9.1 Hz, 1H), 2.41 – 2.33 (m, 
1H), 2.24 – 2.17 (m, 1H), 1.96 – 1.92 (m, 2H), 1.82 – 1.63 (m, 4H), 1.29 (s, 3H), 1.19 (s, 
3H), 1.13 (s, 3H), 0.76 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 207.6, 193.7, 191.6, 
172.3, 137.7, 137.4, 135.1, 133.8, 133.3, 128.8, 128.4, 122.7, 117.9, 86.2, 71.9, 48.2, 
43.6, 41.9, 38.5, 36.6, 35.9, 35.0, 30.8, 28.0, 27.9, 24.7, 21.5; HR-MS: m/z Calcd. for 

























Prepared by Method 1a
a Method 1: allyl or benzyl bromide (1.33 equiv), K2CO3 (1.5 equiv), TBAI (0.38 equiv), Acetone (1.13 M), 70 
oC, 3 h.  b Method 2: alkyl triflate (6.0 equiv) in hexanes/toluene (2.1:1), KHMDS (1.5 equiv),THF, 0 oC to r.t., 





































General Method for the Preparation of O-Alkylated Enols 225 and 228 (Method 1): 
 
An oven-dried 15-mL glass pressure tube fitted with a stir bar was charged with (±)-168A 
(48 mg, 0.0868 mmol).  The tube was then fitted with a septum and flushed with argon.  
Reagent grade acetone (0.08 mL) was added followed by the addition of K2CO3 (18.0 
mg, 0.13 mmol) [note: K2CO3 was crushed with a mortar and pestle directly prior to use] 
and tetrabutylammonium iodide (12.0 mg, 0.0326 mmol).  Allyl bromide (0.01 mL, 0.116 
mmol) was added in a single portion via syringe. [note: Allyl bromide was passed 
through basic alumina prior to use under an argon atmosphere.] The septum was 
removed, and the tube was quickly sealed and heated to 70 oC for 3 h.  The reaction was 
allowed to cool to room temperature before adding water (2 mL).  The mixture was then 
poured into a separatory funnel and extracted with CH2Cl2 (3 x 2 mL).  The combined 
organic layers were washed with water (1 x 2 mL), brine (1 x 2 mL), dried over Na2SO4, 
filtered, and concentrated.  Purification by silica gel chromatography  (1 % – 20 % 






















yl)pent-4-en-1-yl)cyclohexa-2,4-dien-1-one 225: Rf = 0.27 (20 % 
EtOAc/hexanes); IR νmax 3076, 2973, 2926, 2845, 1671, 1635, 1599, 
1532, 1448, 1410, 1373, 1329, 1257, 1199, 1172, 1124, 990, 976, 
912, 890, 816, 718 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.90 – 7.85 (m, 2H), 7.52 – 7.45 
(m, 1H), 7.42 – 7.36 (m, 2H), 5.78 (dddd, J = 17.2, 10.3, 5.0 Hz, 1H), 5.68 – 5.53 (m, 
2H), 5.45 (s, 1H), 5.23 – 5.16 (m, 2H), 5.00 – 4.88 (m, 4H), 4.72 (dd, J = 2.3, 1.4 Hz, 
1H), 4.68 – 4.60 (m, 3H), 4.51 (ddd, J = 4.8, 1.6 Hz, 2H), 3.72 (s, 3H), 2.22 – 2.13 (m, 
2H), 2.10 – 1.91 (m, 6H), 1.88 (dd, J = 13.4, 3.0 Hz, 1H), 1.75 (dd, J = 13.5, 3.7 Hz, 1H), 
1.60 (s, 3H), 1.52 (s, 3H);  13C NMR (125 MHz, CDCl3) δ 196.1, 194.6, 174.7, 171.0, 
147.2, 146.5, 138.8, 137.0, 136.6, 132.5, 131.9, 129.1, 128.1, 118.1, 115.6, 115.4, 114.0, 
112.8, 111.5, 90.8, 69.8, 56.6, 55.0, 44.5, 44.2, 43.5, 43.2, 39.7, 39.0, 18.2, 18.0; HR-
MS: m/z Calcd. for C33H40O4 [M+H+] 501.5005: Found 501.2991. 
2-Benzoyl-3-(benzyloxy)-5-methoxy-6,6-bis((S)-2-(prop-1-
en-2-yl)pent-4-en-1-yl)cyclohexa-2,4-dien-1-one 228:  
Conjugated product 228 was prepared by Method 1 described 
above from a solution (±)-168A (37.8 mg, 0.082 mmol) in 
acetone (0.07 mL) using ground K2CO3 (17 mg, 0.123 mmol), 
tetrabutylammonium iodide (11.4 mg, 0.0308 mmol), and benzyl bromide (0.01 mL, 
0.0842 mmol) at temperatures of 70 oC for 3 h.  Purification by column chromatography 
provided 32.9 mg (73 %) of conjugated product 228.  228:   Rf = 0.14 (15 % 
















1262, 1218, 1172, 1120, 991, 910, 739 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.97 – 7.80 
(m, 2H), 7.56 – 7.46 (m, 1H), 7.46 – 7.34 (m, 2H), 7.34 – 7.22 (m, 3H), 7.19 – 7.07 (m, 
2H), 5.68 – 5.50 (m, 2H), 5.47 (s, 1H), 5.07 (s, 2H), 4.97 – 4.89 (m, 4H), 4.71 (dd, J = 
1.8 Hz, 1H), 4.58 (d, J = 2.1 Hz, 1H), 4.53 (dd, J = 1.9 Hz, 1H), 4.50 (br s, 1H), 3.65 (s, 
3H), 2.23 – 2.07 (m, 2H), 2.07 – 1.89 (m, 6H), 1.86 (dd, J = 13.4, 3.1 Hz, 1H), 1.73 (dd, J 
= 13.4, 3.3 Hz, 1H), 1.56 (s, 3H), 1.52 (s, 3H);  13C NMR (100 MHz, CDCl3) δ 196.1, 
194.7, 174.7, 171.2, 147.0, 146.4, 138.8, 137.0, 136.6, 135.7, 132.5, 129.2, 128.6, 128.3, 
128.1, 126.8, 115.6, 115.4, 114.1, 112.8, 111.5, 91.1, 71.1, 56.6, 55.0, 44.6, 44.2, 43.4, 
43.1, 39.7, 39.0, 18.1, 18.0; HR-MS: m/z Calcd. for C37H42O4 [M+H+] 551.3161: Found 
551.3160. 
General Method for the Preparation of O-Alkylated Enols 232, 233, 234, and 239 
(Method 2): 
 
To a flame-dried, pear-shaped 5-mL flask under argon containing 4-penten-1-ol (0.03 
mL, 0.293 mmol) was added toluene (0.23 mL), hexane (0.51 mL), and 
diisopropylethylamine (0.07 mL, 0.37 mmol).  The solution was cooled to -10 oC, and 
trifluoromethanesulfonic anhydride (0.05 mL, 0.267 mmol) was added in a single portion 
over the course of 5 seconds.  The reaction was allowed to stir for 5 minutes and was then 
























yl)cyclohexa-2,4-dien-1-one 232:  To a separate flame-dried round-bottom flask 
containing (±)-168A (24.9 mg, 0.0541 mmol) under an argon atmosphere was added THF 
(0.18 mL), and the solution was cooled 0 oC in an ice-water bath.   KHMDS (0.08 mL, 
1.0 M in THF) was added over the course of 5 seconds.  The reaction mixture was 
warmed to 5 oC, and the solution of triflate in toluene/hexanes (prepared from 4-penten-
1-ol) was then pulled into a luer lock syringe; the needle (3”, 22G) was quickly replaced 
with a wide needle (18G), fitted with a cotton plug, and the solution was filtered directly 
into the reaction mixture over the course of 10 minutes.  The starting material was fully 
consumed after stirring 45 minutes at 0 oC, and a saturated aqueous solution of NaHCO3 
(5 mL) was added.  The biphasic mixture was then poured into water (10 mL) and 
extracted with Et2O (2 x 10 mL).  The combined organic layers were then washed with 
water (1 x 10 mL), brine (1 x 10 mL), dried over Na2SO4, filtered, and concentrated in 
vacuo to provide a crude residue (91.0 mg).  Purification by column chromatography 
(silica gel, 3 – 25 % EtOAc/hexanes) provided 27.7 mg (97 %) of conjugated product 232 
as a yellow crystalline solid. 232: Rf = 0.34 (20 % EtOAc/hexanes); m.p. 109 – 113 oC 
(CH2Cl2); IR νmax 3074, 2973, 2927, 2839, 1672, 1636, 1599, 1533, 1448, 1412, 1359, 
1349, 1332, 1241, 1204, 1173, 1122, 991, 912 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.90 – 
7.82 (m, 2H), 7.51 – 7.44 (m, 1H), 7.41 – 7.35 (m, 2H), 5.68 – 5.52 (m, 3H), 5.43 (s, 1H), 
5.06 – 4.83 (m, 6H), 4.72 (dd, J = 1.8 Hz, 1H), 4.68 – 4.60 (m, 3H), 3.95 (dtd, J = 6.9, 
6.3, 3.6 Hz, 2H), 3.73 (s, 3H), 2.24 – 2.14 (m, 2H), 2.10 – 1.85 (m, 9H), 1.75 (dd, J = 
13.5, 3.7 Hz, 1H), 1.64 – 1.55 (m, 2H), 1.60 (s, 3H), 1.53 (s, 3H); 13C NMR (100 MHz, 
  
483 
CDCl3) δ 195.9, 194.7, 174.7, 171.4, 147.2, 146.5, 139.0, 137.0, 137.0, 136.6, 132.4, 
129.0, 128.0, 115.6, 115.6, 115.4, 113.6, 112.7, 111.4, 90.7, 68.7, 56.5, 55.0, 44.5, 44.3, 
43.5, 43.1, 39.8, 39.0, 29.3, 28.2, 18.2, 18.0; HR-MS: m/z Calcd. for C35H44O4 [M+H+] 
529.3318: Found 529.3322.  
2-Benzoyl-5-methoxy-3-((3-methylbut-3-en-1-yl)oxy)-
6,6-bis((S)-2-(prop-1-en-2-yl)pent-4-en-1-yl)cyclohexa-
2,4-dien-1-one 233: Purification by column 
chromatography (silica gel, 3 – 21 % EtOAc/hexanes) 
provided 16.2 mg (75 %) of compound 233 as a yellow oil.  
Compound 233 was prepared from a solution of (±)-168A (18.9 mg, 0.041 mmol) in THF 
(0.14 mL) using KHMDS (0.06 mL, 1.0 M in THF) and alkyl triflate (0.221 mmol, 5.8 
equiv) by the protocol described above for Method 2.  Rf = 0.54 (29 % EtOAc/hexanes); 
IR νmax 3071, 2975, 2927, 2860, 1671, 1639, 1536, 1449, 1414, 1355, 1265, 1207, 1173, 
1122, 1034, 992, 918, 893 cm-1; 1H NMR (500 MHz, CDCl3) δ  7.89 – 7.81 (m, 2H), 7.53 
– 7.45 (m, 1H), 7.42 – 7.35 (m, 2H), 5.69 – 5.49 (m, 2H), 5.00 – 4.87 (m, 4H), 4.75 – 
4.61 (m, 5H), 4.56 (br s, 1H), 4.03 (tt, J = 6.8, 3.2 Hz, 2H), 3.74 (s, 3H), 2.26 – 2.13 (m, 
4H), 2.06 (ddd, J = 15.2, 7.2, 3.8 Hz, 1H), 2.03 – 1.91 (m, 5H), 1.87 (dd, J = 13.4, 3.0 
Hz, 1H), 1.75 (dd, J = 13.4, 3.7 Hz, 1H), 1.61 (s, 3H), 1.60 (s, 3H), 1.52 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 196.1, 194.7, 174.5, 171.3, 147.2, 146.5, 140.9, 138.9, 137.0, 
136.6, 132.4, 129.1, 128.0, 115.6, 115.4, 113.6, 112.8, 112.6, 111.4, 91.1, 68.4, 56.5, 
55.1, 44.5, 44.2, 43.5, 43.1, 39.7, 39.0, 37.0, 22.5, 18.2, 18.0; HR-MS: m/z Calcd. for 











Purification by column chromatography (silica gel, 3 – 21 % 
EtOAc/hexanes) provided 26.5 mg (92 %) of compound 234 
as a yellow crystalline solid.  Compound 234 was prepared 
from a solution of (±)-168A (25.8 mg, 0.056 mmol) in THF (0.19 mL) using KHMDS 
(0.084 mL, 1.0 M in THF) and alkyl triflate (0.325 mmol, 5.8 equiv) as described above 
for Method 2. 234: Rf = 0.34 (20 % EtOAc/hexanes); m.p. 105 – 106 oC (CH2Cl2);  IR 
νmax 3074, 2963, 2928, 1671, 1636, 1599, 1533, 1448, 1412, 1354, 1329, 1242, 1205, 
1172, 1122, 988, 912, 893, 818 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.88 – 7.83 (m, 2H), 
7.52 – 7.43 (m, 1H), 7.42 – 7.34 (m, 2H), 5.69 – 5.51 (m, 2H), 5.43 (s, 1H), 5.00 – 4.88 
(m, 4H), 4.71 (dd, J = 1.8, 1.8 Hz 1H), 4.68 – 4.61 (m, 3H), 3.74 (s, 3H), 3.74 – 3.66 (m, 
2H), 2.24 – 2.14 (m, 2H), 2.11 – 1.71 (m, 8H), 1.64 – 1.55 (m, 1H), 1.60 (s, 3H), 1.53 (s, 
3H), 0.74 (d, J = 6.7 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 195.8, 194.6, 174.8, 171.6, 
147.2, 146.5, 139.0, 137.1, 136.6, 132.3, 129.0, 128.0, 115.6, 115.4, 113.5, 112.7, 111.4, 
90.6, 75.8, 56.5, 55.0, 44.5, 44.3, 43.4, 43.1, 39.7, 39.0, 28.4, 18.6, 18.3, 18.0; HR-MS: 
m/z Calcd. for C34H34O4 [M+H+] 517.3318: Found 517.3318.  
2-Benzoyl-3-isopropoxy-5-methoxy-6,6-bis((S)-2-(prop-1-en-
2-yl)pent-4-en-1-yl)cyclohexa-2,4-dien-1-one 239:  
Purification by column chromatography (silica gel, 5 – 20 % 
EtOAc/hexanes) provided 24.4 mg (75 %) of compound 239 as 















(±)-168A (29.9 mg, 0.0649 mmol) in THF (0.22 mL) using KHMDS (0.10 mL, 1.0 M in 
THF) and alkyl triflate (0.392 mmol, 6.04 equiv) as described above for Method 2. 239: 
Rf = 0.21 (20 % EtOAc/hexanes); m.p. 115 – 118 oC (CH2Cl2);  IR νmax 3072, 2979, 
2929, 1672, 1634, 1599, 1581, 1530, 1448, 1411, 1369, 1323, 1205, 1170, 1118, 1099, 
991, 972, 911, 893, 814, 772, 717 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.90 – 7.79 (m, 
2H), 7.52 – 7.44 (m, 1H), 7.42 – 7.33 (m, 2H), 5.69 – 5.52 (m, 2H), 5.45 (s, 1H), 5.03 – 
4.85 (m, 4H), 4.71 (dd, J = 1.9 Hz, 1H), 4.68 – 4.61 (m, 3H), 4.55 (hept, J = 6.0 Hz, 1H), 
3.73 (s, 3H), 2.25 – 2.14 (m, 2H), 2.11 – 1.85 (m, 7H), 1.75 (dd, J = 13.4, 3.7 Hz, 1H), 
1.70 – 1.57 (m, 1H), 1.60 (s, 3H), 1.53 (s, 3H), 1.14 (d, J = 6.0 Hz, 6H); 13C NMR (100 
MHz, CDCl3) δ 195.6, 194.5, 174.8, 170.4, 147.3, 146.6, 139.0, 137.1, 136.7, 132.2, 
129.0, 127.9, 115.5, 115.4, 114.5, 112.5, 111.3, 90.3, 72.0, 56.5, 54.9, 44.5, 44.2, 43.5, 




4a,8-methanobenzo[8]annulene-9,11-dione (±)-216: To a flame-dried 10-mL round-
bottom flask containing 225 (12.2 mg, 0.0244 mmol) was added 98 % formic acid (2 
mL).  The flask was sealed with a yellow cap (14/20), Teflon® tape, and a yellow Keck® 
clip.  The reaction mixture was heated to 75 oC in an oil bath and stirred for 45 minutes.  




















vacuo to provide a crude residue.  Purification by preparative thin layer chromatography 
(silica gel, one elution in 20 % EtOAc/hexanes) provided 1.7 mg (16 %) of (±)-216. 
 
To a flame-dried 10-mL round-bottom flask containing (±)-170 (3.0 mg, 0.00599 mmol) 
was added 98 % formic acid (3 mL).  The flask was sealed with a yellow cap (14/20), 
Teflon® tape, and a yellow Keck® clip.  The reaction mixture was heated to 75 oC in an 
oil bath and stirred for 5.5 h.  After cooling the reaction mixture to room temperature, the 
formic acid was removed in vacuo to provide a crude residue.  Purification by preparative 
thin layer chromatography (silica gel, 15 % EtOAc/hexanes) provided 0.8 mg (27 %) of 
(±)-243, 0.8 mg (27 %) of (±)-244b, 0.6 mg (20 %) of (±)-187, and 0.3 mg (10 %) of (±)-
178.  [note: Characterization data for (±)-178 and (±)-187 are detailed in chapter 4, and 
characterization data for (±)-244b is detailed in chapter 2.] 
(±)-((3S,4aR,6S,8S)-3,6,8-Triallyl-10-benzoyl-2,2,7,7-
tetramethyl-3,4,5,6,7,8-hexahydro-2H,9H-4a,8-
methanocycloocta[b]pyran-9,11-dione (±)-243: Rf = 0.53 (20 
% EtOAc/hexanes); IR νmax 3084, 2977, 2929, 2857, 1771, 
1726, 1666, 1597, 1557, 1449, 1399, 1374, 1327, 1315, 1256, 
1143, 1103, 993, 917, 736 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.72 – 7.65 (m, 2H), 7.56 




































5.59 (m, 2H), 5.19 – 4.96 (m, 7H), 2.71 (dd, J = 14.2, 3.5 Hz, 1H), 2.64 (dd, J = 13.2, 6.5 
Hz, 1H), 2.51 (dd, J = 13.1, 7.7 Hz, 1H), 2.41 – 2.29 (m, 2H), 2.25 (dd, J = 14.4, 5.5 Hz, 
1H), 2.00 – 1.86 (m, 1H), 1.71 (ddd, J = 13.9, 11.0, 10.5 Hz, 1H), 1.20 (s, 3H), 1.11 (dd, J 
= 13.9, 13.9 Hz, 1H), 1.09 (s, 3H), 0.90 (s, 3H), 0.90 – 0.86 (m, 1H), 0.82 (dd, J = 12.8, 
12.8 Hz, 1H), 0.73 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 202.2, 196.3, 167.2, 144.1, 
137.1, 136.9, 136.2, 133.5, 133.0, 131.1, 129.3, 128.6, 120.2, 117.1, 116.6, 69.4, 50.7, 
49.4, 45.0, 41.6, 41.0, 37.8, 35.5, 33.8, 31.6, 30.4, 25.2, 22.0, 21.9, 16.7; HR-MS: m/z 
Calcd. for C32H38O4 [M+H+]: 487.2848, Found 487.2857. 
To a flame-dried 10-mL round-bottom flask containing (±)-183 (11.2 mg, 0.0224 mmol) 
was added 98 % formic acid (2 mL).  The flask was sealed with a yellow cap (14/20), 
Teflon® tape, and a yellow Keck® clip.  The reaction mixture was cooled to 10 oC and 
stirred for 72 h. The formic acid was removed in vacuo to provide a crude residue.  
Purification by preparative thin layer chromatography (silica gel, 15 % EtOAc/hexanes) 
provided 1.3 mg (12 %) of (±)-248, 1.8 mg (17 %) of (±)-184, 0.6 mg (5 %) of (±)-256, 
1.6 mg (14 %) of (±)-252, and 1.2 mg (11 %) of (±)-257. [note: Characterization data for 























98 % formic acid,
r.t., 72 h












methanobenzo[b]oxocine-2,11-dione (±)-248:  Rf = 0.39 (15 % 
EtOAc/hexanes); IR νmax 3077, 2974, 2924, 2854, 1770, 1727, 
1666, 1642, 1597, 1581, 1449, 1393, 1374, 1315, 1259, 1246, 
1145, 1099, 996, 916 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.76 – 7.70 (m, 2H), 7.56 – 
7.49 (m, 1H), 7.43 – 7.35 (m, 2H), 5.99 – 5.85 (m, 1H), 5.67 – 5.54 (m, 1H), 5.47 (dddd, 
J = 17.1, 9.9, 7.3 Hz, 1H), 5.25 – 4.89 (m, 6H), 2.80 (dd, J = 14.1, 3.4 Hz, 1H), 2.73 (dd, 
J = 12.9, 6.9 Hz, 1H), 2.43 – 2.28 (m, 3H), 2.27 – 2.18 (m, 1H), 1.95 (dd, J = 14.8, 4.9 
Hz, 1H), 1.91 – 1.82 (m, 1H), 1.79 – 1.61 (m, 2H), 1.35 – 1.28 (m, 1H), 1.23 – 1.12 (m, 
1H), 1.18 (s, 3H), 1.05 (s, 3H), 0.94 (s, 2H), 0.92 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
203.6, 195.9, 167.4, 142.6, 137.1, 137.0, 136.9, 133.4, 132.5, 129.9, 129.5, 128.5, 120.6, 
117.4, 116.6, 66.0, 50.5, 48.9, 43.3, 41.4, 41.0, 37.8, 34.0, 33.8, 32.5, 31.9, 25.5, 25.3, 
22.2, 20.6; HR-MS: m/z Calcd. for C32H38O4 [M+H+]: 487.2770, Found 487.2773. 
(±)-(4aS,6R)-3,6-Diallyl-8-benzoyl-4-methoxy-7,7-
dimethyl-4a-((S)-2-(prop-1-en-2-yl)pent-4-en-1-yl)-
4a,5,6,7-tetrahydro-2H-chromen-2-one (±)-252: Rf = 0.25 
(15 % EtOAc/hexanes); IR νmax 3077, 2975, 2929, 2858, 
1733, 1666, 1641, 1608, 1449, 1315, 1252, 1176, 1070, 990, 
913 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.78 – 7.72 (m, 2H), 7.54 – 7.48 (m, 1H), 7.42 – 
7.35 (m, 2H), 5.89 (ddd, J = 22.3, 10.4, 5.5 Hz, 1H), 5.84 – 5.77 (m, 1H), 5.64 (dddd, J = 











3H), 3.25 (dd, J = 16.8, 5.6 Hz, 1H), 3.08 (dd, J = 16.5, 6.1 Hz, 1H), 2.57 (d, J = 11.8 Hz, 
1H), 2.37 (dd, J = 14.3, 5.6 Hz, 1H), 2.32 – 2.25 (m, 1H), 2.16 – 1.89 (m, 3H), 1.78 – 
1.65 (m, 1H), 1.60 (s, 3H), 1.57 – 1.49 (m, 1H), 1.48 – 1.37 (m, 2H), 1.23 (s, 3H), 0.98 
(s, 3H); 13C NMR (125 MHz, CDCl3) δ 196.1, 173.8, 164.1, 147.0, 146.7, 137.7, 137.2, 
136.4, 136.3, 133.3, 129.8, 129.0, 128.6, 116.5, 116.3, 115.4, 111.7, 61.4, 44.5, 43.2, 
42.9, 42.3, 39.3, 37.7, 33.6, 29.6, 28.3, 25.6, 21.8, 19.1; HR-MS: m/z Calcd. for 
C33H40O4 [M+Na+]: 523.2824, Found 523.2800. 
(±)-(4aR,6R)-3,6-Diallyl-8-benzoyl-4-methoxy-7,7-
dimethyl-4a-(2-(propan-2-ylidene)pent-4-en-1-yl)-4a,5,6,7-
tetrahydro-2H-chromen-2-one (±)-256:  Rf = 0.3 (15 % 
EtOAc/hexanes); IR νmax 3079, 2967, 2923, 2860, 1736, 
1555, 1640, 1605, 1558, 1449, 1349, 1315, 1261, 1175, 1071, 
915 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.79 – 7.70 (m, 2H), 7.56 – 7.47 (m, 1H), 7.43 – 
7.32 (m, 2H), 5.95 – 5.85 (m, 1H), 5.85 – 5.76 (m, 1H), 5.62 (dddd, J = 16.5, 10.3, 6.4 
Hz, 1H), 5.18 – 5.06 (m, 4H), 4.95 – 4.85 (m, 2H), 4.03 (s, 3H), 3.24 (dddd, J = 16.6, 5.9, 
1.8 Hz, 1H), 3.10 (dddd, J = 16.3, 6.0, 1.6 Hz, 1H), 2.85 (dd, J = 15.4, 5.8 Hz, 1H), 2.65 
(dd, J = 15.6, 6.8 Hz, 1H), 2.52 (dd, J = 14.2, 2.5 Hz, 1H), 2.44 (d, J = 13.6 Hz, 1H), 2.41 
– 2.33 (m, 1H), 2.29 (d, J = 13.8 Hz, 1H), 1.75 – 1.69 (m, 1H), 1.68 (s, 3H), 1.67 (s, 3H), 
1.59 – 1.51 (m, 1H), 1.50 – 1.41 (m, 1H), 1.15 (s, 3H), 0.94 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 196.2, 173.4, 163.5, 146.5, 137.6, 137.2, 135.9, 135.7, 133.3, 132.9, 130.4, 











d]chromen-6-one (±)-257: Rf = 0.26 (15 % EtOAc/hexanes); 
IR νmax 2976, 2923, 2851, 1737, 1667, 1646, 1561, 1452, 
1393, 1349, 1309, 1277, 1237, 1177, 1127, 1065, 913, 710 
cm-1; 1H NMR (500 MHz, CDCl3) δ 7.82 – 7.77 (m, 2H), 7.57 – 7.49 (m, 1H), 7.44 – 
7.38 (m, 2H), 5.92 – 5.75 (m, 2H), 5.75 – 5.62 (m, 1H), 5.18 – 5.00 (m, 6H), 3.18 (dd, J 
= 14.8, 6.1 Hz, 1H), 2.94 (dd, J = 14.9, 6.6 Hz, 1H), 2.74 (dd, J = 14.6, 4.3 Hz, 1H), 2.42 
(d, J = 14.5 Hz, 1H), 2.20 – 2.08 (m, 2H), 1.87 – 1.58 (m, 5H), 1.55 (s, 3H), 1.44 (dd, J = 
13.8, 12.6 Hz, 2H), 1.20 (s, 3H), 1.07 (s, 3H), 0.96 (s, 3H); 13C NMR (125 MHz, CDCl3) 
δ 196.5, 170.2, 162.6, 146.6, 137.3, 137.2, 135.5, 135.5, 133.4, 133.1, 129.2, 128.7, 
117.7, 116.5, 115.5, 115.2, 90.4, 42.3, 40.8, 40.5, 40.4, 37.0, 36.1, 35.0, 34.0, 28.8, 28.8, 
25.1, 22.4, 19.6; HR-MS: m/z Calcd. for C32H38O4 [M+H+]: 487.2848, Found 487.2844. 
 











dx:  Formic acid-d2 (containing 5 % D2O) was added to (±)-183 (6.8 mg, 0.0134 mmol) 
and the solution was transferred to an NMR tube.  (Please refer to final pages of this 
chapter for relevant spectra).  It should be noted that the presence of D2O likely causes 
hydrolysis of the vinylogous methyl ester leading to the dominant formation of O-
cyclized product 184-dx.16m  Each molecule of 184-dx and 249-dx contains differing 
degrees of deuterium incorporation at C20, C21, C22, and C23 methyl groups.  The 
variations in deuterium incorporation does not affect the outcome of our mechanistic 
study.  Mechanistic Analysis: The rapid cyclization of 183 to type A intermediate 249-dx 
in formic acid-d2 (5 % D2O) supports our hypothesis that formic acid first induces the 
formation of product 249 in our proposed mechanism for the formation of bicyclic 
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  (±)-184-dx:  Rf = 0.33 (15 % EtOAc/hexanes); IR νmax 3082, 
2976, 2950, 2854, 1722, 1698, 1641, 1603, 1447, 1349, 1239, 
1218, 1187, 1113, 1046, 1015, 914, 689 cm-1; 1H NMR (500 
MHz, CDCl3) δ 7.54 – 7.43 (m, 2H), 7.42 – 7.33 (m, 1H), 7.30 
– 7.19 (m, 2H), 5.84 – 5.56 (m, 3H), 5.18 – 4.85 (m, 6H), 3.17 
(dd, J = 13.3, 6.0 Hz, 1H), 3.12 (dd, J = 13.5, 7.5 Hz, 1H), 2.43 
– 2.26 (m, 3H), 2.06 – 1.88 (m, 2H), 1.84 – 1.67 (m, 4H), 1.53 
(dd, J = 23.1, 8.3 Hz, 2H), 1.36 – 1.22 (m, 3H), 1.19 (d, J = 8.7 Hz, 2H), 1.15 – 1.09 (m, 
2H); 13C NMR (125 MHz, CDCl3) δ 207.7, 193.5, 192.5, 167.5, 136.8, 136.8, 135.3, 
135.2, 132.0, 128.2, 127.9, 123.2, 117.8, 116.7, 115.6, 84.1, 79.1, 50.9, 47.6, 41.3, 40.1, 
38.8, 35.9, 32.6, 28.8, 28.2 (multiplet), 27.1, 22.7 (multiplet), 21.5 (multiplet), 16.1 
(mutliplet); LR-MS: m/z Calcd. for C32H34D4O4 [M+H+] 489.3:  Found 489.3.  
X-Ray Crystallographic Data 
X-ray crystallographic data for compound (±)-208:  
 
(±)-208
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     Crystals of compound (±)-208 suitable for X-ray analysis were obtained by slow 
evaporation from isooctane.  
 
Computing details 
Data collection: APEX3 (Bruker, 2006); cell refinement: APEX3 (Bruker, 2006); data 
reduction: SAINT (Bruker, 2006); program(s) used to solve structure: ShelXT (Sheldrick, 
2015); program(s) used to refine structure: SHELXL (Sheldrick, 2015); molecular 
graphics: Olex2 (Dolomanov et al., 2009); software used to prepare material for 
publication: Olex2 (Dolomanov et al., 2009). 
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Crystal data 
  C29H32O3 F(000) = 1840 
Mr = 428.54 Dx = 1.033 Mg m-3 
Monoclinic, P2/n Cu Ka radiation, l = 1.54178 Å 
a = 19.1412 (8) Å Cell parameters from 9783 reflections 
b = 13.8592 (5) Å q = 5.3–66.6° 
c = 20.7713 (8) Å m = 0.51 mm-1 
b = 90.424 (2)° T = 100 K 
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V = 5510.1 (4)  Å3 Bar, colorless 
Z = 8 0.39 × 0.14 × 0.12 mm 
 
Data collection 
  Bruker X8 Proteum-R  diffractometer 9664 independent reflections 
Radiation source: rotating anode 8440 reflections with I > 2s(I) 
Montel Rint = 0.044 
w and f scans qmax = 66.7°, qmin = 2.3° 
Absorption correction: multi-scan  SADABS 
(Sheldrick, 2015) h = -22→22 
Tmin = 0.775, Tmax = 0.864 k = -15→16 
55053 measured reflections l = -24→21 
 
Refinement 
  Refinement on F2 Primary atom site location: dual 
Least-squares matrix: full Hydrogen site location: inferred from neighbouring sites 
R[F2 > 2s(F2)] = 0.060 H-atom parameters constrained 
wR(F2) = 0.175  w = 1/[s
2(Fo2) + (0.067P)2 + 4.598P]   where P = 
(Fo2 + 2Fc2)/3 
S = 1.10 (D/s)max < 0.001 
9664 reflections D〉max = 0.32 e Å-3 
633 parameters D〉min = -0.22 e Å-3 
6 restraints  
 
Special details 
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes)  are 
estimated using the full covariance matrix.  The cell esds are taken  into account 
individually in the estimation of esds in distances, angles  and torsion angles; correlations 
between esds in cell parameters are only  used when they are defined by crystal 
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symmetry.  An approximate (isotropic) treatment of cell esds is used for estimating esds 
involving l.s. planes. 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 
 x y z Uiso*/Ueq Occ. (<1) 
O3A 0.15195 (7) 0.89619 (10) 0.30423 (7) 0.0348 (3)  
O3B -0.18739 (7) 0.89843 (10) 0.83667 (7) 0.0341 (3)  
O1B -0.03074 (9) 0.65586 (11) 0.80577 (9) 0.0492 (4)  
O1A 0.18144 (10) 0.65626 (11) 0.45057 (8) 0.0498 (4)  
O2B -0.06899 (10) 0.77991 (13) 0.94342 (8) 0.0547 (5)  
O2A 0.03340 (9) 0.77833 (13) 0.41251 (10) 0.0583 (5)  
C27B -0.15946 (10) 0.84738 (14) 0.73196 (10) 0.0306 (4)  
H27B -0.2004 0.8757 0.7141 0.037*  
C26B -0.14669 (11) 0.85720 (14) 0.80056 (10) 0.0309 (4)  
C27A 0.26483 (11) 0.84388 (15) 0.33444 (9) 0.0322 (4)  
H27A 0.2852 0.8704 0.2968 0.039*  
C26A 0.19016 (11) 0.85526 (14) 0.34323 (10) 0.0318 (4)  
C8A 0.30685 (11) 0.79765 (14) 0.37679 (10) 0.0333 (5)  
C8B -0.11556 (11) 0.79967 (14) 0.69221 (11) 0.0340 (5)  
C11B -0.00923 (11) 0.92949 (15) 0.76428 (12) 0.0388 (5)  
H11B -0.0542 0.9597 0.7500 0.047*  
C18B -0.08053 (11) 0.81035 (15) 0.82946 (11) 0.0350 (5)  
C11A 0.22660 (13) 0.93165 (15) 0.46929 (10) 0.0385 (5)  
H11A 0.2428 0.9586 0.4273 0.046*  
C7B -0.13202 (13) 0.78690 (16) 0.62501 (11) 0.0394 (5)  
H7B -0.1757 0.8108 0.6099 0.047*  
C9A 0.27889 (13) 0.76355 (15) 0.44148 (10) 0.0380 (5)  
C18A 0.15692 (12) 0.81036 (15) 0.40385 (10) 0.0363 (5)  
C20A 0.08618 (13) 0.69338 (16) 0.32801 (12) 0.0429 (5)  
C28B -0.05129 (11) 0.73291 (15) 0.78521 (12) 0.0387 (5)  
C20B -0.16093 (13) 0.69296 (15) 0.89456 (11) 0.0396 (5)  
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C15B -0.02062 (12) 0.89167 (16) 0.83377 (12) 0.0412 (5)  
C15A 0.15113 (13) 0.89318 (16) 0.45782 (10) 0.0392 (5)  
C9B -0.04525 (11) 0.76323 (15) 0.71573 (12) 0.0388 (5)  
C7A 0.38036 (12) 0.78452 (15) 0.36555 (11) 0.0376 (5)  
H7A 0.3984 0.8072 0.3258 0.045*  
C28A 0.20382 (13) 0.73312 (15) 0.43294 (10) 0.0391 (5)  
C24B -0.25051 (12) 0.59364 (15) 0.84526 (12) 0.0417 (5)  
H24B -0.2737 0.5713 0.8075 0.050*  
C25B -0.19559 (12) 0.65877 (15) 0.84016 (11) 0.0391 (5)  
H25B -0.1815 0.6802 0.7988 0.047*  
C10A 0.27846 (14) 0.85160 (16) 0.48807 (10) 0.0417 (5)  
H10A 0.2670 0.8285 0.5319 0.050*  
H10B 0.3260 0.8795 0.4898 0.050*  
C17A 0.10340 (13) 0.97484 (17) 0.43363 (12) 0.0437 (5)  
H17A 0.0966 1.0220 0.4682 0.066*  
H17B 0.0581 0.9480 0.4207 0.066*  
H17C 0.1250 1.0066 0.3966 0.066*  
C19B -0.10072 (13) 0.76284 (16) 0.89375 (11) 0.0411 (5)  
C25A 0.14558 (13) 0.65772 (16) 0.29800 (12) 0.0434 (5)  
H25A 0.1905 0.6774 0.3127 0.052*  
C10B 0.00744 (11) 0.84918 (16) 0.71573 (13) 0.0420 (5)  
H10C 0.0548 0.8238 0.7253 0.050*  
H10D 0.0084 0.8776 0.6720 0.050*  
C23B -0.27155 (14) 0.56126 (16) 0.90497 (14) 0.0510 (6)  
H23B -0.3091 0.5168 0.9086 0.061*  
C19A 0.08710 (13) 0.76274 (16) 0.38378 (12) 0.0431 (5)  
C12A 0.23242 (14) 1.01395 (17) 0.51922 (11) 0.0454 (6)  
H12A 0.1928 1.0590 0.5134 0.054*  
H12B 0.2297 0.9866 0.5632 0.054*  
C5B -0.08995 (14) 0.74337 (17) 0.58176 (12) 0.0494 (6)  
C13B 0.04042 (13) 1.06577 (17) 0.69942 (13) 0.0490 (6)  
H13B -0.0022 1.0999 0.6936 0.059*  
C17B -0.04489 (13) 0.97434 (17) 0.87781 (13) 0.0474 (6)  
H17D -0.0841 1.0083 0.8574 0.071*  
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H17E -0.0062 1.0195 0.8848 0.071*  
H17F -0.0598 0.9478 0.9192 0.071*  
C5A 0.42559 (13) 0.74269 (17) 0.40681 (12) 0.0451 (6)  
C24A 0.13985 (15) 0.59390 (16) 0.24696 (12) 0.0490 (6)  
H24A 0.1808 0.5703 0.2268 0.059*  
C29A 0.32348 (14) 0.68064 (17) 0.46777 (11) 0.0462 (6)  
H29A 0.3075 0.6646 0.5117 0.055*  
H29B 0.3159 0.6230 0.4404 0.055*  
C13A 0.29911 (15) 1.06737 (17) 0.51217 (13) 0.0510 (6)  
H13A 0.3059 1.1007 0.4728 0.061*  
C4A 0.40098 (15) 0.70254 (18) 0.47040 (12) 0.0508 (6)  
H4A 0.4076 0.7547 0.5032 0.061* 0.808 (8) 
H4AA 0.4107 0.7502 0.5055 0.061* 0.192 (8) 
C12B 0.04794 (13) 1.00822 (18) 0.75899 (14) 0.0497 (6)  
H12C 0.0451 1.0516 0.7967 0.060*  
H12D 0.0945 0.9772 0.7597 0.060*  
C29B -0.02052 (13) 0.67841 (17) 0.67424 (14) 0.0504 (6)  
H29C 0.0275 0.6605 0.6876 0.060*  
H29D -0.0511 0.6221 0.6822 0.060*  
C21B -0.18305 (15) 0.65983 (17) 0.95427 (12) 0.0496 (6)  
H21B -0.1605 0.6826 0.9922 0.059*  
C23A 0.07491 (17) 0.56431 (18) 0.22522 (13) 0.0565 (7)  
H23A 0.0711 0.5204 0.1903 0.068*  
C21A 0.02072 (14) 0.66344 (18) 0.30515 (14) 0.0536 (6)  
H21A -0.0205 0.6877 0.3245 0.064*  
C16A 0.12032 (16) 0.85155 (19) 0.52020 (12) 0.0542 (7)  
H16A 0.1489 0.7970 0.5348 0.081*  
H16B 0.0724 0.8296 0.5120 0.081*  
H16C 0.1201 0.9016 0.5535 0.081*  
C16B 0.04789 (13) 0.84761 (19) 0.86123 (15) 0.0549 (7)  
H16D 0.0850 0.8964 0.8606 0.082*  
H16E 0.0617 0.7923 0.8348 0.082*  
H16F 0.0403 0.8263 0.9056 0.082*  
C22B -0.23722 (16) 0.59444 (19) 0.95937 (14) 0.0570 (7)  
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H22B -0.2510 0.5721 1.0006 0.068*  
C22A 0.01556 (17) 0.5992 (2) 0.25482 (15) 0.0616 (8)  
H22A -0.0292 0.5787 0.2403 0.074*  
C6A 0.50187 (14) 0.7387 (2) 0.39218 (15) 0.0570 (7)  
H6AA 0.5161 0.6714 0.3864 0.085*  
H6AB 0.5284 0.7672 0.4279 0.085*  
H6AC 0.5111 0.7750 0.3526 0.085*  
C4B -0.02094 (15) 0.70063 (19) 0.60207 (14) 0.0568 (7)  
H4B 0.0160 0.7501 0.5940 0.068* 0.684 (9) 
H4BA 0.0160 0.7501 0.5940 0.068* 0.316 (9) 
C6B -0.11078 (18) 0.7395 (2) 0.51215 (13) 0.0648 (8)  
H6BA -0.1550 0.7740 0.5059 0.097*  
H6BB -0.1166 0.6720 0.4990 0.097*  
H6BC -0.0744 0.7697 0.4861 0.097*  
C3A1 0.4460 (2) 0.6147 (3) 0.4932 (2) 0.0540 (11) 0.808 (8) 
H3AA 0.4369 0.5591 0.4644 0.065* 0.808 (8) 
H3AB 0.4962 0.6315 0.4899 0.065* 0.808 (8) 
C14A 0.34955 (19) 1.0730 (2) 0.55513 (17) 0.0727 (9)  
H14A 0.3452 1.0409 0.5953 0.087*  
H14B 0.3905 1.1092 0.5461 0.087*  
C14B 0.08730 (17) 1.0742 (2) 0.65371 (18) 0.0725 (9)  
H14C 0.1307 1.0414 0.6574 0.087*  
H14D 0.0777 1.1130 0.6170 0.087*  
C3B1 -0.0057 (4) 0.6119 (5) 0.5574 (3) 0.0508 (16) 0.684 (9) 
H3BA -0.0392 0.5593 0.5664 0.061* 0.684 (9) 
H3BB -0.0109 0.6308 0.5116 0.061* 0.684 (9) 
C2A1 0.4302 (3) 0.5869 (3) 0.5606 (2) 0.0601 (12) 0.808 (8) 
H2A1 0.4411 0.6330 0.5930 0.072* 0.808 (8) 
C1A1 0.4024 (2) 0.5049 (3) 0.5801 (3) 0.0719 (14) 0.808 (8) 
H1AA 0.3905 0.4564 0.5496 0.086* 0.808 (8) 
H1AB 0.3944 0.4944 0.6246 0.086* 0.808 (8) 
C2B1 0.0671 (3) 0.5785 (4) 0.5704 (3) 0.0659 (16) 0.684 (9) 
H2B1 0.1038 0.6236 0.5641 0.079* 0.684 (9) 
C1B1 0.0844 (4) 0.4915 (5) 0.5898 (2) 0.078 (2) 0.684 (9) 
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H1BA 0.0492 0.4443 0.5966 0.093* 0.684 (9) 
H1BB 0.1321 0.4757 0.5971 0.093* 0.684 (9) 
C2A2 0.3960 (9) 0.5543 (14) 0.5507 (7) 0.051 (4) 0.192 (8) 
H2A2 0.3499 0.5289 0.5498 0.061* 0.192 (8) 
C1A2 0.4341 (9) 0.5483 (13) 0.6044 (7) 0.058 (5) 0.192 (8) 
H1AC 0.4802 0.5736 0.6055 0.070* 0.192 (8) 
H1AD 0.4151 0.5186 0.6417 0.070* 0.192 (8) 
C3A2 0.4252 (12) 0.6005 (13) 0.4922 (12) 0.0540 (11) 0.192 (8) 
H3AC 0.4161 0.5561 0.4557 0.065* 0.192 (8) 
H3AD 0.4765 0.6033 0.4981 0.065* 0.192 (8) 
C1B2 0.1287 (6) 0.5400 (7) 0.5746 (5) 0.068 (4) 0.316 (9) 
H1BC 0.1347 0.5711 0.5342 0.081* 0.316 (9) 
H1BD 0.1661 0.5043 0.5932 0.081* 0.316 (9) 
C2B2 0.0690 (5) 0.5463 (9) 0.6043 (6) 0.059 (3) 0.316 (9) 
H2B2 0.0646 0.5145 0.6446 0.071* 0.316 (9) 
C3B2 0.0083 (10) 0.5999 (12) 0.5792 (7) 0.059 (4) 0.316 (9) 
H3BC -0.0315 0.5547 0.5826 0.071* 0.316 (9) 





























Crystals of compound (±)-243 suitable for X-ray analysis were obtained by slow 
evaporation from isooctane. 
 
Computing details 
Program(s) used to solve structure: ShelXT (Sheldrick, 2015); program(s) used to 
refine structure: SHELXL (Sheldrick, 2015); molecular graphics: Olex2 (Dolomanov et 
al., 2009); software used to prepare material for publication: Olex2 (Dolomanov et al., 
2009). 
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Crystal data 
  C32H38O4 Z = 4 
Mr = 486.62 F(000) = 1048 
Triclinic, P¯1 Dx = 1.203 Mg m-3 
a = 11.9285 (17) Å Cu Ka radiation, l = 1.54178 Å 
b = 12.2179 (13) Å Cell parameters from 1740 reflections 
c = 19.451 (4) Å q = 2.9–66.6° 
a = 98.552 (9)° m = 0.61 mm-1 
b = 106.291 (13)° T = 100 K 
g = 90.381 (9)° Prism, colorless 
V = 2687.3 (7)  Å3 0.20 × 0.18 × 0.14 mm 
 
Data collection 
  Bruker X8 Proteum-R  diffractometer 9225 independent reflections 
Radiation source: rotating anode 8699 reflections with I > 2s(I) 
Montel Rint = 0.054 
w and f scans qmax = 66.6°, qmin = 3.7° 
Absorption correction: multi-scan  TWINABS 
(Bruker, 2006) h = -14→13 
Tmin = 0.748, Tmax = 0.864 k = -14→14 





  Refinement on F2 Primary atom site location: structure-invariant direct methods 
Least-squares matrix: full Hydrogen site location: inferred from neighbouring sites 
  
502 
R[F2 > 2s(F2)] = 0.054 H-atom parameters constrained 
wR(F2) = 0.153  w = 1/[s
2(Fo2) + (0.064P)2 + 1.970P]   where P = 
(Fo2 + 2Fc2)/3 
S = 1.08 (D/s)max = 0.001 
9225 reflections D〉max = 0.25 e Å-3 
677 parameters D〉min = -0.25 e Å-3 
0 restraints  
 
Special details 
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes)  are 
estimated using the full covariance matrix.  The cell esds are taken  into account 
individually in the estimation of esds in distances, angles  and torsion angles; correlations 
between esds in cell parameters are only  used when they are defined by crystal 
symmetry.  An approximate (isotropic)  treatment of cell esds is used for estimating esds 
involving l.s. planes. 
Refinement. Refined as a 2-component twin. 
 CheckCIF Alerts and Discussion: 
 PLAT029_ALERT_3_C _diffrn_measured_fraction_theta_full value Low . 0.973 
Note  PLAT906_ALERT_3_C Large K value in the Analysis of Variance .. 2.479 Check   
PLAT911_ALERT_3_C Missing # FCF Refl Between THmin & STh/L= 0.595 292 
Report   PLAT913_ALERT_3_C Missing # of Very Strong Reflections in FCF .. 5 Note 
 Discussion:  During the twin integration there were a number of data rejected  due to 
poor peak shapes, most likely peaks with close overlap of the two twin  components.  The 
number of rejections may have been somewhat larger than  "normal" for a two 
component non-merohedral twin, giving rise to the missing data alerts.  The low 
measured fraction at theta full is commonly observed for triclinic crystals on our 




Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 
 x y z Uiso*/Ueq Occ. (<1) 
O3A 0.22733 (12) 0.56716 (11) 0.20634 (7) 0.0281 (3)  
O3B 0.73147 (12) 0.81088 (11) 0.21524 (8) 0.0276 (3)  
O1B 0.95679 (12) 1.04975 (12) 0.22007 (8) 0.0299 (3)  
O2A 0.30230 (14) 0.84337 (12) 0.29934 (8) 0.0345 (3)  
O2B 0.81619 (14) 0.59686 (13) 0.31935 (9) 0.0364 (4)  
O1A 0.46379 (13) 0.34191 (12) 0.23664 (9) 0.0370 (4)  
O4A 0.14366 (14) 0.48841 (14) 0.09404 (8) 0.0391 (4)  
O4B 0.63412 (13) 0.81933 (13) 0.10214 (8) 0.0365 (4)  
C31B 0.83169 (17) 0.84555 (17) 0.27324 (11) 0.0264 (4)  
C23B 0.89404 (18) 0.76623 (17) 0.30346 (11) 0.0266 (4)  
C31A 0.32459 (17) 0.57109 (17) 0.26744 (10) 0.0249 (4)  
C24B 0.84909 (18) 0.64751 (17) 0.27801 (12) 0.0286 (4)  
C24A 0.33704 (17) 0.76974 (17) 0.26177 (11) 0.0274 (4)  
C23A 0.38378 (17) 0.66824 (16) 0.29334 (11) 0.0255 (4)  
C32A 0.20920 (18) 0.47812 (18) 0.15156 (11) 0.0294 (4)  
C13B 0.85729 (18) 0.96778 (17) 0.29432 (11) 0.0270 (4)  
C25A 0.33392 (17) 0.78053 (17) 0.18576 (11) 0.0273 (4)  
C26B 0.90479 (19) 0.63981 (19) 0.16126 (12) 0.0332 (5)  
H26B 0.9447 0.7104 0.1788 0.040*  
C14A 0.37317 (18) 0.38726 (17) 0.23418 (12) 0.0293 (4)  
C12A 0.24421 (18) 0.41378 (17) 0.31493 (11) 0.0289 (4)  
H12A 0.2726 0.3544 0.3441 0.035*  
H12B 0.2161 0.4722 0.3462 0.035*  
C25B 0.84757 (19) 0.59232 (17) 0.20408 (12) 0.0316 (5)  
C14B 0.86933 (18) 1.00460 (16) 0.22520 (11) 0.0264 (4)  
C12B 0.75431 (18) 1.02919 (17) 0.31453 (11) 0.0292 (4)  
H12C 0.7331 0.9921 0.3514 0.035*  
H12D 0.7834 1.1056 0.3379 0.035*  
C13A 0.35086 (18) 0.46440 (17) 0.29703 (11) 0.0272 (4)  
C8A 0.13871 (18) 0.36508 (17) 0.25153 (11) 0.0288 (4)  
H8A 0.0954 0.4286 0.2317 0.035*  
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C20B 1.00836 (18) 0.79093 (17) 0.36504 (11) 0.0290 (4)  
C17B 1.16956 (19) 0.94761 (18) 0.42281 (12) 0.0322 (5)  
H17C 1.1476 0.9709 0.4681 0.039*  
H17D 1.2231 0.8862 0.4307 0.039*  
C16B 1.05902 (17) 0.90631 (17) 0.36084 (11) 0.0267 (4)  
H16B 1.0807 0.8998 0.3144 0.032*  
C30A 0.39163 (18) 0.70892 (17) 0.14591 (12) 0.0297 (4)  
H30A 0.4335 0.6504 0.1668 0.036*  
C32B 0.70315 (17) 0.86481 (18) 0.15611 (11) 0.0285 (4)  
C15B 0.96708 (18) 0.99334 (17) 0.35817 (11) 0.0285 (4)  
H15C 0.9441 1.0008 0.4037 0.034*  
H15D 1.0029 1.0657 0.3561 0.034*  
C8B 0.64186 (18) 1.03688 (17) 0.25324 (12) 0.0296 (4)  
H8B 0.5998 0.9623 0.2398 0.036*  
C20A 0.49572 (18) 0.68302 (17) 0.35655 (11) 0.0280 (4)  
C2B 0.8569 (2) 0.9020 (2) 0.06834 (11) 0.0357 (5)  
H2B 0.8231 0.8285 0.0553 0.043*  
C22B 1.09384 (19) 0.70144 (18) 0.35215 (12) 0.0331 (5)  
H22D 1.0618 0.6288 0.3551 0.050*  
H22E 1.1693 0.7180 0.3892 0.050*  
H22F 1.1047 0.7006 0.3040 0.050*  
C4B 0.75745 (18) 0.98171 (17) 0.16245 (11) 0.0289 (4)  
C16A 0.54766 (18) 0.56752 (17) 0.36308 (11) 0.0286 (4)  
H16A 0.5725 0.5434 0.3184 0.034*  
C17A 0.65613 (19) 0.56741 (19) 0.42834 (12) 0.0335 (5)  
H17A 0.7095 0.6316 0.4317 0.040*  
H17B 0.6316 0.5759 0.4734 0.040*  
C26A 0.27409 (19) 0.86727 (19) 0.15479 (13) 0.0340 (5)  
H26A 0.2360 0.9175 0.1819 0.041*  
C9A 0.05652 (19) 0.30046 (17) 0.28207 (12) 0.0321 (5)  
H9AB -0.0073 0.2617 0.2412 0.039*  
H9AC 0.1011 0.2436 0.3081 0.039*  
C18B 1.23186 (18) 1.04333 (19) 0.40626 (12) 0.0331 (5)  
H18B 1.2618 1.0299 0.3655 0.040*  
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C18A 0.71999 (19) 0.4638 (2) 0.42264 (13) 0.0361 (5)  
H18A 0.7422 0.4429 0.3795 0.043*  
C5A 0.17525 (19) 0.29417 (17) 0.18857 (12) 0.0318 (5)  
C6B 0.7211 (2) 1.18674 (18) 0.19806 (13) 0.0351 (5)  
H6BA 0.6628 1.2396 0.2061 0.053*  
H6BB 0.7458 1.2007 0.1560 0.053*  
H6BC 0.7890 1.1956 0.2411 0.053*  
C5B 0.66695 (18) 1.06776 (18) 0.18387 (12) 0.0308 (5)  
C15A 0.45516 (19) 0.48138 (18) 0.36456 (12) 0.0312 (5)  
H15A 0.4921 0.4097 0.3702 0.037*  
H15B 0.4268 0.5047 0.4075 0.037*  
C4A 0.26794 (19) 0.36963 (18) 0.16718 (12) 0.0318 (5)  
C19B 1.2484 (2) 1.1439 (2) 0.44329 (13) 0.0380 (5)  
H19C 1.2199 1.1609 0.4844 0.046*  
H19D 1.2889 1.1997 0.4290 0.046*  
C29A 0.3880 (2) 0.72288 (19) 0.07578 (12) 0.0340 (5)  
H29A 0.4272 0.6738 0.0487 0.041*  
C22A 0.58237 (19) 0.76016 (18) 0.33836 (13) 0.0335 (5)  
H22A 0.5955 0.7287 0.2921 0.050*  
H22B 0.6567 0.7676 0.3768 0.050*  
H22C 0.5500 0.8333 0.3347 0.050*  
C27A 0.2702 (2) 0.8802 (2) 0.08451 (13) 0.0382 (5)  
H27A 0.2284 0.9384 0.0632 0.046*  
C10B 0.51428 (19) 1.07395 (19) 0.33777 (13) 0.0357 (5)  
H10B 0.4576 1.0139 0.3197 0.043*  
C6A 0.2322 (2) 0.18822 (18) 0.21246 (14) 0.0387 (5)  
H6AB 0.2948 0.2077 0.2579 0.058*  
H6AC 0.2649 0.1507 0.1749 0.058*  
H6AD 0.1731 0.1387 0.2199 0.058*  
C10A 0.00413 (19) 0.37344 (18) 0.33277 (13) 0.0330 (5)  
H10A -0.0455 0.4286 0.3134 0.040*  
C3B 0.7824 (2) 0.99154 (19) 0.08992 (12) 0.0341 (5)  
H3BA 0.7072 0.9880 0.0514 0.041*  
H3BB 0.8222 1.0646 0.0941 0.041*  
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C27B 0.9038 (2) 0.5847 (2) 0.09325 (13) 0.0403 (5)  
H27B 0.9428 0.6175 0.0644 0.048*  
C28A 0.3275 (2) 0.80811 (19) 0.04534 (12) 0.0365 (5)  
H28A 0.3250 0.8174 -0.0027 0.044*  
C21B 0.9845 (2) 0.7855 (2) 0.43825 (12) 0.0363 (5)  
H21D 0.9311 0.8431 0.4471 0.054*  
H21E 1.0583 0.7975 0.4771 0.054*  
H21F 0.9488 0.7125 0.4371 0.054*  
C3A 0.3034 (2) 0.3185 (2) 0.09926 (13) 0.0415 (6)  
H3AB 0.3506 0.2536 0.1101 0.050* 0.687 (10) 
H3AC 0.2322 0.2925 0.0593 0.050* 0.687 (10) 
H3AD 0.2391 0.3253 0.0553 0.050* 0.313 (10) 
H3AE 0.3156 0.2387 0.1005 0.050* 0.313 (10) 
C9B 0.56357 (19) 1.11905 (18) 0.28431 (13) 0.0348 (5)  
H9BA 0.6102 1.1887 0.3083 0.042*  
H9BB 0.4984 1.1370 0.2439 0.042*  
C21A 0.4691 (2) 0.7373 (2) 0.42653 (12) 0.0355 (5)  
H21A 0.4327 0.8078 0.4188 0.053*  
H21B 0.5421 0.7508 0.4660 0.053*  
H21C 0.4157 0.6879 0.4392 0.053*  
C30B 0.7899 (2) 0.48891 (19) 0.17772 (13) 0.0418 (6)  
H30B 0.7509 0.4552 0.2062 0.050*  
C7B 0.5534 (2) 1.0597 (2) 0.12156 (13) 0.0391 (5)  
H7BA 0.5181 0.9842 0.1116 0.059*  
H7BB 0.5707 1.0775 0.0780 0.059*  
H7BC 0.4987 1.1122 0.1353 0.059*  
C1B 0.9647 (2) 0.9164 (2) 0.06592 (13) 0.0445 (6)  
H1BA 1.0019 0.9885 0.0785 0.053*  
H1BB 1.0056 0.8547 0.0516 0.053*  
C7A 0.0688 (2) 0.2598 (2) 0.12297 (13) 0.0401 (5)  
H7AB 0.0133 0.2140 0.1366 0.060*  
H7AC 0.0940 0.2173 0.0835 0.060*  
H7AD 0.0310 0.3261 0.1068 0.060*  
C28B 0.8463 (3) 0.4824 (2) 0.06782 (13) 0.0492 (7)  
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H28B 0.8458 0.4444 0.0214 0.059*  
C11A 0.0214 (2) 0.3673 (2) 0.40195 (14) 0.0469 (6)  
H11A 0.0704 0.3133 0.4235 0.056*  
H11B -0.0153 0.4169 0.4304 0.056*  
C19A 0.7484 (2) 0.3985 (2) 0.47238 (15) 0.0479 (6)  
H19A 0.7279 0.4162 0.5164 0.057*  
H19B 0.7893 0.3336 0.4642 0.057*  
C29B 0.7893 (3) 0.4349 (2) 0.10951 (14) 0.0539 (7)  
H29B 0.7492 0.3646 0.0914 0.065*  
C11B 0.5434 (2) 1.1109 (2) 0.40799 (15) 0.0514 (7)  
H11C 0.5998 1.1708 0.4282 0.062*  
H11D 0.5079 1.0777 0.4384 0.062*  
C2A1 0.3738 (5) 0.4018 (4) 0.0751 (3) 0.0338 (12) 0.687 (10) 
H2A1 0.3351 0.4621 0.0546 0.041* 0.687 (10) 
C1A1 0.4858 (4) 0.3939 (4) 0.0813 (2) 0.0478 (14) 0.687 (10) 
H1AB 0.5262 0.3342 0.1017 0.057* 0.687 (10) 
H1AC 0.5265 0.4477 0.0655 0.057* 0.687 (10) 
C1A2 0.4142 (8) 0.4099 (8) 0.0360 (6) 0.047 (3) 0.313 (10) 
H1AD 0.3442 0.3991 -0.0030 0.057* 0.313 (10) 
H1AE 0.4814 0.4457 0.0306 0.057* 0.313 (10) 
C2A2 0.4177 (11) 0.3767 (10) 0.0948 (7) 0.038 (3) 0.313 (10) 
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